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Preface 
 
Cervical cancer is the second most prevalent cancer among women worldwide, mainly 
affecting young women. Infection with Human Papilloma Virus (HPV) has been 
identified as the causal agent for this condition. The natural history of cervical cancer 
is characterized by slow disease progression, generally taking over 10 years, from the 
initial infection with HPV, to the diagnosis of cancer. In essence, cervical cancer is a 
preventable disease, and treatable if diagnosed in early stage. Historically, the 
introduction of the Pap smear has markedly reduced the number of new cases in 
countries with an effective prevention program. The burden of disease is highest in 
developing countries, with peak incidence in Eastern Africa. Recently, prophylactic 
vaccines became available, equally contributing to a better disease prevention. 
Unfortunately, the global burden of disease is still very high. 
Cervical cancer research is a multidisciplinary matter, combining efforts of clinicians 
(gynaecologists, pathologists, clinical chemists), epidemiologists, fundamental 
scientists, and sociologists. In this book, focus has been put on research and 
fundamental aspects of HPV related research. Section 1 is titled: Epidemiology of 
Human Papillomavirus and Cervical Lesions. In this section, epidemiological data per 
age group are presented, and data that has been collected in asymptomatic women are 
equally included. In the second section, translation of fundamental findings into novel 
HPV diagnostic and treatment options are summarized. Molecular biology has found 
its way into this field and created many new possibilities, comprising molecular 
biomarkers, and allowing more accurate diagnosis and targeted treatment. The final 
section outlines recent advances in fundamental HPV research. New insights on the 
role of ion channels and the cytoskeleton are presented. Furthermore, signal pathways 
in carcinogenesis are dissected, as well as immunological implications in the 
carcinogenic transformation. Among the novelties in fundamental research, Dr. 
Maramis and co-workers have developed software allowing automation of HPV 
genotyping assays. In addition, new molecular biological tools in the diagnosis and 
treatment of cervical cancer are included, next to the development of a research tool to 
investigate the cellular uptake of the HPV virus. 
X Preface 
 
This book will be a useful tool for both researchers and clinicians dealing with cervical 
cancer, and will provide them with the latest information in this field. 
 
Prof. Dr. Davy Vanden Broeck, MSc, PhD. 
Team leader HPV/Cervical Cancer Research 
International Centre for Reproductive Health 
Ghent University 
Belgium 
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Part 1 
Epidemiology of Human Papillomavirus 
and Cervical Lesions 
 
1 
Epidemiology of Mucosal 
Human Papillomavirus (HPV) 
Infections Among Adult and Children 
Helen Trottier 
Sainte-Justine University Hospital Research Center 
Department of Social and Preventive Medicine, University of Montreal 
 Canada  
1. Introduction 
Human papillomavirus (HPV) infection is recognized today as the main causal factor for 
~100% of cervical cancer cases in the world and of a substantial proportion of many other 
anogenital neoplasms (anal, vaginal, vulvar, and penile cancer). HPV is also implicated in 
the genesis of several other cancers, such as head and neck (oral cavity, pharynx, and 
larynx) cancer and non-melanoma skin cancer and is suspected also to play a causal role in 
the genesis of a few other neoplasms (Trottier et al, 2009). The epidemiology of mucosal 
human papillomavirus (HPV) as been well studied today, especially cervicovaginal HPV 
infection among young women and there are also more available epidemiologic data for 
older women, men and as well as for children. HPV infection is the most common sexually 
transmitted infections in the world. The predominant route of transmission is via sexual 
contact, although vertical and horizontal transmissions also occur. This chapter will review 
the epidemiology of mucosal HPV infections affecting genital, oral and conjunctival mucosa 
in adults and children. This chapter will detail the epidemiology of HPV in adult 
considering young versus older population rather than focussing on adolescent and adult 
populations separately because there is no universal cut-off age group to define high risk 
population as HPV is highly dependant on the onset of sexual activity.  
2. Classification and carcinogenicity of HPVs  
More than 100 HPV genotypes have been catalogued so far and can be classified according 
to the phylogenetics in genera and species (De Villiers et al, 2004) (table 1).  The L1 protein is 
highly conserved among all HPV genotypes and is thus used for taxonomical purposes. 
Different genera of the Papillomaviridae (Alpha, Beta, etc.) share less than 60% nucleotide 
sequence identity in the L1 protein whereas species within a genus share between 60% and 
70% nucleotide identity. A new HPV isolate is recognized as a new genotype when the 
nucleotide sequence of the L1 gene differs by more than 10% from the genotype with which 
it has greatest homology in DNA sequence.  
Papillomaviruses can also be classified according to their tissue tropism (mucosal or 
cutaneous) and oncogenic potential (table 2) (De Villiers et al, 2004). Although it is possible  
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Genus Species Genotypes of HPV 
Alpha-papillomavirus 
Alpha-1 42 
Alpha-2 3, 10, 28,29, 77, 78, 94 
Alpha-3 61, c62, 72, 81, 83, c87, c86, c89, 84, 
Alpha-4 2, 27, 57 
Alpha-5 26, 51, 69, 82 
Alpha-6 30, 53, 56, 66 
Alpha-7 18, 45, 59, c85, 39, 68, 70 
Alpha-8 7, 40, 43, c91 
Alpha-9 16, 31, 33, 35, 52, 58, 67 
Alpha-10 6, 11, 13, 44, 55, 74 
Alpha-11 34, 73 
Alpha-12 RhPV1 
Alpha-13 54 
Alpha-14 c90 
Alpha-15 71 
Beta-papillomavirus 
Beta-1 5, 8, 12, 14, 19, 20, 21, 24, 25, 36, 47, 93 
Beta-2 9, 15, 17, 22, 23, 37, 80, 
Beta-3 38, 49, 75, 76 
Beta-4 92 
Beta-5 96 
Gamma-papillomavirus 
Gamma-1 4, 65, 95 
Gamma-2 50 
Gamma-3 48 
Gamma-4 60 
Gamma-5 88 
Mu-papillomavirus Mu-1 1 
 Mu-2 63 
Nu-papillomavirus Nu 41 
Adapted from De Villiers et al, 2004. 
Table 1.  Phylogenetics of Papillomaviridae affecting humans 
to find all these genotypes in both mucosal and cutaneous tissue, they are classified 
according to their tissue tropism as shown in table 2. This chapter will focus on the 
genotypes of HPV that infect the epithelial lining of the anogenital tract and other mucosal 
areas of the body (mucosal HPV). There are over than 40 genotypes of HPV that infect 
human mucosal from which 13–25 genotypes have been identified as probable or definite 
high-oncogenic risk (HR-HPV) according to their frequency of association with cervical 
cancer and other anogenital cancers (review in Trottier et al, 2006; IARC 2007; IARC 2011). 
Although, the vast majority of infected people will clear mucosal HPV infections without 
any clinical consequences, its role in the pathogenesis of malignant tumours has been well 
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described. HR-HPV is recognized unequivocally as the main causal factor for (~100%) 
cervical cancer, is responsible for a substantial proportion of many other (60-90 %) 
anogenital neoplasms (anal, vaginal, vulvar and penile cancers), and a non negligible 
portion (~30%) of head and neck cancers (oral cavity, pharynx, and larynx), and is suspected 
to play a causal role in many other neoplasms, such as conjunctiva carcinoma and lung 
cancer (Trottier et al, 2009). The latest classification published by the World Health 
Organization’s International Agency for Research on Cancer (IARC) referred HPV-16, 18, 31, 
33, 35, 39, 45, 51, 52, 56, 58, 59 as HR-HPVs (IARC, 2011). This classification included also 
many other genotypes as probably carcinogenic such as HPV genotypes 26, 30, 34, 53, 66, 67, 
68, 69, 70, 73, 82, 85, 97.  Infection with low-oncogenic risk HPVs (LR-HPV), such as HPV-6 
and 11, can cause benign lesions of the anogenital areas known as Condylomata acuminate 
(genital warts), a large proportion of low-grade squamous intraepithelial lesions (LSIL) of 
the cervix, oral papillomas as well as conjunctival papillomas.  HPV-6 or 11 may also cause 
in rare instance recurrent respiratory papillomatosis, which in infants and young children 
can be very morbid and usually perinatally transmitted (Armstrong et al. 2000) whereas in 
adult it is usually sexually transmitted and less severe than in children (Kashima et al, 1992). 
 
Tissue tropism Genotypes of HPV 
 
Mucosal High-risk: 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59 
Low-risk (or probably carcinogenic): 6, 11, 13, 26, 30, 32, 34, 42, 44, 53, 
54, 61, 62, 66, 67, 68, 69, 70, 71, 72, 73, 74, 81, 82, 83, 84, 85, 86, 87, 89, 90 
Cutaneous 1, 2, 4, 5, 8, 9, 12 ,1 4, 15 ,17, 19, 20, 21, 22, 23,  25, 27, 36, 37, 38, 41, 47, 
48, 49, 50, 57, 60, 63, 65, 75, 76, 80, 88, 92, 93, 95, 96 
Both (mixte) 3, 7, 10, 28, 29, 40, 43, 78, 91, 94 
Adapted from De Villiers et al, 2004. Carcinogenic potential classification based on IARC monograph, 
Vol 100B, 2009. 
Table 2. Classifications of HPVs according to their tissue tropism and oncogenic potential 
3. Mode of transmission of mucosal HPV 
3.1 Predominant route of transmission is via sexual contact 
There is a strong and consistent association between sexual activity and mucosal HPV 
infections (Winer et al 2008). The number of lifetime and recent partners is one of the 
strongest risk factors for prevalent infection as well as acquisition in adult (Trottier et al, 
2006).  Further data supporting sexual intercourse as the primary route of genital HPV 
infection include documented transmission of genital warts between sex partners, 
concordance in sex partners for genotype-specific HPV infection, the rarity of genital HPV 
infection in virgin women, and increased risk of HPV acquisition following new and recent 
sex partners (Winer et al, 2008; Winer et al, 2008b; Burchell et al, 2006). The practice of anal 
intercourse is also associated with HPV detection in the anal canal in men who have sex 
with men and to a lesser degree for women (Dunne et al, 2006; Moscicki et al, 1999). 
Transmission may also occur via other sexual practices, such as oral sex, digital-vaginal sex 
and use of insertive sex toys (Edwards et al, 1998; Sonnex et al, 1999; Gervaz et al, 2003). For 
example, oral sex may explain why husband of women with cervical cancer are at higher 
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risk of upper aerodigestive track cancer (Hemminki et al, 2000). Studies on genital HPV 
infection between women who have sex with women also suggest the possibility of 
transmission between female sex partners (Marrazzo et al 2000). More studies are also 
available on the transmissibility of HPV; the evidence is that HPV is highly transmissible 
(Barnabas et al, 2006; Burchell et al, 2010). For example, Barnabas et al. (2006) estimated the 
per-partner male-to-female transmission probability as much as 60% for HPV-16.  
3.2 Vertical transmission  
Non-sexual routes of transmission are believed to be far less common, but possible. 
Transmission of HPV from mother to child (perinatal infection) was first reported in 1956 
(Hajek, 1956) in a case of juvenile laryngeal papillomatosis (JLP). Confirmation of the 
perinatal transmission of HPV in different mucosa (genital, oral) was subsequently 
supported by several studies although the route of transmission is not well understood 
(Syrjänen et al, 2000). Direct maternal transmission during vaginal delivery or at caesarean 
section following early membrane rupture is possible as well as in utero through semen or 
ascending infection from mother’s genital tract (Syrjänen et al, 2000; Favre et al, 1998). 
Transplancental transmission is also possible since HPV DNA has been detected by PCR in 
amniotic fluid of HPV positive pregnant women. HPV 16 DNA has also been found in cord 
blood cells.  See section on children for an estimate of the probability of transmission of HPV 
at birth.  
3.3 Horizontal transmission and other route 
Horizontal transmission had also been reported; possible routes of infection are the fingers 
and mouth, fomites and skin contact outside sexual contact. For example, transmission from 
the anogenital region to hands is possible via self-inoculation (Hernandez et al, 2008). 
Although possible, this non-sexual route of transmission is also believed to be far less 
common than sexual contact route, especially in adult. Obviously, the horizontal route is 
more important in children (excluding sexually abused children) than the sexual route 
although vertical transmission do occurs. For example, the presence of oral HPV DNA is 
detected in buccal cavities of 19–35% of healthy children aged 6–11 years (Puranen et al, 
1997; Summersgill et al, 2001; Kojima et al, 2003). Blood transmission of HPV as well as 
transmission via breast milk is implausible since HPV infection does not produce viremia 
(Cason et al, 2005). 
4. Epidemiology of HPV infection in adult 
4.1 Anogenital HPV infection in women 
4.1.1 Prevalence, incidence, duration, co-infection and re-infection  
There are many studies that have reported on cervical HPV epidemiology. Studies on the 
prevalence of HPV around the world show that the prevalence of cervical HPV infection 
ranges from 2 to 44%. This wide variation in the prevalence estimates is largely explained by 
the age and the region of the populations studied. Typically, HPV prevalence increases 
rapidly following the onset of sexual activity (highest prevalence occurs among young 
women / adolescent). In fact, cervicovaginal HPV infection is rarely observed among 
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virgins, even among those who engage in sexual activity other than intercourse (Kjaer et al, 
2001). The peak after sexual debut is usually followed by an age-related decline in 
prevalence, and occasionally a second but more modest peak in prevalence among older 
women.(~› 45 years) (Trottier et al, 2006). The prevalence of cervical HPV infection is 
estimated at 5.2%, 8.7%, 12.9%, 14.3% and 25.6% in Europe, Asia, North America, South 
America and Sub-Saharan Africa, respectively (Clifford et al., Lancet 2005,  Burchell et al. 
2006).  HPV-16 is the most common genotype in all regions of the world except in Eastern 
Africa, Japan and Taiwan, where HPV 52 is the most frequent genotype  but overall, the top 
ranked genotypes are HPVs 16, 18, 31, 58, and 52 (de Sanjosé et al, 2007). Coinfection with 
multiple HPV genotypes is also a very common finding of many epidemiologic studies. For 
example, among the cohort of Brazilian women, between 1.9% to 3.2%  were co-infected 
with multiples genotypes at a same visit (concurrently infected) whereas when considering 
cumulatively (period prevalence) during the first year and the first 4 years of follow-up, 
12.3% and 22.3% were infected with multiple genotypes, respectively (Trottier et al, 2006b). 
We also have to take into account that positivity for HPV is typically higher in 
cervicovaginal than in exclusively cervical specimens (Bauer et al; 1991).  
The incidence of cervical HPV infections has also been well studied in many cohorts of young 
or college-aged women. These cohort studies have shown that the cumulative incidence of 
cervical HPV infection exceeded 40% after 3 years among women who were initially HPV 
negative at enrolment (Trottier et al, 2006). These studies also had shown that the cumulative 
incidence is higher for high risk genotypes than for low-risk genotypes. As with prevalence, 
incidence rates of HPV in women tend to decline with age, although second peaks are 
sometimes observed in older women. In fact, over 75% of sexually active women will contract 
HPV in their lifetime and its detection is strongly and consistently associated with the number 
of sexual partners. In most cases, HPV infection is transient or intermittent; only a very small 
proportion of cervical HPV infection will persist and progress toward cervical cancer 
(Schiffman et al, 2003). The median duration of cervical infection for any HPV genotype 
appears to range between 4 and 20 months (Trottier et al, 2006).  
Recent evidence shown that re-infection with HPV (with a different or either a same 
genotype) is a common occurrence (Trottier et al, 2010). Prior infection with HPV does not 
provide women with adequate immunity against subsequent infections. In fact, serum 
antibody levels after natural HPV infection when detectable are low and 40-50% of women 
do not develop measurable antibody response after HPV natural infection (Viscidi et al, 
2004; Nonnenmacher et al, 1995; Park et al, 1998; Heim et al, 2002; Skjeldestad et al, 2008). 
Moreover, it has been shown that an infection with a specific genotype does not decrease the 
probability of being infected by a phylogenetically-related genotype (Thomas et al, 2000). 
Recent studies have shown that re-infection with a same genotype, as well as incident 
infection in older women who had multiple lifetime sexual partners, are associated with 
new sexual partners suggesting that infection in adult women may results not only from 
reactivation (infections acquired at a young age that never completely cleared but become 
undetectable and appeared later in life) but also from new exposure via sexual activity 
(Trottier et al, 2010; Munoz et al, 2004).  
Relatively little is known about the epidemiology of anal HPV infection in women compare 
to cervical infection. However the few studies that reported on anal HPV infection shown 
that it is very common (Goodman et al, 2008; 2010; Shvetsov et al, 2009). When both cervical 
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and anal HPV testing is done, anal HPV is more common than cervical HPV (Williams et al, 
1994; Palefsky et al, 2001). More recently, Goodman et al. (2010) reported that cervical and 
anal HPV infections do occur consecutively and that the risk of one increases the risk of the 
other and vice versa. They also reported on prevalence, incidence and clearance rates of 
genotype-specific anal HPV infection in women. The period prevalence of anal HPV was as 
much as 70% for a follow-up period that averaged 1.3 years (Goodman et al, 2008). The 
incidence of anal HPV infection was 50% through a follow-up period of average duration of 
1.2 years whereas the median duration of anal HPV infection was 150 days (Shvetsov et al, 
2009). In sum, data suggest that women's risk of anal HPV infection is at least as common (if 
not more common) as their risk of cervical HPV infection. 
4.2 Anogenital HPV infection in men 
4.2.1 Prevalence, incidence, duration  
Compared to women, far fewer studies have been conducted among men but evidence 
suggests that the prevalence may even be more important in male. Depending of the 
anatomic sites (specifically the glans, corona, prepuce/foreskin and shaft, with improved 
HPV detection if a scrotal, perianal and/or anal canal sample is also obtained), the 
prevalence of anogenital HPV-DNA positivity among men ranges from 0 to 73% and is 
usually more than 20% (Giuliano et al, 2007; 2008; Dunne et al, 2006; Weaver et al, 2004). 
Also, HR-HPV appears to occur in a higher proportion of male than female infections 
(Giuliano et al, 2008b) and such as for women, penile HPV prevalence typically increases 
with the number of sex partners (Giuliano et al, 2007; Dunne et al, 2006; Weaver et al, 2004). 
Importantly and unlike for women, the available data do not indicate marked differences in 
HPV prevalence across age groups in men (Giuliano et al, 2008c). In fact, after the onset of 
sexual activity, HPV prevalence in men is relatively stable across age group.   
Some cohort studies revealed that anogenital HPV incidence is at least as high among men 
as it is in women, with cumulative incidences ranging from 14 to 62% within 3 to 24 months 
(Dunn et al, 2006; Giuliano et al, 2008, Partridge et al, 2006; 2007). Although far fewer data 
are available for men, infection seems to be of short duration compare to women with a 
median duration of 5.9 months and no evidence for a difference in duration between 
oncogenic and non-oncogenic infections (Giuliano et al, 2008; Kjaer et al, 2005; Lajous et al, 
2005). Only one study has reported on the risk of infection with multiple types in male and 
found that coinfection with multiple HPV genotypes was very common; the cumulative 
incidence of multiple genotypes after 24 months of follow-up of heterosexually active male 
university students 18–20 years was 35.6% (Partridge et al, 2007). There is no available study 
concerning the probability of re-infection with a same or a different genotype in men.  
4.2.2 Special case for men who have sex with men 
Men who have sex with men (MSM) have been observed to have a particularly high 
prevalence of HPV infections (Chin-Hong et al, 2004; Palefsky et al, 1998) and especially 
HIV positive MSM (de Pokomandy et al, 2009).  Cohort studies of HIV-positive MSM 
revealed that the prevalence of anal HPV is more than 95% in these men, with high rates of 
multiple HPV genotype infections and lower genotype-specific HPV clearance rates (de 
Pokomandy et al, 2009; Kiviat et al, 1990; Palefsky et al 2005).  
 
Epidemiology of Mucosal Human Papillomavirus (HPV) Infections Among Adult and Children 
 
9 
4.3 Oral HPV infection in adults 
It is clear that oral mucosa act as a reservoir for HPV. A systematic review (Kreimer et al, 
2010) of studies on oral HPV infection among 4070 healthy and cancer free individuals 
estimated the prevalence of oral HPV infection (any genotypes) of 4.5%. More specifically, 
1.3% had oral HPV-16 and 3.5% had carcinogenic HPV. In this systematic review oral HPV-
16 accounted for 28% of all HPV detected in the oral region and there was no difference in 
the oral prevalence between men and women. Other recent studies had shown nearly the 
same prevalence. A study among 1,688 healthy men aged 18 to 74 (median = 31 years) in 
United States, Mexico, and Brazil shown that the prevalence of oral HPV infection was 4% 
(Kreimer et al, 2011) whereas the study of Matsushita et al (2011) estimate oral HPV 
prevalence at 6.1%. Genotypes mostly detected included HPVs -16 and -18 and the tonsil 
appears to be the site with the highest prevalence.  
4.4 Conjunctival HPV infection in adult 
It is also clear that conjunctival mucosa act as a reservoir for HPV. LR-HPV such as HPVs -6 
and -11 as well as HR-HPV, such as genotypes 16 and 33 are associated with the occurrence 
of conjunctival papilloma (Sjö et al, 2007). Ateenyi-Agaba et al. (2010) have tested 
conjunctival biopsy samples from healthy individuals to estimate the prevalence of HPV. 
The prevalence of mucosal HPVs was 3.5%, the prevalence of cutaneous HPVs was 10.5% 
whereas the prevalence multiple-genotype infections was present in 13.3% (Ateenyi-Agaba 
et al, 2010). It is possible that conjunctival tissues are more likely to be infected with 
cutaneous genotypes because of horizontal transmission.  
5. Epidemiology of HPV infection in infant and children  
The few studies available on genital and oral HPV infection in children have shown clear 
evidence of HR-HPV infections in healthy children (Kojima et al, 2003; Summersgill et al, 
2001; Smith et al, 2007; Rice et al, 2000; Syrjänen et al, 2000). Sexual abuse and vertical and 
horizontal transmission may explain the positivity in children. This chapter focuses on the 
evidence about the epidemiology of HPV in children and not on the possible route of 
transmission since it is impossible to distinguish between both routes based simply on the 
clinical/epidemiological data. What is well known is that both routes (sexual and non-
sexual) are possible. For example, perinatal HPV transmission has been unequivocally 
identified as a possible cause for the rare disease called Juvenile-Onset Recurrent 
Respiratory papillomatosis (JORRP) (Wiatrak et al, 2004). 
Confirmation of the perinatal transmission of HPV in different mucosa (genital, oral) is 
supported by several studies. These studies have reported widely varying probability of 
infection in newborns, with estimates from the first couple of days of life ranging from 4 to 
79% among infants born to mothers testing positive for HPV DNA during pregnancy (Table 3).  
Although perinatal transmission may be observed in baby born by caesarean, it is usually 
admitted that caesarean decreases the risk of perinatal infection. For example, a significantly 
higher rate of HPV 16/18 infection was found at birth when infants were delivered vaginally 
than when infants were delivered by cesarean (51.4% versus 27.3%) (Tseng et al, 1998).  A 
systematic review (Medeiros  et al, 2005) reported a higher risk of HPV infection after vaginal 
delivery than after cesarean section (RR: 1.8; 95%CI: 1.3-2.4). The risk of transmission has also 
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been identified as increasing with the rupture of membranes; the longer time rupture of 
membranes occurred before delivery, higher risk of transmission (Tenti et al, 1999).  
 
Study, year; 
country Genotype of HPV 
Sample 
(number of 
HPV+ pregnant 
mother) 
 
Transmission rate 
at birth Follow-up 
Tseng et al, 
1998;   
Taiwan 
16, 18 68  
40 % (buccal and 
genital) delivery 
Puranen et 
al, 1997;  
Finland 
6, 11, 16, 18 
42 
 
 
79% 
(nasopharyngeal) delivery 
Chatterjee et 
al, 1998; 
India 
6, 11, 16, 18 12 42% (buccal) delivery 
Tenti et al, 
1999; 
Italy 
 
6, 11, 16, 18, 31, 
33, 35, 39, 51, 54, 
56, 58, 59, 66, 68, 
69, 70, 83, 84 
37 30% (oropharyngeal) 18 mths 
Bandyopadh
yay et al, 
2003; 
India 
6, 11, 16, 18, 31, 33 38 18% (buccal) 12 mths 
Smith et al, 
2004;  
United States 
6, 11, 16, 18, 31, 
33, 53, 66 172 4% (buccal, genital) 6 mths 
Rintala et al, 
2005; 
Finland 
 
16, 18, 31, 33, 35, 
39, 45, 51, 52, 54, 
56, 58 
Include 77 
newborns 
(15% and 9% of 
newborns had 
genital or oral HPV 
infection, at birth, 
respectively 
2 yrs 
Rombaldi et 
al, 2009; 
Brazil 
6/11, 16, 18, 31, 
33, 42, 52, 58 49 
20% (buccal, 
axillary and 
inguinal regions) 
1 yr 
Castellsagué 
et al, 2009; 
Spain 
6, 11, 16, 18, 31, 
33, 39 66 
19.7% (mouth and 
anogenital 
exfoliated cells) 
2 yrs 
Table 3: Cohort studies on HPV perinatal transmission 
Only a few studies have analysed the probability of persistence among babies born to HPV-
infected mothers such as Rombaldi et al (2009) and Watts et al. (1998) who have reported a 
very low proportion of persistent infection in infants (reported 0% in a 1 and 3-year follow-
up study, respectively) whereas some reported very high proportions ranging from 27 to 
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56% (Fredericks et al, 1993; Kaye et al, 1994; Pakarian et al, 1994; Cason et al, 1995, 2005; 
Syrjänen et al, 2000). These studies have shown that perinatally acquired HPV can persist for 
at least 2 years and that HPV is mostly prevalent during the first year of infancy reaching a 
peak at 6 months of age. 
Anogenital warts may also be transmitted perinatally (Jayasingue et al, 2006; Sinal et al, 
2005; Marcoux et al, 2006; Sinclair et al, 2005; Jones et al, 2007). Boyd (1990) has shown that 
at least 20% of anogenital warts occur because of perinatal transmission. Although the 
incubation period for children is not known, a period of several months typically elapses 
between viral infection at delivery and clinical manifestations (Monk et al, 2007). A review 
of studies of the HPV genotype distribution in anogenital warts in children has shown that 
75% are caused by genotypes 6 and 11, 11% by HPV-2, 6% by HPV-16 and -18 and 3% by 
HPV-27 and -57 (Syrjänen et al, 2000; Sinal et al, 2005; Marcoux et al, 2006; Aguilera-
Barrantes et al, 2007). Since the 1990s, the incidence of anogenital warts has dramatically 
increased in adults as well as in children (Syrjänen et al, 2000). To summarize, it is clear that 
perinatal transmission of HPV occurred although the frequency at which it occurred and 
persist remains controversial. 
It is also clear that infants and children might acquire oral and genital HPV infection 
postnatally from a variety of sources such as direct transmission (person-to-person or auto-
inoculation), indirect transmission (via contaminated objects) and sexual abuse (Syrjänen et 
al, 2000). For example, in their longitudinal study of the prevalence of HR-HPV in oral and 
genital mucosa of infants during their first 3 years of life, Rintala et al. (2005b) found that 
42% of infants (negative at birth) had acquired an oral HR-HPV infection (from which 10% 
had persistent infection) and 36% had acquired a genital HR-HPV infection (from which 
1.5% had persisted). Some cross-sectional studies have estimated the prevalence of HPV 
among children of different age-groups. The estimates of prevalence of HPV (detected by 
PCR) in oral swabs from children aged 0-13 years range from 32 to 52% (Rice et al, 2000; 
Syrjänen et al, 2000). In their review of studies that analyzed PCR-detected HR-HPV during 
infancy and childhood, Cason et al. (2005) reported HPV prevalences ranging from 9 to 55%. 
However, oral HPV infection is likely to decrease with age. The study of Marais et al. (2006) 
had compared oral HPV prevalence among children, adolescent and adult. They found that 
oral HPV infection was highest in children (7.9%), followed by adolescents (5.1%), and 
lowest in normal adults (3.5%).  Mamas et al. (2011) also shown the presence of HPV in the 
lower respiratory tract of healthy children; 8% of bronchoalveolar lavage of children (2-12 
years old) they tested were positive for HPV. Finally, there are no available studies on the 
prevalence of conjunctival HPV in children although papilloma represents 7-10% of 
conjunctival benign tumors in childhood where HPV-6 and -11 are the major genotypes 
responsible for conjunctival lesions (Okan et al, 2010).   
There are some studies that reported cases of squamous cell carcinoma (SCC) involving the 
larynx/lung in childhood which transformed from the recurrent respiratory papillomatosis 
with HPV (Lin et al, 2010; Katsenos et al, 2011) but cancers associated with HPV in 
childhood are not frequent. However, although rare, cancers related to HPV are increasing 
in recent years in children and this increasing correlates with increased prevalence of HPV 
in the community (Chow et al, 2007). Moreover and importantly, they are no longitudinal 
studies available to clarify whether children exposed to HPV (oral, anogenital or 
conjunctival) are at risk of developing carcinoma in adulthood. A better understanding the 
natural history of HPV infection in children is clearly needed. 
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6. Conclusion 
Anogenital HPV infection is very common with high prevalences found in both females and 
males. Typically, anogenital HPV prevalence increases rapidly in adolescents/young adults 
following sexual debut, and the highest prevalence occurs among this population (Kjaer et 
al, 2001). The probability of finding a cervicovaginal HPV infections in women decrease 
after that according to age with a possible peak at older age whereas it is relatively stable 
according to age for men. The predominant route of HPV transmission is through sexual 
contact although vertical and horizontal transmissions are possible. Most sexually-active 
individuals are likely to be exposed to anogenital HPV infection during their lifetimes and 
most infections will be cleared spontaneously within a year. A small fraction of people will 
have persistent infection with HR-HPVs, which is unequivocally established as a necessary 
cause of cervical cancer and is likely to be responsible for a substantial proportion of other 
anogenital neoplasms and non negligible number of head and neck cancers. Persistent 
infection result in substantial morbidity and invoke high costs associated with the treatment 
of clinically relevant lesions. Oral and conjunctival infections may also exist in adults 
although the epidemiology of these infections has been less studied. Children are also 
exposed to HPV as anogenital and oral samples of healthy children have often been found 
positive. The incidence of HPV-associated diseases, such as squamous cell carcinomas, has 
increased in children in recent years which may be, in part, related to an increase in HPV 
prevalence (Syrjänen et al, 2000; Chow et al, 2007). HPV vaccination, one of the most 
remarkable discoveries of the past decade, is currently implanted all around the world and 
is expected to prevent a substantial proportion of cervical and other HPV-related cancers in 
the future. 
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1. Introduction 
In 2007, a worldwide analysis was published that assessed the types of HPV infection found 
in women without cervical disease (1). Of the 291 million women suffered with cervical 
diseases around the world, it was found that 32% are infected with either HPV16 or HPV18, 
or both. Data regarding the HPV burden and incidence rates are available on the WHO/ICO 
Information Centre on HPV and Cervical Cancer Web site (http://www.who.int/ 
hpvcentre). However, HPV prevalence in different regions of Southern China is not 
mentioned in this website. Hence the diversity of HPV prevalence and distribution in 
Taiwan, Hong Kong, and various regions of China is the major focus in this chapter. 
In Hong Kong, HPV DNA has been detected in 4% of women in 1996 and in 11% in 2002 by 
utilizing polymerase chain reaction methods on cervical samples, the most common high-
risk (HR) HPV types identified being, in decreasing order, HPV 16, 58, 53, 18, 33, 45, and 52. 
Moreover, HPV 6 and 11, two types responsible for about 90% of genital warts, are among 
the most frequent HPV types found in Hong Kong population. In Taiwan, the five most 
common HPV types, also listed in decreasing order of frequency, are: HPV 16, 18, 58, 33, 
and 52 for women with cervical cancer, and HPV 16, 52, 58, 18, and 51 for women with 
normal cytology (2, 3). According to literature, there are, to date, fifty cities and provinces 
including Hong Kong and Taiwan whose predominant HPV types are already known. Table 
1 shows the prevalence of HR-HPV in different regions in China such as, Zhejiang Province, 
Tianjin City, Shanxi Province, Hong Kong (HK), Guangzhou, Shandong Province, 
Shenzhen, Fujian, Liaoning Province, Beijing, Gansu province, Shanghai, Sichuan province, 
Guangdong province, Shenyang City, and in Taiwan. HPV type 16 exhibits the highest 
incidence in majority of these regions except Zhejiang province, Guangzhou, Fujian 
province, and in Taiwan (3), where HPV 52 has the highest prevalence. However, an 
investigation by Jin et al. (2010) in the Tibet Autonomous Region (TAR) which included both 
Tibetan and non-Tibetan populations pointed out that the frequency of HPV 33 may be 
higher than HPV 16 for non-Tibetan people, with the order of frequency of HPV genotypes 
being 16, 58, 31, 33, and 52 for Tibetan people. Incidentally, HPV 58 is also the second most 
common HPV type found in Taiwan (2), Chengdu, Liaoning, Beijing, Shenzhen, Shenyang, 
Shanxi, and Hong Kong (Table 1). 
The three major HR-HPV types which can be deduced from Table 1 infect over 50% of 
patients in every city/region included in the list. In Taiwan (2), the TAR, Liaoning, 
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Shenzhen, and Shanxi, the order of frequency of HPV type is 16, 58 and 52, while the order 
that can be found in Shandong, Hong Kong, and Shenyan is 16, 52 and 58. Another 
combination of frequency order, namely, HPV 52, 16, and 58, has also been discovered in 
Taiwan (3), Guangzhou, and Zhejiang, whereas the order 16, 58, and 33 is inherent to 
Beijing, Shanxi, and Shenzhen (4). Both Chengdu and Shenyang (cancer cases) are 
represented by the order HPV 16, 58, and 18. Only cancer cases in Shanxi consist of the 
order 16, 58, and 56. To summarize, HPV 16, 52, and 58 are the three major types affecting 
87% of the geography that includes these selected areas. 
The relationship between geography and HPV types is demonstrated in Figure 1, with A~D 
corresponding to the distribution of HPV 16, 18, 52, and 58, respectively. Coastal areas in the 
southeast such as Taiwan and Hong Kong display a higher prevalence than inland cities. 
HPV prevalence may vary among different regions due to geographical separation, an 
example of which is Taiwan and Hong Kong. The political separation of Taiwan and Hong 
Kong most likely caused the HPV types diverse than mainland China. Moreover, the TAR is 
isolated by mountains from mainland China while Taiwan and Hong Kong are separated by 
sea. Thus, the lower number of HPV patients in the TAR compared with other regions can 
  
 
a b 
 
c d 
 
Fig. 1. The prevalence of major HPV types in some of China areas, Hong Kong and Taiwan. 
Four different HPV types show as (A) HPV16 (B) HPV18 (C) HPV52 (D) HPV58 
 
Human Papillomavirus Type Distribution in Southern China and Taiwan 
 
21 
be attributed to population conservation. In Taiwan, from 52 HPV types screening, HPV type 
52 has the highest frequency (21.48% flowing HPV type 16, 58, 56, 39, 51, 18, 68, 31, 33, 59, 45, 
and 35(3) among HR-HPV types that is distinguish HPV combination compared to other 
regions. This also demonstrates the effect of geography despite Taiwan and China essentially 
being of the same ethnicity only partitioned over 60 years to affect two generations of people 
including marriage. The more independent, younger generation and their sexual culture are 
two major factors that cause the variations in HPV types distribution. 
Since the prevalence of HPV types in each age group can be linked to sexual behavior, it is 
reasonable to investigate the multiple HPV infection types that can be found in patients (Table 
2). In Taiwan, the multiple HPV infection rate is over 19%, only slightly lower than Hong 
Kong’s (22.8%) but distinctly higher compared to others. For instance, most of the 
cities/regions that belong to mainland China, specifically inland cities like Beijng, Shangdong, 
Shanxi, Shengyang, Shenzhen, and Zhejiang, possess only 4~5% multiple HPV infection rates. 
Only Guangdong province has 11.1% between inland and island; however, Guangdong 
province is closest to Hong Kong and is more well-developed than inland cities. In contrast to 
Hong Kong and Taiwan, the TAR is isolated from immigration and might have conservative 
social behaviors, resulting to the lowest fraction of multiple HPV types (1.3%).  
Regions\ 
HPV types 
(%) 
16 18 31 33 35 39 45 51 52 56 58 59 68 References 
Beijing 2.6 0.5 0.4 0.8 0.6 0.1 0.1 0.2 0.02 0.7 1.0 0.3 0.5 (Zhao et al., 2009) 
Chengdu, 
western 
China 
(Cancer) 
68.1 4.9 ND 0.7 ND ND 0.7 ND 2.8 ND 8.3 ND ND (Li et al., 2011) 
Fujian 
province 21.3 11.6 ND 11.2 ND ND ND ND 23.1 ND ND ND ND 
(Wu et al., 
2010) 
Gansu 
Province 
(Cancer) 
80.4 3.6 1.8 1.8 ND ND ND ND 3.6 ND 3.6 3.6 ND (Wu et al., 2009) 
Guangdong 
province 
(Cancer) 
25.0 20.8 ND ND ND ND ND ND 20.8 ND ND ND ND (Lin et al., 2008b) 
Guangzhou 1.19 0.68 1.16 0.59 0.07 0.32 0.24 0.14 2.6 0.27 1.07 0.15 0.39 (Liu et al., 2011) 
Hong Kong 1.24 0.99 0 0.25 0 0.04 0.15 0 1.16 0 1.03 0.09 0.23 (Liu et al., 2011) 
Hong Kong 
(Cancer) 18.3 9.1 ND ND ND ND ND 8 18.3 ND 17.7 ND ND 
(Chan et al., 
2009a) 
Hong Kong 
(Cancer) 43.2 4.8 3.2 3.2 0.8 0.8 1.1 0.5 9.1 0 5.9 0.8 0.8 
(Chan et al., 
2009b) 
Liaoning 
province 
(Cancer) 
19.64 1.8 3.03 4.6 1.03 1.59 0.29 0.77 6.4 0.61 8.39 ND ND (Sun et al., 2010) 
Taiwan 
(Cancer) 18.4 1.7 0.3 3.6 0.6 1.5 0.6 2.9 9.4 0.6 7.6 1.5 0.6 
(Chen et al., 
2006) 
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Regions\ 
HPV types 
(%) 
16 18 31 33 35 39 45 51 52 56 58 59 68 References 
Taiwan 13.4 4.6 3.2 5.8 1.6 3.7 1.8 6.0 10.4 3.7 7.6 1.2 1.4 (Lin et al., 2008a) 
Taiwan 13.69 6.27 3.52 3.42 0.95 8.46 2.38 8.17 21.48 9.03 12.36 2.66 4.66 
(Wang et 
al., 2010) 
Tibetan 1.52 0.21 1.17 1.17 0.04 0.21 0.17 0.21 1.09 0.21 1.17 0.08 0.5 (Jin et al., 2010) 
Shandong 
Province 3.61 1.46 0.85 1.46 0.21 0.42 0.21 0.21 2.34 1.27 1.7 0 2.76 
(Yuan et al., 
2011) 
Sichuan 
province 
(Cancer) 
41.6 3.2 1.1 ND ND ND 1.1 ND 2.1 2.6 1.1 ND ND (Wu et al., 2008) 
Shanxi 
Province 5.7 0.8 0.5 1.2 ND 0.6 0.6 0.6 1.2 0.8 3.2 0.3 0.2 
(Dai et al., 
2006) 
Shenyang 
City 3.4 1 1 0.9 0.3 0.9 0.6 0.6 2.5 0.9 1.9 0.6 0.3 
(Li et al., 
2006) 
Shenzhen 
City 2.5 1.4 1.5 0.3 0.4 1.5 0.7 0.6 2 1 1.6 0.9 0.5 
(Wu et al., 
2007) 
Shenzhen 
City 
(Cancer) 
29.7 18.9 5.4 9 6.3 ND 1.8 ND 1.8 3.6 18.9 9 ND (Shi et al., 2006) 
Zhejiang 
Province 2.5 0.8 0.8 0.8 0.2 0.3 0.3 0.9 3.1 0.4 2.1 0.7 1.0 
(Ye et al., 
2010) 
Table 1. The HR-HPV types distribution in China, Hong Kong and Taiwan  
Numerous investigations focused on HR-HPV due to its higher relationship to cervical 
cancer and high-grade squamous intraepithelial lesion. To survey high-risk and low-risk 
HPV, HR-HPV frequently found in women with ASCUS and CIN3/cervical cancer, and 
might be at least double frequencies than LR-HPV cases (Table 2). The average incidence of 
HR-HPV in population is over 10%, but an extremely high incidence has been found in 
CIN3/cervical cancer cases (Taiwan reports, Table 2). However, the LR-HPV prevalence 
might not be estimated correctly due to less LR-HPV types screening. A survey of 52 HPV 
types reported in Taiwan suggests that the prevalence of LR-HPV (37 types) and HR-HPV 
(15 types) is 10% and 5%, respectively (3). Other HPV reports listed less than 37 LR-HPV 
types and focused only on HR-HPV. The same HPV screening type but few LR-HPV 
screening types caused underestimation for the incidence of LR-HPV that showed in Table 
2. For example, incidences of LR-HPV in Beijing, Hong Kong, the TAR, Shandong, Shanxi, 
Shenyang, Shenzhen, and Zhejiang are 2.0, 2.4, 2.1, 1.7, 3.8, 6.4, 6.6, and 3.5, respectively, and 
5.8, 74.8, 7.1, 11.0, 12.2, 11.7, 12.2, and 10.2 for HR-HPV.  
To compare HPV infections in different geographies around the world, the data from IARC 
and Table1 combined into Appendix 1. For overall HPV infection rate, Kenya has the 
highest HPV prevalence (38.8%) region and Span has the lowest HPV infection (1.5%). The 
Asia region including, China, Hong Kong, Japan, Korea, Taiwan and Thailand, are around 
10~15% of overall infection rate except Thailand (4.8%). The most of developed countries, 
such as, Italy, Japan, Span, Sweden, UK, and USA are less HPV prevalence than most of the 
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developing countries and under-developed countries, such as Argentina, Honduras, Kenya 
and Nigeria. For East-Asia, like, China, Japan, Hong Kong and Taiwan, HPV type 52 is 
higher HPV incidence than HPV 16. Other regions, HPV type 16 is the major incidence. HPV 
type 51 is another typical case for geographic : HPV 51 is higher incidence than HPV 52 in 
Brazil, Costa Rica, Republic of Korea, Scotland, and USA. In China and Hong Kong, HPV 51 
is not significant prevalence in population. For top five prevalence of HR-HPV, HPV 16, 18, 
31, 52, 58 are found in most of the countries/regions but different orders. However, the 
geography separated populations to cause the diverse of HPV infection types can be 
deduced from Appendix 1.  
 
Regions\HPV types (%) Multiple HPV % LR HR References 
Beijing 2.6 2.0 5.8 (Zhao et al., 2009) 
Guangdong province
(Cancer) 11.1 ND 7.4 (Lin et al., 2008) 
Hong Kong (Cancer) 22.8 2.4 74.8 (Chan et al., 2009) 
Taiwan 4.9 4.4 52.3 (Chen et al., 2006) 
Taiwan (Cancer) 19.9 70.4 29.6 (Chao et al., 2008) 
Taiwan (Cancer) 19.4 68.9 31.1 (Lai et al., 2008) 
Taiwan 4.5 10.0 5.0 (Wang et al., 2010) 
Tibetan 1.32 2.14 7.05 (Jin et al., 2010) 
Shandong Province 4.2 1.70 11.04 (Yuan et al., 2011) 
Shanxi Province 4.5 3.8 12.2 (Dai et al., 2006) 
Shenyang City 5.3 6.4 11.7 (Li et al., 2006) 
Shenzhen City 4.4 6.6 12.2 (Wu et al., 2007) 
Zhejiang Province 3.5 2.7 10.2 (Ye et al., 2010) 
Table 2. A list of Multiple HPV infection rate in individual region. 
2. Age related to HPV genotypes 
Based on our previous study of Taiwan cases, the prevalence of LR-HPV is diverse among 
different age groups. For instance, HPV 84 is found most frequently in the 20–29 age group, 
HPV 54 in the 30–39 age group, HPV 53 in the 40–49 age group, and HPV 72 in the over-50 
age group. When the range of HPV genotypes that could be identified among cases of 
multiple infections was examined, 38 HPV genotypes were found in the over-50 age group 
and 40 genotypes in the 40–49 age group. In addition, 41 HPV genotypes were identified in 
the 30–39 age group, while 42 genotypes were discovered in the 20–29 age group (3). HR-
HPV genotypes in Taiwan have the highest peak in the younger population (<20 years old, 
28.1%), subsequently decreasing as it moved from the 20-29 age group (26.7%), 30-39 age 
group (15.5%), and 40-49 (12.1%) age group, to the over-50 age group (10.4%). This pattern, 
however, is different from those found in other regions (Table 3). 
Based on the epidemiological distribution of HPV in Beijing city, the 30-34 age group has the 
highest HPV frequency, while the 25-29 and 50-54 age groups have the lowest (5). By 
contrast, according to Guangdong province cervical cancer cases, older women tended to 
have higher HPV infection rates, as evidenced by the 11.7%, 8.2%, 8.1%, and 3.4% rates 
representing the 51-60, 41-50, 31-40, and 21-30 age groups, respectively (6). For people in 
Guangzhou, a high HPV rate (15.1%) is evident in the 20-29 age group and lower HPV rates 
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(11.7% and 11.8%) can be observed in the 40-49 and over-60 age groups (7). However, there 
is no significant difference in HPV rates among age groups in Guangzhou. In Hong Kong, 
the 20-29 age group has the highest peak in both cancer report and population screening; 
however, the 40-49 age group had less HPV frequency (7, 8) which remains without clear 
explanation. In other south coast cities, namely, Shanghai and Shenzhen, the 20-29 age 
group also exhibited the highest HPV infection rate but in Shanghai only; an opposite trend 
was found in Shenzhen city, where a high infection rate manifested in older people (45-59 
age group). Two recent reports related to Shenzhen city have pointed out the discrepancy 
about HPV prevalence. One demonstrated an increased HPV infection along with elder 
people and another report mentioned the 25-29 age group is the lowest. However, Shenzhen 
city has many plants with numerous temporary residents and tertiary sector workers from 
other counties that might cause residential status being significantly associated with HPV 
positivity. 
 
Regions\Age 
Groups (%) A B C D E F G H References 
Beijing 25-294.9%
30-34
8.2%
35-39 
7.1% 
40-44
7.5%
45-49 
6.4% 
50-54
4.9%   
(Zhao et al., 
2009) 
Guangdong 
province (Cancer)
21-30
3.4%
31-40
8.1%
41-50 
8.2% 
51-60
11.7%     
(Lin et al., 
2008) 
Guangzhou 20-2915.1%
30-39
14.2%
40-49 
11.7%
50-59
14.0%
≧60 
11.8%    
(Liu et al., 
2011) 
Hong Kong 20-2913.0%
30-39
4.9%
40-49 
4.6% 
50-59
7.1%
≧60 
9.6%    
(Liu et al., 
2011) 
Hong Kong 
(Cancer) 
<26 
10.0%
26-30
14.0%
31-35 
9.5% 
36-40
6.0%
41-45 
5.6% 
46-50
7.5%
51-55
6.5%
>55 
3.5%
(Chan et al., 
2009) 
Taiwan <20 28.1%
20-29
26.7%
30-39 
15.5%
40-49
12.1%
≧50 
10.4%    
(Wang et al., 
2010) 
Tibetan 19-299.2%
30-39
9.2%
40-49 
9.1% 
≧50 
9.1%     
(Jin et al., 
2010) 
Shanxi Province 15-2413.3%
25-34
7.5%
35-44 
20.5%
45-54
17.0%
55-59 
14.3%    
(Dai et al., 
2006) 
Shanghai 18-2054.4%
21-30
26.4%
31-40 
30% 
41-50
32.0%
51-60 
31.0%
61-78
31.5%   
(Zhang et al., 
2008) 
Shenyang City <25 2.7%
25-34
11.8%
35-44 
12.5%
45-54
13.0%
55-59 
6.3%    
(Li et al., 
2006) 
Shenzhen City <25 14.3%
25-34
16.2%
35-44 
15.2%
45-59
24.4%     
(Wu et al., 
2007) 
Shenzhen City 15-2415.5%
25-29
17.7%
30-34 
12.6%
35-39
8.8%
40-44 
10.2%
45-49
15.3%
50-59
21.0%  
(Wu et al., 
2010) 
Zhejiang Province 20-2414.5%
25-29
9.3%
30-34 
8.4% 
35-39
10.7%
40-44 
10.7%
45-49
9.2%
50-54
14.4%
55-79
8.6%
(Ye et al., 
2010) 
Table 3. A list of HPV infection rates among different age groups  
Zhejiang province provided more interesting data (9) showing a similar low HPV frequency 
in each age group (Table 3). Although both the 20-24 and 50-54 age groups have slightly 
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higher rates, the highest (14.4%) and lowest (8.4%) frequencies indicated a less diverse range 
of HPV prevalence than in other cities/regions. For the north coast city of Shenyang, HPV 
infection rate initially increases with respect to age, starting from 2.7% for women <25 years 
old to 13% for women 45-54 years old, but then drops to 6.3% for the 55-59 age group. This 
pattern is unique among coastal cities and is compatible with the flat age-curves that have 
been described in other countries such as India and Africa (10). A flat age-curve indicates 
that young women are not infected with new HPV types more frequently than older women 
(11). The number of sexual partners as well as the husband’s extramarital sexual 
relationships are believed to be explanatory of this flat age-curve. For inland cities, the TAR 
has consisted of HPV prevalence around 9% in every age group. For Shanxi province, the 
35-44 age group has the highest peak of infection distribution (20.5%), followed by age 
groups 45-54 with 17.0%, 55-59 with 14.3%, 15-24 with 13.3%, and 25-34 with 7.5%. Finally, 
for Guangzhou, Hong Kong, Shenzhen, and Zhejiang, the age distribution of cervical HPV 
infection shows a bimodal curve in half of the regions, with a first peak at younger women, 
a lower prevalence plateau at middle-aged women, and a variable rebound at older ages 
(≧45 years). One explanation for this is sexual behavior, which is considered an important 
risk factor for HPV infection. On the other hand, HPV incidence associated with unmarried 
status along with a high peak of HPV infection suggests that younger, single women may 
have an increased possibility of encountering complicated sexual relationships (11). 
However, the lower prevalence plateau at middle-aged women may be caused by less 
sexual frequency and single sex partners for married Chinese women. 
3. HPV type distribution in invasive cervical cancer and high-grade 
squamous intraepithelial lesion 
Overall HPV prevalence in invasive cervical cancer (ICC) is 87%, ranging from 86% to 94% 
by region, according to literature. In Jiashan, data for the incidence of invasive cervical 
cancer (ICC) from 1998 to 2002 has been reported. Incidence rates of cervical cancer ranged 
from 2.4 per 100,000 women to 4.6 per 100,000 women in Guangzhou (12). Some areas have 
notably high cervical cancer incidence rates, such as in Yangcheng and Shanxi, where there 
is an estimated rate of about 81 per 100,000 women between 1998–2002 (12). Incidentally, the 
incidence rates for cervical cancer in Hong Kong, Singapore, and Taiwan are 9.6, 10.6, and 
18.6 per 100,000 women, respectively (13). Between these three regions, the incidence of 
cervical cancer is highest in Taiwan and is nearly double than Hong Kong’s. However, it has 
declined since 1993 to 2003.  
Tay et al. (2008) has reported the five most common HPV types in Taiwan to be, in 
decreasing frequency order: HPV 16, 18, 58, 33, and 52 for women with cervical cancer, and 
HPV 16, 52, 58, 18, and 51 for women with normal cytology (13). Due to a high HPV 
prevalence, the Taiwanese National Health Insurance launched a screening program in 1995 
for women aged 30 years old and above. This program included quality control monitoring 
and a training system for medical doctors, public health nurses, cytologists, and medical 
technicians. By 2001, the screening program has been estimated to reduce cervical cancer 
incidence by 29% and mortality by 50%, and has been shown to be cost-effective for 
Taiwanese public health (14). Upon analysis of HPV genotypes present in ICC, HPV 16 was 
found to be the most common type, rating 52% in Asia and 58% in Europe, while HPV18 
was the second most common type which rated from 13% in South/Central America to 22% 
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Table 4. Incidence of HPV infection related to ICC, HSIL and LSIL in China, Hong Kong and 
Taiwan 
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in North America (13). Other HPV types most commonly related to ICC were HPV 31, 33, 
35, 45, and 52. However, the prevalence of both HPV 58 and 52 were notably higher in ICC 
cases in Asia. For example, the prevalence of HPV 58 and 52 was found to be as important as 
the prevalence of HPV 16 and 18 in early cervical cancer patients as well as patients with 
advanced cervical cancer in Taiwan (15). As shown in Table 4, the frequency of HPV in 
HSIL, ICC, and CIN3 samples is higher than in ASCUS, LSIL, CIN1, and CIN2. 
In Beijing, 85.7% of CIN3 patients have been diagnosed with HPV infections similar to 93.3% 
of HSIL patients (Table 4). In ASCUS cases, only 56.0% involve HPV infection (5). In all of 
these cases, HPV 16 was found to be the most common type (2.6% overall; 39.1% of HPV-
positive women), followed by HPV 58 (1.0% overall) and HPV 33 (0.8% overall). For inland 
regions like Shandong and Shanxi province, CIN3/ICC patients have the highest HPV 
infection rate. HPV types 16, 52, 58, and 31 are the most prevalent HPV genotypes found in 
Shandong, whereas HPV 16, 58, 52, 33, and 18 are the predominant genotypes in Shanxi 
province (16, 17). In the TAR, HPV prevalence in HSIL cases is twice that of LSIL patients 
(Table 4). The descending order of HPV incidence among Tibetan women is HPV 16, 33, 58, 
31, 52, and 68 (18).  
For coastal areas like Fujian, Guangdong, Jiangxi, Liaoning, Shanghai, Shenzhen, and 
Taiwan, a similar prevalence of HPV types in ICC/CIN3 cases is observable (Table1 and 
Table 4). In Fujian province, HPV 16 (24.5%), HPV 33 (21.6%), and HPV 52 (19.6%) are the 
major genotypes present in CIN2/3 patients. In addition, HPV 16 (42.7%), HPV 18 (20.8%), 
and HPV 33 (12.5%) are also frequently found in squamous cell carcinoma (SCC) and 
adenocarcinoma (ADCA) (19). For Guangdong and Jiangxi, there is a significantly increased 
risk of elevating the CIN stage with high viral load. Thus, 68.8% of CIN1, 80.3% of CIN2, 
90.2%of CIN3 and 90.0% of CIS contain HR-HPV genotypes like HPV 16 (79.6%), HPV 58 
(5.92%), HPV 33 (3.29%), HPV 18 (1.97%), HPV 6 (1.97%), HPV 31 (1.31%), HPV 39 (1.31%), 
and HPV 68 (1.31%) (20). In Liaoning province, the most common HPV genotypes are HPV 
16, HPV 58, HPV 52, HPV 33, HPV 53, and HPV 31, occurring in 54.6% of ASCUS patients, 
64.1% of CIN, and 83.1% of ICC (21). For the island of Taiwan, the HPV prevalence for 
ASCUS, LSIL, HSIL, and squamous cell carcinoma are 41.2%, 76.9%, 87.5%, and 66.7%, 
respectively. The five high-incidence HPV genotypes are HPV 52, 18, 58, 53, and 70 in 
Taiwanese CIN2 patients (22). For Shanghai city, HPV viral load values in women with 
CINs and cervical cancer were calculated to be 68.8% in CIN1, 66.7% in CIN2, 76.5% in 
CIN3, and 94.1% in cervical cancer (23). For Shenzhen city, the incidence of HR-HPV 
genotypes increased with increasing severity of cervical lesions, such as 50.0% of CIN1, and 
74.0% of CIN2 /CIN3. However, the most common types were HPV52, 16, and 18 in CIN 
samples that are different with population screening which the most common genotypes are 
HPV 16, 52, 58, 31 and 39 (24).  
4. HPV vaccination in Southern China, Hong Kong, and Taiwan 
Based on statistical calculations to determine the link between HPV and cervical cancer, many 
strategies for the prevention of cervical cancer have been proposed, including vaccination in 
younger women and improved HPV screening in older women (25). Two HPV vaccines have 
been generated from the recombinant L1 protein into non-infectious capsids (virus-like 
particles, VLPs). Gardasil™ (Merck and Co, USA) already has approval for vaccination against 
HPV6/11/16/18 in several countries including Singapore and Hong Kong. The bivalent 
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vaccine, Cervarix™ (GlaxoSmithKline, Belgium), has also been approved in both countries. 
Both vaccines were developed for HPV16 and HPV18, which cause approximately 70% of all 
reported cervical cancer cases worldwide (26). Thus, the quadrivalent vaccine can be expected 
to prevent CIN-2 and CIN-3 (CIN-2,3), cervical cancer, as well as genital warts. However, HPV 
18 is less common than HPV 52 and 58 in places like China, Hong Kong, and Taiwan (Table 1) 
where there is no publicly funded vaccination program. Hence vaccination is voluntary and 
paid by individuals.  
HPV vaccination does not increase the clearance of established infections; therefore, young 
females are ideally targeted before the development of sexual behavior. Initiation of HPV 
vaccination in younger cohorts combined with HPV screening in older women is a good 
strategy for HPV prevention. In China and Taiwan, evaluation of HPV vaccination as 
primary care HPV and assessment of the threshold cost per vaccinated girl (CVG) became 
potential feasible strategies in public health. Singapore’s policy regarding the management 
of HPV can be a reference for China and Taiwan. In a cervical cancer awareness survey for 
Singaporean women aged 30-55 years in 2006, 80% have had at least one Pap smear 
although 25% did not fully understand the significance behind it (13). Furthermore, 80% 
were unaware of HPV. In Hong Kong, most women have never heard of HPV or its 
infection by sexual transmission (27). Thus, participants had no knowledge or means of 
understanding the link between cervical cancer and HPV infection. However, participants 
agreed to HPV vaccination for both themselves and their teenage daughters if a health 
department endorsement was provided. Another study demonstrated that 32% of 
participants accepted HPV vaccination prior to receiving an educational booklet, and that 
this number increased to 52% after reading the pamphlet (28). About 48% of women 
remained undecided or disagreed with vaccination after education; 84% were worried about 
the side effects of vaccination, and 63% of women augmented fear of earlier sexual activity 
and unsafe sex. In China, a population-based survey related to knowledge concerning HPV 
vaccination reported that 15.8% of women between the ages of 15–54 have never heard of 
HPV, of which 49% bewared that HPV was related to cervical cancer. Around 87% of 
women agreed to be vaccinated with the prophylactic HPV vaccine and, in addition, 88% of 
women expressed that they would like to have their daughters vaccinated (29). In rural 
Shanxi, 67% of surveyed women did not believe that they were at risk of HPV infection and 
cervical cancer, while 65% of women thought there would be no difference whether or not 
they were vaccinated. However, 98% of the surveyed women preferred to receive 
information about the HPV vaccine from doctors, nurses, and hospital staff rather than from 
family members or friends.  
To improve the coverage of vaccination programs, a low vaccine price is one important issue 
to consider, and 83% of the women hoped that health insurance or the government can 
cover all or part of vaccine-related costs (30). When asked about the vaccine cost, 42% of 
women said they are willing to pay USD 2.50 or less and 50% agreed to pay USD 2.50–14.00, 
while only 8% can afford to pay more than USD 15.00 (31). However, according to 
investigation conducted by Canfell et al. (2011), vaccination combined with once- or twice-
in-a-lifetime screening is sufficiently cost-effective with a CVG of USD 52. But the maximum 
vaccine unit cost per dose is USD 9.00-14.00 that is also implied by maximum CVG of $50–
54. Therefore, HPV vaccination is potentially feasible for Chinese women at a reasonable 
price. However, in order to sustain a wide vaccine coverage, vaccine price would be one of 
the largest barriers for promotion (31).  
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In terms of HPV vaccine safety, data from pharmaceutical companies responsible for 
bivalent and quadrivalent vaccines suggest that some patients could be expected to 
experience mild, transient vaccine-related side effects upon receiving the HPV vaccine (32, 
33). From reports, pain is the most frequently reported adverse effect, with a prevalence 
ranging from 83% to 93% in tested vaccine group (34). With the exception of pain, no 
differences in serious vaccine-related events were prominent between vaccine and placebo 
groups. Data regarding the long-term safety of these vaccines are not yet available. HPV 
vaccination tests also did not include pregnant women. Although incidence of spontaneous 
abortion occurred in 10% of the vaccine group, it also occured in 7% of the placebo group, 
hence there is no significant difference between the two groups (35). Similarly, results from 
the quadrivalent vaccine Phase III studies indicated no observable differences in relation to 
the incidence of spontaneous abortions, late fetal death, or congenital abnormal infants 
between both groups. Even women who became pregnant more than 30 days after vaccine 
administration did not contribute any statistical difference whatsoever (35). 
Currently, available vaccines contain HPV 16 and 18; however, HPV types 52 and 58 are 
more prevalent in Southeast Asia, especially in Hong Kong and Taiwan. Although, HPV16 
and 18 are major genotypes found in CIN3 and cervical cancer patients, HPV types 52 and 
58 also have high prevalence rate in cancer cases. For example, HPV types 52 and 58 have 
25% and 12.5% infection rate in Taiwan (15),  As shown in Table 1, the prevalence of HPV 52 
and HPV 58 in Chengdu, Fujian, Gansu, Guangzhou, Hong Kong, Liaoning, Taiwan, 
Shandong, Shanxi, Shenyang, Shenzhen, and Zhejiang is higher than HPV 18, 6, and 11. This 
indicates that bivalent and quadrivalent vaccines are only capable of covering a small part of 
prospective patients infected with HPV. The emerging question then is, Should women pay for 
HPV vaccines without understanding their HPV infection types or not? It is safe to say at the 
present time that a vaccination program, combined with HPV Pap smear screening, is 
necessary to avoid useless vaccine treatment. The prevalence of HPV 52 and HPV 58 is 
nearly equal to the frequency of HPV 16 in China, Hong Kong, and Taiwan whether in 
cervical cancer-related or population-based surveys (Table 1). Moreover, a 1997–2007 report 
in Hong Kong showed that aside from 68.0% of all histological groups combined, 62.6% of 
squamous cell carcinoma and 93.8% of adenocarcinoma and adenosquamous cell carcinoma 
were covered by HPV 16 and HPV 18. Hence if vaccines included HPV 52 and HPV 58, it 
could increase the coverage by 15.9% for cervical cancers overall, 18.4% for squamous cell 
carcinoma, and 4.1% for adenocarcinoma and adenosquamous cell carcinoma (8). To 
summarize, pharmaceutical companies should make an effort to include more high 
prevalence HPV types in the next generation of vaccines they develop.  
The limitations of vaccine programs must also be recognized, because HPV 16 and 18 
account for approximately 70% of all invasive cervical cancers in nine countries (36), 
excluding Chinese people. Thus, women should be advised that the HPV vaccine does not 
confer full protection against cervical cancer. To reduce the risk of HPV infection and 
cervical cancer, safe sexual practices, which include the use of condoms and routine Pap 
smear testing, are necessary. Another important issue is the HPV genotypes screening. 
There are over 100 different HPV types, but only 13 HR-HPVs were routine in Pap smear 
screening. In our previous data, 52 HPV genotypes were adopted to screen 10,543 cases, of 
which 1,021 involve HR-HPVs and 556 involve non-HR-HPVs. Our investigation supported 
more HPV genotypes prevalence than other literatures. Majority of existing reports focus on 
HR-HPV due to a high risk of cervical cancer associated with it. However, other LR-HPV 
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types may be valuable, especially when indicating the risk in women’s sexual behavior 
which could bring about a high chance of incurring HR-HPV infection in the future. Any 
HR-HPV/LR-HPV infection is worth to notice the cervical cancer possibility in women even 
HR-HPV is significant in ICC/CIN3 samples. Although there are little evidences to prove 
the relationship between LR-HPV and cervical cancer, we would like to point out the 
importance of LR-HPV screening, which could be useful to get rid of HPV attack, if the cost 
is reasonable for both HR-HPV and LR-HPV tests. 
5. Conclusion  
HPV 16, 52, and 58 are the most predominant types of HPV in China, Hong Kong, and 
Taiwan. HPV 18, on the other hand, may have lower prevalence than types 39, 51, and 56 in 
some regions, such as Taiwan. Single/multiple HPV infection types do not distinguish 
between different age groups. The incidence of HPV types reflect women’s sexual behavior 
in different ages. However, HPV 16 is clearly the most common type of HPV in the world. 
Because HPV 16, 52, and 58 are more common than HPV 18 in China, Hong Kong, and 
Taiwan, the protective effect of an HPV16/18 vaccine against HR-HPV infection in these 
regions should be a major consideration because both subtypes are not powerful enough to 
reduce the prevalence of cervical cancer. Geographic variation with regard to distribution of 
HPV genotypes should also be an important consideration, especially in the tailoring of 
vaccines in different regions. The prevalence of HPV genotypes may be caused by the 
complex interplay among different HPV genotypes, safety of sexual practices, and host 
immunogenetic factors.  
6. Appendix: The HPV prevalence around the world 
Area OverallHPV (%)
HPV Genotypes (%) 
Reference 
6 11 16 18 31 33 35 39 45 51 52 56 58 59 68 73 82 
Argentina 16.7 0.1 0.3 4.0 1.9 1.8 1.4 1.9 1.0 1.1 0.4 1.2 0.9 1.3 0.8 0.8 0.2 0.1 (Matos et al., 2003) 
Brazil 13.8 0.5 0.5 2.7 0.8 1.1 0.4 0.2 0.1 0.5 0.7 0.6 0.6 2.1 0.1 0.4 0.2 0.1 (Franco et al., 1999) 
Chile 11.2 0.2 0.4 2.2 0.4 0.5 0.1 0.3 0.7 0.7 0.7 0.8 1.3 1.0 0.9 0.0 0.2 0.0 (Ferreccio et al., 2004) 
China 
(Beijing) 7.9 ND ND 2.6 0.5 0.4 0.8 0.6 0.1 0.1 0.2 0.0 0.7 1.0 0.3 0.5 0.1 ND 
(Zhao et al., 
2009) 
China 
(Guangzho) 8.9 ND ND 1.2 0.7 1.2 0.6 0.1 0.3 0.2 0.1 2.6 0.3 1.1 0.2 0.4 ND ND 
(Liu et al., 
2011) 
China (HK) 5.2 ND ND 1.2 1.0 0.0 0.3 0.0 0.1 0.2 0.0 1.2 0.0 1.0 0.1 0.2 ND ND (Liu et al., 2011) 
China 
(Shandong) 16.5 ND ND 3.6 1.5 0.9 1.5 0.2 0.4 0.2 0.2 2.3 1.3 1.7 0.0 2.8 ND ND 
(Yuan et al., 
2011) 
China 
(Shanxi) 15.9 ND ND 5.7 0.8 0.5 1.2 ND 0.6 0.6 0.6 1.2 0.8 3.2 0.3 0.2 ND 0.2 
(Dai et al., 
2006) 
China 
(Shenyang) 14.8 ND ND 3.4 1.0 1.0 0.9 0.3 0.9 0.6 0.6 2.5 0.9 1.9 0.6 0.3 ND 0.2 
(Li et al., 
2006) 
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China 
(Shenzhen) 15.2 ND ND 2.5 1.4 1.5 0.3 0.4 1.5 0.7 0.6 2.0 1.0 1.6 0.9 0.5 0.1 0.2 
(Wu et al., 
2007) 
China 
(Zhejiang) 13.9 ND ND 2.5 0.8 0.8 0.8 0.2 0.3 0.3 0.9 3.1 0.4 2.1 0.7 1.0 0.0 ND 
(Ye et al., 
2010) 
China 
(Tibetan) 7.8 ND ND 1.5 0.2 1.2 1.2 0.0 0.2 0.2 0.2 1.1 0.2 1.2 0.1 0.5 ND ND 
(Jin et al., 
2010) 
Costa Rica 22.4 0.4 0.2 2.2 1.1 1.1 0.5 0.2 0.4 0.5 1.5 1.1 0.5 1.3 0.3 0.2 0.3 0.3 (Herrero et al., 2005) 
Ho Chi Minh. 10.9 0.0 0.0 3.3 1.2 0.8 1.1 0.3 0.9 0.7 0.8 1.1 1.1 1.5 0.0 0.7 0.1 0.0 (Ahn et al., 2003) 
Honduras 39.0 0.2 1.8 10.9 4.1 3.4 0.7 0.2 0.0 0.0 0.0 0.2 0.0 1.8 0.0 0.0 0.0 0.0 (Ferrera et al., 1999) 
Italy 7.8 0.1 0.2 2.7 0.1 0.3 0.1 0.1 0.3 0.6 0.1 0.3 0.4 0.4 0.1 0.2 0.0 0.0 (Ronco et al., 2005) 
Japan 10.2 0.1 0.0 0.5 0.2 0.3 0.4 0.8 0.1 0.0 0.9 1.2 0.6 0.2 0.2 0.5 0.0 0.0 (Asato et al., 2004) 
Kenya 38.8 0.5 0.5 3.5 2.2 3.3 1.9 2.7 1.4 1.6 1.1 6.2 1.4 2.7 0.3 1.6 ND ND (De Vuyst et al., 2003) 
Mexico 13.5 0.5 1.0 1.8 1.1 1.5 1.0 0.3 1.0 0.6 0.8 0.8 0.3 1.0 0.2 0.3 0.1 0.3 
(Lazcano-
Ponce et al. 
2001) 
Nigeria 24.8 0.4 0.4 3.0 1.7 2.6 0.6 3.0 0.4 2.1 1.1 1.5 2.1 2.5 0.6 0.2 0.5 0.4 (Thomas et al., 2004) 
Republic of 
Korea 15.2 0.7 0.3 1.3 1.2 0.7 0.4 0.3 0.9 0.1 1.8 1.3 1.5 0.7 0.4 0.5 0.5 0.0 
(Shin et al., 
2004) 
Scotland 12.7 ND ND 3.4 1.4 0.7 0.5 0.3 0.4 0.9 0.9 0.8 0.6 0.7 0.7 0.2 0.8 0.1 (Cuschieri et al., 2004) 
Senegal 12.5 0.2 0.0 1.0 0.9 0.4 0.7 0.0 0.1 0.2 0.3 0.5 0.3 0.7 0.4 0.1 0.3 0.1 (Xi et al., 2003) 
South India 14.0 0.2 0.0 2.8 0.8 0.8 0.8 0.8 0.6 0.3 0.4 0.7 1.1 0.2 0.7 0.0 0.2 0.2 (Franceschi et al., 2005) 
Spain Hanoi, 
Vietnam 1.5 0.1 0.0 1.0 0.0 0.4 0.0 0.5 0.1 0.0 0.4 0.0 0.2 0.1 0.2 0.2 0.0 0.0 
(de Sanjose 
et al., 2003) 
Sweden 6.8 ND ND 2.1 0.6 1.1 0.4 0.3 0.2 0.8. 0.4 0.3 0.5 0.3 0.1 ND ND ND (Forslund et al., 2002) 
Taiwan 15.0 0.5 0.1 1.4 0.6 0.3 0.3 0.1 0.8 0.2 0.8 2.1 0.9 1.2 0.3 0.1 0.2 1.6 (Wang et al., 2010) 
Thailand 4.8 0.0 0.0 0.7 0.3 0.3 0.5 0.2 0.3 0.1 0.2 0.3 0.2 0.4 0.1 0.2 0.0 0.0 (Sukvirach et al., 2003) 
UK 3.5 ND ND 1.3 0.7 0.9 0.7 ND ND ND ND ND ND ND ND ND ND ND (Cuzick et al., 1995) 
USA 15.8 0.6 0.6 2.5 0.8 0.9 0.6 0.3 0.7 0.9 1.8 0.8 0.5 0.9 0.7 0.2 0.0 0.0 (Liaw et al., 1999) 
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1. Introduction 
Infection by certain types of Human Papillomavirus (HPV) is closely related to the 
corresponding risk of cervical cancer (Trottier and Franco, 2006). Cervical cancer represents 
the third most common malignancy in women, and the seventh overall, with an estimate 
529.000 new cases in 2008 (Ferlay et al., 2010). More than 85% of the global burden occurs in 
developing countries, where it accounts for 13% of all female cancer (Ferlay et al., 2010).  
HPV subtypes have been associated with the development of cervical, vulvar, anal, penile 
and oropharyngeal cancer in 2002 (Parkin, 2006), representing 5.2% of all cancers 
worldwide. It has also been estimated, on basis of cross-sectional observations (Clifford et 
al., 2005, de Sanjose et al., 2007) that approximately 10% of women worldwide with normal 
cytological findings carry a detectable cervical HPV infection. Therefore, HPV can be 
considered as the most common known sexually transmitted agent worldwide (de Sanjose 
et al., 2007).  
HPV vaccines hold great promise to reduce the global burden of HPV infection as well as 
cervical cancer development. In June 2006, the quadrivalent HPV vaccine types 6, 11, 16, 
and 18 (GARDASILTM, manufactured by Merck and Co., Inc., Whitehouse Station, New 
Jersey) was licensed for use among females aged 9-26 years for prevention of vaccine 
HPV-type-related cervical cancer (Markowitz et al., 2007). On October 2009, the Food and 
Drug Administration (FDA) licensed bivalent HPV vaccine (Cervarix, GlaxoSmithKline) 
for use in females aged 10 through 25 years. Cervarix is the second HPV vaccine licensed 
for use in females in the United States (F.D.A., 2010). Both vaccines might provide 
protection against some other HPV-related cancers in addition to cervical cancer, 
although there are currently only data sufficient to recommend GardasilTM for protection 
against vulvar and vaginal cancers and precancers. GardsilTM is also recommended for 
prevention of genital warts. 
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The well established knowledge for HPV type distribution worldwide is a key feature for 
the rational design of future vaccination, that would include a broadest spectrum, and for 
the development of new HPV screening tests (Clifford et al., 2005). To contribute for this 
effort, we hereby present a worldwide description of HPV type distribution in women 
without cervical abnormalities. 
2. Population data 
To describe HPV type distribution, the geographical definition of the regions was based on 
Globocan, a project of the International Agency for Research on Cancer, that presents 
incidence, prevalence and mortality estimates of 27 major cancer for all countries in the 
world (Ferlay et al., 2010). The geographical areas include four regions in Africa (Northern, 
Southern, Eastern and Western), three regions in the Americas (central, south and northern), 
four regions in Europe (Northern, Southern, Eastern and Western), and four regions in Asia 
(Eastern, Southeastern, Southern and Western). 
3. Worldwide HPV type distribution in women with normal cytology 
3.1 Africa 
Africa has a population of 274.49 millions women ages 15 years and older who are at risk 
of developing cervical cancer (WHO/ICO, 2007a). Current estimates indicate that every 
year 80419 women are diagnosed with cervical cancer and 53334 die from the disease 
(WHO/ICO, 2007a). Cervical cancer ranks as the second most frequent cancer among 
women between 15 and 44 years of age (WHO/ICO, 2007a). The prevalence of HPV is 
higher in African women with normal cytology than in women from other world regions 
and about 24.9% of women in the general population are estimated to harbor cervical 
HPV infection at a given time. Furthermore, HPV16 infections are found most commonly 
than infections caused by other HR types in regions of the world apart from Sub-Saharan 
Africa, where infections by other oncogenic HPV types, most significantly, HPV35, may 
dominate.  
3.1.1 Northern Africa 
In the Northern Africa, there are available studies from Tunisia, Morocco, Egypt and Algeria 
that describe the HPV distribution in women with normal cytological findings. 
Tunisia has a population of 3.68 millions women and every year, 314 of them are diagnosed 
with cervical cancer, the third most common cancer in female, and 148 die from the disease 
(WHO/ICO, 2007a). About 14.6% of women in the general population are estimated to 
harbor cervical HPV infection at a given time (WHO/ICO, 2007a). A pilot study was carried 
out in 2006 by De Marco et al to identify the HPV prevalence in the country (De Marco et al., 
2006). HPV prevalence among healthy women was 45% and HPV16 and HPV58 were the 
most common high risk (HR) types with a prevalence rate of 38% and 27% respectively 
(Table 1). HPV82 ranked third with 15% prevalence and types 31, 33 and 35 had 4% 
prevalence while there were no cases of HPV18. HPV72 and HPV83 were the only low risk 
(LR) types with 4% each. Overall prevalence appear to be within the expected range and 
well in agreement with the 39% already reported in Hassen et al cohort (Hassen et al., 2003). 
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In Morocco, statistical data showed that cervical cancer represents a serious health problem, 
with 500 new cases annually registered in the National Institute of Oncology, Rabat (Amrani 
et al., 2003). A study conducted by Alhamany et al determined the prevalence of the most 
oncogenic HPV in the Moroccan population (Alhamany et al., 2010). The cervix samples 
were collected from healthy women between 17 and 80 years of age. HPV DNA 
detection/typing was acquired by PCR with MY09/MY11 primers with specific probes for 
HPV16, 18, 31, 33, 35 and 45.  HPV DNA was identified in 15.9% of women: 13.7% had 
HPV16, 8.9%had HPV18, 3.2% cases had HPV31, 0.8% had HPV33, 2.4% case had HPV35, 
1.6% of HPV45 and 69.4% had an unknown HPV type infection (Table 1). The HPV 
prevalence in Moroccan women was in concordance with the overall world distribution of 
HPV in asymptomatic women. HPV16 was the predominant infectious type and, once again 
in concordance with the worldwide tendency (Figure 1).  
A population-based study identified the HPV type distribution and prevalence in Algerian 
women (Hammouda et al., 2011), where cervical cancer is the second most common cancer. 
From the 11.51 millions women at risk of developing the disease, 1398 will be diagnosed per 
year and 797 will die (WHO/ICO, 2007a). HPV prevalence among women with normal 
cytology was 5.3% with 33 single infections and 6 multiple infections (Table 1). Prevalence of 
HR and LR types was 2.9% and 2.7% respectively, and HPV31 was the most common type 
(1.1%) followed by HPV16 (0.5%). Regarding LR types, HPV6 and HPV66 were the most 
common – 0.5%. This study is the first population-based HPV survey carried out in 
Northern Africa, and revealed a rather low burden of HPV infection. In addition, the 
prevalence of HR HPV in Algeria can be directly compared with women attending cervical 
screening in Europe and Canada (Figure 1).  
3.1.2 Southern Africa (Sub-Saharan Africa) 
In South Africa, despite the high prevalence of cervical cancer, few studies have been 
performed to describe the HPV type distribution in the country. A study enrolling 848 
women with normal cytological findings was reported by Allan et al in 2008. The median 
age of the women was 44 years, ranging from 21 to 59 years.  The specimens were HPV 
typed by a reverse line blot assay (Roche). The most prevalent types were LR HPV83 (2.6%), 
followed by HR HPV53 (2.2%) and HPV16 (2.0%). The prevalence of HPV16 and HPV18 was 
3.3% while the HPV prevalence (20.4%) was high when compared with that reported in 
studies of populations elsewhere in the world (Table 1, Figure 1). 
3.1.3 Eastern Africa (Sub-Saharan Africa) 
A study carried out during the second phase of a cervical cancer screening project in 
Zimbabwe analyzed 1579 women classified as normal cytology (Womack et al., 2000). 35% 
of women had an HPV infection detected by HCII. Fukuchi et al performed serial HPV 
testing in a cohort of human immunodeficiency virus (HIV)-negative women to assess the 
HPV incidence and prevalence (Fukuchi et al., 2009). Testing was performed using 
MY09/MY11 consensus HPV L1 primers and specimens that tested positive were further 
studied to determine the specific HPV type. HPV prevalence at enrollment was based on a 
total of 1987 healthy women. The overall HPV prevalence was 24.5% and the HR HPV 
infection rate corresponded to 16.1% (Table 1). 
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Fig. 1.  HPV prevalence in women without cervical cancer 
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Among the prevalent infections, HPV58 was the most common HR type with 5% of women 
testing positive, followed by HPV16 and HPV18 with 4.7% and 2.3%, respectively. HPV70 
was the most common LR type with 2,4%. HPV6 and HPV11 were rare in this cohort with 
0,7% and 0,2% of women testing positive, respectively. The most common HPV types found 
in multiple infections were HPV types 58, 16, 70, 18, 53 and 33. The frequency of HPV58 is 
relatively high when compared with North America and Europe and it is associated with 
3.3% of cervical cancer globally and 1.5% of cancer in Africa (WHO/ICO, 2007b). 
In Mozambique, Castellsagué et al evaluated the HPV distribution in 196 women with 
normal Papanicolaou (Pap) smears. They used PGMY09/PGMY11 primer system in a 
reverse line-blot strip-based assay (Castellsague et al., 2001). The overall HPV DNA 
prevalence was 32%. In addition to the high prevalence of HPV infections, the most 
striking features in the epidemiology of HPV infection in this population were the high 
frequency of multiple simultaneous infections and the unexpected singularity of the type-
specific HPV distribution. In 2008 Castellsagué et al reported a second study on HPV 
genotypes distribution in Mozambique. They collected cervical samples from 195 women 
without cervical abnormalities and tested them for HPV genotyping by SPF10-LIPA25 PCR 
system (Castellsague et al., 2008). HPV prevalence was 75.9%, the highest reported in the 
present work (Table 1, Figure 1). In descending order of frequency, the most frequent 
types were: HPV51 (23.6%), HPV35 (19.6%), HPV18 (14.2%), HPV31 (13.5%) and HPV52 
(12.8%). 
In Kenya, there are 10.32 million women in the general population, 2454 will be diagnosed 
with cervical cancer and 1676 will die from the disease (WHO/ICO, 2007a). In 1992, HPV 
prevalence was 19.5% among women with normal cytology (Czegledy et al., 1992). HPV16 
was the most common type, followed by HPV18. To improve the epidemiological 
knowledge in Kenya, another HPV prevalence survey was developed in 2010 (De Vuyst et 
al., 2010). Among 454 women with normal cytological findings, 40.3% had a HPV DNA 
positive result (Table 1). The most common types were HPV58 with 9.9% prevalence, 
followed by HPV16 (7.5%) and HPV53 (6.6%). This study shows a high prevalence of HPV, 
similar to that found in other Sub-Saharan African populations. Not surprisingly for sub-
Saharan Africa, half of HPV-positive women were infected with multiple types (Figure 1). 
3.1.4 Western Africa (Sub-Saharan Africa) 
Nigeria is the most populous country in Sub-Saharan Africa, with approximately 117 million 
inhabitants and an incidence of cervical cancer in Ibadan (1998-1999) of 19.9 per 100 000 
(Cancer, 2003). To investigate the prevalence of cervical infection with HPV in the country, 
women with a sexually active life were tested (Thomas et al., 2004). HPV positivity was 
assessed by general primer-mediated GP5+/6+ PCR and by hybridization with an enzyme 
immunoassay (EIA). Among 844 women with normal cytology findings, the HPV 
prevalence was 24.8% with 18.3% of HR infections and 6.5% of LR infections (Table 1). The 
most commonly found HPV types, in either single or multiple infections, were HPV42 
(4,4%), HPV16 and HPV35 (3%), HPV81 (2.7%), and HPV31 (2.6%). Other study on HPV 
infection in women without cervical cancer in Nigeria evaluated 844 women with normal 
cervical findings (Okolo et al., 2010). About 26.3% women were HPV positive. The 
prevalence of HPV16 and HPV35 were equally frequent (12.2%) followed by HPV 31 (11%). 
Human Papillomavirus and Related Diseases 
 – From Bench to Bedside – Research Aspects 44
Low risk and multiple HPV infections were also common with 44.9% and 27.8% 
respectively. The prevalence of HPV of 24.8% to 26.3% found in Nigeria studies is consistent 
with previous reports of the elevated prevalence of HPV in women of Sub-Saharan Africa.  
To investigate HPV infection in Guinea, 831 healthy women aged 18-64 years from the 
general population were investigated (Keita et al., 2009). The overall presence of HPV DNA 
was determined by performing a general primer GP5+/6+ mediated PCR and HPV 
positivity was assessed by hybridization of PCR products in an EIA.  HPV prevalence was 
47.9% (Table 1). Prevalence of HR and LR types (29.3%, 29.1%, respectively) was similar. The 
commonest HR HPV types were HPV16 (6.7%), HPV45 (4.7%), HPV52 (4.0%), and HPV18, 
HPV35 and HPV58 (3.2% each). HPV66, HPV42 and HPV81 were the most commonly 
detected LR types. Totally, 29% of women had single type infection and 37.9% had multiple 
type infections.  
In Senegal, Xi et al (2003) conducted a study among previously unscreened women to 
determine the prevalence of specific HPV types. HPV detection and typing analyses were 
carried out using a PCR-based reverse-line blot strip test (Xi et al., 2003). HPV DNA was 
detected in 13% women with normal cytology results, where 6.2% had a single type 
infection and 1.2% had a multiple type infection (Table 1). The most commonly detected 
types were HPV16 (1.0%), HPV54 (1.0%) and HPV18 (0.9%). 
In a case-control study in the Cote d’Ivoire, the relationship between HIV infection and 
invasive cervical cancer was tested in 120 women with normal cytology. HPV DNA was 
detected by means of L1 consensus PCR assay (PGMY09/PGMY11 primer system), followed 
by typing in the Roche linear probe assay (Adjorlolo-Johnson et al., 2010). The prevalence of 
HPV infection was 31.1% and the most common types were HPV16, HPV18, HPV45, HPV35 
and HPV31 (Table 1).  
3.2 America 
America has 336 millions of women older than 15 years which are at risk of developing 
cervical cancer (WHO/ICO, 2010a). Annually, 81000  of cervical cancer cases were 
diagnosed and 36000 of women died with the disease (WHO/ICO, 2010a). Cervical cancer 
ranks as the fourth most frequent cancer in women in America and the second most 
frequent among women between 15 and 44 years of age. 
3.2.1 South and Central America 
Latin America continues to be an important burden of cervical cancer (Murillo et al., 2008). 
South and Central America, along with Sub-Saharan Africa and Southeast Asia, exhibited 
some of the highest incidence rates worldwide (Gage et al., 2003). The incidence of cervical 
cancer is highest among poor women with few years of schooling, who tend to be diagnosed 
at advanced stages of the disease (Murillo et al., 2008). Even when these women are 
screened or diagnosed, less than one fourth of them receive adequate follow-up and care 
(Gage et al., 2003). Numerous countries in the region have attempted to implement 
cytology-based screening programs but without success, even in countries where cytology 
has been available for many years and where organized health care systems exist. While the 
lack of impact is frequently attributed to problems associated with program performance, 
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new screening technology and prophylactic HPV vaccines emerge as promising alternatives 
for cervical cancer control (Murillo et al., 2008). Nevertheless, to ensure success of these 
technological advances, public health programs will still need to be organized and 
structured to maximize the benefits that could be obtained with the adoption and 
implementation of novel methods to control cervical cancer (Murillo et al., 2008). Latin 
America has a high HPV prevalence among women with normal cytology (Table 1) but the 
incidence of this disease varies between rich and poor countries, even between regions 
within a country (Figure 1). Age–specific prevalence ranges from 30% among women 
younger than 25 to 11% among women aged 45-54 (Figure 2).  It is very high among teen-
agers and then it slowly declined until 45-54 years of age to increase again significantly 
among women more than 55 years (20%). HPV16 was the most prevalent type among 
women with normal cervical histology but other common HPV genotypes are HPV18, 
HPV52, HPV31, and HPV6.  
In Mexico cervical cancer is the most common cancer among women and its incidence rate is 
the highest world-wide. Mexico has a population of 37.45 million women aged 15 years and 
older who are at risk of developing cervical cancer (WHO/ICO, 2010k). Annually 10000 
women are diagnosed with cervical cancer and 5000 die from the disease (WHO/ICO, 
2010k). In countries like Mexico, cervical cancer early detection programs have had a 
minimal impact on the incidence and death rates (Lazcano-Ponce et al., 1999, Lazcano-Ponce 
et al., 2003, Ogedegbe et al., 2005). In addition, in poor regions, Pap smears have generally 
proven to be ineffective (Chu et al., 2007), frequently due to inadequate sampling of the 
specimen (Raab et al., 2008), poor fixation, and lack of competencies (Tworek et al., 2007). 
The consequence is a very high number of false-negative results (DeMay, 1996). The HPV 
prevalence among women with normal cervical cytology in Mexico was 14.5% (Table 1). As 
in Chile, Columbia, and Costa Rica, the age standardized–HPV prevalence among healthy 
women follows a bimodal distribution. HPV DNA was detected in 16.7% among women 
less than 25 years, with the prevalence declining rapidly to 3.7% between 45 and 54 years 
(12.3%), and increasing again to a maximum of 23% among women with 65 years of age. The 
HR HPV types were predominant in the first peak while LR HPV types were more frequent 
among women over 65 years of age. The most common genotype was HPV16, followed by 
HPV53 and HPV31.  
Cervical cancer and breast cancer are leading causes of cancer-related morbidity and 
mortality in Costa Rica. In a population where every year 1.5 million of teenagers are at risk 
for cervical cancer, 403000 cervical cancer cases were diagnosed and 158000 women older 
than 15 years died with the disease (WHO/ICO, 2010h). HPV prevalence among women 
with normal cervical histology was high (22.4) (Table 1). Infection with a single type 
occurred in 16.6%, and 5.8% of women were infected with at least two HPV genotypes. The 
LR HPV types were predominant compared with HR HPV types, infecting 12.5 and 9.9% of 
women, respectively. HPV71 was the most frequent genotype. The prevalence of type 
HPV16 was relatively low, while the HR HPV58, HPV51, and HPV52 were relatively 
frequent. This finding placed Costa Rica close to African and Asian countries, where the 
HPV58 and HPV52 were the most frequent. As in the areas of Latin America where a high 
HPV prevalence was detected, the age-specific prevalence followed a bimodal distribution 
with the highest peaks at the extremes of ages. HR HPV genotypes were more common in 
women younger than 25 years old, with a decrease in prevalence in the intermediate age 
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group, and a minor peak in the older women. On the contrary, LR HPV genotypes showed 
an initial peak in prevalence among young women, a decreasing in the middle age group of 
women, and a highest peak among women over 60 years.  
 
Fig. 2. HPV age-specific distribution in women without cervical cancer 
In Brazil cervical cancer incidence remains among the highest in Latin America. North 
and Northeast regions have a higher mortality than Eastern and Southern states. 
Annually, 20000 cervical cancer cases were diagnosed and 8000 of Brazilian women in the 
general population died with the disease (WHO/ICO, 2010d). Cervical cancer is the 
second most frequent cancer in women in Brazil. Approximately 70 millions of women 
older than 15 years are at risk of developing cervical cancer (WHO/ICO, 2010d). The 
prevalence of HPV infection among women with normal cervical cytology was 21.1% 
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(Table 1). It was close to Canada and USA with 25.4% and 25.6%, respectively (Roteli-
Martins et al., 2011). A decline in the HPV prevalence was found with increasing age. The 
most frequent HPV genotypes among healthy women were HPV16 and HPV72. The 
prevalence of HR types (16 ,18, 31, 33) was 5.3%, while the prevalence of LR types (72, 54, 
6) was 10 fold lower (0.5%). The prevalence of HPV infection was linked to sexual 
behavior. HPV DNA increased with increasing number of regular partners. Women with 
two or more sexual partners had a higher prevalence of HPV DNA, but this finding was 
not statistically significant.  
In Chile, cervical cancer is the sixth cause of death from malignant tumors and it represents 
a major public health problem (Chilean Ministry, 2005). Every year, 1500 cervical cancer 
cases are diagnosed in Chile and 721000 Chilean women in the general population died 
(WHO/ICO, 2010f). These deaths represents a major social and economic impact, because 
this type of cancer affects relatively young women in their reproductive age (Chilean 
Ministry, 2005). In fact 6.25 millions of women older than 15 years are at risk of developing 
cervical cancer (WHO/ICO, 2010f). The level of HPV infection (11.2%) among Chilean 
women with normal cytology is similar to the prevalence found in other Latin American 
countries, such as Mexico (14.5%), Columbia (14.9%) but higher than in many parts of 
Europe and Asia (Table 1). Seventy-six (73.6%) HPV infections involved a single genotype 
while 28 (27.1%) involved multiple types. The most common HPV genotypes were HPV16 
and HPV56, followed by HPV70, HPV52, HPV58, and HPV59. The prevalence by age 
showed a bimodal curve with the two picks at the young and old ages and with a nadir in 
the middle age. For HR HPV infections the highest peak was represented by younger ages 
while for LR HPV by older groups. Consequently, among healthy women among 15 and 19 
years of ages HR HPV was more frequent and LR HPV was less frequent. The new LR HPV 
increase after age 70 might be a result of the selective elimination of HR HPV by treatments. 
Similarly in Columbia and Costa Rica the second peak is mostly due to LR HPV while in 
Mexico the increase is caused by both HR and LR. Interesting, single widowed and divorced 
women had higher HPV infection, compared with married women. Moreover the number of 
partners was correlated with HPV infection. Women who reported their husbands had 
extramarital sexual relationships had high prevalence of HPV, but this did not reach 
statistical significance.  
In Columbia cervical cancer is the principal cause of cancer mortality among women. 
Annually, 4700 cervical cancer cases are diagnosed and 2000 Colombian women in the 
general population died with the disease (WHO/ICO, 2010g). Approximately, 15 millions 
of women older than 15 years are at risk of developing cervical cancer (WHO/ICO, 2010g). 
The overall HPV DNA prevalence rate among healthy women was 14.9% (Table 1) which is 
similar to that reported in other high-risk populations. Of the HPV-positive women, 11.4% 
were infected with HR types and 3.2% with LR types. Similarly to Chile, the HPV age-
standardized prevalence among women with normal cytological findings showed a bimodal 
curve, with a highest peak (26%) among women below age 20 and a lower peak among 
women over 55 (13.2%). HPV prevalence among women aged 45-54 was very low (2.3%). 
HR HPV infections were more prevalent then LR HPV infections except among women 
aged over 55. Mexico and Costa Rica presented some increase in HPV infection among 
woman in peri-and post-menopause as well. But while in Costa Rica the predominance was 
LR HPV, in Mexico the predominance was HR HPV with an increasing of LR HPV in 
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younger women. This could due to a reactivation of HPV infection by decreased immune 
response or by hormonal changes (Ginaldi et al., 1999). The most common genotype found 
was HPV16 followed by HPV58. Although HPV16 is the predominant type detected 
worldwide, HPV58 was noted with high prevalence as well. Multiple infections were 
detected in 29.7% of HPV-positive women, with a high frequency among women less than 
25.  
Cervical cancer ranks as the second most frequent cancer in women in Argentina, and the 
second most frequent cancer among women between 15 and 44 years of age. Argentina has a 
population of 14.74 million women ages 15 years and older who are at risk of developing 
cervical cancer (WHO/ICO, 2010b). Current estimates indicate that every year 4000 women 
in the general population are diagnosed with cervical cancer and 1809 die from the disease 
(WHO/ICO, 2010b). The disease was not homogeneous in all the country, developed 
provinces of Argentina, in the northwest, had an incidence of cervical cancer nearly four 
times higher than Buenos Aires. The main problem is due to lack of prevention and control. 
For decades poor women with low education levels and less access to information were 
often brought into the hospital in a state of abnormal vaginal bleeding and advanced 
cervical cancer. In the last years, a vaccine has been developed to prevent HPV for girls from 
10 to 11 years in areas at high risk. The HPV prevalence among women without cervical 
abnormities was 15.4% (Table 1). This value was slightly high compared with other part of 
the country and other geographical regions of the world (range 7.7-13.9%) (Clifford et al., 
2005). Among all HPV-positive women 8.9% had an infection with a single HPV type, while 
3.3% had multiple HPV types detected. The HR HPV genotypes were predominant 
compared to LR HPV. The most common HPV genotype was the HR HPV16, followed by 
LR HPV6. Differently from the other Latin American countries, the prevalence decreased 
consistently with the age, reaching the lowest point among women over 65 years of age.  
3.2.2 North America 
The incidence of cervical cancer in the United States and Canada has declined for some time 
until to be relatively low (Dailard, 2003). The major reason the rates are so low, despite high 
rates of HPV infection, is the widespread availability of Pap tests (Dailard, 2003). Pap-test 
can detect not only early-stage cervical cancer, but also cervical dysplasia. Since the Pap test 
was introduced, cases of cervical cancer in the United States have decreased dramatically 
(74%) between 1955 and 1992 (Dailard, 2003). HPV prevalence among healthy women in 
North America was high in the United States and Canada (Table 1, Figure 1). Age–specific 
prevalence among women with normal cytology ranged from 30% among women younger 
than 25 to 1% among women aged 45-54.  It was very high among teen-agers and then it 
slowly declined until 45-54 years of age for significantly increase again among women more 
than 55 years (20%) (Figure 2). Only Unites States showed a significant decreasing with age 
(Figure 2). HPV16 was the most prevalent type among women with normal cervical 
cytology.  
HPV was estimated to be the most common sexually transmitted infection in the United 
States (Winer et al., 2003, Tarkowski et al., 2004, Revzina and Diclemente, 2005, Manhart et 
al., 2006, Trottier and Franco, 2006). An estimated over 122 millions of women in the general 
population, showed that approximately 40% of the population are currently HPV-infected 
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(WHO/ICO, 2010l). Each year in the United States, 11000 cases of cervical cancer were 
diagnosed and 4000 women died with the disease (WHO/ICO, 2010l). Almost half of the 
infections were among women 15-25 years old. The prevalence of HPV infection among 
women with normal histology was 25.6% (Table 1), including 20.9% with an HR HPV type 
and 7.4% with an LR HPV genotype. HPV16, the most common cervical infection 
worldwide, was the most common prevalent type, followed by HPV52 and HPV53. It is 
notable that HPV18 and HPV31 were not found as commonly as in other areas of America 
or Asia. Similar to other studies in Europe, the prevalence of HPV increased from 14 years to 
24 years, and then decreased significantly with the age. There was a 20-fold variation in the 
prevalence of HPV infection between young women and women over 55. 
HPV is among the most common sexual transmitted disease (STD) in Canada (Public health, 
2007). HPV infection affects about 550 000 Canadians in the general population annually, 
and at some point in their lives 80% of sexually active women will be infected by one or 
more of the 100 HPV types (WHO/ICO, 2010e). Of those infected, approximately 1400 
women were diagnosed with cervical cancer and 544 women died with the disease 
(WHO/ICO, 2010e). Cervical cancer ranks as the 11th most frequent cancer among women 
in Canada, and the second most frequent cancer among women between 15 and 44. In 
September 2009, a school-based HPV vaccine program was commenced in all 14 provinces 
and territories of Canada (Ogilvie et al., 2010). The vaccine has the potential to change the 
demographics of cervical cancer among young women (Kaplan-Myrth and Dollin, 2007).  
The HPV prevalence among Canadian women with normal cytology was 25.4% (Table 1). 
The HR HPV infections were more frequent than LR HPV. The most common HPV type 
among HR and LR infections was HPV16 that was detected in 4.6% of the population under 
investigation, while HPV18 was detected only in 1.6% of the population. Similarly to Latin 
American countries, the HPV age-specific prevalence in healthy Canadian women showed a 
bimodal distribution, with about 20% of prevalence in younger and older women and a 
decrease among 40-49 years old.  HR HPV types were common in single infections among 
women younger than 40 years of age but made a smaller contribution to single infections in 
older women.  
3.3 Asia 
Cervical cancer is a significant problem in developing countries and resource-insufficient 
areas such as Asia (Behbakht et al., 2004). This is partially related to poor availability of 
health care, which is induced by social and cultural barriers that decrease patient 
compliance and interrupt physician education (Cooper et al., 2005).  It is also related to the 
fact that HPV vaccines will be first introduced into industrialized countries and only later in 
developing countries. Asia has more than 1000 million women who are at risk of developing 
cervical cancer (WHO/ICO, 2010c). About 313,000 cases of cervical cancer are diagnosed 
each year, with 160.000 women in the general population dying from the disease 
(WHO/ICO, 2010c). It is the second most common female cancer in the region, where a 
woman dies of cervical cancer every 4 minutes, often in the prime of her life. The statistics 
consider almost half of the world's cervical cancer cases are diagnosed in Asia, but the 
distribution is heterogeneous, presumably because of the ample geographical and cultural 
diversities of Asian population (Figure 1) (Clifford et al., 2005).  For example HPV 
prevalence in woman with normal cytology was high in Japan and Russia but not in China 
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or India, where the prevalence was only intermediate, or in Thailand or Vietnam, where the 
number of infections was the lowest (Table 1).  Those data are not in agreement with 
historical cervical cancer incidence that showed rates of cervical cancer low for China and 
high for India (Parkin, 2002). The discrepancies might reflect a more liberal sexual behaviour 
developed in recent decades, forming new HPV epidemiology in Asian countries (Li et al., 
2006). This finding could predict a rising cervical cancer epidemic in the world with a so fast 
growing to match the HIV epidemic. HPV prevalence tended to be lower than in other 
regions of the world, with the exception of Russia and Japan. Age–specific prevalence 
among healthy women ranged from 33% among women younger than 25 to 13% among 
women aged 45-54 (Figure 2).  It was very high among teen-agers and then it slowly 
declined until 45-54 years of age for significantly raising again to 21% among women more 
than 55 years (Figure 2). HPV16 was the most prevalent type among women with normal 
cervical histology but other common HPV genotypes were HPV52, HPV58, HPV31, and 
HPV32. It is noteworthy that Eastern Asia (South Korea, Japan, and Thailand) had the 
lowest contribution of HPV16 compared with the other Asian regions.  In South Korea the 
most frequent HPV types were HPV70 and HPV33 with 1.34% and 0.85% against 0.24% of 
HPV16. In Japan and in Thailand the most frequent HPV types were HPV52 and HPV72 
with 6.4% and 0.78%, respectively, against 4.1% and 0.48% of HPV16. Moreover only 0.6% of 
woman with normal cervical histology tested positive for HPV18, which is very common in 
western countries.  
3.3.1 Eastern Asia 
In China the age standardized–HPV prevalence was similar to those areas with high 
incidence rates of cervical cancer like Latin America and India but lower than in the high-
risk regions in Asia and South Africa (Dai et al., 2006).  It was homogeneous in all the 
country, in urban populations in North- and South-east of China (Li et al., 2006) as well as in 
the rural population in Central China (Dai et al., 2006).  The highest HPV prevalence in the 
general population was found among middle aged women even if a peak was seen among 
women younger than 25 years. Castle et al. suggested HPV persistence in over 45 years old 
women than acquisition of new infection (Castle et al., 2005). Thus, a high prevalence might 
indicate a reactivation of HPV infection. Furthermore, China is a conservative society, 
especially the central area, so it is likely that middle aged women are more frequently 
exposed to the HPV than young women (Dai et al., 2006). One of the limitations of HPV 
prevalence studies in China is the difficulty to obtain specimens from unmarried women 
(Dai et al., 2006). Indeed in some studies the age-specific pattern of HPV infection for the 
tertiary sector workers was different with a gentle decline with increasing age (Winer et al., 
2003). The prevalence of HR HPV infections (8.7%) in healthy women was similar to the 
global average (9.2%) (Clifford et al., 2005) while the infection with LR HPV genotypes was 
lower (Sun et al., 2010) (Table 1). The most common identified HPV type was HPV16 but 
HPV52 was predominant as well, more than in non-Asian populations (Clifford et al., 2005).  
Only 1.80% of healthy women in China were diagnosed with HPV18 infection. The 
prevalence of single-type HPV infection was 9.4% while the prevalence of multiple-type 
HPV infection was 2.6%. 
HPV infection is the most prevalent but also the least known STD in Japan. (Garland et al., 
2008). Cervical cancer ranks 7th in women overall and 2nd in women aged 15-44 years 
(Clifford et al., 2005, WHO/ICO, 2010j). Fifteen thousand women in the general population 
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are diagnosed with cervical cancer yearly, leading to 3500 deaths (JMH, Castellsague et al., 
2007). Prevalence of HPV infection in the Japanese population has been usually conducted 
in small geographic areas, and little information regarding nationwide HPV prevalence was 
available. The proportion of HPV-positive cases among woman with normal cytology was 
21.7% and decreased with aging (Table 1). Women aged 20-25 years with normal cytology 
and HPV infection were relatively high compared with other women from the Asian Pacific 
region, with the exception of Australian women (Garland et al., 2008). Although the studies 
were not based in the same geographic region and used different primer systems HPV DNA 
positivity appears to be very high in Japanese women (Onuki et al., 2009). In the most recent 
studies, the HPV prevalence in Japan resulted increased. The high prevalence might reflect a 
more liberal sexual behaviour developed in recent decades or could be due to differences in 
the detection methods (Onuki et al., 2009). New PCR primers used in recent studies have a 
higher sensitivity. Among the high-risk types, HPV52 was the most prevalent among 
healthy women in Japanese population, while HPV16 was more closely associated with 
cervical abnormalities (Konno et al., 2008). HPV16 and HPV51 were the second and the third 
most prevalent HPV types. The numbers of single and multiple-HPV infections were high 
(20.7% and 13.5%, respectively) (Table1).   Several women were positive for five HPV types 
(0.6%).  
The incidence of cervical cancer in Korea has steadily increased over the past 10 years and 
with a pattern of a developing country because of the increase in incidence and mortality 
related with cervical cancer. HPV prevalence in Korean women has been found to be diverse 
according to age groups, areas, socioeconomic status, and methods for detection of HPV 
DNA. However, most reports have shown that the prevalence of HPV infection among 
women with normal cervical histology was 10-15% with an average of 8.5%, in agreement 
with intermediate-risk developing countries (Table 1). The incidence of HPV infection was 
significantly higher in females between 20 and 30 years than in older women. Then it 
declined at age 50-59 years and increased again above 60. DNA from HR HPV types was 
predominant over LR HPV types below age 35, whereas LR HPV types were as equally 
frequent as HR HPV types in women aged 35 and older. The most common HPV genotype 
in either single or multiple infections was HPV70 followed by HPV33 and HPV16. Together 
they infected half of HPV DNA positive women. Single infections (9.8%) were more 
frequent than multiple infections (1.75). 
3.3.2 South-eastern Asia 
Vietnam is one of the poor, developing countries. Malnutrition and infectious diseases are 
still major health problems. Cervical cancer ranks in a relatively modest position of priority 
and the geographical distribution is not homogenous within the country. It used to be 
frequent in both the North and South but there is a gender difference between two regions: 
it was higher in the South than in the North. In the North the HPV detection in women 
without cervical abnormalities was very rare (2%); in the South the HPV detections among 
healthy women (10.9%) were 5-fold higher than in the North. The overall HPV prevalence 
was very low (5.2%), lower than worldwide average (Table 1). Infections with multiple HPV 
types were 9-fold more common in the South (4.5%) than in the North (0.4%). In Vietnam 
the most frequent HPV genotype was HPV16, followed by HPV52. A peak in the HPV 
prevalence among women younger than 25 years was found only in the South that then 
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significantly decline with age. In North no clear age-pattern emerged, but the highest 
prevalence was found among women 35-44 years of age group. The differences between the 
regions cannot be due to technical reason, as women were randomly chosen in the same 
way and the samples were examinated in parallel.  It may rather be due to the greater 
isolation between North and South during many decades of socialist economy.  
Cervical cancer is the leading cancer in Thailand. Despite that, the prevalence of HPV 
infection was relatively low (4.7%) among women with normal cervical history, suggesting 
the spread of the infection to be relatively limited (Table 1). The vast majority of women 
tested reported having only one sexual partner in their lifetimes. Women who reported 
more than 2 sexual partners appeared to be at an increased risk of HPV detection, but only 
borderline statistical significance was estimated. HPV prevalence among healthy women 
was higher in the North area of Thailand than in South regions. This does not appear to be 
explained by differences in sexual habits or in HPV detection methods, as all samples were 
analyzed in parallel and in the same laboratory. The majority of HPV-positive women had 
infections with HR HPV type (61%) and the most common genotypes were HPV72 and 
HPV16. Multiple infections were found in 1.5% of HPV-positive women. The age-
standardized prevalence among women with normal cytological findings was two fold 
higher in population from North Thailand than in South Thailand. In both cases, HPV DNA 
positivity was higher among women younger than 25 years of age and then formed a 
plateau among women older than 35 years of age. The prevalence of HR HPV types reached 
the highest value (6.5%) among women aged 25-34 years while the highest LR HPV 
prevalence (5.1%) was found among women younger than 25 years of age. The 
representativeness of HPV DNA prevalence among women younger than 25 is limited, 
because young women in Thailand generally were not willing to undergo a pelvic 
examination. 
3.3.3 Western Asia 
Iran is a country with a low prevalence of HPV. The incident of HPV infection among 
women with normal cytology in Iran was only 5,5% lower than the worldwide average but 
similar to that in low-prevalence areas (Table 1). Age–specific prevalence among healthy 
women was 4.5% among women aged between 20-40 years and gradually increased to 20% 
in 50-59 years old women. The prevalence of high-risk HPV was around 2% among younger 
women and decreased to zero in the older age group. The decreased occurrence with 
increasing age may suggest that the HPV infection at a young age is transient and it is 
eradicated by the immune-system. For the same reason not all HPV-infected women 
develop cervical abnomarlities (Centurioni et al., 2005, Onuki et al., 2009). The most 
common HPV genotype in either single or multiple infections was HPV16 followed by 
HPV18. 
3.3.4 Southern Asia 
In India the incidence of cervical cancer is high and the majority of Indian women had 
difficulties to access appropriate screening facilities. The country is exploring various 
strategies for preventing the disease and the vaccination is one of the solutions (Ghim et al., 
2002, Das et al., 2008). The vaccine was found to be safe and highly immunogenic and 
possibly able to protect women already exposed to natural infection as well as HPV-naïve 
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women (Swarz, 2007, Keam and Harper, 2008). In India the HPV prevalence among women 
with normal cervical histology was 12% which was similar to other geographical regions of 
the world (range 7.7-13.9%) (Clifford et al., 2005) (Table 1). Bao et al found a higher HPV 
infection in healthy women from hospital-based studies (25%) than from population based 
studies (10.9%) (Bao et al., 2008). HPV16 was the predominant type found in Indiam women 
without cervical abnomarlities and it was more common than HPV18 in perfectly 
accordance with other analysis from Asia (Clifford et al., 2005, Clifford et al., 2006). The 
HPV16/18–positive fraction was 32% with some variations between North and South India, 
with North more significant than South. After these, HPV33, HPV56, and HPV52 accounted 
for additional 16%. The prevalence of single-type HPV infection was 9.7% while the 
prevalence of multiple-type HPV infection was 2.4%. A limitation of HPV prevalence 
studies among women without cervical neoplastic desease in India was a reduced number 
of studies that fulfilled all the inclusion criteria. The few existing were not representative of 
each region; the Western and the central areas were not well documented.   
3.4 Europe 
In 2007, Europe had a population of 321.8 million and each year 59931 women are 
diagnosed with cervical cancer and 29812 die from the disease (WHO/ICO, 2007b). In this 
continent, cervical cancer is ranked as the 7th most common cancer in women, and as the 
second most frequent cancer among women between 15 and 44 years of age. About 6.6% of 
women in general population are estimated to harbor cervical HPV infection at a given time, 
and 73.3% of invasive cervical cancer are attributed to HPV16 and 18 (WHO/ICO, 2007b). 
3.4.1 Northern Europe 
The effectiveness of HPV testing in primary cervical cancer was evaluated in the United 
Kingdom (Kitchener et al., 2006). The HPV detection was performed on 42647 healthy 
women (20-64 years) by HC2 and typing through Roche reverse line blot assay. The age-
specific prevalence pattern was 7.3% in the 20-29 years old group, 25.9% between 30-49 
years, 11.6% in the 50-64 years of age and 44.8% in the oldest group, with ages among 50-64. 
Regarding HPV types, there was a 2.2% prevalence of HPV16 and HPV18 together and 8.2% 
of other HR HPV types, meaning that 11.3% of normal cytology samples were infected with 
a HR type (Table 1). In 2010, another study evaluated prevalence of type-specific HPV 
infections in the country (Howell-Jones et al., 2010). The Roche Linear Array test was used 
and the six most common HPV infections in women with normal cytology were HPV16, 61, 
62, 53, CP6108 and 54, in descending order; HPV18 was only the nineteenth most common 
type. Infection with HR HPV was identified in 12.2% of participants. 
In 1997, a population-based prospective cohort study evaluated the HPV infection in 1000 
randomly chosen young Danish women (Kjaer et al., 1997). The participants were healthy 
women distributed over the age range (20-29 years); 30, 32 and 38% were 20-23 years old, 24-
26 and 27-29 years old. Overall HPV DNA was detected in 15.4% women, 73.8% women had 
HR HPV types. LR HPV6, 11 was found in 30% of the women. Of the positive samples, 
approximately 10% contained more than one HPV type (only 3% harbored both HR and LR 
HPV types). Prevalence of any HPV type was associated with age: 19.4% of group age 20-23, 
14.1% of 24-26 and 13.1% of 27 to 29 years old. In 2008, a study assessed the type-specific 
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HPV prevalence to estimate the preventive potential of an HPV 16/18 VLP vaccine in 
preventing cervical cancer (Kjaer et al., 2008). 11918 women with normal cytology and a 
mean age of 36.3 years old were tested by HC2. The HPV prevalence was 22.9%, 19.2% 
infected with HR HPV types and 7.4% with LR HPV types (Table 1). Multiple HPV 
infections (12.1%) were more prevalent than single HPV infections (9.3%). The most 
common HPV type was HPV16 (4.8%) followed by HPV31, 52 and 51 (3.8-3.6%). 
In Sweden, Dahlstrom et al. (2010) evaluated the HPV distribution and the risk of cervical 
adenocarcinoma using 282 women with normal smears. The HPV prevalence was 24.8% 
(Table 1). Among all HPV-positive women 8.8% had an infection with a single HPV type, 
while 6% had multiple HPV types detected. The HR HPV genotypes were predominant 
compared to LR HPV. The most common HPV genotype was the HR HPV16, followed by 
HR HPV31 and LR HPV 42. 
Keegan et al. (2007) reported an analysis of the cytological and HPV status of Irish women 
undergoing opportunistic cervical cancer screening. Detection of HPV was performed using 
MY09/MY11 consensus primers and then samples were sequenced to genotype the virus. 
886 women with normal cytology were analyzed. HPV DNA was detected in 11.4% of the 
samples tested (Table 1). Regarding age distribution, the study samples ranged from 16 to 72 
years. There were 27 HPV positive cases in women bellow 25 years, 48 cases between 25-30 
and 26 cases in women with more than 35 years. The samples with normal cytological 
findings had HPV16 and HPV18 as the most common HPV types.  
In Norway, a study investigated the cross-sectional positivity for HPV in 736 women with 
normal cytological findings (Trope et al., 2009). 30 years or older women were recruited 
from 4 Norwegian hospitals and were attending routinely administered clinical services 
with normal Pap smear cytology, normal cytological results from the preceding 2 years and 
no previous history of treatment of cervical neoplasia. A total of 10.6% women with normal 
cytology tested positive for HR HPV using Amplicor HPV test (Roche) (Table 1). 
3.4.2 Southern Europe 
Dutra et al (2008) characterized the HPV genotype distribution in 275 Portuguese women 
with normal cytology findings. The samples aged from 16 to 81 years old. HPV DNA was 
detected and typed using the commercially available Papillomavirus Clinical Arrays kit. The 
virus was detected in 30 women (10.9%) and it was more prevalent in age groups ranging 
from 25 to 34 years old and from 40 to 54 years old (Table 1). There were 1.8% cases of LR 
HPV infection, 6.1% cases of HR HPV and 2.5% cases of undetermined risk infection. The 
most common types were HPV31 (26.67%) and HPV16 (10%).  
In 2011, the prevalence and distribution of HR HPV genotypes in Spanish women was 
studied (Lindemann et al., 2010). HC2 was carried out and all positive samples were further 
studied with Linear Array HPV Genotyping test (Roche). The author found 298 healthy 
women infected. The most prevalent type was HPV16 (17.8%) followed by HPV31 (12.8%) 
and HPV52 (12.4%). In total, 17 HR HPV types were identified.  
Agarossi et al. (2009) studied the prevalence and the distribution of oncogenic HPV 
genotypes in Italy. HPVs were detected using HC2. Positive samples were genotyped by 
PCR. HPV 16 or 18 were present in 4% of healthy women and both were detected 
 
Human Papillomavirus Worldwide Distribution in Women Without Cervical Cancer 55 
simultaneously in only 14 women. A study conducted by Rossi et al, analyzed the 
distribution of high and low risk HPV types in Italy (Giorgi Rossi et al., 2011). The presence 
of HR and LR types was investigated through HC2 in 3151 women with normal cytology 
aging from 25 to 64. The HC2 positive specimens were amplified and typed with “consensus 
high risk HPV genotyping test”. HPV prevalence was 9.7% (Table 1). A HR HPV infection 
was found in 6.2% of women and LR HPV infection in 2.7%. The most common types were 
HPV16 found in 67 samples (2.1%) and HPV31 (0.8%). 
In Greece, two molecular methods of HPV detection were used in a large sample of women 
(Tsiodras et al., 2010). The two methods were: commercially available HC2 and an in house 
PCR using consensus primers GP5+/6+. During the 4 years period, 1029 women with 
normal cytology were evaluated (mean age: 34,2 ± 12,1 years old). HC2 detected HPV 
infection in 10.2% and the PCR methodology identified 18% of infected women (Table 1). It 
was also possible to genotype HPV by PCR, and 2.7% multiple HPV cases were detected. 
The most common types were HPV33 and HPV6 with 10 cases each, HPV6 with one case 
and HPVX (undetermined) was identified in 159 cases. There was not any case of HPV16, 18 
or 11.  
Grahovac et al investigated the prevalence of HPV among Croatian women attending a 
regular gynecological visit (Grahovac et al., 2007). 205 women (21-37 years old) without 
obvious cervical changes were analyzed. HPV DNA detection and genotyping was 
performed by HC2 assay and additionally by consensus and type-specific primers directed 
PCR. The overall prevalence of HR HPV in the group of women was 35.6% with HPV16 
found in 43.8% cases followed by HPV31 (17.8%), HPV33 (9.5%) and HPV18 (6.8%) (Table 
1). The prevalence of HPV of undetermined type was 13.7% and 6 were the cases with 
multiple HPV infections (8.2%).  
3.4.3 Eastern Europe 
Not many studies were developed on HPV prevalence in Russia, although some reports 
have been released until now. In many related socio-medical aspects, Russia seem to be 
similar to European countries. But the sexual attitudes were long considered 
“inappropriate”.  Decades of poor knowledge on the reproductive hygiene and ignorance of 
the risks of STD might have been affected the distribution of HPV. The HPV prevalence 
among healthy women in Russia was one of the highest revealed in this study. HPV was 
detected in 29% of the women with normal cervical cytology (Table 1, Figure 1). The largest 
proportion of HPV-positive cases was regarding women on reproductive age and no 
significant decline of the infection was observed in older women. HPV16 was the most 
prevalent type being present in 21% of the infected women alone and in 5% in combinations 
with other HPV types. Other common types were HPV31, HPV66, and HPV39.  A strong 
correlation between excessive number of contraceptive abortions and the presence of HPV 
was observed among young Russian women (Popov, 1991)  
The HPV prevalence was also investigated among 3187 healthy women in the two new 
independent states of former Soviet Union (Kulmala et al., 2007). HPV detection, type 
distribution and viral load analysis in DNA samples from cervical scrapes were done with 
real-time PCR-based assay. The overall HPV prevalence in Belarus and Latvia were 27.5% 
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and 26.2% respectively and HPV16 was the most prevalent type followed by HPV31 and 
HPV33 in Belarus and HPV39 in Latvia (Table 1). 
In 2008 the relationship between the distribution of HPV types and the outcome of 
cytological examination was investigated in Poland (Szostek et al., 2008). Forty-two women 
with normal cytology were analyzed. HPV DNA amplification and genotyping was 
performed with the SPF10 primer set and reverse hybridization line probe assay (INNO-
LiPA). The virus was found in 21.4% women and the percentage of single and multiple 
infections were 9.5%. The most common HPV types were HPV51 and HPV52 while the two 
more worldwide common  HPV16 or HPV18 were not found.  
The prevalence of HPV in healthy women in Hungary was assessed in 2002 by Kornya et al 
(Kornya et al., 2002). The HPV DNA was detected using the Digene Hybrid Capture HPV-
DNA assay and the virus could be shown in 60 out of 1018 cytology normal samples, 
(prevalence of 5.9%) (Table 1). 
In 2010, Anton et al. analyzed the distribution of HPV genotypes in Romanian healthy 
women. HPV was detected and genotyped using the commercially available INNO-LiPA. 
From the 285 women, 43.5% had an HPV infection and the most common type was HPV16 
(15.4%), followed by HPV18, 31 and 51 (Table 1).  
3.4.4 Western Europe 
In France, Vaucel et al (2010) assessed the HPV overall and type-specific prevalence in 980 
women with normal cytological diagnosis (mean age 38.5).  PCR was performed with 
MY09/MY11 primers and genotyping by sequence PCR products. About 13% of women 
were HPV positive, and 3% showed multiple HPV infection (Table 1). The proportion of 
HPV positive women varied significantly according to age with the highest prevalence 
(44%) observed bellow 20 years of age. Thereafter, the prevalence decreased with increasing 
age reaching about 10% above 35 years. The most prevalent HPV genotypes were, by 
descending order of frequency HPV16 (3.6%), HPV53 (1.4%), HPV6 (1.0%), HPV31 (0.9%) 
and HPV33 (0.7%).  
In a study on the occurrence and distribution of HPV infection in the Flemish region 
(Belgium), 581 cytological normal women, ranging from 17 to 85 years old, were studied 
(Sahebali et al., 2003). All samples were tested with MY09/MY11 consensus primers and the 
HPV positive group was retested with type-specific primers for 14 HR types. HPV 
prevalence was 26.7% (Table 1). HR HPV and LR HPV prevalence were 17.9 and 8.8%, 
respectively.  
The prevalence of HPV types in women screened by cytology in Germany was evaluated by 
Klug et al in 2007 (Klug et al., 2007). HPV detection was performed by HC2 test and all 
positive samples for this assay were genotyped using PGMY09/PGMY11 PCR followed by 
reverse line blot assay. The study included 7833 women with no cervical abnormalities 
aging between 30 and 60 years. 4.4% of tested women had an HPV infection, 3.1% resulted 
single infections and 1.2% multiple infections. (Table 1). The most HR common types were 
HPV16 (1.1%), HPV31 (0.5%) and HPV52 (0.4%). In the LR HPV infections, HPV73 was the 
commonest type (0.4%).  
In the Netherlands, a study compared two molecular detection tests using 1437 women with 
normal cytology findings aging from 40 to 60 (Hesselink et al., 2010). The authors compared 
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the clinical performance of Papillocheck HPV assay with that of the GP5+/6+ PCR method. 
The Papillocheck assay found a HPV prevalence of 5.2%. About 3.7% of the infections were 
HR HPV positive and 1.5% were LR HPV positive (Table 1).  
In Switzerland, Dobec et al. (2009a) analyzed HPV genotype distribution in women without 
cervical abnormalities. It comprised 680 cervical specimens of females with ages from16 to 
88 years (mean age, 40 years) tested for HPV with Linear Array HPV genotyping. Any HPV 
was detected in 17.2% of women and HR HPV was found in 8.1% of the study group (Table 
1). The highest HPV prevalence was observed in age group 21-30 and showed a continuous 
decrease in older age groups. The seven most common HR HPV types were HPV16 (12%), 
HPV31 (9.4%), HPV52 (6%) and HPV45, 58 and 59 (4.3%, each). HPV6 was detected in 4.3% 
of the 117 HPV positive specimens and infection with single and multiple HPVs was found 
in 10.9% and 6.3%, respectively.  
4. Discussion and conclusions  
Our analysis included 47 countries with studies testing HPV infection in women with 
normal cytological findings. Figure 2 shows HPV prevalence by age and continent. In all 
regions, a peak in HPV infection was found at teen-agers (≤25 years), declining until middle 
age. In America and Asia, a modest second peak is observed at age ≥45 years, while in 
Europe, Africa and U.S.A.  There is not an increase of infection but a continuous decline.   
In HPV prevalence worldwide (Figure 1), there were significant differences not only 
between continents but from region to region. In America, the prevalence starts increasing 
from the South to the North, ranging from 11.20% to 25.60% respectively. Despite the high 
rates of HPV infection in North America (Canada and U.S.A.), the widespread availability of 
Pap tests and effective cervical screening programs, there are low rates of cervical cancer. In 
the South and Central American countries, the incidence of cervical cancer varies between 
poor and rich countries as well as the HPV prevalence rates.  
In Asia the distribution is heterogeneous presumably because of the ample geographical 
and cultural diversities but nevertheless is lower than in other world regions. In Western 
and South-eastern Asia the prevalence is approximately 5% and arises to 12 and 14% in 
Southern and Eastern Asia with a maximum prevalence in Japan (21.7%). 
In Europe, the low rates of HPV infection are located Western countries, such as Germany 
(4.4%) and Netherlands (5.2%) probably due to a correct vaccine implementation and high 
population knowledge about the virus. The prevalence starts increasing in Southern and 
Northern Europe countries (12.6%) and reaches the maximum European prevalence in 
Eastern countries (43.5%).  
The highest prevalence percentages are found in the African continent (Guinea,47.9% and 
Mozambique, 75.9%). The Southern and Northern countries have the lowest continent 
prevalence, 20.4 and 23.5% respectively. The poorest countries have the highest infection 
rates with 24.6% in Western and 25.3% in Eastern African countries.  
There is an increasing effort in generating epidemiological data on the carriage of cervical 
HPV in normal cytological samples. In most cases, the regions with high HPV prevalence 
are the ones with the highest cervical cancer incidences and the regions with lower 
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prevalence had the lowest incidences. These findings suggest that a correct vaccination 
program will affect dramatically the cervical cancer incidence.  
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Incidence of Invasive Squamous Cell Carcinoma 
Diagnosed with Opportunistic Screening in >70 
Years-Old Women: Italy as a Case Study 
Teresa Pusiol 
Section of Cytopathology, Institute of Anatomic Pathology, Rovereto Hospital 
Italy 
1. Introduction 
Cervical cancer is still one of the leading cancers worldwide (1), although there is a 
discrepancy between developed and developing countries. In developed countries, there is a 
continuous decline in incidence and mortality, whereas in developing countries, there is a 
more stable or even increasing pattern. The latter is more likely to be due to the lack of 
screening and infectious cofactors than to ethnic differences. Cervical cancer remains the 
only human malignancy that has been successfully reduced by medical intervention. 
Organised screening (OrS) for cervical cancer by the conventional Pap smear is the only 
means with proven efficacy of reducing the incidence and mortality of this disease in 
countries where it has been successfully implemented. According to the official statistics, the 
age standardized incidence rate of cervical cancer in Italy currently (2002) levels of at 
8.1/100.000 with a mortality rate of 2.2/100.000 (2). Italy  is another European country with 
no unified national screening programme, but each region has adopted a screening policy of 
its own. (3)Cervical cancer screening in Italy started as a spontaneous activity, with no 
national organization, which, not unexpectedly, led to incomplete population coverage. The 
Italian health system is managed by Italy’s 20 Regions (Figure 1).  
Since 1996, Italian national guidelines have recommended to Regions the implementation of 
organised screening programmes for cervical cancer. These recommendations, largely based 
on European guidelines, include personal invitations to women aged 25 to 64 years for a Pap 
smear every three years, a monitoring system, and quality assurance for each phase of the 
programme. Surveys designed to assess the level of implementation of organised 
programmes in Italy and to collect process indicators have been conducted by Italian Group 
for Cervical Screening since 1997 (4,5,6,7,8,9,10,11,12,13). Their results have been published 
by the Osservatorio Nazionale Screening (ONS),(National Centre for Screening Monitoring) 
since 2002. Since 1993 in Trentino province (North Italy) an Organized Screening (OrS) exist 
for women 25-65 aged. The target population comprises 146737 women. In the period 1993 – 
2006 the pap-smears of OrS were examined in the Institutes of Anatomic Pathology and 
Cytopathology of S.Chiara Hospital Trento and Rovereto Hospital. Since 2007 the 
Cytopathology Section of Institute of Anatomic Pathology of Rovereto Hospital have 
examined only pap-tests of Opportunistic Screening (OpS), i.e. left to the woman’s initiative. 
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OpS may be considered as all Pap-test performed outside an OrS program. For example, 
some women have Pap-test at their doctor’s office during their physical examination 
independently of personal letter invitation of OrS. In Italy the complete screening history of 
women diagnosed with invasive cervical cancer has been performed only in Friuli Venezia 
Giulia – North eastern Italy -.  In these region an OrS was initiated in 1999, targeting women 
aged 25 – 64 years, who are invited to have a Pap-test every 3 years. The screening histories 
of Cervical Intraepithelial Neoplasia (CIN)3 - squamous cell carcinoma in >65 years-old 
women may be made with study of OpS, because the OrS offers a free-of-charge Pap-test 
every 3 years to all women aged 25-64 years. In the present study we have examined the 
screening histories, treatment, human papillomavirus (HPV) detection of CIN3- invasive 
squamous cell carcinoma in >65 years-old women, diagnosed in the period 2007-2010 with 
opportunistic Pap-tests in the Cytopathology Section of Institute of Anatomic Pathology of 
Rovereto Hospital.  
 
Fig. 1. Italy’s regions 
2. Materials and methods 
In the period 2007-2010 the Cytopathology Section of Institute of Anatomic Pathology of 
Rovereto Hospital have been examined 28589 opportunistic Pap smears. The standard 
technique of conventional opportunistic Pap smears involves taking two samples (one from 
the endocervix with cytobrush and one from ectocervix with Ayre spatule) and  smearing 
the cytological materials on two slides. The cytological diagnosis was performed using the 
2001 Bethesda System (14). An experienced cytopathologist whose diagnostic experience 
exceeds 20 years have examined all abnormal smears and 10% of the normal smears 
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previously observed a senior cytotechnologist. Colposcopic and cervical biopsies were taken  
by an experienced colposcopist (in practice for more than 10 years) and review by a senior 
colposcopist as part of the routine. HPV genotyping by PCR  was performed in all 
histological specimens (biopsy, cone, hysterectomy) with diagnosis of low grade and high 
grade intraepithelial lesions and invasive cervical carcinoma. 
3. Results 
111 cases (0,38%) of CIN3-squamous cell carcinoma has been identified in 28589 
opportunistic Pap smears. The distribution of women for decades is reported in Table 1. 
Between the women >64 years-old with CIN3-squamous carcinoma cytological diagnosis all 
were > 70 years-old and were not invited to OrS because of age > 64 years. We have 
reported in Table 2 the age, histological diagnosis, treatment and HPV detection of 8 
patients over 70 years with CIN 3 squamous cell carcinoma cytological diagnosis.  
Total number 
opportunistic 
Pap-tests 
≤ 20 Years 
(percentage). 
21 – 40 Years 
(percentage). 
41 – 70 Years 
(percentage). 
 
> 70 Years 
(percentage). 
28.589 892 (3.2%) 11240 (39.3%) 
14848 
(51.9%) 
 
1620 
(5.6%) 
Table 1. Opportunistic screening: decades of age of 28.589 women in the period 2007-2001 
 
Number 
patients Age Treatment 
Histological diagnosis 
(pT) HPV finding 
1 81 
Hysterectomy with 
bilateral salpingo-
oophorectomy 
CIN3 HPV16 
2 82 Cone biopsy CIN3 Negative 
3 71 Cone biopsy CIN3 HPV58 
4 79 Cone biopsy + radiotherapy 
Keratinizing squamous 
cell carcinoma NOS Negative 
5 75 
Hysterectomy with 
bilateral salpingo-
oophorectomy 
Non keratinizing 
squamous cell carcinoma 
(pT1b1) 
Negative 
6 82 Biopsy Keratinizing squamous cell carcinoma NOS Negative 
7 72 biopsy + radiotherapy Keratinizing squamous cell carcinoma NOS HPV58 
8 75 
Hysterectomy with 
bilateral salpingo-
oophorectomy + 
radiotherapy 
Non keratinizing 
squamous cell carcinoma 
(pT1b1) 
Negative 
Table 2. Age, treatment, histological diagnosis, HPV detection in women over 70 years-old 
with CIN3-squamous cell carcinoma. NOS= not other specified 
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The Pap smear was performed by gynecologist to the woman’s initiative. In the Pap smear 
of keratinizing squamous cell carcinoma  the cells showed significant nuclear and 
cytoplasmic abnormalities, the later usually showing a marked deviation from normal cells 
of the same origin. The malignant  keratinized cells had a characteristic bright orange or 
occasionally yellow cytoplasm that was dense and lack the transparent qualities of normal 
squamous cells. The size of keratinized cancer cells may vary from very large, comparable 
with normal superficial cells, to small, about the size of small parabasal cells. Their shape 
varies from round or polyhedral to quite irregular and bizarre (Figure 2). 
 
Fig. 2. Cancer cells with elongated keratinized eosinophilic cytoplasm and hyperchromatic 
nuclei in necrotic and hemorrhagic background. (Papanicolaou 40X). 
The nuclei were usually large for the size of the cells. As is often the case in the presence of 
cytoplasmic keratinization, nuclear pyknosis and karyorrhexis may occur, conferring on the 
nucleus a dark appearance. “Tadpole” cells were present. They were elongated, club-shaped 
cells, with one board and one narrow end. The round or irregular hyperchromatic nucleus 
was eccentrically located within the larger area of the cytoplasm . The degree of cytoplasmic 
keratinization was variable. The spindly squamoid cells were an unusual finding in the Pap 
smear. These cells were narrow, elongated, and needle-shaped. Keratinization was not 
necessarily seen, the cytoplasm may be either eosinophilic or basophilic. The nuclei  were 
nearly always elongated and  hypercromatic (Figure 3). 
 
Fig. 3.  Spindly squamous cancer cells. Note the markedly hyperchromatic  nuclei and the 
cytoplasmic keratinization. (Papanicolaou 40X). 
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The squamous “pearls” was a very rare finding in Pap smear of squamous cell carcinoma. 
These were concentrically arranged clusters of being  squamous cells. The difference 
between the benign and malignant “pearls” was in the configuration of the nuclei which, in 
the cancerous pearl, are enlarged and hypercromatic. In  the Pap smears of non-keratinizing 
squamous cell carcinoma  the malignant cells were solitary or arranged in syncytia (Figure 
4) and show anisokaryosis. The nuclei were relatively large with unevenly distributed, 
coarsely granular chromatin and may have irregular nucleoli. The Pap smear of CIN-3 were 
characterised by cells with nuclear-to-cytoplasmatic ratio significantly increased. The 
cytoplasm remained well-defined resembling that of very immature metaplastic cells. 
Nuclei tended to be considerably hyperchromatic, and marked irregularities of nuclear 
envelope might be present. The cytological characteristics of menopause were found in the 
Pap smear with malignant cells (Figures 5-6) and CIN-3. 
 
Fig. 4. A cluster concentrically arranged of undifferentiated cancer cells  (Papanicolaou 40X). 
 
Fig. 5. Cellular pattern of advanced menopause: the cells are parabasal with filaments of 
nuclear material resulting from breakdown of nuclei. A cluster of undifferentiated cancer 
cells of invasive squamous carcinoma with dark hyperchromatic nuclei is found. 
(Papanicolaou 10X). 
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Fig. 6. Cellular pattern of intermediate menopause with cluster of neoplastic squamous cells 
containing hyperchromatic and irregular nuclei. (Papanicolaou 10X). 
The cytologic patterns of the advanced atrophic menopause were influenced by dryness of 
the genital tract and scarsity of recoverable cellular material. The predominant cell was of 
the size and the degree of maturity corresponding to the parabasal cells. Two main effects of 
dryness might be observed: one was the uniform enlargement of the cell accompanied by a 
characteristic uniform gray discoloration of the degenerated nucleus; the second was by 
nuclear pyknosis and karyorrhexis. In the smear material of the eosinophilic pyknotic type 
there might be a striking variation in cell size and shape. Some cells might be relatively 
large, approaching the size of superficial cells, whereas others were the size of small 
parabasal cells. Sheets of spindly cells with elongated cytoplasm and large, pale nuclei may 
make their appearance in cervical smears and sometimes might be difficult to interpret. 
Nuclear pyknosis may be quite striking and often simulates the hyperchromasia of cancer 
cells; one must search for evidence of karyorrhexis in the form of granules of nuclear 
material within the cytoplasm. In some instances of extreme dryness, the cells break up 
during the process of smearing and will appear as standards and filaments of blue- staining 
nuclear material. The endocervical columnar cells in smear of the cervics were usually scarse 
or absent. When observed , the endocervical cells were smaller than during the childbearing 
age, although their columnar configuration was  still preserved. The nuclei, although of 
normal size, may appear somewhat hypercromatic, and the cytoplasm was scanty, opaque, 
and shows no evidence of secretory activity except for an occasional vacuole. One Pap 
smear CIN-3 and one Pap smear of keratinizing squamous cell carcinoma cointained cells 
with koilocytotic changes (Figure 7). In the  biopsies of CIN-3 maturation ( including surface 
keratinization ) was absent or confined to the superficial third of the epithelium. Nuclear 
abnormalities were marked throughout most or all of the thickness of the epithelium. 
Mitotic figures were numerous and were  found at all levels if the epithelium. Abnormal 
mitoses were frequent. Focal koilocytosis was present in one case.  Keratinizing squamous 
cell carcinoma were histologically characterized by mature squamous cells arranged in 
irregularly shaped nests or cords that varied considerably in size. The most striking feature 
was the present of keratine pearl within the nests of neoplastic squamous epithelium 
(Figures 8 and 9). 
Incidence of Invasive Squamous Cell Carcinoma Diagnosed With  
Opportunistic Screening in >70 Years-Old Women: Italy as a Case Study 
 
71 
 
Fig. 7. Cellular pattern of intermediate menopause with nuclear enlargement of parabasal 
cells. Superficial squamous cell with koilocytotic atypia is present. (Papanicolaou 10X). 
 
Fig. 8. Cone biopsy of keratinizing squamous invasive carcinoma of the cervix. Nests of  
keratinizing, markedly atypical squamous neoplastic cells are evident. (H&E 10X). 
 
Fig. 9. Cone biopsy of keratinizing squamous invasive carcinoma of the cervix. Nest of  
keratinizing, markedly atypical squamous neoplastic cells is surrounded by dense 
inflammatory infiltrate . (H&E 10X). 
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Individual squamous cells were large ,with abundant eosinophilic cytoplasm, and many 
showed individual cell keratinization. The cells were closely apposed and often had 
prominent intercellular bridges. The nuclei may be enlarged or pyknotic. Mitotic activity 
was relatively low compared with the other tumor types. 
The non-keratinizing tumors were composed of generally recognized polygonal squamous 
cells that might have individual cell keratinization and intercellular bridge but keratin 
pearls were absent (Figure 10). Cellular and nuclear pleomorphism was more obvious than 
in the well differentiated tumours, and mitotic figures were usually numerous. 
 
Fig. 10. Cone biopsy of non-keratinizing squamous invasive carcinoma of the cervix. The 
neoplasm is composed of nests of tumor cells with basaloid differentiation.(H&E 10X). 
4. Discussion 
In 1990 cervical cancer comprised 10% of cancers in women for a total of approximately 
470,000 cancer cases world-wide (15), representing the third most common cancer in females 
and the most common cancer in Sub-Saharan Africa., Central America and South Central 
Asia. Approximately 230,000 women die annually from cervical cancer and over 190,000 of 
these are from developing countries. Zimbawe and India stand out not only for their high 
incidence, but also  for an unfavourable incidence to mortality ratio. Some relatively high-
incidence countries can also be  found in Eastern and Central Europe (16).The incidence and 
mortality of invasive squamous cell cervical carcinoma have decreased dramatically in the 
United States over the last three decades. The incidence in the United States was 34/100,000 
in 1947, 15/100,000 in1970, and 12/100,000 in 1986 (17). Although the incidence was 
decreased in the United States before the implementation of mass cervical cancer screening 
programs, screening has had an additional major impact on both the incidence  and 
mortality (65,111). The significance of cytologic screening in reducing the incidence of 
cervical cancer is further underscored by comparing the 4.5/100,000 incidence per year in a 
screened population to the 29/100,000 incidence in an unscreened population(18). Both 
cohorts exhibited similar epidemiologic characteristics. In the United States, approximately 
half of the women who develop cervical cancer have not had a cervical smear in the 
preceding 3 years(19). According to the most recent global estimates, invasive squamous cell 
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carcinoma is the second most common cancer in women world-wide, with the exception of 
skin cancer. There are approximately  493,000 new cases of invasive cervical cancer 
worldwide and 274,000 women die of the disease annually (20). The highest rates are 
reported in Latin America, where cervical cancer accounts for half of all female cancers. The 
annual incidence of invasive cervical cancer in women between 30 and 50 years  of age in 
high-risk areas is 1/1,000. In developing countries throughout the world, cervical cancer is a 
major public health problem and is one of the leading causes of death (21). Recent increases 
in incidence and mortality rates have been observed in some Western countries including 
Canada, Great Britain, Sweden, and Norway (22,23,24,25). In the United States, there were 
12,800 new cases and 4,600 cervical cancer deaths in 2000 (26). The incidence among blacks 
and Hispanics is two times higher than among whites in the United States. Moreover, in a 
recent study, after adjusting for a number of demographic factors, age, Federation  of 
Gynecology and Obstetrics (FIGO) stage, other tumor characteristics, and treatment, black 
women had a higher mortality rate than white women, indicating that race is an 
independent predictor of cervical cancer survival (27). Socioeconomic, religious, sexual, 
obstetric, dietary factors, immunosuppression, smoking, and oral contraceptive intake have 
been studied in relation to cervical cancer. Studies suggest that dietary carotenoids and 
vitamin C have a protective effect against cervical cancer (28,29). The risk of cervical cancer 
is increased by the number of sexual partners, the age at which sexual intercourse is 
initiated, and the sexual promiscuity of the male partner. Husbands of women with cervical 
cancer have more sexual partners than husbands of controls (30). In a recent study, smokers 
had a two-fold excess risk of cancer, with the risk linked to smoking intensity and duration 
(31). The effect was most striking among women who had smoked continuously up to the 
time of cancer diagnosis and women who began smoking late in life, suggesting that 
smoking played a promotional role in cervical cancer rather than an initiating role. Long-
duration use of hormonal contraceptives is associated with an increased risk of cervical 
cancer, but the public health implications depend largely on the extent to which the 
association remains long after the use of the contraceptives has ceased (31). Invasive 
squamous cell carcinoma is uncommon before the age of 30 years. Half of the patients, 
however, are less than 50 years old (32). In the United States, 22 percent of all women with 
cervical cancer are under the age of 35 years (33), but most are between 45 and 55 years of 
age al the time of diagnosis. Cervical cancer, however, can occur at almost any age between 
17 and 90 years.  The majority of the patients present with intermittent painless vagina, 
bleeding, often first noted after sexual intercourse or douching. With advancing disease, 
bleeding may become continuous, and be accompanied by a malodorous discharge and 
pain. Pain is frequently referred in the flank or leg as a result of tumor invasion of the pelvic 
wall or sciatic nerve. A cervical biopsy is mandatory for diagnosis. Although sampling 
problems and incorrect  interpretation are partly responsible for false negative smears, 
necrosis and inflammation on the surface of the tumor may result in only an “atypical 
smear” that lacks obvious tumor cells. Consequently, the cervix that is abnormal by 
inspection or palpation is biopsied, even if the cytology smear is normal. In addition to 
biopsy of the ectocervix, an endocervical curettage Is performed as an integral part of the 
evaluation because invasive carcinoma, particularly adenocarcinoma, frequently involves 
the endocervical canal and may not be visible on the ectocervix. Cervical cancer is the most 
common gynecologic cancer to occur during pregnancy: about 3 lo 10 percent of cervical 
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cancers occur in pregnant women. In these women, 83 percent present with stage I disease 
(34).  Invasive cervical cancer can be divided in two major histological types: squamous cell 
carcinoma and adenocarcinoma. In terms of percentages, 80–85% of cases are squamous cell 
carcinoma, 10% are adenocarcinoma, and 3% are adenosquamous carcinoma and other rare 
tumours (35). HPV infection is the most common sexually transmitted disease, with more 
than 80% of the population infected at some time in their life. The main risk factor is 
undoubtedly genital infection with HPV.  HPV infections are found in almost all pre-
invasive lesions, so-called CIN and invasive squamous cell cancers (36). Based on the still-
rising figures of HPV infections, one could consider it to be one of the most prevalent 
sexually transmitted pathogen diseases worldwide (1). From an epidemiological point of 
view, an HPV infection meets the criteria as a causal agent for cervical cancer (37,38). 
Current epidemiological and fundamental data have confirmed infection with HPV to be 
the basic cause of the disease (37,38). Having sexual contact is the main source of HPV 
infection. It is estimated that for every three people who have sex with a HPV-positive 
person, two will develop an infection within the next few months (1-19). In the majority of 
cases (75%), the infection will be asymptomatic. The peak prevalence of genital HPV 
infections is soon after the onset of sexual activity in women. HPV deoxyribonucleic acid 
(DNA) persists for about 6–12 months in the genital tract and spontaneously disappears in 
the majority of patients until an infection with a new type occurs. A persistent infection is 
the most important risk factor for initiating malignant transformation in the cervical 
epithelium. The time from initial infection to pre-invasive and, ultimately, invasive disease 
appears to be at least 10–15 years (1). Based on their association with cervical cancer, 
genotypes of HPV are divided into low-risk and high-risk groups, according to their 
presence in malignant lesions of the cervix.  Functionally high risk HPV types infection 
contributes to carcinogenesis and tumour progression predominantly through the action of 
two viral oncogenes, E6 and E7. The coordinated expression of E6 and E7 has been town to 
transform rodent cells and immortalize primary human keratinocytes (39,49). The E6 and E7 
proteins of high-risk HPVs have been demonstrated to be able to associate with the products 
of p53 and retinoblastoma susceptibility (Rb) genes, respectively, and inactivate the 
functions of these tumour suppressor proteins (40,41). The E6 protein exerts rapid 
degradation of p53, in corporation with E6-associated protein (E6-AP), via ubiquitin-
mediated proteolysis pathway (42, 43). The E7 protein mediates the release of the E2F 
transcription factor from pRb-E2F complex (44). Mutational analysis of HPV 16 E6 protein 
revealed that a certain level of the activity to degrade p53 is required for E6 to manifest its 
transforming function (45). The p53 mutations are the most frequent genetic abnormalities 
found in a wide variety of human malignant tumours (46). Once DNA damage occurs, p53 
protein is induced and arrests cells in the G1 phase to enhance DNA repair (47), or triggers 
apoptosis following DNA damage (48). These functions of p53 protein are important to 
maintain the genomic integrity. Mutant p53 proteins are devoid of these functions, because 
they lose the ability of DNA contact or destabilize the structure of the core domain (49). In 
this way, once p53 is mutated, DNA damage is fixed and subsequent genetic rearrangement 
progress which may be putative mechanisms to initiate cancer. Thus far, exceptionally low 
prevalence (0-6%) of the p53 mutations had been documented in cervical carcinomas (50, 51, 
52, 53, 54). The p53 protein in cervical carcinoma is thought to be inactivated presumably 
due to complex formation with HPV E6 oncoprotein. Although Crook et al initially 
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postulated that p53 mutations were confined to the HPVnegative cervical carcinomas 
(55,56), several recent studies implicated that p53 mutation was a very rare event and the 
occurrence was not strictly correlated with HPV status in primary cervical carcinomas 
(50,51,52,53,54). It has been also shown that p53 mutants identified in the HPV-positive 
anogenital cancers exhibit increased resistance to HPV E6-directed degradation, suggesting 
that mutation of p53 may play a role in the progression of the HPV-positive cervical cancer 
(56). The p53 mutation has been found only in 0–6% of cervical carcinomas. In light of recent 
studies demonstrating that mutation of p53 gene was found in over 20% of the patients with 
vulvar carcinoma (57, 58), a disease of elderly women and a known HPV- related 
malignancy, Nakagawa et al (59) analysed mutation of the p53 gene in 46 women with 
cervical carcinomas at the age of 60 or more (mean; 71 years, range; 60–96 years). Of the 46 
patients, 41 had squamous cell carcinoma (keratinizing type, ten; large cell non-keratinizing 
type, 31) and five had adenocarcinoma (endocervical type, four; endometrioid type, one). 
On the basis of the FIGO criteria, 12 women had Stage I, 18 Stage II, 15 Stage III and 1 Stage 
IV. The presence of HPV and its type were analysed by polymerase chain reaction (PCR)-
based assay using the consensus primers for L1 region. Mutation of the p53 gene was 
analysed by PCR-based single-strand conformation polymorphism and DNA sequencing 
technique. Point mutation of the p53 gene was detected in 5 out of 46 (11%) cervical 
carcinomas: 1 of 17 (6%) samples associated with high-risk HPVs (HPV 16 and HPV 18) and 
4 of 27 samples (15%) with intermediate-risk HPVs, whereas no mutation was found in 2 
HPV negative cases. The mutated residues resided in the selective sequence known as a 
DNA-binding domain. The immunohistochemistry revealed the overexpression in cancer 
tissues positive for p53 mutation. All of the observed mutations of the p53 gene were 
transition type, suggesting that the mutation may be caused by endogenous mutagenesis. 
Although falling short of statistical significance reduces the strength of the conclusion, data 
presented by Nakagawa et al imply that p53 gene mutation, particularly along with 
intermediate risk HPV types, may constitute one pathogenetic factor in cervical carcinoma 
affecting elderly women. To clarify the age-related genetic events in cervical cancer in 
elderly (>65 years) women, Saito et al (60) have analyzed for HPV typing via polymerase 
chain reaction, the expression of p53 via immunohistochemical study, and clinical behaviour 
66 tissue specimens obtained from patients with stage Ib-IIb cervical carcinoma. Of this 
group, 50 women aged 64 years and younger were designated as the younger group (mean 
age 46.7), and 16 women aged 65 years and older were designated as the older group (mean 
age 67.6) The prevalence of HPV DNA was higher in the younger group than in the older 
group (84.0 vs. 50.0%) as was the detection rate of HPV 16 (44.0 vs. 6.3%). In contrast, HPV 
18, 33, 52, 58, were frequently detected in older patients. The positive rate of p53 
overexpression in the older group was similar to that in the younger group (46.7 vs. 48.8%). 
There was no significant difference in the incidence of lymph node metastasis, histology, 
and the distribution of clinical stage between the two groups. In elderly Japanese women 
with stage Ib-IIb, the association of HPV of types other than HPV 16 is suggested to 
influence the progression of cervical cancer.  The most common member of the high-risk 
group is HPV 16, which accounts for more than 60% of all cervical cancers. The high-risk 
types account for more than 95% of all cases of cervical cancer. One of the main differences 
between high- and low-risk types is the possibility of integration in the genome. 
Approximately 1percent of the high-risk HPV types and only 0.1% of the low-risk HPV 
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types will lead to the development of cervical cancer (61). In our case HPV 16 and HPV 58 
were detected in two cases of CIN3 and HPV 58 in one case of squamous cell carcinoma. In 
one case of CIN3 and in 4 cases of squamous cell carcinoma the HPV type has been not 
detected. Two hypotheses may be made. There is a subset of squamous cell carcinomas that 
is unrelated to HPV. Other hypothesis takes into account that  HPV 16 is only integrated in 
72 percent of all invasive cervical cancers(62). The finding of the absence of HPV 16 DNA 
integration in some carcinomas implies that integration is not always required for malignant 
progression, but does not exclude the importance of HPV integration in the initiation of 
cervical cancer. Hypothetically, after the development of a carcinoma, the abnormal clone 
could lose the viral DNA. HPV 18, on the other hand, shows 100 percent integration. The 
epidermal growth factor receptor (EGFR) represents a cell membrane receptor characterized 
by an extracellular ligand-binding domain and an intracellular domain with tyrosine 
activity involved in signal transduction. EGFR receptor ligands such as epidermal growth 
factor (EGF) and tumor growth factor > binding to EGFR lead to a cascade of cellular events 
that are responsible for DNA synthesis, cell proliferation, mutation, survival maturation, 
and apoptosis (63). Aberrant EGFR expression results in abnormal growth, inhibition of 
apoptosis, angiogenesis,and  the promotion of invasion/metastasis (64). EGFR 
overexpression has been observed in several malignancies (65). Cyclooxygenase (Cox) is the 
enzyme involved in the conversion of arachidonic acid to prostaglandins in the critical steps 
of tumor onset and progression. Two Cox isoforms have been characterized. Cox-1 is 
expressed constitutively in almost all tissues and serves homeostatic functions. Cox-2, which 
is highly inducible by growth factors, prostaglandins, and tumor promoters, plays a key role 
in inflammatory response (66). Cox-2 overexpression has been reported in many neoplasms; 
its overexpression is associated with carcinogenesis and is linked to proliferation, 
neoangiogenesis, high microvessel density, and inhibition of apoptosis (67). Some authors 
have also clarified that the aggressiveness of Cox-2 expression in different malignant 
neoplasms is due to the ability of this substance to modulate adhesion molecule and 
protease expression (68,69). To find information on invasive squamous cervical carcinoma in 
the elderly, Giordano et al ( 70) have analyzed 110 invasive squamous cervical carcinomas 
obtained from 2 groups of patients for HPV status by polymerase chain reaction study, for 
immunohistochemical EGFR, Cox-2 expression, and clinicopathologic features.  In this study 
64 women 60 years or younger were designated as the younger group and 46 who were 61 
years or older were designated as the older group. The HPV status and the expression of 
Cox-2 and EGFR in the younger and older women were compared and correlated with the 
grading, staging neoplasm, and lymph nodal status. Overall survival curves were drawn 
using Kaplan-Meier estimates and were compared using log-rank tests in the whole series of 
110 patients.  The number of neoplasms with higher staging was significantly greater than 
those in the younger women. The mortality was higher in the older group than in the 
younger patients. In the elderly, the presence of HPV DNA in 65% of cases, and in the 
absence of sexual activity, could be due to reactivation of latent HPV infection. In 
accordance with data provided by the literature, this finding demonstrated that HPV DNA 
can be detected in elderly women and can be associated with cervical carcinoma (59,71,72). 
Thus, it is possible that, in elderly women, HPV presence, in the absence of sexual activity, 
could be due to reactivation of latent HPV infection because of impairment of host 
immunologic response (73). The overexpression of Cox-2 in a number of cases was 
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significantly higher in the older group than in the younger group, but this immunoreactivity 
is not related to the staging, grading, EGFR expression, or to the presence of HPV. The 
simultaneous expression of Cox-2 and EGFR had a poor prognostic significance, showing 
lower survival rates than cases without this immunoreactivity. On multivariate analysis, 
Cox-2 and EGFR immunopositivity did not reveal any correlation between these markers 
and prognosis probably because the number of cases considered was not particularly high. 
Inadequate immunologic control of HPV infection resulting in viral persistence is likely an 
important determinant of risk of progression to cervical neoplastic disease. Previous studies 
have provided evidence supporting this view. Higher prevalence of HPV infection is 
observed in HIV-infected individuals (74, 75). Studies have also reported associations 
between deregulation of cytokine production and impairment of CD4+ T cell–mediated 
immunity and cervical precancers (76,77,78,79). Finally, the consistent association observed 
between HLA alleles and cervical neoplasia argue for a role of the host immune response to 
HPV in cervical cancer pathogenesis (80). Immunologic competence has been reported to 
decrease with aging (81-93).  Garcia Piňeres et al (72) examined the association between 
lymphoproliferative responses to antigens/mitogens and persistent HPV infection in 
women older than 45 years. Women included in this study were participants in a 10,000-
woman population-based cohort study of cervical neoplasia in Costa Rica. Women older 
than 45 years and HPV DNA positive at a screening visit were selected as cases (n = 283). 
Garcia Piňeres et al  selected a comparably sized control group of HPV DNA–negative 
women, matched to cases on age and time since enrollment (n = 261). At an additional 
clinical visit, women were cytologically and virologically rescreened, and cervical and blood 
specimens were collected. Proliferative responses to phytohemagglutinin (PHA), influenza 
virus (Flu), and HPV16 virus-like particle (VLP) were lower among women with persistent 
HPV infection [median counts per minute (cpm): 72,849 for PHA, 1,241 for Flu, and 727 for 
VLP] than for the control group (median cpm: 107,049 for PHA, 2,111 for Flu, and 2,068 for 
VLP). The decreases were most profound in women with long-term persistence and were 
only observed for the oldest age group (≥65 years).  The results of this study indicate that an 
impairment in host immunologic responses is associated to persistent HPV infection. The 
fact that effects were evident for all studied stimuli is suggestive of a generalized effect.  
Since 1993, at least 7 studies have described the screening histories of women with invasive 
cervical cancer (95,96,97,98). The number of cases in these studies was between 469 and 
481All studies concluded that the lack of a cervical smear history is the major reason why 
the disease still occurs. The percentage of women with invasive cervical cancer that had no 
screening history varied between 28% in Connecticut, USA (99) and 54% for Maori women 
in New Zealand (100). This percentage strongly depends on the population coverage of 
screening. With a 100% coverage, the percentage will only include young women diagnosed 
before the starting age of the programme. In 2007 the almost 30%of the Italian population 
not included in organised programmes is partly the result of an implementation process still 
in progress in some Regions in Southern Italy, but mainly of a very limited or completely 
absent implementation in a few Regions in Northern Italy. In 2008 the extension of 
organised cervical cancer screening programmes in Italy had had a  target population  
13.8095.025 women, corresponding to 78,44% of Italian women aged 25-64 years vs 69% in 
2006.  During 2008, 39.69% of invites women were screened, vs 39.83% in the previous year. 
The results of single regions are not homogeneous(Table 3-13).  
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 2008 2007 2006 
Women 25-64 yrs 
included in the target 
population of 
organised 
programmes 
13.094.025 11.872.810 11.362.580 
Population 25-64 yrs 78,44 71,77 69,01 
Nominal extension 25,34(3.356.931/13.247.487) 25,58(3.055.353/11.943.507) 25,32(1.116.006/2.899.817) 
Compliance with 
invitation (%) 39,69(1.332.376/3.356.931) 39,83(1.217.000/3.055.353) 38,49(1.116.006/2.899.817) 
NORTHERN ITALY
Women 25-64 yrs 
included in the target 
population of 
organised 
programmes 
5.210.405 4.942.788 4.911.641 
Population 25-64 yrs 68,42 65,42 65,09 
Nominal extension 29,5(1.541.010/5.222.404) 28,46(1.415.361/4.972.858) 27,17(1.341.812/4.938.269) 
Compliance with 
invitation (%) 47,67(734.577/1.541.010) 46,93(664.344/1.415.361) 45,62(612.069/1.341.812) 
CENTRAL ITALY
Women 25-64 yrs 
included in the target 
population of 
organised 
programmes 
3.252.167 3.008.931 3.029340 
Population 25-64 yrs 98,09 91,86 93,95 
Nominal extension 26,52(890.868/3.359.359) 27,16(822.548/3.028.432) 26,84(814.208/3.033.546) 
Compliance with 
invitation (%) 40,17(357.846/890.868) 40,23(330.925/822.548) 35,70(290.632/814.208) 
SOUTHERN ITALY AND ISLANDS
Women 25-64 yrs 
included in the target 
population of 
organised 
programmes 
4.631.453 3.921.091 3.421.599 
Population 25-64 yrs 80,38 68,65 60,09 
Nominal extension 19,83(925.053/4.665.724) 21,38(817.444/3.942.217) 21,38(743.797/3.479.433) 
Compliance with 
invitation (%) 27,73(239.953/925.053) 27,12(221.731/817.444) 28,68(213.305/743.797) 
The data of Liguria region have not been reported. 
Legend: 
Nominal extension: percentage of the resident population aged 24-64 that is included in the target 
population of active organised programmes.  
PPV = Positive predictive value.  
DR = Detection rate.  
ASCUS = Atypical squamous cells of undetermined significance. 
CIN = Cervical Intraepithelial Neoplasia. 
Table 3. Extension of organised cervical cancer screening programmes in Italy. 
(http://www.osservatorionazionalescreening.it) 
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 ABRUZZO BASILICATA 
 2005 2006 2007 2008 2005 2006 2007 2008 
Nominal extension (%) 24,9 33,5 20,2 23,8 52 64,6 54,9 54,4 
Number of invitated women 87.398 118.054 73.981 88.974 90.013 111.808 96.613 95.476 
Compliance to invitation (%) 24,9 33,5 20,2 23,8 52,0 64,6 54,9 54,4 
Compliance with 
recommendation to repeat 
cytology% 
26,9 32,9 18 31,5 32,9 36,1 36,9 33,4 
Inadequate (%) 2,4 3,2 3,9  2,6 2,2 3 1,8 
Recommendation  to repeat 
cytology(%) 2,8 3,7 4,3 4,5 2,1 2,1 4,3 2,4 
Compliance colposcopy with 
referral for ASCUS+ 62,3 60,4 68,7 77,2 96,3 95,8 68,7 97,1 
DR° for lesions CIN2+ 
unadjusted 2,7 2,5 3 4,2 1,2 1,1 1,1 0,9 
PPV for CIN2+ of ASCUS+ 
referred to colposcopy 16,2 16,2 10,8 12,1 5,1 5,5 3,5 4,3 
Table 4. Organised cervical cancer screening programmes in Italy: value of some process 
indicators in Abruzzo and Basilicata regions between 2005-2008(National Centre for 
Screening Monitoring). (http://www.osservatorionazionalescreening.it) 
 CAMPANIA  EMILIA ROMAGNA 
 2005 2006 2007 2008  2005 2006 2007 2008 
Nominal extension (%) 24 14,9 17 18,5  27,8 31,4 30,8 33,4 
Number of invitated women 357.06 241.64 283.00 285.59  332.65 
377.4
0 
379.16
2 
409.37
6 
Compliance to invitation (%) 24,0 14,9 17,0 18,5  27,8 31,4 30,8 33,4 
Compliance with 
recommendation to repeat 
cytology% 
16,8 26,1 27 27,2  57,1 50,8 56 56,5 
Inadequate citology (%) 2,1 2,6 2,6 2,7  1,5 1,7 2 2 
Recommendation  to repeat 
cytology(%) 2,1 1,8 2,3 1,6  2,8 2,9 2,7 3,1 
Compliance colposcopy with 
referral for ASCUS+ 75,3 63,9 40 63,4  89,1 83,2 85,9 88,8 
DR° for cytologyc lesions 
CIN2+ unadjusted 1,6 1,3 1,4 1,5  3,6 3,8 4 4,4 
PPV for CIN2+ of ASCUS+ 
referred to colposcopy 17,4 11,7 12,8 17,2  14,6 15,7 17,9 16,4 
Table 5. Organised cervical cancer screening programmes in Italy: value of some process 
indicators in Campania and Emilia Romagna regions between 2005-2008(National Centre for 
Screening Monitoring). (http://www.osservatorionazionalescreening.it) 
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 LAZIO LOMBARDIA 
 2005 2006 2007 2008 2005 2006 2007 2008 
Nominal extension (%) 13,7 22,1 24,2 23,3 24,9 27,1 29,7 25,7 
Number of invitated women 227.356303.896299.466360.688 136.919154.165164.979 198.728 
Compliance to invitation (%) 13,7 22,1 24,2 23,3 24,9 27,1 29,7 25,7 
Compliance with 
recommendation to repeat 
cytology% 
24,1 21,8 31,3 30,3 37,8 41,5 41 39,7 
Inadequate citology (%) 3,5 1,9 2,6 3,9 2,2 2,4 2,5 2,4 
Recommendation  to repeat 
cytology(%) 2,9 2,4 2,7 2,7 1,5 1,4 2 1,9 
Compliance colposcopy with 
referral for ASCUS+ 92 86,6 91,3 87,6 86,3 83,9 93 86 
DR° for cytologyc lesions 
CIN2+ unadjusted 3,2 1,8 2,4 2,7 3,3 3 4 4 
PPV for CIN2+ of ASCUS+ 
referred to colposcopy 14,9 10,2 12,3 12 27 21,5 22,3  
Table 6. Organised cervical cancer screening programmes in Italy: value of some process 
indicators in Lazio and Lombardia regions between 2005-2008(National Centre for Screening 
Monitoring). (http://www.osservatorionazionalescreening.it) 
 
 MOLISE  PIEMONTE 
 2005 2006 2007 2008  2005 2006 2007 2008 
Nominal extension (%) 59,6 18,6
Activated 
only for 4 
months 
21,5  29,7 27 30 31,8 
Number of invitated women 50 16  23  365.893 330.188 371.226 396.661 
Compliance to invitation (%) 59,6 18,6  21,5  29,7 27,0 30,0 31,8 
Compliance with 
recommendation to repeat 
cytology% 
21,7 14,4  19,3  42,4 42,9 43 44,7 
Inadequate citology (%) 6,3 6,3  12,1  2,8 2,6 3 3,2 
Recommendation  to repeat 
cytology(%) 1,4 2,2  2,5  1,8 1,9 2 2 
Compliance colposcopy with 
referral for ASCUS+ 61,5 37,1  63,1  90,7 91,6 92,2 90,5 
DR° for cytologyc lesions 
CIN2+ unadjusted 1,5 0,62  1  2,1 2 2,2 2,3 
PPV for CIN2+ of ASCUS+ 
referred to colposcopy 17,3 7,7  5,9  17,7 15,1 17,2 17,2 
Table 7. Organised cervical cancer screening programmes in Italy: value of some process 
indicators in Molise and Piemonte regions between 2005-2008(National Centre for Screening 
Monitoring). (http://www.osservatorionazionalescreening.it) 
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 TRENTINO  PUGLIA 
 2005 2006 2007 2008 2005 2006 2007 2008 
Nominal extension (%) 37 30 30,1 29,8   8 9,9 
Number of invitated women 52.305 43.455 45.104 44.852   41.094 105.599 
Compliance to invitation (%) 37,0 30,0 30,1 29,8   8,0 9,9 
Compliance with 
recommendation to repeat 
cytology% 
35,7 36,2 37 53,2   36,2 17,2 
Inadequate citology (%) 4,8 5,7 5,5 5   3 4 
Recommendation  to repeat 
cytology(%) 1,5 1,3 1,3 1,2   4,4 1,2 
Compliance colposcopy with 
referral for ASCUS+ 75,5 78,5 79 76   45,9 59,2 
DR° for cytologyc lesions CIN2+ 
unadjusted 3,4 2,4 3,2 2,4   0,3 0,7 
PPV for CIN2+ of ASCUS+ 
referred to colposcopy 29,6 23,9 31,5 28,3   1,6 9,2 
Table 8. Organised cervical cancer screening programmes in Italy: value of some process 
indicators in Trentino and Puglia regions between 2005-2008(National Centre for Screening 
Monitoring). (http://www.osservatorionazionalescreening.it) 
 SARDEGNA SICILIA 
 2005 2006 2007 2008 2005 2006 2007 2008 
Nominal extension (%) 27 24,6 20,4 26,4 26,1 24,6 21,1 21,2 
Number of invitated women 38.813 35.368 29.329 74.765 153.31 126.90 131.256 133.590 
Compliance to invitation (%) 27,0 24,6 20,4 26,4 26,1 24,6 21,1 21,2 
Compliance with 
recommendation to repeat 
cytology% 
24 23,7 31,4 33,7 19,03 29,1 25,4 19,7 
Inadequate citology (%) 6,3 5,8 6 6,1 3,4 3,5 0,3 1,9 
Recommendation  to repeat 
cytology(%) 5,2 5,6 5,7 3 2,8 3,2 3,8 4 
Compliance colposcopy with 
referral for ASCUS+ 82,6 93,1 88,2 91,1 70,5 73,4 81 83,9 
DR° for cytologyc lesions 
CIN2+ unadjusted 3,7 4,5 5,7 4,2 1,9 2,6 3,1 3 
PPV for CIN2+ of ASCUS+ 
referred to colposcopy 29,2 8,6 11,5 15,2 9,7 16,3 12,9 9,6 
Table 9. Organised cervical cancer screening programmes in Italy: value of some process 
indicators in Sardegna and Sicilia regions between 2005-2008(National Centre for Screening 
Monitoring). (http://www.osservatorionazionalescreening.it) 
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 TOSCANA UMBRIA 
 2005 2006 2007 2008 2005 2006 2007 2008 
Nominal extension (%) 28,7 29,8 31,3 29,9 27,3 29,3 23,5 31,5 
Number of invitated women 291.516 303.307 319.444 309.365 67.635 73.206 58.556 78.215 
Compliance to invitation (%) 28,7 29,8 31,3 29,9 27,3 29,3 23,5 31,5 
Compliance with 
recommendation to repeat 
cytology% 
44,1 46,6 48 49,6 44,4 47,1 58,2 47,5 
Inadequate citology (%) 2 2,1 1,8 1,5 1,7 3,4 1,3 2,3 
Recommendation  to repeat 
cytology(%) 1,6 1,6 1,5 1,5 2 2 1,6 1,6 
Compliance colposcopy with 
referral for ASCUS+ 78,5 77,6 81,3 82,7 68,3 70,7 66,1 78 
DR° for cytologyc lesions 
CIN2+ unadjusted 2,6 2,9 2,8 3 3,3 4,2 2,4 4,2 
PPV for CIN2+ of ASCUS+ 
referred to colposcopy 21,8 25,1 24,2 23,9 57,3 29,1 22,6 34,2 
Table 10. Organised cervical cancer screening programmes in Italy: value of some process 
indicators in Toscana and Umbria regions between 2005-2008(National Centre for Screening 
Monitoring). (http://www.osservatorionazionalescreening.it) 
 VALLE D'AOSTA  VENETO 
 2005 2006 2007 2008 2005 2006 2007 2008 
Nominal extension (%) 31,8 32,6 28 26,7 22,8 24,1 24,4 25,7 
Number of invitated women 11.490 11.486 9.728 9.478 305.925 315.619 321.37 346.4 
Compliance to invitation (%) 31,8 32,6 28,0 26,7 22,8 24,1 24,4 25,7 
Compliance with 
recommendation to repeat 
cytology% 
62 63,8 59,4 73,8 44,47 43,8 44,8 41,8 
Inadequate citology (%) 5,5 4,5 1 0,8 5,7 4,7 5,4 5,4 
Recommendation  to repeat 
cytology(%) 3,4 4,5 2,4 1,6 2,8 2,8 3 3,1 
Compliance colposcopy with 
referral for ASCUS+ 85 94,1 93,9 95,2 90,5 91,6 92,3 91,6 
DR° for cytologyc lesions CIN2+ 
unadjusted 2,5 2,5 3,8 1,6 2,7 2,9 2,8 3,3 
PPV for CIN2+ of ASCUS+ 
referred to colposcopy 12,2 12,9 20,8 13,9 12,8 13,3 13,1 14 
Table 11. Organised cervical cancer screening programmes in Italy: value of some process 
indicators in Valle D’Aosta and Veneto regions between 2005-2008(National Centre for 
Screening Monitoring). (http://www.osservatorionazionalescreening.it) 
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FRIULI VENEZIA GIULIA  MARCHE 
 2005 2006 2007 2008 2005 2006 2007 2008 
Nominal extension (%) 30 27,8 25,2  32,4 31,8 32,7  
Number of invitated women 98,619 90,948 86,085  145,35 134,79 140,03  
Compliance to invitation (%) 30,0 27,8 25,2  32,4 31,8 32,7  
Compliance with 
recommendation to repeat 
cytology% 
54,9 51,9 56,2  33 36,2 35,2  
Inadequate citology (%)  6,5 6   1,1 2  
Recommendation  to repeat 
cytology(%) 2,3 2,2 2,1  1,9 1,8 2  
Compliance colposcopy with 
referral for ASCUS+ 88,8 90,7 88  90,4 80 84,7  
DR° for cytologyc lesions CIN2+ 
unadjusted     2,1 1.05 2,1  
PPV for CIN2+ of ASCUS+ 
referred to colposcopy     26,4 12,1 17,1  
Table 12. Organised cervical cancer screening programmes in Italy: value of some process 
indicators in Friuli Venezia Giulia and Marche regions between 2005-2008(National Centre 
for Screening Monitoring). (http://www.osservatorionazionalescreening.it) 
 ALTO ADIGE (SUDTIROL)  CALABRIA 
 2005 2006 2007 2008 2005 2006 2007 2008 
Nominal extension (%) 22,4 13,4 26,1  41,4 24,2 35,6  
Number of invitated women 32,194 18,542 37,699  21,619 94,105 162,16  
Compliance to invitation (%) 22,4 13,4 26,1  41,4 24,2 35,6  
Compliance with 
recommendation to repeat 
cytology% 
32,2 34 32,2  25 25 24,4  
Inadequate citology (%) 1,1 0,75 0,85   2,3 3,6  
Recommendation  to repeat 
cytology(%)     0,6 2,2 2,7  
Compliance colposcopy with 
referral for ASCUS+     71,4 75,5 81,7  
DR° for cytologyc lesions CIN2+ 
unadjusted     0,9 2.24 1,3  
PPV for CIN2+ of ASCUS+ 
referred to colposcopy     25 9,5 6,3  
Table 13. Organised cervical cancer screening programmes in Italy: value of some process 
indicators in Alto Adige and Calabria regions between 2005-2008(National Centre for 
Screening Monitoring). (http://www.osservatorionazionalescreening.it) 
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The main examined process indicators has been not reported in all the  regions. The 
distinction between  OpS and OS screening has not been done. In the literature numerous 
studies has been reported the recommendations and the results of cervical cancer 
screening(100-101-102-103-104). With regard to screening histories  of invasive cervical 
carcinoma, in Italy has been not published studies with exception of OrS programme of 
Friuli Venezia Giulia. Zucchetto et al (105) have examined the screening histories of 438 
women with invasive cervical cancer diagnosed in Friuli Venezia-Giulia between 1999 and 
2005. 82 cases (49.7%) were found in >65 years-old women. 165 (37.7%) women were not 
screening. 69 (15.8%) women were not invited to OrS because of age >64 years old. 
Histological type and HPV detection of invasive cervical cancers has been reported. The 
study of Zucchetto et al (105) shows that the lack of screening among older women and of 
compliance with organized programs among women in the target population are the main 
limitation in cervical cancer secondary prevention.  The results of Zucchetto et al (105) are in 
agreement with research conducted in northen Europe. Bos et al (106) have analized the 
screening history of 3.175 women with invasive cervical cancer diagnosed in the years 1994-
1997 in the Netherland. 57% of 3175 women with invasive cervical cancer had no previous 
smears. Given the high proportion of women with invasive cervical cancer older than 64 
years at diagnosis, the possibility of inviting them to have at least one Pap smear in life after 
64 years should be taken in consideration. In according to American Cancer Society 
Guidelines for the early detection of cancer and the guidelines of other national regional 
screening programme, women 70 years of age or older who have had 3 or more normal Pap-
test in a know and no abnormal Pap-test results in the last 10 years may choose to stop 
having Pap-test. But according to National Cervical Screening program the current policy of 
screening women of New Zealand is to continue organized regular screening until aged 69 
years with pap test every three years if the women have ever been sexually active remain in 
place. The present study should be support the screening policy to perform Pap test every 3 
years until aged 75 years, independently to sexual activity. In older post-menopausal 
women the transformation zone may be difficult to see. The cervix is often much smaller 
and the amount of cervical cells found in the smears may be not optimal. We believe that 
two samples (one from the endocervix with cytobrush and one from ectocervix with Ayre 
spatule) and  smearing the cytological materials on two slides is the procedure of choice in 
order to obtain adequate material. 
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1. Introduction 
Cervical cancer is the best known example of a common human malignancy with a proven 
infectious etiology. Clinical, epidemiological and molecular analyses have long indicated 
that persistent infection with high-risk human papillomaviruses (HPVs) is causally 
associated with cervical cancer. Although new prophylactic vaccines and highly sensitive 
HPV typing methods are currently available, cervical cancer continues as the most common 
tumor in developing countries, where most of the annual half a million new cases occur 
(Arbyn et al., 2011). Besides socio-cultural issues restraining professional gynecological care, 
the relatively high cost of these technologies has limited their availability where they are 
most needed. Thus, there is a pressing need for affordable and readily available detection 
and therapeutic tools for HPV infection and cervical cancer. In the last two decades, novel 
diagnostic and therapeutic approaches based on synthetic oligonucleotides and genomic 
information have developed into promising tools to fight human disease. 
2. HPV and cervical cancer 
Genital dysplasia and cervical cancer are associated with persistent infection of a subset of 
HPVs referred as high-risk, including HPV types 16, 18, 31, 33, 45, 52 and 58 (Clifford et al., 
2003). High-risk HPVs normally replicate in keratinocytes from stratified squamous 
epithelia of their hosts where the 8-kb double-stranded circular DNA genome is usually 
retained in an episomal form. The highly conserved high-risk HPV genomes consist of six 
common early genes (E1, E2, E4, E5, E6 and E7) and two late genes (L1 and L2) coding for 
the capsid proteins (Figure 1). The early genes contribute to cellular transformation, viral 
regulation and DNA replication (Moody & Laimins, 2010). In addition, the HPV genome 
also comprises a highly variable non-coding regulatory region, the long control region 
(LCR), which contains the viral origin of replication and regulatory elements targeted by 
several cellular transcription factors and the viral E2 gene (Hebner & Laimins, 2006).  
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Fig. 1. Map of the HPV genome. Early (E) and ate (L) genes are indicated. The arrow 
indicates the early promoter. 
2.1. HPV targets for diagnostic and therapeutic oligonucleotides 
The relationship between cervical cancer and high-risk HPVs is related to the integration of 
viral DNA to the host genome with the disruption of the viral regulator E2 (Pett & Coleman, 
2007; Vernon et al., 1997), and to the production of viral proteins E6 and E7 which are 
sufficient and necessary to acquire and maintain a transformed phenotype (Pirisi et al., 1988; 
Xue et al., 2010). Because E2 is usually absent in cervical tumor cells and E6/E7 genes are 
retained and expressed in most tumors, these features are often referred to as the hallmarks 
of cervical cancer (Alvarez-Salas & DiPaolo, 2007). In the absence of E2 protein, high-risk 
HPV E6 and E7 genes are continuously transcribed from a single promoter resulting in 
polycistronic mRNA containing both transcripts (Wang et al., 2011). The E6 and E7 protein 
products interact and functionally neutralize key cellular regulatory proteins, so that cell 
proliferation continues. 
High-risk HPV E6 protein targets numerous cellular pathways to insure viral DNA 
replication and is a key oncogene in HPV associated neoplasias. E6 was first shown to 
interact with the p53 tumor suppressor protein (Werness et al., 1990) and the E6-AP complex 
to act as a ubiquitin protein ligase (Huibregtse et al., 1991) inducing the specific 
ubiquitination and degradation of p53 (Scheffner et al., 1993). Thus, high-risk HPV E6 
results in blockage of p53-mediated apoptosis. Interestingly, E6 has been found interacting 
with the extrinsic apoptotic factors TNFR-1, FADD and caspase-8 (Filippova et al., 2002; 
Tungteakkhun et al., 2010) suggesting alternative apoptosis inhibitory functions. Although 
E6-mediated degradation of p53 is considered a key event for the onset of cellular 
transformation, it is clear that E6 possess other p53-independent transforming and anti-
apoptotic activities, such as telomerase activation (Gewin et al., 2004; Klingelhutz et al., 
1996; Oh et al., 2001). Many other cellular targets of high-risk E6 proteins have now been 
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described, including PDZ domain-containing targets such as the human homologue of the 
tumor suppressor DLG (discs large protein) (Gardiol et al., 1999), MUPP1 (Lee et al., 2000) 
and MAGUK (membrane-associated guanylate kinase) proteins  (Glaunsinger et al., 2000), 
and a number of transcription regulators (Etscheid et al., 1994; Zimmermann et al., 1999), 
disrupting cell adhesion, polarity, epithelial differentiation and  reducing  immune  
recognition  of  HPV infected cells (Howie et al., 2009).  
The E7 protein plays a vital role in the viral life cycle by disrupting the tight link between 
differentiation and proliferation, thus allowing viral replication in normal keratinocytes that 
would be otherwise withdrawn from the cell cycle (McLaughlin-Drubin & Munger, 2009). 
E7 protein from high-risk HPVs targets pRB and disrupts the E2F-mediated transcriptional 
regulation resulting in the up-regulation of genes required for G1/S transition and DNA 
synthesis (Duensing et al., 2001; Munger & Phelps, 1993).  HPV-16 E7 can directly bind the 
G1/S transition antagonists E2F1  (Hwang et al., 2002) and E2F6 (McLaughlin-Drubin et al., 
2008) thus ensuring that the infected cells remain in an S-phase-competent  state  allowing 
HPVs to bypass negative growth signals. The steady-state level and metabolic half-life of 
pRB are decreased in HPV-16 E7-expressing cells, because E7 can induce the degradation of 
pRB through the ubiquitin-proteasome system (Berezutskaya et al., 1997; Boyer et al., 1996). 
High-risk HPV E7 proteins also contribute to cell cycle dysregulation through the 
abrogation of the growth inhibitory activities of p21CIP1 and p26KIP1 (Funk et al., 1997; Jones 
et al., 1997; Zerfass-Thome et al., 1996). Other functions associated to high-risk HPV 
expression include epigenetic reprogramming through induction of KDM6A and KDM6B 
histone demethylases (McLaughlin-Drubin et al., 2011), trophic sentinel signaling 
abrogation and autophagy induction (Zhou & Munger, 2009), induction of genomic 
instability (Duensing et al., 2000), and disruption of Anoikis signaling through interaction 
with p600 (Huh et al., 2005). 
3. Oligonucleotide applications to cervical cancer and HPV infection 
Although the independent E6 and E7 functions may cause genomic instability, cell 
immortalization and transformation by themselves, the unregulated expression of both 
proteins is considered the major contribution of HPVs to cervical cancer development. The 
demonstration of the existence of stable molecular targets in high-risk HPVs has justified the 
development of small oligonucleotides for cervical cancer detection and treatment. High-
risk HPV-16 and 18 express E6 and E7 proteins from a single polycistronic mRNA 
(Schneider-Gadicke & Schwarz, 1986; Smotkin et al., 1989), suggesting that  targeting of 
either E6 or E7 mRNA would likely impede both E6/E7 translation resulting in similar 
growth arrest phenotypes. Several groups have identified that inhibition of these genes 
translation resulted in tumor growth suppression confirming E6/E7 as attractive targets for 
cervical cancer therapy (Alvarez-Salas et al., 1998; Shillitoe, 2006; Venturini et al., 1999). 
In the last decades, novel therapeutic approaches based on genomic information developed 
into promising tools to fight human disease. Therapeutic oligonucleotides are short DNA or 
RNA molecules designed to disrupt expression or function of disease-related genes. 
Approaches to therapeutic oligonucleotide technology include: 1) Blocking of gene 
transcription by triplex-forming oligodeoxyribonucleotides (TFOs); 2) Translation inhibition 
by AS-ODNs, small interfering RNAs (siRNAs) and ribozymes; 3) Inhibition of protein 
function by nucleic acid aptamers and 4) Immunostimulatory oligonucleotides (IM-ONS) 
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(Alvarez-Salas, 2008). Diagnostic oligonucleotides refer to the application of DNA or RNA 
oligonucleotides for diagnostic purposes. Diagnostic oligonucleotide technologies comprise 
oligonucleotides designed for 1) Priming polymerase chain reaction (PCR or RT-PCR) 
detection, 2) Hybridization-based technologies (hybrid capture or microarrays) and 3) 
Binding with target proteins (aptamers). Here, we will only discuss diagnostic 
oligonucleotides used as aptamers for HPV detection because PCR and hybridization 
technologies have been extensively used for HPV diagnostics for decades and the subject 
has been comprehensively analyzed elsewhere (Stanley, 2010).   
3.1 Antigene technology 
TFOs can hybridize with particular sequences in double-stranded DNA (dsDNA) through 
the formation of Hoogsteen or reverse-Hoogsteen hydrogen bonds between the TFOs and 
homopurine stretches found in the major groove of the target DNA (Letai et al., 1988; Moser 
& Dervan, 1987). TFOs have potential for manipulating gene structure and function in living 
cells, inhibiting transcription by interfering with regulatory protein binding or blocking 
mRNA elongation (Carbone et al., 2003) (Figure 2A). Although finding appropriate targets 
for TFO action in genomic DNA may be an issue, TFO technology has a potential advantage 
over oligonucleotide-based control of translation (antisense and siRNA technologies) 
because there are generally one to two targets per cell as compared with the hundreds to 
thousands copies of mRNA targets (Vasquez & Glazer, 2002).  
 
       A                     B 
Fig. 2. A) Antigene technology. Triplex-forming oligonucleotides (TFOs) hybridize with 
DNA to block transcription. B) Antisense oligonucleotides (AS-ODNs) gene silencing. As-
ODNs hybridize with the 5’-UTR (1) or within the coding region (2) of the target mRNA. 
Formation of DNA-RNA heteroduplexes induces RNaseH (3) activity over the RNA target 
(3a) producing degradation and thus inhibiting translation. Stable hybridization with the 
target 5’-UTR mRNA can inhibit ribosome anchorage (4).  
3.1.1 Antigene technology on cervical cancer 
Several natural triplex-forming sites have been identified within the HPV-16 genome 
(Malkov et al., 1993). However, only a few attempts have been reported on the use of TFOs 
against HPV. An initial report for the low-risk HPV-11 established an intramolecular triplex 
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DNA formation using a TFO directed to a 22nt-long homopurine stretch within the LCR (nt 
21-42) overlapping a Sp-1 and a E2 binding site plus the origin of replication. Although the 
stability of the triplex DNA formation was comprehensively demonstrated, no functional 
effect on HPV-11 transcription/replication was reported (Hartman et al., 1992). Other report 
also established formation of pyrimidine-purine-pyrimidine or pyrimidine-purine-purine 
triplex DNA with the HPV-16 fragment nt 554-685 under favorable conditions using 
complementary pyrimidine or purine TFOs. The observed DNA triplexes exhibited 
remarkable sequence specificity (Cherny et al., 1993). 
Optical DNA melting experiments and co-migration assay were used to establish stable 
triplex DNA formation at homopurine-homopyrimidine-rich target sites present in the 
HPV-16 E7 gene (nt 656-673). The target sequence was specifically recognized by several 17-
mer purine TFOs designed to form antiparallel or parallel triplex DNA helices (Popa et al., 
1996). Despite the reported success on triplex DNA formation using TFOs and different 
HPV targets, there are no reports on the application of TFOs to inhibit HPV transcription 
suggesting that intracellular conditions may not allow effective antigene-based therapies. 
3.2 The antisense approach 
Antisense inhibition uses DNA sequence information to synthesize an oligonucleotide 
complementary to a target mRNA and specifically inhibit or modify translation by three 
main mechanisms: A) Translational arrest by inhibiting ribosome binding at the 5’-UTR 
(Crooke, 1999); B) Induced degradation of the target mRNA by RNaseH (Agrawal et al., 
1990) (Figure 2B), and C) Translational modulation by exon-skipping (Du & Gatti, 2009). The 
aim of all antisense approaches is to reduce the quantity of the target protein in order to 
revert or prevent progression of a disease process.  
Two main classes of antisense oligonucleotides have been used to silence or modulate gene 
expression providing that the target sequences are exposed (in a single stranded form 
lacking secondary structure or protein binding). One class makes use of AS-ODNs 
complementary to the target mRNA. AS-ODN hybridization to its complementary target 
mRNA by Watson–Crick base pairing should provide enough specificity and affinity to 
produce translational arrest (physical blockage of ribosome binding) of the target mRNA. 
Additionally, the formation of DNA-RNA heteroduplexes leads to the activation of RNaseH 
thus inducing cleavage of the target mRNA (Bonham et al., 1995). The second antisense 
oligonucleotide technology class consists of small, catalytic RNA or DNA molecules. The 
catalytic core of these molecules produces cleavage of a target RNA once the catalytic 
moiety has hybridized with a Watson-Crick complementary sequence (Benitez-Hess & 
Alvarez-Salas, 2006). This mechanism may be contrasted with AS-ODNs that require 
cellular RNaseH activity following hybridization in order to cleave the target mRNA. 
3.2.1 AS-ODNs applications as therapeutic moieties 
Early use of unmodified AS-ODNs showed that they were highly unstable in biological 
fluids due to the presence of exonucleases thus limiting their use as therapeutic moieties. 
Later, several nucleotide analogues were introduced to increase ODN stability. To avoid 
changes in hybridization specificity, modifications were limited to the phosphate and ribose 
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backbone of DNA/RNA oligonucleotides. First generation modified AS-ODNs consisted of 
sulfur-substituted DNA on the free oxygen molecules constituting a phosphodiester bond. 
Phosphorothioated ODNs (PS-ODNs) display a high degree of stability in biofluids while 
retaining the ability to form RNaseH substrates leading to efficient, highly specific 
degradation of the target mRNA (Agrawal & Zhang, 1997). RNaseH activity is mostly 
nuclear and thus would likely produce cleavage of the pre-mRNA within the nucleus before 
splicing (Wagner et al., 1993). However, the strongly polyanionic nature of PS-ODNs cause 
in vivo issues regarding affinity, specificity, cellular uptake, biodistribution and toxicity thus 
limiting their therapeutical use (Akhtar & Agrawal, 1997). Nevertheless, PS-ODNs have 
been the most extensively studied AS-ODNs in various animal models and humans leading 
to oligonucleotide-based drugs such as Fomivirsen (Vitravene™) or Affinitak (Patil et al., 
2005).  
The use of other modifications such as methylphosphonates, ethylphosphonates or 2'-O-
methyl, confer high affinity for target sequences and extraordinary stability in biofluids, but 
they do not activate RNaseH (Mercatante & Kole, 2000). Thus, these modifications are better 
suited for modulating gene expression or exon-skipping approaches rather than gene 
silencing (Sierakowska et al., 2000). Second-generation AS-ODNs provide molecules with 
RNaseH activity but minimal off-target effects. Mixed-backbone oligodeoxynucleotides 
(MBOs) contain strategically placed segments of phosphorothioated backbones (able to 
induce RNaseH activity on the target mRNA) mixed with segments of either modified 
oligodeoxyribonucleotides or oligoribonucleotides (reducing off-target effects). The 
advantages of MBOs over PS-ODNs are increased biological activity, reduced polyanionic- 
and CG-dinucleotide-related side effects and increased in vivo stability (Agrawal & Zhao, 
1998). A third-generation AS-ODNs contains DNA/RNA oligonucleotides with 2'-O-methyl 
modification in addition to a phosphorothioate core and methylphosphonate ends further 
reducing toxicity. Improved stability, high specificity and low toxicity characterize these 
molecules, allowing for efficient destruction of target mRNA at nanomolar concentrations 
(Sternberger et al., 2002).  
3.2.2 Antisense technology on cervical cancer therapy  
Earlier reports on high-risk HPV E6 and E7 functions used plasmid-borne full-length antisense 
RNA to show that inhibition of HPV-18 E6/E7 expression results in growth arrest in C4-1 cells 
(von Knebel Doeberitz & Gissmann, 1987; von Knebel et al., 1988). Later, plasmid-borne 
antisense RNA delivery was shown to induce apoptosis in CaSki cells via up-regulation of p53 
and apoptosis induction (Cho et al., 2002). Delivery of antisense RNA using adenoviral vectors 
and retroviral vectors on SiHa and CaSki cells resulted in the reduction of HPV16 E7 protein 
expression and cell proliferation. These changes were accompanied by cell cycle arrest, up-
regulation of RB, down-regulation of E2F-1 and BCL-2 and dose-dependent and retarded 
tumor growth of CaSki cells, a cervical cancer line with multiple copies of HPV-16 (Choo et al., 
2000; Hayashi et al., 1997). More recently, non-neuroinvasive HSV-1 vectors, lacking the γ134.5 
gene, were used to express antisense RNA complementary to the first 100nt of the HPV-16 E7 
gene. These recombinant viruses down-regulated E7 protein expression in CaSki cells in a 
dose-dependent manner (Kari et al., 2007). Overall, these results confirmed the validity of 
targeting high-risk HPV E6/E7 for cervical cancer therapy. Nevertheless, due to the difficulties 
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of administrating plasmids, large antisense RNA molecules or even infectious viruses to 
patients, the use of small antisense moieties such as AS-ODNs, catalytic oligonucleotides or 
siRNAs might be a better alternative.  
Pioneering attempts on E6/E7 targeting by AS-ODNs directed antisense PS-ODNs to the 
translational start site of E6/E7 mRNA (Steele et al., 1993; Tan & Ting, 1995). In vivo testing 
on CaSki, SiHa and HeLa cells (all cervical cancer cell lines containing high-risk HPV) 
showed that these PS-ODNs produced cell growth inhibition. Nevertheless, no data was 
provided to show growth inhibition due to a true antisense mechanism. Later, a rational 
approach to antisense exposed regions was applied to HPV-16 E6/E7 using fast-hybridizing 
RNA segments obtained from partially digested E6/E7 mRNA (Kronenwett & Sczakiel, 
1997). A selection of AS-ODNs directed against such exposed sequences resulted in growth 
inhibition of cultured SiHa cells (Venturini et al., 1999).  
Our group developed AS-ODNs covering a so-called "antisense window" within a stable 
HPV-16 E6 (nt 410-445) region (Alvarez-Salas et al., 1995). Two short antisense PS-ODNs 
complementary to nt 410-445 produced efficient growth inhibition of monolayer and agar-
growth HPV-16-containing tumor cell lines in a dose-dependent manner. One of such PS-
ODNs also inhibited tumor growth in nude mice (Alvarez-Salas et al., 1999; Marquez-
Gutierrez et al., 2007). Interestingly, the combined use of both AS-ODNs resulted in the 
additive but not synergistic growth inhibition suggesting that they can be applied together 
to overcome issues related to genital HPV genomic variability (Marquez-Gutierrez et al., 
2007). Nevertheless, the high doses used in these studies (within the micromolar range) 
suggest that further modifications are required to improve therapeutical efficiency avoiding 
off-target effects. Overall, current AS-ODN applications to high-risk HPV E6/E7 gene 
silencing as a therapy for cervical cancer appears promising and relatively safe, providing 
that the tested PS-ODNs are administered locally to control off-target issues commonly 
observed with phosphorothioated moieties. Nevertheless, second and third-generation AS-
ODNs remain to be clinically tested as the advancement of other gene silencing technologies 
(i.e. siRNA and shRNAs) overcame an otherwise very effective molecular therapy.  
3.3 Therapeutic catalytic oligonucleotides 
Small ribozymes and DNAzymes are oligonucleotides possessing, at the very least, 
enzymatic RNA cleavage and ligation activities (Haseloff & Gerlach, 1988; Santoro & Joyce, 
1998). Ribozymes were initially described as catalytic RNA moieties found in the self-
splicing group I introns from the unicellular algae Tetrahymena (Kruger et al., 1982), and 
within the RNA active site of Escherichia coli RNaseP (Guerrier-Takada et al., 1983). 
However, the relatively large size of these two ribozymes precluded gene 
modulating/silencing applications. Later, small catalytic RNA cores from naturally 
occurring ribozymes were isolated from the circular genomes of certain pathogenic plant 
RNA viroids (Haseloff & Gerlach, 1989). In particular, two catalytic moieties have been 
intensely used as therapeutic agents; the hammerhead and hairpin ribozymes. By simply 
altering the native substrate recognition sequences, natural cis-cleaving ribozymes can be 
engineered to recognize and cleave any target RNA in trans by Watson-Crick hybridization 
(Michienzi & Rossi, 2001) (Figure 3A). Consequently, ribozymes received considerable 
attention as potentially valuable tools for the inhibition of virus replication, modulation of 
tumor progression, and analysis of cellular gene function (Morrissey et al., 2002). 
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        A               B 
Fig. 3. A) Catalytic oligonucleotides mode of action. Ribozymes or DNAzymes hybridize 
and cleave the target mRNA. B) RNA interference (RNAi) mechanism. Double-stranded 
RNA (dsRNA) found in a given mRNA are recognized and cleaved by DICER to yield small 
interfering RNAs (siRNAs) that in turn are incorporated into the RISC complex to cleave the 
mRNA from which they were derived. By administrating synthetic siRNAs the RISC 
complex may be manipulated to target a particular mRNA. 
3.3.1 The hammerhead ribozyme 
Hammerhead ribozymes are small (30-40nt) catalytic RNA moieties composed of three basic 
components including a highly conserved catalytic domain flanked by two base-pairing 
sequences and a complementary sequence within the target RNA containing the sessile 
phosphodiester bond. Natural catalytic centers can be formed within contiguous RNA 
sequences or by sequences several nucleotides apart (Epstein & Gall, 1987; Hutchins et al., 
1986). Providing that the target RNA is single-stranded, hammerhead ribozymes can cleave 
any substrate RNA containing the triplet 5´-NUX-3´, where U is conserved, N is any 
nucleotide and X can be C, U or A (Vaish et al., 1998). Cleavage occurs 3’ to the 5’-NUX-3’ 
triplet (Uhlenbeck, 1987), generating 5’ hydroxyl termini and a 2’,3’-cyclic phosphate at the 
cleavage site (Hutchins et al., 1986; Prody et al., 1986).  
3.3.2 The hairpin ribozyme 
Hairpin ribozymes are about 60nt long and efficiently catalyze a reversible, site-specific 
cleavage reaction. Structurally, hairpin ribozymes are composed by the substrate recognition 
domain A located aside the catalytic domain B and the target RNA containing the target site. 
The established cleavage requirements for heterologous substrates indicate that the substrate 
sequence must contain a 5’-BN*GUC-3’ motif (where * is the site of cleavage) (Anderson et al., 
1994; Hampel et al., 1990). Cleavage occurs at the 5’ side of guanosine and yields two products: 
the 3’-product containing the 5’-hydroxyl terminus newly formed within a terminal G, and the 
5’-product containing the 2’,3’-cyclic phosphate (Yu & Burke, 1997).  
3.3.3 Catalytic DNA 
DNAzymes are small (~30nt) catalytic DNA oligonucleotides capable of cleaving target 
RNA molecules in a sequence specific manner (Baum & Silverman, 2008). These molecules 
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represent a new generation of catalytic oligonucleotides artificially obtained through in vitro 
selection procedures by their capacity to catalyze the cis-cleavage of a target RNA sequence. 
Similar to ribozymes, DNAzymes hybridize substrate RNAs by Watson-Crick pairing and 
cleavage results in RNA fragments containing 2’,3’-cyclic phosphate and 5’-hydroxyl ends, 
suggesting a common mechanism (Santoro & Joyce, 1998). Therefore, the same widely tested 
design rules for AS-ODNs and ribozymes can be readily applied for therapeutic 
DNAzymes. However, unlike ribozymes, usage of DNAzymes as therapeutic moieties has 
the advantage of simpler and cost-effective synthesis, easier administration and higher 
stability in biofluids (Dass et al., 2008). So far, the 10-23 DNAzyme is the most commonly 
used in therapeutic applications. The 10-23 moiety structure resembles that of a 
hammerhead ribozyme consisting of a 15nt catalytic core flanked by two target recognition 
arms complementary to the target RNA (Santoro & Joyce, 1997). Cleavage is strictly 
dependent on Mg++ and is specifically produced at a RY (R, purine; Y, pyrimidine) junction 
within the target RNA  (Cairns et al., 2003; Faulhammer & Famulok, 1997). Although the 10-
23 DNAzyme is active at 37°C it may require nucleotide modifications to keep high activity 
under physiological conditions (Takamori et al., 2005). Other DNAzymes with different 
structural and catalytic features have been successfully used as sensors for ions, molecules 
and even proteins (Ali et al., 2011; Zhang et al., 2011). Thus, DNAzymes offer a wide array 
of possible therapeutical and diagnostic applications. 
3.3.4 Hammerhead ribozymes and HPV 
Early reports on ribozyme use against HPV assumed that translational start regions within 
mRNA are poorly structured thus allowing accessibility to antisense moieties. These reports 
were limited to cell-free experimentation and characterization of ribozyme cleavage on HPV 
target transcripts. Hammerhead ribozymes directed to HPV-16 nt 110 and 558 and 
expressed from plasmids showed efficient cleavage of HPV-16 E6/E7 transcripts in cell-free 
tests in different conditions of ionic strength, Mg++ concentration and temperature. 
Evaluation of the simultaneous activity of both ribozymes suggested a cooperative effect to 
disrupt HPV-16 E6/E7 gene expression (Lu et al., 1994). Similarly,  targeting HPV-16 E6/E7 
genes by hammerhead ribozymes specific to nt 240 and 597 showed that target size is 
important for catalytic activity (He et al., 1993). Chen et al., developed hammerhead 
ribozymes targeting HPV-18 E6/E7 genes (nt 120, 309 and 671) that were initially tested by 
incubation of total RNA from HeLa and Vero cells with in vitro transcribed ribozymes 
resulting in the efficient and specific degradation of HPV-18 transcripts from HeLa cells. In a 
more unorthodox approach E. coli was used to co-expresses both the ribozymes and a 1266nt 
fragment from HPV-18 (including E6 and E7 genes). Ribozymes were induced by infection 
with a helper phage (T7/M13) resulting in the progressive down-regulation of the HPV-18 
target. Finally, ribozyme anti-tumor activity was tested on HeLa cells resulting in a cell 
growth reduction, increased serum dependency, and reduced foci formation in soft agar 
(Chen et al., 1996; Chen et al., 1995) .  
3.3.5 Hairpin ribozymes and HPV 
Hairpin ribozymes are usually more efficient at 37°C than hammerhead ribozymes and co-
factors are not a strict requirement for activity because the catalytic mechanism appears to 
rely on structural components (Walter et al., 1998). However, efficient cleavage by hairpin 
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ribozymes requires a specific sequence within the target RNA (5’-GUC-3’ motif). We 
performed a comprehensive search for hairpin ribozyme target sites within HPV-16 E6/E7 
genes showed six potential target sites. A hairpin ribozyme directed to site 434 (R434) was in 
vivo tested for cis-cleavage using a plasmid-borne HPV-16 E6/E7 transcripts containing 
ribozymes at the 3’-UTR. Only R434-containig transcripts caused significant delay in the 
growth rate of transfected cells and inhibited E6/E7 immortalization (Alvarez-Salas et al., 
1998). Although this report demonstrated the feasibility of hairpin ribozyme use as a 
therapeutic antisense moiety for cervical cancer, the larger size of hairpin ribozymes limited 
their application as plasmid-borne moieties. Thus, we developed multiplex expression 
systems (triplex) based on hairpin ribozymes for R434. Such systems resulted in the 
complete release of multiple independent catalytic units from a single transcript by a self-
processing mechanism, allowing individual R434 activity and increasing efficiency of 
degradation of E6 RNA (Aquino-Jarquin et al., 2008; Aquino-Jarquin et al., 2010). The 
measured activity of a single R434 unit resulted in 30% inhibition of HPV-16 E6/E7 mRNA 
in SiHa cells, suggesting that multiple ribozymes directed against the same or other target 
sites might result in complete inhibition (Aquino-Jarquin et al., 2008). 
It is worth mentioning that notwithstanding the relative success on inhibiting HPV E6/E7 
by ribozymes, the catalytic features from both hammerhead and hairpin ribozymes 
dramatically drop within the cellular environment. Intracellular variables affecting activity 
include Mg++ availability, co-localization with the target, nuclease action and protein 
binding (Benitez-Hess & Alvarez-Salas, 2006). Plasmid-borne ribozymes usually contain 
stem-loop or tRNA structures to extend intracellular life that may get targeted by several 
RNA-processing mechanisms thus impeding activity (Alvarez-Salas L.M., unpublished data). 
Alternatively, because of their small size (~30nt) hammerhead ribozymes may be 
synthesized including modified nucleotides to escape nuclease and RNA processing 
mechanisms but this alternative usually brings deleterious off-target effects that may 
mislead data interpretation and limit clinical application. The therapeutical use of ribozyme 
in cervical cancer has never approached to the simple, efficient and relatively safe use of AS-
ODNs. Therefore, because the proven high ribozyme specificity and catalytic features for 
HPV transcripts it is likely that ribozymes may be better suited for diagnostic usage in 
cervical cancer. 
3.3.6 DNAzymes on cervical cancer therapy 
DNAzymes have become one of the most versatile oligonucleotide technologies available. In 
the last few years, DNAzymes have been used as therapeutical agents, computing DNA, 
biochemical analysis tools and sensors (Baum & Silverman, 2008; Stojanovic et al., 2005). 
However, there are only a few reports on DNAzyme application in the fields of cervical 
cancer and HPV. Our first report on a modified 10-23 DNAzyme directed to HPV-16 E6/E7 
mRNA “antisense window” showed efficient down-regulation of E6/E7 transcripts both in 
vitro and in vivo resulting in specific inhibition of proliferation and cell death in a dose-
dependent manner (Reyes-Gutierrez & Alvarez-Salas, 2009). To improve efficiency and 
intracellular stability the DNAzyme was modified with locked nucleic acids (LNAs) 
producing more thermostable DNAzyme-RNA complexes resulting in better cleavage 
efficiency (Benitez-Hess et al., 2011). In our hands, DNAzyme technology merged the 
relative simplicity and affordability of DNA synthesis and modification with the expected 
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benefits of enzymatic catalysis yielding a therapeutical moiety superior in performance and 
specificity when compared to AS-ODNs and even siRNAs at the nanomolar range. 
3.4 The small RNA revolution: siRNAs, shRNAs and miRNAs 
The mechanism of RNA interference (RNAi) is a natural and wide-spread gene knockdown 
phenomenon induced by the formation of double-stranded RNA (dsRNA) segments in most 
mRNAs (Elbashir et al., 2001; Fire et al., 1998; Sharp, 1999). The RNAi process occurs in the 
cytoplasm where dsRNA regions within mRNAs are digested into double-stranded 21–23nt 
fragments, with a 2nt 3’-overhand, by the RNaseIII-like enzyme DICER (Bernstein et al., 
2001). Subsequently, these small fragments, now called small interfering RNAs or siRNAs, 
are denatured by a helicase and one strand (leader or guide strand) is then incorporated into 
an RNA-induced silencing complex (RISC) that includes DICER, AGO2, TRBP and other 
members of the Argonaute family (Cullen, 2006; Hammond et al., 2001; Meister et al., 2004; 
Nykanen et al., 2001). The activated RISC complexes containing the guide strand hybridize 
and cleave the homologous mRNA from which they were derived. Therefore, there are no 
genes coding for particular siRNAs (Bartel, 2004). Recent reports suggest that siRNA activity 
exhibit serious dependence on the target site, as is the case for other antisense-based 
technologies, which might significantly limit the convenient use of siRNA (Miyagishi et al., 
2003). Target recognition by activated RISC complexes appear to rely on the perfect 
matching between the target sequence and a 2-8nt region within the guide strand known as 
“seed” region (Lin et al., 2005).  
By using synthetic siRNAs administrated exogenously, the RNAi machinery can be 
manipulated to silence a given mRNA (Figure 3B). These siRNAs can bypass the earlier 
steps in the RNAi pathway and can be loaded directly onto the RISC complex. Both 
synthetic siRNAs and vector-borne delivery of the equivalent short hairpin RNAs (shRNAs) 
have been used as potential therapeutic moieties for cervical cancer. Because shRNAs rely 
on the vector used, we will only focus in the developments of siRNAs as true therapeutic 
oligonucleotides. Although powerful, the widely reported gene silencing effects of siRNAs 
do not appear specific in many instances as down-regulation of unintended targets with 
partial sequence complementarities and stimulation of innate immune by type I interferon 
(IFN-I) and/or inflammatory cytokine responses have been often reported (Jackson et al., 
2003; Judge et al., 2005; Kalali et al., 2008).  
On the other hand, miRNAs are also small 20–25nt long non-coding dsRNAs with very 
specific functions modulating gene expression by hybridizing to complementary sequences 
present in the 3′ UTR of many protein-coding mRNAs (Bartel, 2004). Unlike siRNAs, the 
miRNAs are coded in the genome of most metazoans (including humans) by independent 
loci or within intronic regions of other genes (Cullen, 2004; Kim & Kim, 2007). They are 
initially transcribed by the RNA polymerase II as primary miRNAs (pri-miRNAa) (Lee et al., 
2004), which are cleaved into pre-miRNA hairpins by the RNaseIII-like nuclease DROSHA 
and PASHA/DGCR8 (Gregory & Shiekhattar, 2005). Pre-miRNAs are exported from the 
nucleus by the EXPORTIN-5  (Yi et al., 2003). Intronic pre-miRNAs are generated as a 
product of splicing of the host gene (Berezikov et al., 2007). Once in the cytoplasm, the pre-
miRNA hairpins merge to the RNAi pathway and are cleaved by DICER to produce mature 
miRNAs that are incorporated into RISC and interact with their targets (Valencia-Sanchez et 
al., 2006).  
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3.4.1 RNAi therapeutics on HPV 
Early attempts to silence high-risk HPV gene expression using siRNAs indicated selective 
E6/E7 mRNA. E6 silencing by a siRNA directed to HPV-16 nt 224-242 induced 
accumulation of cellular p53 protein, transactivation of the cell cycle control p21 gene and 
reduced cell growth but no apoptosis. Surprisingly, E7 silencing produced by a siRNA to nt 
662-680 induced apoptotic cell death. HPV-negative cells appeared unaffected by the anti-
viral siRNAs (Jiang & Milner, 2002). Because the polycistronic expression of HPV-16 E6 and 
E7 both siRNAs would have similar effect on E6/E7 expression and thus similar phenotypes 
(Butz et al., 2000). Although no explanation has been provided for this puzzling result, it is 
likely that the reported observations may be related to off-target effects. 
Later it was reported that vector-borne and synthetic siRNAs directed against the HPV-18 
E6 gene (nt 385-403) restored dormant tumor suppressor pathways in HPV-positive cancer 
cells that are otherwise inactive in the presence of E6. This ultimately resulted in massive 
apoptotic cell death, selectively in HPV-positive tumor cells (Butz et al., 2003). More recently 
a siRNA molecule targeting the E7 region of the bicistronic HPV-18 E6 and E7 mRNA (nt 
142-160) reduced expression of E6 and E7 in HeLa cells. Application of siRNAs against E6 
and E7 also inhibited cellular DNA synthesis and induced morphological and biochemical 
changes characteristic of cellular senescence. These results demonstrate that reducing E6 
and E7 expression is sufficient to cause HeLa cells to become senescent thus establishing 
that targeting of E6/E7 mRNA affects synthesis and functions of both E6 and E7  (Hall & 
Alexander, 2003). The simultaneous targeting of HPV-18 E6/E7 has also been reported to 
induce apoptosis and reduce proliferation of HeLa cells (Qi et al., 2010). Interestingly, it has 
been shown that cellular apoptosis induced by siRNA directed to HPV-18 E6 in HeLa cells 
relies on the p53 and ubiquitin proteolysis pathway thus inhibiting cell proliferation and 
promoting cell apoptosis. Anti-oncogene and upper regulation of immunization-related 
genes produced regression of the malignant phenotype after E6 inhibition (Min et al., 2009). 
Other synthetic siRNA decreased the levels of HPV-16 E6/E7 mRNA and induced nuclear 
accumulation of p53 in SiHa cells. The siRNA also suppressed monolayer and anchorage-
independent growth associated with p21CIP1/WAF1 induction and hypophosphorylation 
of retinoblastoma protein. Furthermore, SiHa cells treated with the anti-E6 siRNA prior to 
subcutaneous injection, formed tumors in NOD/SCID mice that were significantly smaller 
than in those treated with a control siRNA (Yoshinouchi et al., 2003). Thus, sequence-
specific targeting of high-risk HPV E6/E7genes, siRNAs may be developed into novel 
therapeutics that can efficiently inhibit growth of cervical cancer cells. Nevertheless, in vivo 
delivery of siRNAs is still a major obstacle to their clinical use.  
As with other oligonucleotide-based therapeutical approaches, in vivo delivery of siRNA is 
mostly affected  by ribonuclease degradation, rapid  renal  excretion  and  nonspecific  
uptake  by  the reticuloendothelial  system (Whitehead et al., 2009). Additionally, siRNAs 
are polyanions that do not readily cross the cell membrane. In turn to avoid these issues, 
siRNAs are often synthesized with phosphorothioated or 2’-O-modified bases and 
encapsulated in delivery systems allowing enhanced stability in biofluids and cell uptake, 
escape immune recognition, and improve pharmacokinetics by avoiding excretion and renal 
filtration (Lorenz et al., 2004; Sorensen et al., 2003). Encapsulated siRNAs still need to  
co-localize with the appropriate target cell/tissue type leading to more complicated 
therapeutic strategies. Thus, several considerations regarding biodistribution, extracellular 
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and intracellular transport must be addressed in addition to potency and biostability before 
clinical use of siRNAs. Nevertheless, the recent success in clinical trials using siRNA to treat 
age-related macular degeneration (Bevasiranib), respiratory syncytial virus infection (ALN-
RSV01) and the targeted in vivo gene silencing via systemic delivery of siRNA using 
transferrin-tagged, cyclodextrin-based nanocapsules for human cancer therapy (CALAA-01) 
have demonstrated the therapeutic feasibility of siRNAs (Shim & Kwon, 2010).  
In the last few years, siRNA use for silencing high-risk HPV E6/E7 has been widely 
reported although emphasis shifted from design and targeting to delivery and specificity, as 
highly active siRNAs are now commercially available. Many reports showed successful 
E6/E7 inhibition, but most of them were limited to cell culture, lacking of toxicity controls 
(Jonson et al., 2008; Lea et al., 2007; Sima et al., 2008; Yamato et al., 2008). A recent report, 
undertook a more comprehensive approach by designing and testing nine different siRNAs 
against either the E6 or E7 genes of HPV-16 or HPV-18 in several combinations. The siRNAs 
were tested on CaSki or HeLa cell lines resulting in significant cell growth and colony 
formation inhibition in both cell lines with a significant increase in apoptosis. The siRNAs 
had no effect in HPV-negative C33-A cells, demonstrating a lack of off-target effects. In 
addition, a xenograft study showed that intratumor injection of the siRNAs reduced tumor 
growth in BALB/c nude mice (Chang et al., 2010). 
The transient nature of antisense technology (including siRNAs) forced research on long 
expression using vector-borne shRNAs. Although many reports have established the 
feasibility of this approach (Bai et al., 2006; Bousarghin et al., 2009; Gu et al., 2011), it is clear 
that prolonged siRNA expression may lead to dysfunction of the RNAi pathway (Tang et 
al., 2006) or other intracellular effects (Koivusalo et al., 2006) due to the sudden rise in p53 
and pRB proteins after siRNA treatment (Sima et al., 2008). Thus, siRNA treatment has been 
used to enhance already established therapies for cervical cancer such as paclitaxel (Liu et 
al., 2009), cisplatin (Wu et al., 2011) and TRAIL (Eaton et al., 2011) with sometimes mixed 
results depending on the condition of p53 expression (Koivusalo et al., 2005). 
As noted above, nucleotide modifications at specific positions enable oligonucleotides to 
avoid intracellular nuclease degradation and meddling with the endogenous RNAi 
pathway, but they also help to overcome off-targeting issues in siRNAs (Jackson et al., 2006). 
In addition, DNA inclusion in the seed region of the guide strand and its complementary 
sequence within the siRNA, so-called a double-stranded RNA–DNA chimera (dsRNA-
DNA), abolishes off-target effects sacrificing some silencing activity (Ui-Tei et al., 2008). 
Application of dsRNA-DNA chimeras from previously reported and highly active siRNAs 
to nt 497, 573 and 752 within HPV-16 E6/E7 mRNA (Yamato et al., 2008), resulted in 
reduced cytotoxicity in two of three chimeric siRNAs (497 and 752), but not in the other 
(573), correlating with their reported off-target effects. Silencing activity was marginally 
affected in chimeric siRNAs 497 and 573 and moderately in 752. Chimeric siRNA 497 
induced E6/E7-specific growth suppression of cervical cancer cells and E6/E7-immortalized 
human keratinocytes (Yamato et al., 2011). 
The delivery of antisense moieties has also attracted much attention in siRNA research. 
Unlike AS-ODNs, there is a stringent requirement for transfection of siRNAs that has 
limited its applications as powerful cell culture inhibitors. To become truly useful 
therapeutic moieties, in vivo delivery methods have been developed for cervical cancer 
treatment using siRNAs besides the obvious use of vector-borne shRNAs. These approaches 
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vary from the traditional direct intratumor injection (Fujii et al., 2006) to more innovative 
methods such as dendrosomal nanoparticles delivery (Dutta et al., 2010), encapsidation in 
HPV-16 virus-like particles (Bousarghin et al., 2005), encapsulation in lipidic particles (Wu et 
al., 2011) and coating of quantum dots (Zhao et al., 2011). All of these approaches showed 
the feasibility of in vivo siRNA treatment for cervical cancer. No clinical reports have been 
published so far. 
3.4.2 MicroRNAs (miRNAs) in cervical cancer 
The participation of miRNAs as regulatory molecules in differentiation, apoptosis, and 
proliferation strongly suggested a role in cervical cancer. Although miRNAs are not 
therapeutic or diagnostic oligonucleotides in strict sense, they can be used as synthetic 
moieties to block key biological processes leading to malignant transformation. Because the 
HPV life cycle is linked to epithelial differentiation and requires actively proliferating  
keratinocytes, it has been hypothesized that HPV proteins may modulate miRNA 
expression. Interestingly, high-risk HPVs do not encode for any known miRNA (Cai et al., 
2006; Lui et al., 2007), although they may control expression of cellular miRNAs to regulate 
the activities of cellular proteins through expression of viral regulatory proteins (i.e. E5, E7 
and E7) (Greco et al., 2011; Wang et al., 2009; Zheng & Wang, 2011). In the last few years, 
many alterations in cellular miRNA patterns in cervical cancer tissue or cervical cancer cells 
have been reported, suggesting that knowledge of differential miRNA expression may have 
a significant diagnostic and prognostic value (Lui et al., 2007). 
High-risk HPV E6 may exert modulation of miRNA expression through p53 down 
regulation. Cervical cancer cells containing high-risk HPVs show reduced expression of 
miR-34a, a p53 effector with tumor-suppressor abilities. Reduction of miR-34a expression in 
HPV-containing human keratinocytes correlated with expression of viral E6. Furthermore, 
siRNA knockdown of viral E6 expression in high-risk HPV-containing cervical cancer cell 
lines lead to increased expression of p53 and miR-34a and accumulation of miR-34a in 
G0/G1 phase cells. Ectopic expression of miR-34a in HPV-containing and HPV-negative 
cells resulted in substantial cell proliferation inhibition and moderate apoptosis, suggesting 
HPV modulation of cellular miRNA expression (Wang et al., 2009). The HPV-16 E6 was also 
found to decrease expression of miR-23b in SiHa and CaSki cells by repressing the promoter 
and increased expression of its cellular target, the urokinase-type plasminogen activator 
(uPA), a known inductor of cell migration in cervical cancer cells. The link between HPV-16 
E6 and miR-23b transcription was associated to the presence of a p53 binding site within the 
miR-23b promoter, suggesting a cell migration modulatory role for E6 (Au Yeung et al., 
2011). 
High-risk HPV E7 expression in human keratinocytes modulated expression of human miR-
203 and its downstream target, ΔNp63. Although the underlying mechanism is not fully 
understood, E7 is sufficient for blocking miR-203 expression probably by modulation of the 
mitogen-activated protein kinase (MAPK) pathway signaling. The p63 family, is related to 
the p53 tumor suppressor. ΔNp63 isoform is expressed at high levels in proliferating 
undifferentiated basal keratinocytes, and its expression is down-regulated in differentiated 
non-proliferating cells. Down-regulation of ΔNp63 has been associated to regulation of 
epithelial proliferation and differentiation. Thus, inhibition of miR-203 allows HPV 
productive replication in differentiating cells (Melar-New & Laimins, 2010). Interestingly, 
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expression of the high-risk HPV-16 E5 protein (considered an overall enhancer of E6/E7 
activities) resulted in rapid (96 hours) alteration of  miR-146a, miR-203 and miR-324-5p and 
their target genes in transfected keratinocytes, suggesting a miRNA regulatory role for E5 
(Greco et al., 2011). 
Genomic microarray analyses in normal and cervical cancer tissues using the same miRNA 
array platform showed increased expression miR-15b, miR-16, miR-17-5p, miR-20a, miR-
20b, miR-21, miR-93, miR-106a, miR-155, miR-182, miR-185, and miR-224 and decreased 
expression of miR-29a, miR-34a, miR-126, miR-127, miR-145, miR-218, miR-424, miR-450, 
and miR-455) in cervical cancer tissues (Li et al., 2010; Wang et al., 2008). Further 
confirmation of miR-126, miR-143/145, miR-155, and miR-424/450 alterations was 
performed by deep sequencing (Witten et al., 2010). Other studies with customized miRNA 
arrays and different assay platforms showed increased miR-21 expression in cervical cancer, 
a common occurrence in cancer cells (Lui et al., 2007). More interestingly, miR-143 and miR-
145 showed basically null expression in cancer samples, suggesting the potential value of 
these miRNAs as tumor markers (Lui et al., 2007; Pereira et al., 2010). Yet another study 
concluded that infection with high-risk HPV lowered miR-218 expression suggesting a role 
for miR-218 in the pathogenesis of cervical cancer. Nevertheless, the specific role of all these 
miRNAs in cervical carcinogenesis and HPV infection is unknown.  
The growth inhibitory activity of miR-34c-3p was recently shown by our group in SiHa cells 
but not in other cell types. Although the inhibitory mechanism is not clear, transfection of a 
mi34c-3p mimic resulted in specific fast apoptosis induction (24 hours), inhibition of colony 
formation, cell migration and invasion, suggesting a potential therapeutic use for this 
miRNA (Lopez & Alvarez-Salas, 2011).  
3.5 Aptamers 
Aptamers are single-stranded oligonucleotides that, unlike AS-ODNs and siRNAs, function 
by folding into specific globular structures that dictate high-affinity binding to a variety of 
targets (Cerchia et al., 2002). They are often referred as functional homologues of the 
antibodies and are obtained through the use of the systematic evolution of ligands by 
exponential enrichment (SELEX) procedure. The SELEX method is a PCR-based in vitro 
selection procedure of large oligonucleotide libraries that recapitulates natural evolution 
resulting in the isolation of specific ligands that bind with high affinity to a wide variety of 
proteins and cell surface epitopes (Ellington & Szostak, 1990; Tuerk & Gold, 1990). These 
molecules have been used in flow cytometry, biosensors, affinity probe electrophoresis, 
capillary electrochromatography, and affinity chromatography (Yan et al., 2005).  
Notwithstanding the obvious value of aptamer for diagnostics, the incorporation of 
modified nucleotides into RNA transcripts resulting in stability in biofluids has 
considerably increased the use of aptamers as probes to inhibit protein functions (Pagratis et 
al., 1997). Nuclease-resistant RNA and DNA aptamers to block cell adhesion events gained 
importance in the last years. Wang et al., selected RNA aptamers that bind to infectious 
human cytomegalovirus and inhibit viral infection in vitro, showing the feasibility of the 
SELEX technique for the evolution of novel compounds that protect cells against infection 
by pathogens such HPV (Wang et al., 2000). Furthermore, combinatorial synthesized 
nuclease-resistant RNA and DNA aptamers are promising candidates for use in diagnostic 
and therapeutic onsets.  
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3.5.1 Aptamers on HPV detection and therapy 
Even though oligonucleotide aptamer technologies have been available for a number of 
years, it is only beginning to be established for HPV detection. During its life cycle, HPV 
expresses proteins according the cellular differentiation program that is modified after E2 
disruption and the onset of malignant transformation (Pett & Coleman, 2007; Xue et al., 
2010). Such features offer several protein targets for the detection of HPV infection and 
molecular diagnosis of cervical cancer by using aptamers as diagnostic oligonucleotides. The 
first aptamer directed against high-risk HPV proteins was obtained using a modified SELEX 
in which unspecific sequences were eliminated applying an antidote-like strategy (Toscano-
Garibay et al., 2011). This RNA aptamer effectively recognized the viral protein in a purified 
form with affinity comparable to other aptamers that bind small proteins. In addition, the 
interacting mechanism was common to those observed for little targets; it folds into two 
hairpin structures and wraps E7 making contact with independent sites located on the CR1 
and CR3 protein domains. Even though its behavior with infected cell extracts showed a 
cross-recognition between at least two types of HPV, this aptamer constitutes an important 
step towards the design of reliable and affordable detection methods. 
A second set of aptamers obtained against E7 has established the effect of a single nucleotide 
changes on the function of aptamers over the protein activity. By changing only one 
nucleotide (U>C) anti-E7 aptamers prevented the formation of pRB-E7 complexes, 
meanwhile the replacement of two bases conducted to inactive sequences (Nicol et al., 2011). 
These observations suggest that following a mutation-by-mutation planning process or even 
using error prone PCR, some of the obtained aptamers could improve intracellular stability 
to impede the activity E7 proteins and eventually become a complement for therapies 
against cervical cancer.  
4. Conclusion 
Over the last few years, small oligonucleotides have been proved as feasible alternatives to 
HPV infection and cervical cancer therapy. The most common and successful approaches 
appoint to antisense technology in the form of siRNAs and AS-ODNs against different 
target sequences within high-risk HPV E6/E7 mRNA. Above all, siRNA technology shows a 
higher capacity than AS-ODNs to inhibit HPV expression. However, siRNA-induced 
inhibition of high-risk HPV E6/E7 is still far from practical use, limiting research to cell 
culture applications. Several issues regarding the transient nature of siRNA-mediated 
inhibition and the associated and always difficult to control off-target effects have 
undermined the clinical application of this otherwise powerful technology. The ability to 
efficiently and stably produce and deliver sufficient amounts of siRNA to the proper target 
tissues still requires further refinement although recent advancements in siRNA delivery 
(encapsulation) and the use of modified nucleotides in synthetic siRNAs may finally allow 
clinical testing for cervical cancer. The use of vectors-borne shRNAs appears as a more 
distant solution due to the multiple ethical and biological issues arising from the use of viral 
vectors and the still impractical non-viral approaches (i.e. liposomes, dendrosomes, 
quantum dots, etc.). 
Even though off-targeting and delivery issues might be overcome the intracellular presence 
of any antisense moiety or siRNA must confront the role of innate immune responses. AS-
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ODNs have been shown to induce distinct classes of innate responses that can mislead data 
interpretation by masking true antisense effects in the clinical setup. In particular, the 
presence of CpG dinucleotides along the AS-ODN sequence that activate the immune 
system through Toll-like receptor 9 (TLR9), resulting in cytokine release and antitumor 
cytotoxicity (Kandimalla et al., 2005; Sivori et al., 2004). Transfection of unmodified siRNAs 
and shRNAs trigger a similar response through TLR3 and TLR7 (Judge et al., 2005). In fact, a 
whole new class of oligonucleotides known as IM-ONs that is virtually unexplored in the 
HPV and cervical cancer setup as therapeutical moieties or vaccine adjuvants.  
The involvement of miRNAs in cervical carcinogenesis has opened a new dimension in HPV 
research. Although many reports establish the alteration of a myriad of miRNAs, it is 
becoming clear that most of these are artifacts. A more stringent protocol should be used to 
establish participation of miRNAs in cervical cancer including functional assays in HPV-
positive and HPV-negative cervical cells and in situ detection in normal and tumor cervical 
tissues. Nevertheless, HPV modulation of miRNA expression is firmly established. The use 
of aptamers in cervical cancer diagnosis and HPV detection is promising as the natural 
history of HPV infection offers a plethora of targets previously addressed with antibodies. 
As SELEX-derived oligonucleotides grow in diversity and specificity, new and cost-effective 
aptamer-based technologies will provide fast and reliable prevention and early screening 
strategies that will compete with massive vaccination programs in the future. No use of 
aptamers in cervical cancer therapy has been reported, but the use of AS-ODNs and 
aptamers currently accepted by the FDA and the advent of new RNA therapeutic targets 
(i.e. miRNAs), suggest that the best options for the clinical application of oligonucleotides 
against cervical cancer are yet to come. 
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1. Introduction 
Despite hundreds of clinical trials being conducted for cancer patients, the overall response 
is below 4% and cancer remains a major health problem worldwide (Roberts, 2007; Kamb et 
al., 2007). Indeed, early detection of the disease should help improve diagnosis and 
treatment leading to a reduction in cancer mortality. The arising link between human 
papilloma virus (HPV) and ion channels presents a very interesting opportunity for the 
early diagnosis and therapy of different types of cancer, including cervical, head and neck, 
oral cavity and lung cancer, some of them within those of the highest incidence in the world. 
HPV infection has been proposed as the main etiological factor for cervical cancer 
(Walboomers et al., 1999; zur Hausen, 2002).  Nevertheless, HPV infection has been also 
suggested to be associated with head, neck and oral cavity cancer (Anaya-Saavedra et al, 
2008). Interestingly, in a population of taiwannesse women, more than 90% of lung cancer 
cases were not associated to cigarrette smoke (Chen et al., 1990). Analysis of HPV expression 
and its E6 oncoprotein in lung cancer biopsies from non-smoker taiwannesse women, led to 
suggest HPV as a lung cancer risk factor in such population (Cheng et al., 2001; 2007). 
Therefore, HPV presence might be used as an early marker for several types of cancer. 
Ion channels play important roles in cell physiology, including excitability, neural 
transmission, cardiac contraction, pancreatic cell metabolism, apoptosis and cell 
proliferation. Accordingly, alterations in either channel activity or expression are associated 
to several diseases (Ashcroft, F. 2006), and cancer is not an exception. Actually, several ion 
channels are suggested as tumor markers and therapeutic targets for different types of 
cancer, including those malignancies associated to HPV infection.  
Ion channels are integral membrane proteins transfering small ions through the 
hydrophobic lipid bilayer of the cell membrane, such as potassium (K+), sodium (Na+), 
chloride (Cl-) and calcium (Ca2+). They are present in the plasma and intracellular 
membranes of every cell type in the human body. Most ion channels require the presence of 
a stimulus to be activated (gated), this can be accomplished by changes in the membrane 
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potential (voltaged-gated ion channels), neurotransmitters or other molecules (ligand-gated ion 
channels), as well as light, temperature, mechanical forces, etc. Ion channels play an 
important role in a variety of cellular functions regulating every aspect of the cell 
physiology, the voltage-gated channels provide the ionic currents to generate and spread 
neuronal activity, calcium channels trigger synaptic transmission, hormonal secretion, and 
muscle contraction, and some channels participate in the regulation of cell migration, cell 
cycle progression, apoptosis and gene transcription. An increased number of human 
diseases has been found to result from defects in ion channel function or expression, 
including epilepsy, cardiac arrhythmias, skeletal muscle disorders and diabetes (Hübner, C. 
& Jentsch, T. 2002; Ashcroft, F. 2006). Since channels play an important role in proliferation 
and growth, and because cancer is a multifactorial disease, these membrane proteins also 
participate in tumor development. Many types of human cancers show alterations on ion 
channel expression presumably to help to transform healthy cells into malignant, invasive, 
and fast growing tissue (Schönherr, R. 2005).  
In this Chapter, we begin with a general overview of ion channels in cancer followed by the 
specific description of the participation of potassium, calcium, sodium and chloride 
channels in tumor cells. Then we focus on cervical cancer as the best example of a 
malignancy in which a link between HPV and ion channels can be found. Lastly, we 
describe in detail the regulation of human oncogenic ether à-go-go-1 (Eag1) channels by HPV 
oncogenes and estradiol.  
2. Ion channels in cancer 
The control of cell proliferation involves diverse signaling pathways, growth factors, and 
receptors, which have a restrict regulation in order to maintain the cell homeostasis 
(Vermeulen, et al., 2003). From a general view, the eukaryotic cell cycle consists of four 
phases (Figure 1) and some checkpoints  (Norbury, C. & Nurse, P. 1992; Massagué, J., 2004). 
Ion channels coordinate the upstream and downstream signals that converge on the cell 
cycle machinery. Both voltage- and ligand-gated channels have been implicated in the 
control of different cell cycle checkpoints in normal as well as neoplastic cells. Cell 
proliferation involves at some point the activation of Cl- channels, K+ channels and Ca2+ 
channels; these channels appear to play an active role in the pathways leading to 
duplication of any given cell (Kunzelmann, K. 2005). 
There are more than 400 genes encoding ion channel subunits that regulate the flow of ions 
across the plasma membrane and the intracellular organelle membrane.  In tumor cells, 
during the change from normal to cancer phenotype, a series of genetic alterations occur in 
which genes encoding ion channels might be affected. This might lead to changes in either 
channel expression or activity, which may be responsible, in part, of the pathophysiological 
features that cause malignant growth.   
Many types of ion channels have been described to play a potential role in the development 
and growth of cancer cells, some of them are listed in Table 1. Hallmarks of cancer have 
been recently reviewed and include altered cell cycle progression, self sufficiency in growth 
signals, insensitivity to antigrowth signals, evasion of apoptosis, adaptation to harsh 
conditions, sustained angiogenesis, tissue invasion and metastasis (Hanahan, D. & 
Weinberg, R., 2011). Most of the ion channels that contribute to the development of cancer 
The Human Papilloma Virus – Ion Channel Link in 
Cancer: An Alternative Opportunity for Diagnosis and Therapy 125 
have the capacity to induce proliferation by regulating the cell cycle at some point. Cell 
proliferation is a highly regulated process in which ion channels participate as regulators of 
the cell cycle, but surprisingly, the same ion channel mechanisms that regulate cell 
proliferation are involved in the control of apoptosis (programmed cell death) (Wang, Z. 
2004). Cell proliferation and apoptosis are two counterparts that are responsible for 
maintaining normal cellular functions. Abnormal enhanced proliferation and/or impaired 
apoptosis alters the cell homeostasis leading to loss of control of the cellular growth.  
 
Fig. 1. Phases of the eukayotic cell cycle.  
Details of the different types of ion channels involved in proliferation or invasion of tumor 
cells are described in Table 1.   
2.1 Potassium channels 
Potassium channels are the most extense family of ion channels and some of the most 
studied in cancer. Several potassium channels are overexpressed in tumors as compared to 
the corresponding healthy tissues. Some types of these channels include Kv´s (voltage-gated 
potassium channels), KCa (calcium-activated potassium channels), K2P (two-pore domain) 
and Kir (inward rectifier). All of these classes of potassium channels are further subdivided 
into subfamilies (Chandy & Gutman, 1993), and they regulate a vast diversity of functions in 
the cells including maintenance of the cell membrane potential, regulation of the cell volume 
(Lang, 2007), and cell cycle progression (Blackiston et al., 2009).   
Potassium ions are important for the osmotic regulation of cell volume by working in 
concert with the Na+-H+ exchanger and the Na+-K+ ATPase, contributing to the regulation of 
intracellular pH (pHi) (Ikuma et al., 1998). Thus, K+ channels participate in physiological 
and pathological proliferation by playing a role in membrane potential, cell volume and pHi 
change during cell-cycle progression. K+ channels also provide a hyperpolarizing effect on 
membrane voltage during cell cycle and therefore stimulate calcium influx. This increase in 
intracellular Ca2+ concentration is needed during progression through G1 phase and the 
G1/S transition (Wonderlin and Strobl, 1996; Kulzenmann, 2005). Usually, cancer cells have 
less negative voltage membrane than normal cells (Marino et al., 1994); therefore, it is likely 
that they would require a higher expression of certain types of K+ channels to produce the 
transient hyperpolarization required to proceed with cell cycle progression. Therefore, K+  
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Channels name 
IUPHAR Type of cancer Reference 
K+ channels   
Kv 1.3 Breast, Colon, Prostate 
Abdul, M.,  et al. (2003) ; 
Abdul, M. & Hoosein, N. (2002a) ; 
Abdul, M. & Hoosein, N. (2002c) 
Kv 1.5 Glioma Preussat, K., et al. (2003) 
Kv 3.4 Oral Squamous cell carcinoma Chang, K., et al. (2003) 
Kca 1.1 Cervical, Ovarian, Breast, Glioma 
Han, et al. (2007); Ouadid, H., et al. (2004a); 
Liu, X., et al. (2002) 
Kca 3.1 
Prostate, Breast, Melanoma, 
Pancreas 
Parihar, A., et al. (2003); Ouadid, H., et al. 
(2004b); Jäger, H., et al. (2004); 
Gavrilova, O., et al. (2002) 
Kv 10.1 
Breast, Colon, Cervix, Gastric,  
Prostate, Sarcoma, Ovarian 
Pardo, L., et al. (1999); Hemmerlein, B., et al. 
(2006); Ousingsawat, J., et al (2007); 
Farias, L., et al. (2004); Ding, X., et al. (2007); 
Mello, F., et al. (2006); Asher, V.,  et al. (2010) 
Kv 11.1 
Colon, Endometrial, Glioma, 
Leukemia, Stomach 
Lastraioli, E., et al. (2004); 
Cherubini, A., et al. (2000); Masi, et al., (2008); 
Smith, G., et al. (2002); 
Pillozzi, S., et al. (2002); Shao, X., et al. (2008) 
K2p 9.1 Breast, Lung Mu, D., et al. (2003); Pei, L., et al. (2003) 
Kir 3.1 Lung Plummer, H., et al. (2005) 
Ca+2 Channels   
Cav 1.2 Colon Wang, X., et al. (2000) 
Cav 3.2 Prostate Mariot, P., et al. (2002) 
Na+ Channels   
Nav 1.2 Prostate Anderson, J., et al. (2003) 
Nav 1.4 Prostate Bennett, E., et al. (2004) 
Nav 1.5 Breast, Ovarian Roger, S., et al. (2003); Gao, R., et al. (2010) 
Nav 1.6 Cervical, Glioma 
Hernandez, E., et al. (2011); 
Schrey, M., et al. (2002) 
Nav 1.7 Prostate Diss, J., et al. (2205) 
Other channels   
Cl channels Breast, Cervical, Hepatoma, Glioma, Prostate 
Abdel, M., et al. (2003); Mao, et al. (2009);  
Roman, R., et al. (2001); Olsen, M., et al. (2003) ; 
Shuba, Y., et al. (2000). 
TRPC1 Prostate Vanden, F., et al. (2003) 
TRPV6 Breast, Colon, Ovarian, Prostate, Thyroid 
Bolanz, K., et al. (2008); Vanden, F., et al. (2003); 
Zhuang, L., et al. (2002); Fixemer, T., et al. 
(2003) 
TRPM8 Breast, Colon, Lung, Melanoma, Prostate 
Tsavaler, L., et al. (2001); 
Yamamura, H., et al. (2008) 
P2X7 Cervical, Leukemia, Neuroblastoma, Feng, Y., et al. (2006); Wiley, J., et al. (2002); Per Larsson, K., et al. (2002) 
Table 1. Examples of ion channels involved in cancer.  
channel activation is particularly important for the early G1 phase of the cell cycle. During 
G1/S transition and S phase, cells swell and activate a regulatory volume decrease (RVD) 
mechanism, which allows shrinkage of the cell after mitosis. RVD requires efflux of water 
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and solutes, which is due to simultaneous opening of K+ and Cl- channels (Kulzenmann, 
2005), allowing the cell to proliferate. Another evidence associating K+ channels with 
proliferation is that voltage-gated K+ channels blockers inhibit proliferation in many cell 
types; this has been observed in normal physiological proliferation (lymphocytes) and in 
pathological conditions (as in cancer cells). Thus the cells require K+ channels in order to 
proceed with cell cycle progression (Wonderlin and Strobl, 1996). 
Most studies are devoted to the impact of voltage-gated potassium channels on proliferation 
of tumor cells, particularly those of epithelial origin (Abdul & Hoosein, 2002; Farias et al., 
2004; O’Grady & Lee, 2005; Pardo, 2004; Pardo et al, 2005; Arcangeli et al., 2009). One of the 
most studied voltage-gated potassium channel in cancer is the Eag1 channel. Eag1 displays 
oncogenic properties and shows a very restricted distribution in normal tissues (Pardo et al., 
1999; Hemmerlein et al., 2006) but it is expressed in many types of tumors including 
cervical, breast, lung, prostate, liver and colon carcinoma (Farías et al., 2004; Hemmerlein et 
al., 2006; Ousingsawat et al., 2007). Inhibition of either channel activity or expression leads 
to decreased tumor cell proliferation both in vitro and in vivo (Pardo et al., 1999; Gómez-
Varela et al., 2007; Ousingsawat et al., 2007). The restricted distribution of Eag1 and its role 
in proliferation have converted this ion channel in an attractive tool for diagnose and 
therapy of many cancers. 
It has also been shown that several K+ channels associate with other proteins related to  
proliferation, for instance Kv11.1 channels associate with 14-3-3 (Kagan et al., 2002), Src 
(Cayabyab, 2002), or TNF-_ receptors (Wang et al., 2002), Kv1.3 associate with integrins 
(Levite et al., 2000) and p56lck (Hanada et al., 1997), and Kv10.1 associates with calmodulin 
(Schönherr et al., 2000). Increased expression of K+ channels in tumors offers an additional 
tool for cancer diagnose and treatment.  
2.2 Calcium channels 
Calcium entry via different channels activates intracellular signalling cascades. Calcium 
channels play pivotal roles in many human diseases, particularly of the cardiac and nervous 
systems, for example, epilepsy, hypertension and migraine. In addition, these channels have 
been involved in pain and cancer. Cytosolic Ca2+ activity is necessary throughout the cell 
cycle since it plays a critical role on the regulation of cell proliferation (Whitfield et al., 1995; 
Parekh & Penner, 1997; Berridge et al., 1998, 2000, 2003). It has been shown that decreased 
levels of extracellular Ca+2 inhibit the progression through the G1 phase, causing cells to 
remain at the G1/S boundary. Moreover, Ca2+ is highly concentrated in intracellular stores 
and is released from the endoplasmic reticulum or mitochondria upon mitogenic 
stimulation (Nilius et al., 1993; Lepple et al., 1996). In excitable tissues, Ca2+ influx occurs 
through voltage-gated Ca2+ channels depending on the cell type. In non-excitable tissues, 
hyperpolarization of the membrane voltage is important for the increase of intracellular 
Ca2+, providing the driving force for Ca2+ entry from the extracellular space.  
Among voltage-gated Ca2+ channels, members of the Cav3 subfamily, and in particular 
Cav3.2 channels, are implicated in proliferation. It has been observed that voltage-gated 
calcium channels CaV1 (L-type currents), are expressed in non-proliferative phases, while 
expression of CaV3 channels (T-type currents) often increases during the proliferative 
phases. This is observed in both normal and cancer cells, although the precise physiological 
significance is uncertain. Cav3.2 channels are expressed in several cancer-derived cell lines, 
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and blockage of the channel generates antiproliferative action (Roger  et al., 2006, Panner & 
Wurster, 2006). T-type calcium channels have been found in lung carcinoma cells (Oguro-
Okano et al., 1992) and calcium influx through different ion channels has been suggested to 
participate in migration and invasion of prostate, breast and fibrosarcoma cells (Monet et al., 
2009; Yang et al., 2009; Huang et al., 2004).  
Other types of calcium channels have also been involved in cancer progression and 
prognosis. For instance, expression of the Ca+2 channel TRPV6 was correlated with prostate 
cancer grade, in which patients with positive TRPV6 prostate cancer had a poor prognosis 
(Fixemer et al., 2003).  
2.3 Sodium channels 
Voltage gated sodium channels (VGSCs) that selectively conduct sodium due to changes in 
membrane potential, allow sodium entry and thus the propagation of depolarization along 
the plasma membrane of nerve, muscle and other electrically excitable cells. Non-voltage-
gated sodium channels like the degenerin/epithelial sodium channel (ENaC) superfamily, 
which are permeable also to lithium and potassium, is a group of proteins involved in 
diverse biological processes, including sodium homeostasis, salt taste, nociception, pain 
transduction, touch sensation and mechanotransduction (Goldin et al., 2000).  Sodium 
channels have various functional and pharmacological properties in different tissues and 
species, and VGSCs in particular play an important role in generating action potentials. 
There are ten genes that encode VGSCs α subunits, from which nine constitute a single 
family named NaV1 (NaV1.1 to NaV1.9), whose members associate with one or more 
auxiliary β subunits (NaVβ1 to NaVβ4) to form the whole channel protein complex (Yu et al., 
2003). The remaining isoform, NaX, shows a structure diverging from the NaV1 family and 
seems to be gated by sodium concentration and not by voltage.  
VGSCs have been suggested as participants in the development of cancer. Enhanced 
metastasis correlates with the appearance of membrane channels and currents that are 
characteristic of excitable membranes. Metastasis is a process where cells escape from a 
primary tumor, enter circulation (blood or lymph), migrate and invade other tissues, 
proliferate and form secondary tumors. In in vitro experiments, it has been shown that 
VGSCs are associated to proliferation, motility, and invasion of  breast,  lung,  ovary and 
prostate cancer  (Roger et al., 2003; Gao et al., 2010; Diss et al. 2005; Chioni et al., 2010; Roger 
et al., 2007;  House, et al., 2010; Bennett et al., 2004). In prostate cancer cells, the main VGSC 
overexpressed is the NaV1.7 subunit, while in breast, colon and ovary the NaV1.5 subunit is 
the predominant subunit overexpressed. In addition, functional expression of VGSCs 
(mainly NaV1.7, NaV1.6 and NaV1.5) is often associated with metastasis and VGSCs have 
been found in biopsies from prostate and breast metastatic cancer (Roger et al., 2006). The 
mechanisms responsible for VGSCs upregulation and for their pro-invasive roles are still 
poorly understood, but diverse hypothesis exists. One hypothesis strongly suggests that 
there is a regulation of growth factors release and/or activity which is common to all the 
cancers described, highly malignant cancer cell types that overexpress VGSCs also express 
growth factors such as epidermal growth factor (EGF) and nerve growth factor (NGF) 
(Brackenbury & Djamgoz, 2007; Uysal & Djamgoz, 2007), empasizing that growth factors 
could play a major role in upregulating VGSCs. Another hypothesis describes that 
embryonic genes, which are silent in the cells of the mature organ, are re-expressed in cancer 
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cells (Monk  & Holding, 2001). This might be the case for VGSCs, since highly metastatic 
cancers (prostate and breast) mostly express embryonic isoforms of VGSCs (Diss et al., 2005; 
Fraser et al., 2005). Hence overexpresion of VGSCs contributes to the physiological and 
pathophysiological invasive processes in several metastatic cancers, representing a potential 
target to inhibit invasion and metastasis.  
2.4 Chloride channels 
Cl− channels play a crucial role in controlling the ionic composition of the cytoplasm and the 
volume of cells. According to their gating mechanisms there are five classes of chloride 
channels: 
- Voltage-gated chloride channels (CLC). 
- Volume/swell-regulated/sensitive anion/chloride channels (VRAC). 
- Cystic fibrosis transmembrane conductance regulator (CFTR). 
- Calcium-activated chloride channels (CLCA). 
- Ligand-activated chloride channels, which mainly form synaptic channels.  
Cl- channels play a crucial role in controlling the ionic composition of the cytoplasm and the 
cell volume. Cl- channels are expressed in a variety of tumor cells and participate in cell 
proliferation, invasion and migration. Proliferation is associated with volume increase along 
the G1 phase, but non-specific cell swelling can inhibit proliferation. To regulate their 
volume, cells are endowed with various ions and organic osmolyte transport proteins that 
become activated upon cell swelling or shrinkage. In the presence of a significant water 
permeability of the plasma membrane, water follows osmotically, resulting in a regulated 
change of cell volume. This is called regulatory volume increase (RVI) or regulatory volume 
decrease (RVD). RVI most often involves the uptake of Na+ and Cl−, for instance, by the 
concomitant activation of Na+/H+ and Cl−/HCO3- exchangers. Na+ is replaced by K+ 
through the Na+-K+-ATPase, resulting in a net intracellular accumulation of KCl. In RVD, 
intracellular KCl may be extruded by KCl cotransporters or by the concerted activation of 
swelling-activated Cl− channels and K+channels (Jentsch et al., 2002). Cell proliferation has 
been shown to correlate with increases in cell volume in fibroblasts, mesangial cells, 
lymphocytes, human promyelocytic leukemia cells (HL-60 cells), hybridoma cells (GAP A3), 
smooth muscle cells and cervical carcinoma cells (HeLa cells). The signaling of cell 
proliferation needs at some stage transient cell shrinkage, which may require the activation 
of Cl- channels. Usually, intracellular Cl- is above electrochemical equilibrium and activation 
of Cl- channels leads to Cl- efflux and thus depolarization. As long as K+ channels are active, 
the Cl- outward movement is paralleled by K+ efflux. The loss of KCl and water shrinks the 
cells (Lang et al., 1998).  
It has been observed that pharmacological inhibition of Cl- channnels impairs the cell ability 
to migrate and limits tumor progression in experimental tumor models (McFerrin & 
Sontheimer, 2006). The outer membrane of mitochondria contains a Cl- selective porin, the 
so-called voltage-dependent anion channel (VDAC). On the other hand, VRAC´s modulate 
progression of nasopharyngeal carcinoma cells through the G1 restriction point and endow 
nasopharyngeal carcinoma cells with enhanced proliferation ability. In addition, it is 
reported that VRAC displays cell cycle-dependent expression in tumor cells. Also CLC-3, an 
important member of the CLC superfamily, plays a crucial role in a variety of cellular 
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processes, including cell proliferation and cell cycle progression, and it has been 
demonstrated that inhibition of CLC-3 protein expression down-regulates invasion and 
migration ability of tumor cells. 
3. Ion Channels in apoptosis 
Cell homeostasis requires a delicate balance between formation of new cells by cell 
proliferation and cell elimination by apoptosis (programmed cell death). Apoptosis 
eliminates abundant and potentially harmful cells (Green & Reed, 1998). Apoptotic 
pathways involve several proteins with great enzymatic cell degrading potential including 
Bcl-2, caspases and cytochrome C. This process is initiated by death-promoting molecules 
such as TNF-α or CD95 Fas ligand, DNA damage, lack of growth factors, or cell exposure to 
genotoxics like radiation or oxidants. Apoptosis evasion might be one of the first steps for 
the transformation of nomal cells into cancerous cells, and it is a tightly regulated and 
highly efficient cell death program which requires the interplay of multiple factors. Upon 
receving specific signals instructing the cell to enter apoptosis, distinctive changes occur in 
the cell including shrinkage, nuclear condensation, DNA fragmentation, formation of sub-
cellular apoptotic bodies, and mitochondrial depolarization. Ion channels have been 
involved in the regulation of apoptosis.  
Potassium ions must leave the cell as an obligatory step in the apoptotic pathway. 
Activation of K+ channels and loss of intracellular K+ has been directly correlated to trigger 
apoptosis (Wang, 2004). Therefore, inhibition of apoptosis might take place by either 
increasing extracellular K+ concentration (Prehn et al., 1997; Colom et al., 1998) or inhibiting  
K+ channels (Lang et al., 2003). In any case, cellular K+ loss seems to be an important trigger 
of apoptosis in a wide variety of cells. Activation of K+ channels leads to hyperpolarization 
of the cell membrane, thus increasing the electrical driving force for Cl- outflow into the 
extracellular space. Then, if K+ channel activity is paralleled by Cl- channel activity, it leads 
to cellular loss of KCl with osmotically obliged water and hence to cell shrinkage, a hallmark 
of apoptosis (Lang et al., 1998). Subsequently, metabolic enzymes are activated, such as 
caspases and nucleases, which further propagate death signals. Remarkably, all these 
enzymes are controlled by the intracellular K+ concentration and while the concentration of 
various ions may change during apoptotic cell shrinkage, that of K+ plays a necessary and 
probably pivotal role in the cell death program. Cl- and K+ conductances must stay within a 
certain values in order to support proliferation, otherwise programmed cell death is 
triggered (Lang et al., 2004).  
Sustained increase of cytosolic Ca2+ activity has been shown to trigger apoptosis in a 
variety of cells (Green & Reed, 1998; Spassova et al., 2004; Parekh & Putney, Jr., 2005). 
Cytosolic Ca2+ may trigger mechanisms required for cell proliferation and stimulate 
enzymes executing apoptosis. Ca2+ signal convergence results in activation of intracellular 
channels that leads to cytochrome C release from mitocondria. During apoptosis, small 
amounts of mitochondrial cytochrome C translocate to the endoplasmic reticulum and 
trigger Ca2+ release via IP3R channels. This leads to a bursting Ca2+ overload, which 
coordinates massive cytochrome C release from mitochondria, leading to activation of the 
caspase cascade, essential for the development of apoptosis (Boehning, D. et al., 2003). Both 
the magnitude, space- and time- occurrence of Ca2+ entry is a major determinant to trigger 
apoptosis.  
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Both cell proliferation and apoptosis involve at some point activation of Cl- channels, K+ 
channels and Ca2+ channels.  Due to complex interaction with other signaling pathways, a 
given ion channel may play a dual role in both cell proliferation and apoptosis. 
At this point we focus on cervical cancer, a very well recognized cancer type strongly 
associated to HPV infection and ion channel expression. A potential link between HPV and 
ion channel expression has been also proposed for this type of cancer. 
4. Overview of ion channels in cervical cancer 
Expression of several ion channels has been reported in cervical cancer suggesting these 
proteins as potential markers and/or therapeutic targets for this malignancy. Large Ca2+-
activated K+ (BK) channels are ion channels activated by changes in membrane electrical 
potential and/or by increases in the intracellular concentration of Ca2+, contributing to cell 
proliferation and migration (Yuan et al., 2010).  BK channels are expressed in HeLa cells, and 
it has been observed that they play a significant role in the regulation of proliferation of this 
cell line. Blockage of BK channels in HeLa cells results in tumor cell apoptosis and cycle 
arrest at G1 phase. The transduction pathway underlying such anti-proliferative effects is 
linked to the increased expression of apoptotic protein p53 and the decreased expression of 
its chaperone heat shock proteins (Hsp). Heat shock proteins function as intra-cellular 
chaperones (proteins that bind to and stabilize an otherwise unstable conformer of another 
protein) for other proteins, such as p53 (Zylicz M, King FW, Wawrzynow A., 2001); upon 
cell stress, the levels of these proteins increase dramatically. Other K+ channels induce 
expression of heat shock proteins to exert tissue protective effects (Shinohara et al. 2004), 
suggesting that the intracellular potassium homeostasis may play a certain role in 
modulating heat shock proteins. The tumor suppressor gene p53 is involved in a variety of 
cellular processes including induction of G1 arrest and apoptosis by transactivating a 
number of downstream genes (Jin S, Levine A., 2001). One of those genes is p21 Cip1 (cyclin-
dependent kinase inhibitor 1A), which is a cell-cycle regulatory protein that interacts with 
cyclin-CDK2 and -CDK4, inhibiting cell cycle progression at G1. The expression of p21 is 
tightly controlled by p53, through which this protein mediates the p53-dependent cell cycle 
arrest at G1 phase (Zamzami N, Kroemer G., 2005). Blockage of BK channels increases p53, 
p21Cip1, and Bax protein levels inducing cell arrest and apoptosis. In adition, inhibition of 
BK channels decreased the expression levels of some Hsp´s, which could be an upstream 
signaling of the BK channel-mediated p53 change. This would keep p53 under negative 
control by the activity of BK channels, inhibiting apoptosis in cervical cancer (Han et al., 
2007). 
Purinergic ATP-gated nonselective ion channels (P2X receptors) have been also suggested to 
participate in cervical cancer. These channels are permeable to Ca2+, Na+and K+ (Burnstock, 
2004) and several members have been identified and termed P2X1 through P2X7. 
Extracellular ATP is a physiological ligand that activates P2X7 receptor (Surprenant et al., 
1996). Under normal conditions, extracellular ATP is present in only low concentrations, but 
increases significantly under inflammatory conditions and in response to tissue trauma (e.g., 
ischemia/hypoxia). The ionotropic purinergic P2X7 receptors activate a diverse range of 
cellular responses thay play a role in evading apoptosis of cervical cancer cells.  In normal 
cervical epithelial cells, the activation of P2X7 receptors forms a pore that increases calcium 
influx and induces apoptosis via the Ca2+-dependent mitochondrial pathway. Human 
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cervical cancer cells express a P2X splice variant (P2X7j) that do not mediates P2X7-
dependent apoptosis, causing downregulation of the functional P2X7 receptor, thereby 
preventing the Ca2+ influx required to trigger apoptosis and leading to defective apoptosis 
and enhanced growth of cervical cancer cells (Feng, et al., 2006). 
Voltage-gated sodium channels (VGSC) have also been detected in cervical carcinoma cells 
that may be involved in metastasis. Expression of NaV1.4, NaV1.6 and NaV1.7 channels has 
been detected in biopsies from cervical cancer (Díaz et al., 2007). Whether the activity of the 
sodium channel participates in the invasiveness of cervical cancer cells remains to be 
determined, but the pharmacological blockade of VGSCs commonly results in the reduced 
migration of highly metastatic cell lines, whereas the facilitation of channel opening by 
agonists enhances migration without impairing cell proliferation or viability (Roger et al., 
2007).  The abnormal expression of these VGSCs might be used as a tumor marker and a 
potential therapeutic target for cervical carcinoma. 
It has been suggested that the expression of volume-activated current (ICl,vol) in HeLa cells 
contributes to the cell cycle dependent regulation of cell migration. The density of ICl,vol was 
positively correlated to the rate of cell migration during cell-cycle progression indicating 
that volume-activated Cl- channels are involved in the cell-cycle-dependent migratory 
behaviour of HeLa cells. Moreover, expression inhibition of the voltage-gated chloride 
channel ClC-3 arrested HeLa cells in S phase (Mao et al., 2009). The capacity of Cl- channels 
to participate in migration could be associated to cell volume regulation, since regulatory 
volume decrease plays an important role in migration of tumor cells. Cl- channels helps the 
cell to undergo changes in their shape and volume, facilitating tumors cells to move trough 
the extracellular space.  In the following section we describe the very interesting oncogenic 
Eag channels, which are to our best knowledge the only known channels regulated by HPV 
oncogenes.  
5. Oncogenic Eag1 K+ channels in cervical cancer and regulation by HPV 
oncogenes 
Ether à go go (Eag1) K+ channel has gained great interest in cervical cancer diagnosis and 
therapy (Farias et al., 2004). Eag1 is a voltage gated K+ channel first described as a cell-
cycle regulated channel (Brüggemann et a., 1997; Camacho et al., 2000), and was the first 
ion channel identified to display oncogenic properties (Pardo et al., 1999).  These channels 
are widely distributed in the central nervous system, but their expression in peripheral 
tissues is very restricted, finding the channel only in placenta, transiently in myoblasts, 
testis and adrenal glands (Occhiodoro et al., 1998; Pardo et al., 1999; Hemmerlein et al., 
2006). This restricted distribution in normal tissues is one of the most attractive features of 
Eag1 as a potential tumor marker. Eag1 channels are overexpressed in various cancer cell 
lines including IGR1, IPC298, and IGR39 from melanoma, SH-SY5Y from neuroblastoma, 
MCF-7 from breast cancer and HeLa from cervical cancer. Eag1 channels have 
transforming properties, they confer lose of contact inhibition and sustained growth in the 
absence of serum. Cells transfected with Eag1 channel and implanted into 
inmunosuppreseed mice induce formation of aggressive tumors (Pardo et al. 1999). Eag1 
has been found to be overexpressed in many types of tumors including breast, lung, 
prostate, liver and colon (Hemmerlein et al., 2006). Thus, Eag is a promising tumor 
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marker. On the other hand, inhibition of either channel activity or expression decreases 
proliferation of tumor cells both in vitro and in vivo (Pardo et al., 1999; Ousingsawat et al., 
2007; Gómez-Varela et al. 2007; Downie et al., 2008; Díaz et al., 2009). Therefore, Eag is 
also a promising therapeutic target for many types of cancer (Camacho, 2006; Pardo & 
Stühmer, 2008). 
Eag1 mRNA expression was found in 100% of cervical cancer human biopsies while only in 
33% of normal control samples (Farias et al., 2004).  Interestingly, in this study it was 
observed that in one of the patients that was submitted to hysterectomy without any 
previous evidence of cervical malignancy (negative pap smears), postsurgery pathological 
studies showed an unexpected endocervical adenocarcinoma expressing Eag1. This case, 
although unique in such study, emphasizes the potential significance of Eag1 as a tumor 
marker in cervical cancer (Farías et al., 2004; Camacho, 2006). In addition, one of the normal 
cervical samples that were positive for Eag1 expression was correlated with HPV infection. 
This led to suggest that Eag1 expression in normal cervix could be an early sign of tumor 
development associated to HPV infection.  
The primary transforming activity of high-risk HPVs is provided by the E6 and E7 
oncoproteins which act cooperatively in the development of HPV-induced cancers. A 
primary target of E7 is the retinoblastoma (Rb) family of proteins that control the activity of 
E2F transcription factors, which are key regulators of S phase genes. The efficient abrogation 
of Rb function by E7 leads to increased levels of p53 and, consequently, the E6 proteins have 
evolved to target p53 for degradation. Researchers investigated the potential link between 
HPV infection and Eag oncogenic channels by transfecting normal human keratinocytes 
with E6 and/or E7 HPV oncogenes (Díaz et al., 2009). They observed that normal human 
keratinocytes do not express Eag channels. Interestingly, keratinocytes transfected with 
either E6, E7 or both HPV oncogenes, displayed a strong Eag channel expression. This 
finding suggests a novel mechanism by which HPV induces tumor formation, namely, up-
regulation of the oncogenic Eag1 channel. 
Regulation of Eag1 channels by E6/E7 HPV oncogenes suggests that the regulation of Eag1 
in cervical cancer might be via p53 and Rb pathways. A novel signaling pathway has been 
described that might explain how Eag is regulated by p53.  It appears that Eag1 is a terminal 
component in the p53-miR-34-E2F1 pathway. miR-34 is a micro RNA, which silences 
expression of target genes through the RNA interference pathway and is commonly 
downregulated in human cancers; one example is miR-34, which is a direct target of p53.  
miR-34 transcription is activated by p53, and expression of miR-34 inhibits proliferation by 
inducing cellular senescence and cell cycle arrest at G1. When cellular stress or damage 
exist, p53 increases, causing the miR-34 transcription to increase, and the increased miR-34 
will decrease the trancription factor E2F1. One of the target genes for transcription of E2F1 is 
the K+ channel Eag1. Supression of E2F1 will repress Eag1, this will diminish Eag1 
expression and function, resulting in a shut down of the cell proliferation or a cell cycle 
arrest, thus upregulation of miR-34 represses E2F1 and Eag1.  Therefore, p53 negatively 
regulates Eag1 expression by a negative feed forward mechanism through the p53-miR-34-
E2F1 pathway (Lin et al., 2011). This pathway might also help to explain the effect of the E7 
oncogene on Eag regulation. E7 binds to Rb disrupting the Rb–E2F complexes, resulting in 
the constitutive expression of E2F1-responsive genes including Eag1. 
Human Papillomavirus and Related Diseases 
 – From Bench to Bedside – Research Aspects 134 
6. Effect of estrogens on HPV and eag channels 
HPV infection has been suggested as a necessary but not sufficient factor to induce cervical 
cancer. Thus other contributing factors have been proposed, especially estrogens. The 
uterine cervix is highly responsive to steroidal hormones and the use of oral contraceptives 
and multiple pregnancies have been shown to significantly increase the risk for cervical 
cancer in HPV-infected women (Moreno et al., 2002; Muñoz et al., 2002). In mice models for 
HPV-associated cancers, estrogen is required for the development of cervical and vaginal 
cancers (Brake & Lambert, 2005). The estrogen receptor alpha (ERα) is also required in mice 
for these cancers to develop and ER antagonists can cause efficient regression of cancer, 
dysplasia, and atypical squamous metaplasia, preventing malignant progression (Chung & 
Lambert, 2009).  Other studies also suggest the relevance of estrogen in the carcinogenesis of 
cervical cancer. Growth stimulation of SiHa cervical cancer cells by estrogens appeared to be 
related to the increased expression of HPV E6/E7 oncogenes, estradiol stimulated both cell 
growth and transcription of E6/E7 viral oncogenes (Rosembaum, et al., 1989; Kim, et al., 
2000). In addition, overexpression of aromatase, the enzyme that transforms testosterone 
into estrogen, is known to increase estrogen activity in breast tissue, and in cervical cancers 
it has been reported that 35% of human cervical cancer tested express aromatase, but  
 
Fig. 2. Regulation of Eag1 oncogenic Eag1 channels by HPV oncogenes and estradiol. Eag1 
might become extremely up-regulated since HPV oncogenes are in turn regulated by 
estradiol, leading cervical cells to cancer. 
The Human Papilloma Virus – Ion Channel Link in 
Cancer: An Alternative Opportunity for Diagnosis and Therapy 135 
aromatase expression was not detected  in precancerous or normal cervical tissue samples. 
Aromatase overexpression induced the expression of cyclin D1, proliferating cell nuclear 
antigen and HPV oncogenes (Nair, et al., 2005). It was also observed that women that 
expressed higher levels of estrogen receptors transcripts were significantly more likely to 
have cervical HPV infection; it may be that the presence of the receptor allows cellular 
acquisition of HPVand increased viral transcription (Shew, M., et al. 2005).  These data 
suggest that a mechanism of synergistic cooperation exist between estrogen exposure and 
viral oncogenes, so it raises the possibility that steroidal hormones, such as estrogen, might 
affect cancers of the cervix, much like that of other hormonally responsive female organs. In 
summary, several studies suggest that estrogens play a critical role not only in the genesis of 
cervical cancer but also in its persistence and continuous development. 
Eag1 channel expression is also up-regulated by estrogens. HeLa cells transfected with ERα 
and treated with 17-β estradiol, induce a strong up-regulation of Eag1 channels. These 
results suggest ERα activation as one of the mechanisms of the estrogenic regulation of 
Eag1. Thus the regulation of the Eag1 channel in cervical cancer is mediated by HPV 
oncogenes and estrogens (Diaz, L., et al., 2009). HPV-infection in cervical cells might lead to 
a very significant increase in oncogenic Eag channels. Since estrogens might regulate both 
HPV-oncogens and Eag1 channels, these related pathways might easily drive the cell into a 
tumor phenotype (Figure 2). 
7. Conclusion 
Ion channels are emerging as potential tools for diagnosis and treatment of many types of 
cancer including those where HPV infection plays a major role. Particularly, up-regulation 
of the oncogenig human Eag channel by HPV oncoogens offers a novel mechanism by 
which HPV associates to some types of cancer. Since several ion channels are up-regulated 
by HPV oncogenes and/or factors closely associated to HPV, for instance estrogens, 
simultaneous detection of HPV infection and ion channel expression should provide an 
alternative option for early detection of tumors. Besides, HPV detection might also serve to 
target ion channels involved in tumor progression. This combined approach should help 
reduce cancer mortality.   
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1. Introduction  
Human papillomaviruses (HPV) are involved in the aetiology of human carcinomas arising 
in different anatomical locations such as skin, anogenital region and oropharynx (Marur et 
al., 2010; Pfister, 2003; zur Hausen, 2002). The virus infects stratified epithelia of these 
locations, producing new infectious viral particles. HPV life cycle is intimately dependant of 
a proper squamous cell differentiation, so simple cell culture systems are unable to 
recapitulate essential processes for a complete virus replication. Mucosal HPVs are 
responsible of benign lesions and carcinomas of the anogenital region and oropharynx. 
There are a few types of mucosal HPVs that are present in cancers in these anatomical 
locations, and they are called high-risk types (mainly HPV types 16 and 18) (de Sanjose et 
al., 2010). Furthermore, low-risk mucosal HPV types are responsible of frequent benign 
lesions in the same locations (mainly HPV types 6 and 11) (zur Hausen, 2002). Although 
these HPV-lesions (condylomas and respiratory papillomatosis) do not evolve normally to 
overt tumours, they are difficult to treat. 
Cervical cancer is the second leading cause of deaths by cancer in women worldwide, 
representing an important disease in developing countries. The vast majority of cervical 
carcinomas (about 85%) are infected with high-risk HPVs, so viral infection is considered the 
major main etiological agent of this malignancy (de Sanjose et al., 2010). Head and neck 
squamous cell carcinoma (HNSCC) is the sixth most common cancer worldwide. An 
important proportion of human HNSCC are infected with high-risk HPV (about 20%), 
especially in the oropharynx, where about 50% of the cancers have been found to harbour 
viral DNA (Marur et al., 2010). HNSCC is etiologically associated with tobacco use and 
alcohol consumption. Epidemiological and molecular studies have suggested than HPV-
negative and HPV-positive tumours represent different subtypes of HNSCC with different 
clinical consequences. The infected HNSCC display a better clinical outcome after treatment 
with radio or chemotherapy.  
Cutaneous HPVs, similarly to mucosal viruses, are associated to benign lesions (such as skin 
warts) or premalignant actinic keratosis or squamous cell carcinomas (SCC), especially in 
patients of the rare genodermatosis Epidermodysplasia verruciformis (EV) or in organ 
transplant recipients (OTRs) (Pfister, 2003). In these patient populations, the infection with 
certain HPV types, belonging to the beta family (beta-HPVs), is clearly associated with the 
appearance of those skin pathologies, mostly in sun exposed areas of the body. Although 
the majority of cervical carcinomas are produced by 2 major HPV types (HPV16 and 
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HPV18), epidemiological studies have demonstrated that SCCs arising in papillomavirus-
infected skin are associated to diverse HPV types, and that multiple infections frequently 
appear in a single sample (Berkhout et al., 2000; Harwood et al., 2000). Collectively these 
epidemiological data show that the infection with HPV is associated with a relevant number 
of human malignancies, and the finding of effective anti-HPV therapies represents an 
important medical challenge. 
The most important high-risk HPV genes involved in carcinogenesis are the E6 and E7 early 
genes, as they are expressed in pretumoral and invasive cervical carcinomas. Importantly, a 
number of cellular targets for E6 and E7 have been described so far, some of which may be 
functionally inactivated in vivo, giving to the appearance of malignant cervical tumours. 
Tumour suppressors targeted by virus oncogenes are the retinoblastoma protein (pRb) and 
p53, which are inhibited by high-risk HPV E7 and E6 virus oncogenes, respectively (Dyson 
et al., 1989; Werness et al., 1990). E7 protein from HPV16 binds directly the 3 members of the 
retinoblastoma protein family: pRb, p107 and p130. Upon interaction, these proteins are 
targeted for degradation (Boyer et al., 1996; Gonzalez et al., 2001), releasing the transcription 
factor complex E2F that induces the expression of genes involved in G1-S transition, thereby 
activating cellular proliferation. HPV16 E7 protein can also inhibit other negative regulators 
of the cell cycle, such as p21cip1 thought direct binding (Funk et al., 1997; Helt et al., 2002; 
Jones et al., 1997). Although the virus DNA is normally maintained in the basal cells as an 
episome, during the malignant transformation of cervical lesions both E6 and E7 are 
integrated into the cellular genome (Smith et al., 1992), concomitantly with a more efficient 
oncogene expression. The interaction with pRb, p53 and p21cip1 tumour suppressors, and 
additional targets or/and genetic alterations may eventually transform infected cells and 
induce the formation of invasive carcinomas. Cutaneous betaHPVs are thought to act by 
potentiating the harmful effects of UV radiation, for example by impairing DNA repair and 
apoptosis following UV-induced damage through E6 molecular activities (Akgul et al., 2005; 
Giampieri et al., 2004; Jackson et al., 2000; Jackson & Storey, 2000). Mucosal high-risk HPVs 
could possibly act together with steroid hormone signalling and/or tobacco consumption 
(Moreno et al., 2002; Munoz et al., 2002). Finally, immunosupression also contributes to 
carcinoma progression, especially for skin SCCs. 
2. HPV analysis models 
In order to recapitulate virus life cycle towards virion production, or to analyze the 
phenotypical and molecular consequences of the expression of HPV genes in stratified 
epithelia, several models have been described. Organotypic (raft) cultures of skin where first 
described in 1988 to partially recapitulate the differentiation defects of human biopsies of 
cervical intraepithelial neoplasia (CIN) lesions, which are the precursor lesions of invasive 
HPV-related cervical cancers (McCance et al., 1988). The system provides an in vitro assay 
where primary human foreskin epithelial cells, seeded onto a collagen matrix, are forced to 
differentiate and reconstitute human skin (Asselineau & Prunieras, 1984; Kopan et al., 1987). 
On the other hand, transgenic mouse models expressing HPV genes have demonstrated the 
oncogenic activities of some early viral genes, mainly E6 an E7 (Griep et al., 1993). Viral 
transgenes have been expressed under the control of the K14 promoter, normally expressed 
in the basal layer of mouse stratified epithelia (Arbeit et al., 1994). Advantages and 
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disadvantages of both model systems will be described below. Furthermore, we perform a 
comparison of the HPV-mouse models with transgenic mice with conditional expression of 
the host genes normally targeted by virus oncogenes, and whose functional inactivation is 
essentially involved in virus carcinogenesis, such as retinoblastoma proteins or p21cip1 
(targeted by E7) and p53 (targeted by E6). 
2.1 Organotypic (raft) cultures and HPV 
Raft cultures allow primary human keratinocytes (PHK) to achieve stratification and 
differentiation morphologically similar to foreskin (Asselineau & Prunieras, 1984; Kopan et 
al., 1987). In this system, PHK cells are seeded on a dermal equivalent consisting of a porous 
collagen gel containing fibroblasts. At confluence, the assembly is raised to the medium-air 
interface. The keratinocytes stratify and exhibit a differentiated morphology, generating a 
living skin equivalent. This system was originally used to study the features of HPV-
immortalized cell lines or cell lines obtained from cervical pathological biopsies (Blanton et 
al., 1991; McCance et al., 1988; Woodworth et al., 1992). These early studies demonstrated 
altered differentiation patterns and morphological features resembling human cervical 
neoplasia such as suprabasal mitosis, enlarged nuclei, abnormal mitotic figures, or 
koilocytosis. Later, rafts were used to produce virus particles using different strategies. 
Thus, Meyers et al. were able to produce virions using raft cultures of the cell line CIN-612 
treated with TPA (Meyers et al., 1992). Similarly, mature particles were obtained from 
condyloma containing HPV11 explanted on rafts (Dollard et al., 1992). 
The raft culture system has been an essential tool to analyze some of the molecular functions 
and consequences of the expression of E6 and E7 oncogenes from high-risk mucosal HPVs. 
Using retrovirally infected PHKs, it was demonstrated that E7 was able to induce DNA 
replication in suprabasal differentiated keratinocytes (Cheng et al., 1995), an activity directly 
linked to the capacity of binding retinoblastoma family or “pocket” proteins, as 
demonstrated by using E7 mutant proteins. Furthermore, most of the morphological 
features observed using HPV-cell lines where reproduced expressing E7 protein, and more 
clearly, with the combined expression of E6 and E7 oncogenes. 
Recently, a system to produce autonomous HPV-18 genomes and high titer, mature virus 
particles was described using Cre-loxP-mediated recombination and organotypic cultures of 
PHKs (Wang et al., 2009). Interestingly, the method showed that E6 protein, and thus p53 
degradation, was necessary to obtain a productive HPV program, including viral DNA 
amplification and production of virus capsid protein L1. 
2.2 Mouse models of HPV-mediated carcinogenesis 
Transgenic mouse models have been frequently used to analyze the molecular and 
phenotypic consequences of the expression of oncogenes in tumour development. Early 
studies demonstrated that E6 and E7 early genes from HPV16 induced tumours when the 
expression was targeted to the ocular lens (Griep et al., 1993), or the skin of transgenic mice 
(Arbeit et al., 1994; Lambert et al., 1993). These studies contributed importantly to the 
establishment that E6 and E7 genes are directly implicated in the carcinogenic potential of 
HPV16 in an animal model. Furthermore, they opened new and important research areas 
that have significantly contributed to the understanding of the molecular activities of both 
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oncogenes in the context of HPV-associated carcinogenesis. Additionally, similar mouse 
models using early genes from cutaneous HPVs, associated with human skin SCC, have also 
helped to demonstrate their carcinogenic potential (Dong et al., 2005; Schaper et al., 2005).  
Transgenic mouse containing the E6 and E7 genes from HPV16 under the control of the 
human keratin 14 (K14) allow expression of the virus genes in stratified epithelia, such as 
skin or mucosal tissues. Reproducible multi-stage progression from hyperplastic and/or 
dysplastic lesions to squamous cell carcinomas of the epidermis was observed in K14-
16E6E7 animals (Arbeit et al., 1994; Coussens et al., 1996). Concomitant with tumour 
progression, a disorganization of the normal differentiation was observed based of 
histological analysis and expression patterns of keratin markers such as keratin 5 (K5, 
normally expressed in basal cells), keratin 10 (K10, normally expressed in spinous cells) and 
filaggrin (normally expressed in granular cells). Furthermore, proliferative cells appeared 
ectopically in suprabasal cells and the mitotic index was augmented in premalignant and 
malignant skin lesions. 
Herber et al reported in 1996 the first experimental evidence that the E7 protein from HPV16 
is able to induce carcinogenesis in an animal model (Herber et al., 1996). Histological 
analysis of K14-16E7 mice demonstrated that E7 causes epidermal hyperplasia in skin, but 
also in mouth palate, oesophagus, forestomach and exocervix. Late in life, K14-16E7 animals 
develop highly differentiated and locally invasive skin carcinomas. Also, expression of E6 in 
K14-16E6 mice not only increased cell proliferation and induced epidermal hyperplasia, but 
also leads the development of skin tumours (Song et al., 1999). In contrast to the tumours 
derived from K14-16E7 transgenic mice, which were primarily benign, those appearing in 
K14-16E6 transgenic mice were mostly malignant, indicating that E6 alone not only is 
sufficient to induce tumour development but it also confers increased malignant potential in 
vivo. 
The mouse models above described recapitulated in the skin the pathological features 
observed in human CIN lesions and cervical carcinomas. Moreover, these models 
demonstrate that most of these features are due to the expression of E6 and E7 HPV16 
oncogenes. However, the K14-HPV16 animals did not develop spontaneous tumours in the 
cervix nor in the head and neck region.  Importantly, Arbeit et al demonstrated that chronic 
estrogen administration induced cervico-vaginal squamous carcinomas in K14-16E6E7 
animals (Arbeit et al., 1996). Previous epidemiological analyses already showed that the 
prolonged use of contraceptives, most of which contain estrogen, did double the risk of HPV 
neoplasia and malignancy (Brisson et al., 1994). Importantly, no control animals neither K14-
16E6E7 mice develop pathological neoplasias or carcinomas, demonstrating for the first time 
a synergism between estrogens and HPV oncogenes in cervical carcinogenesis. 
Human HNSCC is associated with tobacco use, and an important proportion of tumours are 
HPV-infected. Strati et al demonstrated that K14-HPV16 animals, when treated with the 
chemical carcinogen 4-nitroquinoline 1-oxide (4NQO), increased dramatically the animal’s 
susceptibility to HNSCC (Strati et al., 2006). 4NQO causes a spectrum of DNA damage 
similar to that caused by tobacco-associated carcinogens, and it induces cancers in the oral 
cavity in rodents when it is supplied in their drinking water. 4NQO-treated, HPV16-
transgenic mice developed HNSCC at a much higher frequency than no transgenic mice, 
and display tumours with molecular characteristics similar to the human counterparts. 
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Cutaneous beta-HPVs are associated with actinic keratosis and skin SCCs in 
immunocompetent but mainly in immunosupressed patients, such as OTR. Some of these 
viruses (HPV5 and HPV8) were originally described in EV patients (Jablonska & Majewski, 
1994; Lutzner et al., 1984), but these and other beta-HPVs have been generally associated to 
human skin cancer. As for high-risk mucosal HPVs, transgenic mouse models have been 
generated in order to analyze the carcinogenic properties of cutaneous HPVs. Schaper et al 
demonstrated that the early region of HPV8, containing the E2, E6 and E7 genes, was able to 
induce single or multifocal tumours in 91% of K14-HPV8 animals and skin carcinomas in 6% 
of all examined mice (Schaper et al., 2005). This report was the first experimental proof of 
the carcinogenic potential of an EV-associated HPV-type in vivo. A few months later, Dong 
et al described skin hyperproliferation and susceptibility to chemical carcinogenesis in 
transgenic mice expressing the E6 and E7 genes of HPV38 (another EV-associated beta-HPV) 
under the control of the bovine homolog of human keratin 10 (K10) promoter (Dong et al., 
2005). Although transgenic K10-HPV38 mice did not develop spontaneous tumours, two-
stage carcinogenesis protocols led to a high incidence of papillomas, keratoacanthomas and 
SCC in the transgenic mouse skin compared with nontransgenic control mice. These results 
showed HPV38 E6 and E7 display transforming properties in vivo. 
3. Synergism and individual contribution of E6 and E7 oncogenes to HPV16-
induced carcinogenesis 
K14-HPV16 transgenic animals have been valuable tools to demonstrate the essential role of 
virus E6 and E7 oncogenes in stratified epithelia carcinogenesis. The individual contribution 
of both genes as well as the synergism has been studied for carcinoma models in skin, cervix 
and head and neck. Thus, E6 is the most important oncogene in skin cancer as the tumours 
arising are more malignant than those that appeared in K14-16E7 animals (Song et al., 2000; 
Song et al., 1999) (Fig. 1). An analysis including chemical carcinogenesis with DMBA/TPA 
demonstrated that E6 acts weakly at the promotion stage of carcinogenesis in the formation 
of benign tumours, but strongly at the progression stage, which involves the malignant 
conversion of these benign tumours (Song et al., 1999). In contrast, E7 primarily affected the 
promotion stage of carcinogenesis. These results provide direct evidence that E6 and E7 
contribute differently to carcinogenesis; E7 promotes the formation of benign tumours, and 
E6 acts primarily to accelerate progression of these benign tumours to the malignant stage. 
Consistent with this model, the authors found that E6 and E7 cooperated in inducing 
tumour formation in mice expressing both oncogenes. 
In the case of estrogen induced cervical carcinomas in K14-HPV16 animals, E7 was found to 
be the most important oncogene (Fig. 1). Importantly, although p53 levels were eliminated 
in cervical epithelium of estrogen treated K14-16E6 mice, neither neoplasia nor cancer was 
observed. Again, a synergism was observed with both E6 and E7 oncogenes, giving rise to 
large, extensively invasive cancers (Riley et al., 2003). 
Similarly, the individual contribution of each virus oncogene was analyzed in the HNSCC 
model of K14-HPV16 animals. The results demonstrated that E7 is the major transforming 
oncogene in HPV-associated HNSCC, whereas E6 is more likely to play a secondary role in 
contributing to later stages of carcinogenesis (Strati & Lambert, 2007) (Fig. 1). As described 
above for skin and cervical carcinogenesis, again both E6 and E7 oncogenes act 
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synergistically to produce a higher grade of disease and slightly increased tumour 
multiplicity. 
 
Fig. 1. Transgenic mouse models of HPV16-carcinogenesis. K14-HPV16 mouse models 
develop carcinomas in the head and neck region, skin, and cervix. While spontaneous 
tumors arise in the skin, HNSCCs appear in cooperation with the 4NQO carcinogen, and 
cervical carcinomas in cooperation with estrogens. Characterization of K14-16E6, K14-16E7, 
and K14-16E6E7 mice have demonstrated that E6 is the main virus oncogene in skin SCC, 
and E7 in HNSCC and cervical carcinoma. On the other hand, transgenic animals with 
deletion in HPV-cellular targets have demonstrated that p53 or pRb/p107 are major tumor 
supressors in skin. In the presence of estrogens, deletions of p53 or p21 give rise to 
carcinogenesis in the mouse cervix. Finally, continuous activation of Akt in the absence of 
p53 induces spontaneous carcinomas in the head and neck region. For references, see text. 
4. Role of cellular targets of HPV oncogenes in carcinogenesis 
A number of cellular proteins are targets of HPV oncogenes. However, the real contribution 
of these targets in human pathology during the carcinogenesis process is not completely 
understood. Compelling evidences have demonstrated that p53 and pRb are the major 
cellular targets of high-risk HPV E6 and E7 oncogenes, respectively. The role of both cellular 
proteins as tumour suppressors in the vast majority of human cancer has been fully 
established. However, the importance of their inhibition during the carcinogenesis 
associated to HPV-infection has not been completely characterized. K14-HPV16 models 
have demonstrated that E7 is the main oncogene in HNSCC and cervical cancer, but in skin 
tumour formation only participated at the initiation step. Interestingly, both E6 and E7 
oncogenes act synergistically to induce tumour formation and malignancy in the three types 
of cancer. 
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4.1 Skin cancer 
In relation with skin cancer, mouse models with conditional somatic deletion of pRb and/or 
p53 have been characterized. The elimination of pRb in the epidermis of transgenic mice 
using the Cre-lox system (K14Cre;RbloxP/loxP) produces hyperplasia, altered differentiation 
and ectopic suprabasal proliferation in the skin (Balsitis et al., 2003; Ruiz et al., 2004) but not 
spontaneous tumours. This phenotype resembles the epidermal histological features of K14-
16E7 animals, which is in line with the inactivation of pRb due to E7 expression (Balsitis et 
al., 2003). However, when both E7 was expressed and Rb was deleted in the same tissue, 
increased hyperplasia and dysplasia were observed, suggesting that E7 possesses pRb-
independent effects. E7 protein from HPV16 is also able to inactivate the other two members 
of the retinoblastoma family, p107 and p130. It is tempting to speculate that the epidermal 
phenotype observed in K14-16E7 animals could be partially due to inactivation of pRb, but 
also of p107 and/or p130. Interestingly, we have previously demonstrated that the absence 
of p107 alleles in K14Cre;RbloxP/loxP mice (K14Cre;RbloxP/loxP;p107-/-) increased the 
K14Cre;RbloxP/loxP epidermal phenotype with augmented hyperplasia, proliferation and 
altered differentiation (Lara et al., 2008a; Ruiz et al., 2004), which was associated to a 
equivalent increase in the expression of pRb-dependent gene expression program (Lara et 
al., 2008a; Ruiz et al., 2004). However, we were not able to observe an increase in the 
K14Cre;RbloxP/loxP epidermal phenotype in K14Cre;RbloxP/loxP;p130-/- animals, suggesting 
that p107 (and not p130) could functionally compensate some of the pRb-dependent 
functions. Although K14Cre;RbloxP/loxP;p107-/- animals died soon after birth, thus 
precluding analysis of phenotype in adult animals, we were able to analyze the 
consequences of somatic inactivation of both pRb and p107 by transplanting 
K14Cre;RbloxP/loxP;p107-/- neonatal skin onto immunodeficient NOD/Scid mice. The grafted 
transgenic skin develops well differentiated SCC, characterized by a reduced apoptosis 
possibly due to a defective p53 pathway (Lara et al., 2008b) (Fig. 1). Moreover, the 
K14Cre;RbloxP/loxP;p130-/- mice do not develop spontaneous tumours with age. Altogether, 
these data suggest that the spontaneous skin SCCs that appear in K14-16E7 animals could be 
due to simultaneous inactivation of pRb and p107 in the epidermis, although inactivation of 
all three pocket proteins cannot be discarded. In this regard, the elimination of p130 and 
p107 also produces severe skin defects, indicating that these two proteins also exert 
overlapping functions that cannot be carried out by pRb in epidermis (Ruiz et al., 2003). 
In relation with p53, others and we have demonstrated that p53 is a major tumour 
suppressor in skin (Jonkers et al., 2001; Martinez-Cruz et al., 2008) (Fig. 1). When 
K14Cre;RbloxP/loxP animals were treated with the DMBA/TPA chemical carcinogenesis 
protocol, they display reduced number and smaller tumours than the control, RbloxP/loxP 
littermates. However, these tumours also displayed a more malignant phenotype partially 
due to the absence of p53 (Ruiz et al., 2005). These results strongly suggested that p53, in the 
absence of pRb, had compensatory tumour suppressor activities. The essential role of p53 as 
a tumour suppressor in skin was fully demonstrated when analyzing K14Cre;p53loxP/loxP and 
K14Cre;RbloxP/loxP;p53loxP/loxP animals. Both transgenic animals developed spontaneous 
tumours in the skin with full penetrance, although the onset was earlier in the case of double 
conditional knock-out (Martinez-Cruz et al., 2008). No major differences were observed in 
overt tumours, which were characterized as moderately differentiated or undifferentiated, 
locally aggressive and metastatic. Interestingly, the gene expression pattern of tumours from 
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both mouse genotypes resembles that of human tumours with mutations in p53 (Garcia-
Escudero et al., 2010). As previously described, K14-16E6 mice develop spontaneous 
tumours with a more aggressive behaviour than K14-16E7 tumours. Altogether the results 
would indicate that E6 is the most important HPV oncogene in skin as it is able to inhibit 
p53, a predominant tumour suppressor in skin. 
Finally, p53-independent activities have been described for E6 in skin. Numerous cellular 
proteins interact with E6. One group of proteins, the PDZ partners (including hDLG, 
hSCRIBBLE, MUPP1, and MAGI) interact to the C-terminal four amino acids of E6 through 
their PDZ domains, leading to their degradation. Additionally, E6’s binding to PDZ proteins 
may explain the E6 ability to transform cells in tissue culture and to confer tumorigenicity to 
cells in xenograft experiments (Kiyono et al., 1997). Mice with a mutant of E6 lacking the last 
six amino acids of its carboxyl terminus (K14-16E6Δ146-151) were generated, and allowed to 
demonstrate that the ability of E6 to bind PDZ domain partners is necessary for E6 to confer 
epithelial hyperproliferation in vivo. The K14-16E6Δ146-151 mice exhibit a radiation response 
similar to that of the K14-16E6 mice, demonstrating that this protein, as predicted, retained 
an ability to inactivate p53. 
4.2 Cervical cancer 
Using K14-HPV16 transgenic mice and estrogen treatment, mouse models have 
demonstrated an essential contribution of the E7 oncogene in cervical cancer. Furthermore, 
repression of the E7 oncogene efficiently cleared already established carcinomas.  In order to 
elucidate the role of pRb in suppression of cervical cancer, K14Cre;RbloxP/loxP animal were 
hormone treated. The results demonstrated no carcinoma formation, suggesting that pRb-
independent activities are exerted by E7. Further evidence was provided by the generation 
of RbΔL/ΔL mice. This gene construct bears three alanine mutations in pRb that interact with 
E7, thereby producing a mutant pRb protein that fails to bind E7 (Lee et al., 1998). On the 
other hand pRbΔL retains the ability to bind E2Fs, induces G1 arrest in pRb-negative SAOS2 
cells, and is phosphorylated and inactivated by cyclin D/cdk4 complexes similarly to wt 
pRb (Dick et al., 2000). pRbΔL also represses gene expression from E2F-responsive promoter 
constructs, although incrementally less effectively than wt pRb. On the other hand, pRbΔL 
fails to bind cellular LxCxE motif-containing proteins, and pRbΔL -induced G1 arrest cannot 
be reversed by expression of HPV-16 or HPV-18 E7 (Dick et al., 2000; Isaac et al., 2006). 
K14E7RbΔL/ΔL mice were used to analyze cervical carcinoma formation. The development of 
spontaneous tumours indicates, again, that other molecular activities of E7, independent of 
pRb, make critical contributions to cervical carcinogenesis. Although the role in cervical 
carcinogenesis has not been tested, it is possible that p107 may act as a tumour suppressor in 
this tissue in the absence of pRb, as we have been demonstrated for skin SCC (Lara et al., 
2008b). However, we cannot discard an essential role of other tumour suppressors, such as 
p130 or p21Cip1, also targeted by high-risk E7. 
Using knock-out animals, Shin et al described that cervical disease was significantly 
increased in p21 -/- mice compared with p21+/+ mice, showing that p21Cip1 can function as 
a tumour suppressor in this tissue (Shin et al., 2009) (Fig. 1). Importantly, the induction of 
cervical cancers by E7 was not increased in the absence of p21Cip1, arguing against the 
hypothesis that the ability of E7 to inhibit p21Cip1 contributes to carcinogenesis. However, 
 
Analysis Models for HPV-Related Pathobiology 
 
155 
cervical carcinogenesis in mice expressing a mutant form of HPV-16 E7, E7CVQ, which 
cannot inactivate p21Cip1, was reduced when compared with that in K14-16E7 mice. 
Nonetheless, K14-16E7CVQ mice still displayed augmented levels of cervical carcinogenesis 
compared with non-transgenic mice, indicating that activities of E7, besides its capacity to 
inactivate p21Cip1, also contribute to cervical carcinogenesis. 
The interaction of E6 with many cellular proteins, including p53, leads to their 
destabilization. This property is mediated, at least in part, through the ability of E6 to recruit 
the ubiquitin ligase E6-associated protein (E6AP) into complexes with these cellular 
proteins, resulting in their ubiquitin-mediated degradation by the proteasome pathway. 
Shai et al addressed the requirement for E6AP in mediating acute and oncogenic 
phenotypes of E6, including induction of epithelial hyperplasia, abrogation of DNA damage 
response, and induction of cervical cancer (Shai et al., 2010). Loss of E6AP had no 
discernible effect on the ability of E6 to induce hyperplasia or abrogate DNA damage 
responses. Nevertheless, in cervical carcinogenesis studies, there was a complete loss of the 
oncogenic potential of E6 in E6AP-null mice. Thus, E6AP is absolutely required for E6 to 
cause cervical cancer. However, when K14Cre;p53loxP/loxP were treated with estrogen, nearly 
all mice developed cervical cancer, in sharp contrast to its complete absence in treated K14-
16E6; p53loxP/loxP mice, indicating that HPV16 E6 must only partially inactivate p53 (Shai et 
al., 2008) (Fig. 1). p53-independent activities of E6 also contributed to carcinogenesis, but 
these activities were manifested only in the presence of the HPV16 E7 oncogene. 
4.3 Head and neck squamous cell carcinoma 
Individual and synergistic contributions of E6 and E7 oncogenes were also determined in a 
mouse model for human HNSCC where K14-HPV16 animals are treated with the 4NQO 
carcinogen. The results showed that E7 is the major oncogene (Strati & Lambert, 2007) in 
HPV-associated HNSCC, whereas E6 is more likely to play a secondary role in contributing 
to later stages of carcinogenesis. Mutations in p53 have been described in about 50% of 
human HNSCC, demonstrating that the inactivation of the p53 pathway is a highly relevant 
molecular event for carcinogenesis in this region. In the case of HPV-infected HNSCC, the 
frequency of mutations is very low as E6 would be able to inhibit p53 function. However, 
we have recently described a mouse model where an active form of the Akt1 kinase (myr-
Akt) expressed in stratified epithelia under the control of the keratin 5 (K5) promoter is able, 
in the absence of p53 (K5myrAkt;K14Cre;p53loxP/loxP), to induce HNSCC (Moral et al., 2009) 
(Fig. 1). This mouse model recapitulates most of the pathological features of human 
HNSCC, such as local lymph node metastasis. The results corroborate the epidemiological 
studies about the role of p53 in human HNSCC, as K5myrAkt animals display significant 
reduction in the development of overt tumours although they display high number of 
pretumoral lesions and also display increased susceptibility to chemical carcinogenesis 
protocols (Moral et al., 2009; Segrelles et al., 2007). Possibly, the treatment with 4NQO 
induces mutations that inactivate the p53 pathway, thus explaining the secondary role of E6 
in the HPV-associated HNSCC mouse model. Alternatively, the E6 protein may not 
completely inactivate p53 in head and neck, as suggested before in the case of cervical 
cancer (Shai et al., 2008). 
Furthermore, a conditional deletion of pRb did not recapitulate all E7-mediated cancer 
phenotypes in HNSCC (Strati & Lambert, 2007). As in the case of cervical cancer mouse 
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models, the results highlight the importance of pRb-independent functions of E7 in head 
and neck carcinogenesis, although do not preclude an important role for the E7-pRb 
interaction. 
5. Analysis of preclinical therapies in the mouse cervical cancer model 
Interfering with the expression of E7 in HPV-positive cell lines derived from human cervical 
cancers inhibits their ability to proliferate, indicating that the expression of E7 is important 
in maintaining the transformed phenotype in vitro. Accordingly, in vivo experiments using 
transgenic mice with inducible repression of the E7 oncogene of HPV16 demonstrated that 
E7 expression in estrogen induced cervical carcinomas is necessary to maintain established 
tumours and high-grade cervical dysplasia (Jabbar et al., 2009). The results obtained suggest 
that E7 is a relevant target nor only for anticancer therapy but also for the treatment of HPV-
positive dysplastic cervical lesions. 
Mouse models of human cancer are necessary tools to understand basic processes of 
carcinogenesis in a living organism, but also as tools to analyze preclinical therapies. In this 
sense, Chung et al have recently described that estrogen receptor antagonists are effective 
preventive and therapeutic drugs in mouse models of cervical cancer (Chung & Lambert, 
2009). The authors demonstrated that ICI 182, 780 (a complete ER antagonist) and raloxifene 
(a selective ER modulator) efficiently clear cancer and precursor lesions in both the cervix 
and the vagina. Importantly, these findings suggest that ER antagonists could help to 
control this gynecological disease of the women lower reproductive tract.  
6. Conclusion 
Analysis models of HPV based on organotypic cultures of human skin or transgenic mice 
have helped to understand the function and carcinogenesis role of HPV oncogenes. Thus, 
the role of E6 and E7 as major oncogenes has been established and the contribution of each 
of them, as well other cofactors, has been analyzed. Human cancers associated with HPV-
infection are multifactorial diseases, in which genetic predisposition, tobacco or estrogen 
consumption, radiation exposure, or immunosuppression are factors that could contribute 
to its appearance or development. In K14-HPV16 animal models, E7 is the most important 
virus oncogene for cervical cancer and HNSCC. Although pRb is the major E7 target, there 
are pRb-independent functions for E7-mediated carcinogenesis. In the case of skin SCC, E6 
gives rise to more malignant tumours that E7, which coincides with a role of p53 as an 
important tumour suppressor in K14Cre;p53loxP/loxP animals. Furthermore, these p53 mutant 
mice develop aggressive tumours in skin and cervical cancer models with high penetrance, 
showing that E6 from HPV16 is not able to completely inactivate p53. On the other hand, 
transgenic mice have helped to demonstrate tumorigenic activity of cutaneous beta-HPV 
oncogenes in vivo, for the first time. 
Human papillomaviruses are infectious agents with clinical importance. Although already 
developed vaccines are a preventive treatment against non-malignant and malignant virus-
associated lesions, new HPV therapies are necessary for already infected people. In this 
sense, raft cultures have the advantage that they are done with PHKs (the proper cellular 
target and species of HPV-infection), but the disadvantage that the time window to test 
therapies is limited to a few days. On the other hand, mouse models allow testing long-term 
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effects of new possible anti-HPV treatments in a living organism, but the differences 
between mouse and human species must to be taken into account. Future models, able to 
bypass these drawbacks must be developed in the future for a better success in preclinical 
analysis, thus delivering new effective treatments to HPV-pathologies in the future. 
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1. Introduction 
A decline in the incidence and mortality of cervical cancer has been observed in most 
Western countries since the first third of the past century. This may be mainly attributed to 
the introduction of Pap test, that is considered one of the milestones in medicine. 
Nevertheless, worldwide burden of cervicocarcinoma is still enormous. This fact is well 
known among the scientific community, and has led to an extensive search for optional 
screening tools and predictive markers, currently under testing in different countries.  
2. A brief history  
Modern research on Papillomavirus and Papillomaviruses began more than 150 years ago. 
In a famous paper, the Italian physician Rigoni-Stern analyzed death certificates of woman 
in Verona, during the period 1760-1839. He noted that cervical cancer was common among 
prostitutes, married women and widows but rare in virgins and nuns. He concluded that 
the development of this cancer should be related to sexual contacts. Later, in 1898, 
McFadyean and Hobday successfully transmitted canine oral papillomatosis, while Codeac 
transmitted warts from horse to horse, in 1901. In spite of a limited number of studies on 
Papillomavirus in subsequent decades, it was almost 80 more years later when this area of 
research engendered broad interest. In 1934 Rous and Beard noted that papillomas of 
domestic rabbits frequently converted to squamous-cell carcinomas. Although Rous 
conceptually preceded his contemporaries by several decades, the importance of his 
ponderous work was only acknowledged in 1966, when he received the Nobel Prize. Rous’s 
research was not specifically driven towards the agent causing rabbit papillomas, but using 
the frequent progression of rabbit papillomas to squamous-cell carcinomas, he provided an 
universal model to analyse cervical cancer development. From this point, a number of 
anecdotal reports of the malignant conversion of genital warts appeared in the medical 
literature and resulted in a persistent interest about the possible role of HPV infection in 
cervical cancer. This interest began more concrete with the failures in finding traces of 
Herpes simplex virus type 2 (HSV2) DNA in cervical cancer biopsies. These fails prompted 
the search for other potential infectious etiology. In the mild-1970s, within precancerous 
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cervical lesions, Meisels and Fortin firstly observed areas of koilocytic atypia, which they 
considered to be the cytopathic effect of HPV infection (Meisels & Fortin, 1976). 
In 1978, Della Torre et al., in Italy, and Laverty et al. in Australia, firstly demonstrated the 
presence of HPV virions within dense bodies of koilocytes, but deeper investigations were 
limited by the inability to propagate HPV in cultured cells or in simple animal models. By 
the end of 1970s, the revolutionary advent of recombinant DNA technologies and 
molecular cloning techniques, provided the key for advanced investigation on HPV 
biology, in order to confirm the role of Papillomavirus in cervical cancer etiology (Zur 
Hausen et al., 1977). Topically, in 1983, Harald zur Hausen et al., for the first time isolated 
HPV-16 from a cervical cancer biopsy and cloned its genome. Using HPV-16 sequence and 
Southern blotting technology, zur Hausen detected this genotype in about one-half of 
cervicocarcinoma biopsies (Boshart et al., 1984) and demonstrated the selective 
transcription of viral E6 and E7 oncoproteins in cervical cancer derived cell lines 
(Schwartz et al, 1985).  zur Hausen’s findings indirectly demonstrated the heterogeneity of 
the Human Papillomavirus family; this fact consequently led to the classification of 
genital HPVs into low-risk and high-risk oncogenic groups, in dependence of the ability 
to induce cancer. In 2008, Dr. zur Hausen will receive the Nobel prize for medicine. 
Actually, there is uniform agreement regarding the central role of high-risk HPV-infection 
in cervical cancer and the necessary but far from sufficient etiopathogenetic role of the 
virus in causing cervicocarcinomas (Solomon, 2003).  
The practical implication of this long series of studies is evident: an enormous  increase  in 
the quality of diagnostic approach of precursor lesions of cervical cancer and the 
development of preventive vaccine (Zur Hausen, 2002). 
3. HPV and its life cycle 
Papillomavirus are small, non-enveloped, epitheliotropic, double-stranded DNA viruses that 
can infect basal epithelial cells of the skin or inner lining of tissue and induce cellular 
proliferation in a specie-specific manner. More than 100 genotypes of Papillomavirus have 
been isolated and branded molecularly; they were categorized as cutaneous or mucosal type.  
Basing on their association with cervical cancer and precursor lesions, HPVs can be grouped 
in: “high risk” (HR) or “oncogenic” types (16, 18, 26, 31, 33, 35, 39, 45, 51, 53, 56, 58, 59, 66, 
68, 73, 82, and  “low-risk” (LR) or “non-oncogenic” types (6, 11, 40, 42, 44, 54, 61, 70, 72, 81, 
89), related to benign epithelial proliferation but not with cancer (Munõz et al., 2004, 2006). 
Among the nineteen oncogenic HPV types, five are most often found to be associated with 
cervical cancer; particularly, virus 16 is accountable for about half of cervicocarcinoma cases 
discovered in Northern America, Europe and Australia; viruses 18, 31, 33 and 45 are 
responsible for additional 30% of cases (Cliffort et al., 2003; De Sanjosè et al., 2007; Kraus et 
al., 2006).  All papillomaviruses show a common genetic structure: a single molecule of 
double-stranded circular DNA of about 7900 base-pairs genome, enclosed in a non-
evenloped icosahedral capsid. HPV-DNA encodes for eight open-reading frames (ORFs) 
which are transcribed from the single encoding DNA strand. The genome is functionally 
divided into three regions. The first is a non-coding one, referred as Long Control Region 
(LCR) or Upper Regolatory Region (URR). This section of HPV’s genome includes enhancer 
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and silencer sequences that regulate DNA replication by controlling the transcription of the 
ORFs. The second is the Early (E) Region, consisting of ORFs E1, E2, E4, E5, E6 and E7, 
which are implicated in viral replication and oncogenesis. The third is the Late (L) region, 
that encodes the L1 and L2 structural proteins. 
4. A silent but epidemic virus 
The global burden of HPV-associated disease is very high. At present, HPV infections 
represent the most common sexually transmitted disease (SMT) in the world (Snijders et al., 
2006). In the United States alone, it was estimated that 6.2 million of new infections occur 
annually, with an approximately prevalence of 20 million (Clifford et al., 2005). 
Within population, the prevalence of HPV infection in asymptomatic women is estimated to 
range from 2% to 44%; the highest peak was reported in women younger than 25 years of age. 
The vast majority of HPV infection is transient and resolves within 2 years without 
necessarily led to clinically significant cervical lesions. Only 10% of infected women remain 
HPV-positive within 5 years. In 2008 (the most recent year for which statistics are available), 
12,280 women in the United States had cervical cancer, and 4,021 died from the disease 
(Arbyn M et al., 2011). Rates of infection appears actually to be in incessant and rapidly 
increasing. 
Interest in HPV and cervical pathology is primarily justified by the morbidity and mortality 
caused by cervical epithelial cancer: cervicocarcinomas represents the second most common 
cancer among women worldwide. Its worldwide burden is enormous, with over 500,000 
new cases of cervical cancer diagnosed each year, and 280,000 deaths recorded (Jemal A et 
al., 2010; Parkin D et al., 2002). While in developed Western countries screening 
programmes have significantly reduced the incidence of disease, about 80% of 
cervicocarcinomas cases still occur in underdeveloped countries. 
The natural history of cervical cancer is characterized by a well-defined pre-malignant 
phases. These pre-malignant changes represent a spectrum of abnormalities ranging from 
Low-grade Squamous Intraepithelial Lesion (LSIL) to High-grade Squamous intraepithelial 
Lesions (HSIL). In the United States, about five hundred thousand high-grade precursors 
and 2-3 milion cases of low-grade lesions are referred for colposcopic assessment each year. 
The attendant costs for the management of these lesions was estimated in 3-6 billion dollars 
(Stoler, 2004). 
Prospective studies showed that infection with oncogenic HPVs precedes the development 
of cervical neoplasia, and that it’s necessary, even if not sufficient, to have HR-HPV infection 
to develop squamous intraepithelial lesion (SIL) or invasive cervical cancer (ICC). Virtually 
all cervical cancers test positive for HR-HPV DNA. Surprisingly, the etiopathogenetic role of 
HPV for cervical cancer is higher than smoke is for lung cancer and than Human Epatitis B 
(HBV) is for liver cancer (Carter JR et al., 2011). 
HR-HPVs increased the risk of developing cervical cancer in the order of 50-300 fold. A 
meta-analysis of Smith et al. shows that the overall prevalence of HR-HPVs in ICC is on the 
order of 87%, ranging from 86% to 94% by region. Overall, HR-HPVs prevalence in HSIL 
ranges from 78% in Asia to 88% in Europe (Smth et al., 2007). 
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There is a broad variation between the most prevalent HR-HPV types around the world. 
However, types 16 and 18 remain the most common in cervical lesions, causing 60-80% of all 
cervical cancers. HPV-16 ranges from 52% in Asia to 58% in Europe; HPV-18 ranges from 
13% in South-Central America to 22% in North America (Smith et al., 2007). 
It was originally believed that there was an irreversible progression of cervical disease from 
low-grade  to high-grade lesions and then invasive cervical cancer. However, through a 
much greater understanding of the natural history of HPV infection, we actually know that 
the majority of low-grade lesions would regress without treatment. To the necessary activity 
of HR-HPV, other co-factors such as smoking, long-term oral contraceptive pill use, human 
immunodeficiency virus (HIV) co-infection, high parity, Chlamydia Trachomatis and HSV 
infections, immune suppression as well as nutritional and dietary factors may be associated 
to induce cervical cancer. Generally, the vast majority of these condition adversely affects 
antigen-processing Langerhans cells, needed for cell-mediated immunity, or enhances HPV 
gene expression in the cervix, thus promoting the integration of the virus into the host 
genome. 
5. Molecular basis of the transformation: Knowledge is power 
HPV life cycle is linked to the differentiation of the infected epithelial cell; it starts with the 
penetration of virions in the basal cells layers (stratum germinativum), through micro-
abrasions of the transformation zone of the cervix. The ability of HPVs to establish their 
genome in basal cells relies mainly upon E1, E2, E6 and E7 genes. Normally, when basal 
cells undergo cell division , it  loses contact with the basement  membrane and migrates into 
the suprabasal compartment, where it withdraws from the cell cycle and initiates a 
programme of terminal differentiation. In HPV infection, suprabasal cells fail to withdraw 
from the cell cycle. 
During acute infection, to replicate its genome and successfully produce infectious virions, 
HPV switches to amplify its DNA at high copy number, synthesises capsid protein and 
causes viral assembly, within the differentiated keratinocytes of the suprabasal layers of 
cervical epithelium. In this context many viral gene products are implicated. E7 has been 
shown to be necessary to induce suprabasal DNA synthesis, assisted by E5. E4 gene is 
essential for HPV-DNA replication and for the  expression of L1 and L2 genes. E4 also 
interrupts cytoplasmic cytokeratin network, causing condentation of tonofilaments at the 
cell periphery, and perinuclear cytoplasmic halo; the results is the koilocyte. Encapsidation 
of viral DNA, to generate viral progeny into differentiated cellular compartment,  is 
qualitatively dependent upon L2 gene. L2 may be also play a role during intracellular 
transport of virions, and  in the localization of viral DNA within host nucleus. 
During latent  infection, HPV stays as non-productive within the basal layer of the 
epithelium and establish itself as a low copy number episome, usually once molecule/cell 
cycle (Doorbar, 2005). At the basal and parabasal cellular levels only very little, if any, gene 
expression of the virus can be observed. Conversely, expression of early E1, E2, E4, E5, E6 
and E7 genes is evident within differentiated cells of the upper layers of the epithelium, 
which have lost the capacity to replicate their genome and are at no further risk of acquiring 
functional mutations. The above mentioned mechanism is a meticulous HPV strategy that 
allows maximal production of virions, causing almost no injury to infected host. The 
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situation changes radically if regulatory intracellular mechanisms driving the control of the 
viral are disturbed and deregulated. In this case, the expression of genes involved in the 
replication of viral genome occurs also in epithelial stem cells, which lost their capacity to 
differentiate. The inhibition of the differentiation process leads to a cellular state that cannot 
support the full viral life cycle. Interference of viral genes with cellular pathways that 
control replication and life cycle of epithelial cell might result in chromosomal instability. In 
epithelial stem cells with chromosomal instability, HPV DNA integrates into the host 
genome. HPV integration sites are randomly distributed over the whole genome, with a 
clear predilection for fragile sites (Wentzensen et al., 2004). Whether any property of the 
virus drives this integration event or whether it reflects random recombination events 
remain still unclear; however, two consequences of integration are certain: the loss of E2 
regulatory gene and the selective up-regulation of viral E6 and E7 oncogenes. Disruption or 
deletion of E2 gene, occurring during HPV-DNA integration, interferes with down-
regulation of E6/E7 transcription genes and leads to an increased and selective expression 
of E6/E7 oncoproteins, in replicating epithelial stem cells. As result, E6/E7 proteins bind to 
cell cycle regulators, stimulate cell-cycle progression and induce cellular instability 
(Doorbar, 2005). When E6 gene product binds to p53, physiological activities of p53, which 
governs G1 arrest and DNA repair or apoptosis, are abrogated (Doorbar, 2006; Tang et al., 
2006). E6 protein of non-oncogenic HPV types does not bind p53 at detectable levels and has 
no effect on p53 stability, in vivo. When E7 gene product binds to the hypophosphorilated 
form of the pRb, the result is the disruption of pRb-cellular transcription factor E2F-1 
complex, the release of E2F-1 and the transcription of genes whose products are required to 
enter in phase S of cellular cell cycle. Non-oncogenic E7 protein binds to pRb with a 
decreased affinity (Litchtig, 2006). Together E6/E7 proteins deregulate cell cycle checkpoints 
G1/S and G2/M. 
Host cells showing viral E6/E7 expression may acquire defects in differentiations, immortal 
phenotype, chromosomal instability and an increased probability of mutation allowing to 
invasion. Such described are obviously extraordinary molecular accidents occurring during 
HPV cell cycle and, in view of many HPV-infected cells, are extremely rare events. On the 
other hand, the continuous and deregulated E6/E7 activity in cervical stem cells 
compartments, enhances the selection and the growth of mutated cell clones. Then 
persistence represents the essential and indispensable requisite to develop cervical cancer. 
Numerous studies concerning HPV infection in immunocompromised population, reported 
that E6/E7 would also play an important role in the inhibition of the host cell immune 
response (Kraus et al., 2006), particularly by down-regulating the expression of Interleukin-8 
(IL-8). IL-8 is a T-cell chemoattractive molecule (Guess & Mc Cance, 2005), that also 
suppresses the expression of the Monocyte Chemoattractant Protein 1 (MCP-1) in epithelial 
cells of female genital tract (Biswas & Sodhi, 2002). E6/E7 would also favour the evasion of 
infected cells from the antiviral and antiproliferative activities of Tumor Necrosis Factor 
Alpha (TNF-α) (Scott et al., 2001).  
6. The ancient Pap test 
The concept of utilizing  exfoliative cytology to identify women with cervical cancer was 
introduced by Papanicolaou and Babes, in 1920s. Next, Papanicolaou refined the technique 
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and demonstrated that conventional cytology could also be used to identify precancerous 
lesions of the cervix. The shift from using cytology as a way to identify cases of invasive 
cervical cancer to using it to identify women with pre-neoplastic lesions was extremely 
significant. It meant that cervical cytology could be used to prevent cervical cancer, over 
than to identify cases in early phases. 
In the 1960s, cervical cytology began to be extensively used. In about 30 years, cytology-
based screening reduced the incidence of cervicocarcinomas by up to 75% in countries that 
have been able to realize quality-controlled screening programs (Arbyn et al., 2011). No 
improvements or modifications of the Pap test were instituted during this time, as there was 
no doubt that well-organized screening programs, realizing high compliance and good 
quality control, were effectual in saving lives. 
The process of change began when the article “Lax Laboratories” was published in the Wall 
Street Journal in 1987 (November, 2), by Bogdanich. The phrase “The Pap Test Misses Much 
Cervical Cancer Through Labs Errors”, implying that false negative Pap tests resulted largely 
from carelessness of doctors, alerted the public. The accuracy of cervical cytology began to be 
questioned. The article led to increased people awareness, and climaxed with the introduction, 
in 1988, of the governmental regulatory document known as CLIA 88 (Clinical Laboratory 
Improvement Act). CLIA 88 enforced regulations to ensure high quality testing 
At the same time, in 1988, the National Cancer Institute sponsored a workshop to address 
the standardization of diagnosis in cervical cytology. The workshop introduced a new 
classification system designated as “The Bethesda System” (TBS). TBS, further revised in 
1991 and 2001, provided a uniform format and offered a standardized terminology, 
specifically emphasizing communication of clinically relevant information (National Cancer 
Institute Group, 1989). TBS has been widely accepted and is endorsed by both Pathology 
and Gynecological Societies. 
In the 1990s, it was realized that the efficacy of Pap test have reached a nadir, and meta-
analyses indicated that both sensitivity and specificity of a single Pap test in detecting cervical 
intraepithelial neoplasia or invasive cancer is in the order of 80-85% and 76%, respectively 
(Stoler et al., 2001). A review of the UK program found that, within women developing 
invasive cervical cancer, 47% had an apparently adequate screening history during the 
previous 5 years (Sasieni et al., 1996); some of these patients also had a history of negative 
smear results. These considerations suggested that the frontiers of effectiveness of 
conventional cytology have been reached and that was imperative to improve the diagnostic 
assessment of the Pap test. This fact has been well recognized among the scientific community 
that emphasize the necessity to find other solutions to cope with this increasing problem. 
Prerequisites for an effective screening program is a high quality in sampling technique, in 
processing and in reporting. Basing on these considerations, technology entered in cytology 
practice with a variety of optional screening tolls to replace or complement conventional 
Pap test; among these, monolayer cytology and computer-assisted cytology .  
7. Challenges with conventional screening methods 
7.1 Monolayer cytology 
The low sensitivity of a single cervical smear is due to a variety of factors, including: 
incorrect or inadequate sampling of cervix; poor transfer of cells to the glass slide; non-
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representative sample placed on the slide; poor fixation. Particularly, sampling and 
preparing are together guilty for about two-third of false-negative tests (Cibas et al., 2008).  
To minimize false-negative cytology results and to improve the diagnostic accuracy of 
cervical cytology, some programs proposed to repeat the Pap test every year, to balance the 
relative limited sensitivity of conventional cytology; however, this conduct would 
compromise cost-efficacy of  Pap test and the possibility to use an algorithm with greater 
screening intervals and similar safety. New methods of collection and processing would 
need to surmount all these problems. 
Liquid-based cytology (LBC) was introduced in the mid-1990s, as a way to improve the 
performances of Pap test. By this technology, clinician does not prepare the specimen at the 
bedside by spreading the exfoliated cells onto a glass slide, but the cervical sampling device 
(i.e. spatula or brush) is rinsed in a vial containing a fixative-transport medium. In 
laboratory,  slides are prepared using an instrument that mixes the specimen and transfers 
an exact number of cells onto a filter membrane, with minimal cellular overlap. Then, the 
filter with the cells are transferred onto a slide and stained using the Pap stain (Abulafia et 
al., 2003). The automated process of such slides preparation prevents drying artefacts (very 
common in conventional Pap slides) and eliminates non-diagnostic debris, such as blood, 
mucus and inflammatory cells. Background material such as inflammatory exudates, 
cytolysis, microorganisms and tumor diathesis can still be identified but it does not obscure 
the epithelial cells  (Davey et al., 2006). 
To date, there are three currently FDA-approved LBC techniques, These include: SurePathTM 
System (TriPath Imaging Inc., Burlington, NC, USA), ThinPrep® System (Hologic, Crawley, 
UK) and MonoPrep System (MonoGen, Lincolnshire, IL) (Cibas et al., 2008). 
ThinPrep and SurePath methods are the most widely studied technologies in literature; their 
underlying principles are similar, the only difference being that ThinPrep collects samples 
into methanol-based preservative solution, while SurePath dispenses cells into ethanol-
based fluids. 
More than forty publications promote the use of these preparation methods. In particular, 
all the authors show statistically significant improvement (about 10% or more) of the 
diagnostic sensitivity of conventional cytology in all categories of cervical disease (Bernstein 
et al., 2001; Davey at al., 2007; Nance et al, 2007; Papillo et al., 2008.). 
Currently, LBC constitutes over 80% of cervical screening tests in USA. In 2003, the UK 
National Institute for Clinical Excellence (NICE) recommended the introduction of LBC as 
primary way to process samples in cervical cancer screening programs (Stoykova et al., 
2008). The National Health Service of the United Kingdom agreed to introduce LBC 
throughout the country, in view of the reduction of inadequate specimens from 9% with 
conventional cytology to 1-2% with LBC (Nance et al., 2007). 
LBC techniques improved the quality of the smear, being cytological evaluation and 
interpretation facilitated by the thin layer of evenly distributed cells. Abnormal cells are not 
hidden in thick areas of the slide; Then, will follow an increased detection of the lesions 
(such as HSIL lesions), a reduction of the number of false-negative diagnosis and the 
diminution of unsatisfactory specimens. Moreover, the availability of residual cellular 
material, preserved for several week at room temperature, is usefulness for additional 
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investigations, such as immunocytochemistry or molecular procedures. In the USA, the 
Consensus Guidelines for the Management of Women with Cytologic Abnormalities 
considered HPV-DNA testing on residual LBC specimen to be the preferred approach to 
managing women with ASC-US cytological results. This suggestion was based on the 
grounds that HPV-DNA reflex testing could offer the advantage that women do not need to 
return to additional clinical  examination (Wright at al., 2002).  
7.2 Computer-assisted cytology  
Screening of Pap smears is monotonous. It was recognised that the monotony of screening 
large numbers of normal slides promotes periods of lack of attention during which 
abnormal cells may be disregarded. Among women who have cervical cancer and have been 
screened, 14% to 33% of the cases represent failure to detect abnormalities. It is therefore not 
surprising that great efforts have been made to automate also this aspect of cervical cancer 
screening. The aim of computer-assisted reading of cervical smears is to increase the 
sensitivity of cytological testing by finding cells known to be very difficult to detect in 
conventional slides. This technology should also increase productivity by excluding normal 
slides or part of the slides from manual screening and by selecting most atypical images to 
be checked by cytologists (Dunton, 2000). 
In the mid-1990s two automated devices, based on traditional computer image technology 
and neural network software, have been subjected to extensive multicentre trials and 
subsequently approved by the American Food and Drug Agency for screening cervical 
smears: PAPNET system (Neuromedical Sciences Inc, Amsterdam ) and AutoPap 300 
(NeoPath Inc, Redmond Washington USA). Both are interactive systems, which select 
smears for manual review by the screener. They were initially approved for quality control 
or supplementary screening of cervical smears. Subsequently they were admitted for 
primary screening. 
PAPNET was introduced as a pre-screening method of conventional Pap smears. The 
smears were analysed using a combination of algorithmic and neural network programs; 
then, 128 images of the most abnormal looking cells or cell groups were selected for 
inspection by the screener. 
The images were stored on compact disc and viewed by the screener on a video monitor 
placed in the laboratory. The screener triages the images and decides whether the slide is 
negative or requires manual review. Those slides which were triaged negative were not 
subjected to manual microscopic review. 
AutoPap was also designed to also pre-screen conventional slides. This technology uses a 
computer algorithm method to classify and score glass slides to overall level of abnormality. 
All slide were processed through the device and then, on the basis of “abnormality index”, 
they were ranked in descending order of potential abnormality and broken into quintiles. 
This system, now manufactured by TriPath inc. and called FocalPoint®, was designed to 
look for abnormalities slide by slide and to rule out the 25% of slides with the lowest risk. 
These slides were automatically excluded from the list of those requiring manual 
microscopic review thus reducing the screener’s workload by 25%. Slides with the most 
severe abnormalities were completely reviewed by scientists. 
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FocalPoint is intended to be used on both conventionally-prepared and SurePath™ cervical 
cytology slides. This system analyses the samples using a series of algorithms and assigns a 
score to the sample. The sample is then graded into a group called “No Further Review” 
(NFR) or into one of 5 risk categories. The purpose of this assignation is to make 
unnecessary to look at the NFR category. Cytoscreeners can instead concentrate themselves 
on looking at the slides graded as abnormal. The operator is guided to the areas containing 
the cells of interest (Fields of View/FOV) which have been detected by the system. 
Recently, Cytic Corporation developed its computer assisted system, the ThinPrep Imager®, 
which received FDA approval for use with ThinPrep slides. A bench-op image processor 
analyses ThinPrep slides, which were reviewed by  cytotechnologists, by using a microscope 
with a motorized stage. Special software drives the reviewer to the 22 most abnormal fields 
on the slides. Full manual review is required only if any of the 22 fields contain a suspicious 
or abnormal cell. 
Devices of computer-assisted screening were tested in extensive multicentre  trials 
comparing automated and manual screening of the same slides. All trials found that 
automated systems were at least as sensitive as manual screening; however, in automation 
more smears could be analysed per unit of time. On the other hand, due to high 
development costs, these systems were not found to be cost effective for the use in 
laboratories processing less than 50,000 smears per annum; this fact excluded many 
laboratories in the USA and Europe.  
8. The revolution: Molecular diagnosis 
The awareness of the viral origin of cervicocarcinoma, the refinement of the techniques for 
cytological diagnosis and the introduction of liquid-based medium for collection of 
cytological specimens has open new and interesting options to improve cervical cancer 
screening programs. 
The consciousness that cervical cancer is a multistep process and that it occurs in women 
who have been infected with oncogenic HPVs, led to the development of molecular 
techniques able to identifying carcinogenic Papillomavirus in cervical sample (Bosch et al., 
2002). The era of diagnosis based on aetiology was beginning. 
Serological assays to detect antibodies against HPV capsid or against functional protein 
received attention as investigational tools, both in epidemiological and clinical studies 
(Jochmus-Kudielka et al, 1989; Galloway, 1992). However, serology detected humoral 
immune response to HPV antigens, which may reflect cumulative exposure to HPV 
infection acquired in mucosal sites other than genital; moreover, it was unreliable to 
determine whether an HPV infection was present or past (Dillner J, 1999), by using 
serological tests.  So, an accurate diagnosis of HPV infection could only be based on the 
detection of viral nucleic acid. 
Testing for Human Papillomavirus by different molecular tools has been proposed as an 
adjunct or as an independent screening tool, with several potential advantages. Testing for 
the etiological agent of cervical cancer offers the opportunity to detect women at increased 
risk of cervical cancer at the stage of latent and subclinical infection, preceding by several 
months to years the clinical stages detectable by the Pap test. 
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Wide range of methods to detect HPV-DNA in cytological specimens are available. They 
evolved considerably in the last 25 years. Initial methods were based on direct probe 
hybridation technology, such as dot blot and Southern blot. Besides being labor-intensive 
and time-consuming, these techniques showed low sensitivity and required large amounts 
of DNA in clinical samples. So they have largely been superseded by amplification 
technology. Amplification techniques can be further classified into two separate 
categories:(i) target amplification assays (i.e., PCR, in which a target nucleic acid is 
amplified) and (ii) signal amplification assays (in which the signal generated from each 
probe is increased by a compound-probe or branched-probe technology). To date, all the 
above methodologies (Figure 1) have been applied to HPV detection field (Zappacosta et al., 
2008).  
 
Fig. 1. Technology assessment in cervical cancer screening 
8.1 Southern blot  
The first method for HPV detection was the Southern blot (Sb). Sb utilizes enzymes to break 
HPV-DNA chain extracted from the specimen. The product, integrated into a gel, is 
subjected to electrophoresis, that separates viral DNA basing on the size of each fragment. 
DNA fragments are next transferred to a nitrocellulose membrane and hybridized with HPV 
genomic probes, which are labelled with radioisotopes. In addition to poor labour 
applicability (reliance on radiolabelled probes) and high time-consuming, Sb procedures 
showed low sensitivity, mainly due to the need of large amounts of DNA in clinical 
samples. For all these reasons, Sb technique has now largely been superseded by 
amplification technologies. 
8.2 Direct hybridization 
In situ hybridization (ISH) is a direct probe method that assess the presence of a target 
nucleic acid or gene expression within either paraffin-embedded tissue or cervical smear. 
The nucleic acid probes used in ISH are derivatized, typically with biotin, in multiple sites. 
Detection is frequently achieved employing a sandwich approach, involving streptavidin-
chromogen complexes. Improvements in sensitivity of ISH have been reached with 
fluorescent probe (FISH) utilization, in order to add a further amplification of the signal. The 
major advantages of ISH/FISH techniques is that HPV-DNA can be identified inside 
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specific cells (normal, koilocytes, neoplastic) and that viral physical status may also be 
determined (integration versus episomal) (Hopman et al., 2005). Low sensitivity and 
specificity (30% and 72%, respectively), nucleic acid degradation during sample processing, 
and high time-consuming (due to multiple assays which must be carried out for HPV 
genotyping), are the main factors that make these techniques troublesome in its 
performances (Seedlacek, 1999). 
Laboratories using molecular assays for detection of infectious organisms should use 
standardized tools. In this context, the World Health Organization (WHO) has initiated an 
International Collaborative Study enrolling several laboratories worldwide (Pagliusi & 
Garland, 2007). The aim of developing HPV international standard reagents is to capacitate 
diagnostic laboratories to be able to validate their own assays and to determine their 
analytical sensitivity. Within surveillance studies, this standardization will allow 
comparison of HPV-DNA detection between different geographic localization, populations 
and anatomical sites over time. Standardization is particularly important in view of  post-
vaccine population responses data. 
High-throughput assays suitable for large-scale cervical cancer screening are currently based 
on two different amplification technologies: Polymerase Chain Reaction (PCR) and  
hybridization-based assays (i.g., Hybrid Capture 2 assay). The advantages and disadvantages 
of these basically different assays will be extensively discussed below together with the 
analysis of several recent studies comparing the performances of both techniques. 
8.3 Polymerase chain reaction 
PCR is a selective target amplification assay capable of exponential and reproducible increase 
in the  HPV sequences present in biological specimens. The amplification process can 
theoretically produce one billion HPV-DNA copies from a single double-stranded molecule. 
after 30 cycles of amplification, For this reason, PCR has very high level of molecular 
sensitivity and permits the detection of less than 10 copies of HPV-DNA in a mixture 
There are two main approaches to detect HPV-DNA by PCR: type-specific PCR and 
consensus PCR. The latter are able to amplify sequences from several different HPV types, 
because they target conserved DNA regions in the HPV genome. The most extensively used 
PCR assay utilizes consensus primers that target a highly conserved region of HPV L1 
genome, thus amplifying a vast spectrum of HPV types in one reaction. Initially, most 
laboratories used PCR assay with degenerated primers pair MY09/11. These primers are 
now been replaced by a new set of oligonucleotides pool: GP5/6 and modified GP5+/GP6+, 
PGMY09/11 (modified MY09/11), SPF1/2, the last one especially appropriated for 
formalin-fixed paraffin-embedded tissue samples, which often offer a small amount of 
amplifiable DNA (Boulet et al., 2008; Perrons et al., 2005). Amplification with each of these 
primers provides different size amplification products, resulting in varying sensitivity for 
HPV-DNA detection. Although discrimination of sequence homology is better for longer 
sequences, and would theoretically permit improved HPV types resolution, shorter 
fragments tend to confer better sensitivity when potentially degraded specimens, such as 
paraffin-embedded tumor tissue, are used.  
Up to date literature reports clinical sensitivity of PCR protocols varying from 75% to 95% 
(Kulusingam et al., 2002), with a median of 82%. Of interest is the PCR versus HC2 data 
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obtained from ALTS study: on 278 cases of CIN3/cancer, PCR test employing the 
PGMY09/11 primers achieved clinical sensitivity and specificity of 87.4% and 55.6% 
respectively, while the corresponding value for HC2 test were 95.5 and 51.1% (Belinson et 
al., 2001; Zappacosta et al., 2010. 
The commercial assay by Roche Diagnostics, Amplicor® HPV test (Roche Molecular 
Systems, Inc., Branchburg, NJ, USA) has been recently released, although not yet FDA 
approved. The test is designed to amplify HPV DNA from 13 high-risk genotypes (16, 18, 31, 
33, 35, 39, 45, 51, 52, 56, 58, 59, and 68), by using biotinylated  primers to define a sequence 
of approximately 165 bp in length within the polymorphic L1 region of the HPV genome, 
and to simultaneously assess the presence of human β-globin gene as a positive control. The 
test do not discriminate HPV genotypes specifically. In the International Papillomavirus 
Congress which took place in Mexico City during 2004, several studies showed data related 
to the utilization of Amplicor® test in two different LBC media (ThinPrep® and Surepath™) 
and illustrated the performance of the test in different clinical settings. Particularly, van den 
Brule at al., (Hessenlink et al., 2005) compared Amplicor® test with the GP5+/GP6+ PCR 
assay in cervical samples collected in PreservCyt® medium. The two tests gave similar 
results, but the sensitivity of Amplicor® appeared slightly higher. Roche assay and HC2 test 
gave identical results in detecting high-grade CIN (Monsonego J et al., 2005).  
The scenario changes when HPV genotyping is needed. HPV genotyping is now considered a 
relevant tool for women management, in order to identify persistent type-specific oncogenic 
HPV infection, and for the stratification of cancer risk. Among HPV-positive women, 20% to 
40% harbour at least two genotypes (Mendez et al., 2005). Interest in multiple HPV infections 
has recently increased as prophylactic vaccines against HPV have been introduced (Jenkins, 
2008). Moreover, the correct profiling of HPV types in patients with multiple infections is 
important to learn more about the natural history of cervical cancer. Constant progress in HPV 
typing based on PCR methods has been made over the past few years. The majority of 
available protocols uses degenerate and/or consensus primers, followed by the examination of 
the generated PCR product through sequence analysis, restriction fragments length 
polymorphisms analysis or hybridization with type-specific probes in different formats (such 
as the reverse line blot assay [van den Brule et al., 2002] or bead-based multiplex HPV 
genotyping method [Schmitt et al., 2006]). The use of these technologies offers the advantage of 
detecting a large spectrum of HPV types by a single PCR. However, they may be less efficient 
in detecting specific HPV types, in cases of multiple infections (Schmitt et al., 2010). 
Generally, amplification-based methods, mainly PCR, are currently the most sensitive 
methods for the detection of HPV-DNA. They are ideal instruments for research and 
epidemiological purposes, since they allow the detection of low viral load infections, also 
minimizing the risk of misclassification of HPV infection status. However, due to the 
frequent contamination problems and consequent false-positive results as well as to the 
costs which are still too high, they are not routinely applicable in diagnostic laboratories. In 
order to overcome these problems, Digene Diagnostics developed Hybrid Capture System 
DNA detection. 
8.4 Hybrid capture 2 
Hybrid Capture 2 (HC2, Qiagen, Valencia, CA)  is a simple, high-throughput, semi-automated 
HPV-DNA test, operating on the principle of signal amplification. HC2 is the only HPV test 
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currently approved by the US FDA. The method utilizes long (> 1 kb) single-strained RNA 
probes which are complementary to the entire HPV-DNA genomic sequence. DNA is firstly 
denatured  and subsequently mixed with RNA probe pool in a buffered solution. Two RNA 
probe pool are used. The test can be performed using both probe pool together or separately. 
Probe A recognizes non-oncogenic HPV types (6, 11, 42, 43, and 44); pool B identifies 
oncogenic HPVs (16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59 and 68). DNA-RNA complexes are 
immobilized onto microplates which has been coated with polyclonal IgG antibody that 
recognize specific DNA-RNA hybrids, at room temperature. The immobilized hybrids are 
then identified by a second DNA-RNA antibody, conjugated to alkaline phosphatise and 
bounded to a chemiluminescent substrate, CDP Star (Figure 2). Microplates are then 
transferred into a software program where results are analysed; in particular, CDP Star ligh is 
measured by a luminometer. The intensity of the light emitted by each specimen is expressed 
on a scale as RLUs (Relative Light Units), relative to the average reactivity measured in 
triplicate wells with a positive control containing 1.0 pg of HPV-16 DNA/ml.  
 
Fig. 2. Hybrid Capture 2 Technology. A - HPV-DNA denaturation; B – single-stranded RNA 
probes recognizes oncogenic HPV-DNA; C - DNA-RNA complexes are immobilized onto 
microplates coated with polyclonal IgG antibody; D – identification of immobilized hybrids 
by a second DNA-RNA alkaline phosphatise conjugated antibody, bounded to CDP star; E – 
a luminometer measures light emitted by the specimen (Digene-Qiagen website, modified)  
The first generation of HC assay (HC1) was a tube-based detection system and probed for 
only nine HR-HPV types. The analytical sensitivity of the assay was 50,000 copies of HPV-16 
DNA. 
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Several studies evaluated the clinical sensitivity and specificity of this first generation assay 
mainly against PCR and histology (Cavuslu et al., 1996; Cope et al., 1997; Shah et al., 1997). 
As expected, HC1 was less sensitive than PCR and other application techniques, but its 
specificity and positive predictive value (PPV) were higher than those of PCR. To improve 
the sensitivity of HC1, the Digene Corporation modified the first generation assay. The 
improved second-generation assay (Hybrid capture 2) is commercially available from the 
beginning of 1998. In this technology, the analytical sensitivity was increased to 1,000 HPV-
DNA copies. Studies comparing first and second generation of Hybrid Capture technology 
shoved concordance in 96.8%. Interestingly, in all discordant samples containing HPV-DNA 
types covered by the probes included in both assay generation, the RLU/cutoff value ratios 
obtained in the second-generation assay were very low, which would indicate that low HPV 
viral load was the reason that produced false-negative results in the first-generation assay. 
HC2 assay is actually considered more sensitive than HC1, as well as more rapid, easier to 
perform and thus more appropriate for the routinary detection of HPV infection. In 
addition, as RLU signal is proportional to the amount of HPV-DNA present in the specimen, 
HC2 assay could be occasionally used to deduce viral load, on a semi-quantitative basis. The 
main advantage of HC2 test is the high sensitivity and the abundant clinical data which 
allowed to its FDA approval. Moreover, since HC2 test is less affected by cross-specimen 
contamination than PCR, it don’t need for special laboratory (Carozzi et al., 2005; Cubie et 
al., 2005). On the other hand, there are many limitation to this techniques which have to be 
taken into account. First, the test cannot determine the specific HPV type present in the 
sample; this fact limits the recognition of persistent infection by the same viral type, which is 
the most important risk factor that induce cervical lesion to progress to invasive cancer. 
Second, at the standard FDA-approved cut-off of 1 pg/ml (RLU ≥1.0) and even at higher 
discriminating levels, RNA probes suffers from a cross-reactivity with non-oncogenic viral 
types and with certain oncogenic untargeted HPV types (53, 66, 67, 73) (Howard et al., 2004). 
Cross-reactivity with other oncogenic-HPV types might be beneficial for test sensitivity. On 
the other hand, cross-reactivity with non-cancer-causing types would have an adverse 
impact on clinical specificity and positive predictive value of the test, especially in 
population with a high prevalence of non-oncogenic types (Castle et al., 2003).  
During 2003, a prototype version of Hybrid Capture 3® (HC3), possibly the next generation 
of HC2, has been evaluated for the detection of CIN3 and cancer. HC3 was designed to 
minimize cross-reactivity with untargeted HPV types. HC3 showed slightly higher 
sensitivity that HC2 for the detection of CIN2+ lesions but equal specificity. Actually, HC3 
has not been marketed yet. 
HC2 technology is amenable to automation,  in case of high-volume screening use. The next-
generation Hybrid Capture® (NextGen, QIAensemble™, Qiagen Inc., Gaithesburg, MD), 
consists of a fully automated platform (JE2000™) which utilizes a reengineered HC2 test.  
The implementation of analytical specificity, the maintenance of  comparable levels of 
analytical sensitivity, the longer on-instrument stability of reagents, the detection of HPV-16 
and 18 at lower copy number, the reduction of assay time (< 2.5 hrs compared to up to 5 hrs 
for HC2), as well as the reduction of the cross-reactivity with non-oncogenic HPV types 
(Eder et al., 2009), are the main advantages of NextGen. To validate the use of NextGen 
within screening context, pre-clinical studies using specimens from patients with 
histologically confirmed CIN2+ lesions are needed.  
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9. New paradigms in cervical cancer screening 
Detection of oncogenic-HPV DNA is considered to be potentially useful in three clinical 
application: in population screening, as a primary test or in combination with cytology to 
detect cervical cancer precursors; in triaging, to select which cytological lesions must to be 
referred for colposcopy; in follow-up of women treated for high-grade intraepithelial lesion, 
to accurately identify patients with residual or recurrent lesion. 
In adjunct to cytology, the purpose of HPV-DNA assay is the detection of latent or 
subclinical infection among symptoms-free women. In 2001, Belinson et al., performed a 
large cross-sectional study (1997 women ageing 35-45) in order to compare the sensitivity of 
LBC and HC2 test for the detection of CIN2+ lesions (Belinson et al., 2001). Essentially, the 
rationale of the use of adjunctive HPV-DNA testing is based on the accepted concept of 
necessary causality of HPV in determining cervical cancer and on the basis of the very high 
negative predictive value (90-100%) of the combination HPV-DNA test/LBC. Combining 
HPV-DNA test with LBC improves the performance of Pap test alone, especially when 
cervical cytology is ambiguous (i.e., ASC-US and LSIL lesions). Using mathematical models 
to evaluate clinical and economics outcomes. Goldie at al., concluded that using HPV-DNA 
test plus cytology in women ≥ 30 years of age were more effective in reducing cancer 
incidence. Combining molecular biology and LBC could also result in increasing the 
screening interval for women testing negative at both cytology and DNA testing. Longer 
screening intervals with more sensitive tests would be the strategy providing the most 
advantageous balance between benefits and costs (Goldie et al., 2004). 
In triage, the goal is to guide the management of patients with borderline or mildly 
diskaryotic smears (ASC-US and LSIL, respectively). ASC-US/LSIL Triage Study, a 
multicenter and randomized clinical trial sponsored by National Cancer Institute (NCI), 
evaluated three management strategies for women with ASC-US and LSIL cytological 
results: (i) immediate colposcopy; (ii) repeated cytology with referral to colposcopy if 
cytological findings showed HSIL lesion; (iii) HPV triage, with referral to colposcopy in case 
of HPV-DNA positivity (Rodriguez et al., 2008; Solomon et al., 2001). 
ALTS established that: (a) HPV-DNA triage is as sensitive as immediate colposcopy in 
HSIL+ detection; however, molecular testing would spare all HPV-negative women from 
emotional and financial weight of colposcopy. (b) repeating cytology, would refer more than 
two-third of ASC-US/LSIL abnormalities to colposcopy. ALTS study attested that HPV-
DNA method represents the best triage (Munoz et al., 2003). In the USA, HPV-DNA testing 
has been definitively integrated into cervical cancer screening programs and has become the 
standard of care in the triage of women over the age of 30, having minor cytological 
abnormalities (Wright et al., 2002); the rationale is the high proportion of HPV-DNA 
negative women (about 50%) among ASC-US group and the consequent extremely low risk 
of developing high-grade lesions. In this context, the role of DNA testing is to focus on those 
women ASC-US/DNA-positive in which colposcopic assessment is justified. 
Following treatment with cryosurgery, laser ablation or LEEP for HSIL cervical lesion, 5-
25% of patients may develop residual or recurrent high-grade disease (Kocken et al., 2011). 
Standard of care has been close cytological and colposcopic follow-up at 6, 12 and 24 months 
after treatment. However, since follow-up Pap test has a low specificity in detecting residual 
HSIL and given that HPV is cleared from the cervix following adequate treatment, DNA 
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testing has been evaluated to predict the presence of residual dysplasia (Nam et al., 2009). In 
a recent meta-analysis, Zielinski et al. considered 11 studies evaluating HR-HPV DNA 
testing in monitoring women after treatment of CIN2+ lesions. It has been shown that the 
association HPV-DNA testing/cytology reached a NPV of 99% (Zielinski et al., 2004). The 
adoption of such algorithm of surveillance would mean to focus colposcopy only on women 
positive for both Pap and DNA test. 
The consciousness of the necessary causality of HPV in determining cervical cancer defined 
new possible approaches to screen and prevent cervical cancer. In population screening, as a 
primary test, the purpose of HPV-DNA assay is the detection of latent or subclinical 
infection among symptom-free women (Rebolj et al., 2011). 
Most authors evaluated the performances of cytology (conventional or LBC) and HPV 
testing (PCR or HC2) in detecting CIN2+ lesions or cervical cancer in several populations. 
Despite various study design, various ranges of age, various HPV detection techniques, 
various cervical lesions prevalence rates, the global survey of results leads to three main 
conclusions: for CIN2+ or greater (CIN2+), HPV testing is more sensitive (88-98% versus 51-
86%) and has an higher negative predictive value (NPV) than cytology; specificity of DNA 
testing is lower than that of cytology (83-94% versus 92-99%); The sensitive and NPV of 
combined testing is near to 100%. The objective is then to start the primary screening by the 
most sensitive and automated test, HPV testing, and in second time to use the best 
specificity of cytology for diagnosis and triage (Arbyn et al., 2009). Women with abnormal 
smears would be immediately refer to colposcopy. Since a single negative HPV-DNA test 
reliably predicts a low risk of subsequent CIN2+, it would be justified to extend screening 
intervals.  (Bulkmans et al., 2007). 
Current European Guidelines for quality assurance in cervical cancer screening recommend 
implementation of pilot program with a validated HPV-DNA test within national organized 
cervical cancer screening programs and, if effective, permanent implementation of such 
programs (Arbyn et al., 2008). Longitudinal studies assessing the incidence of CIN2+ lesions 
are then essential to define the role of HPV testing in cervical cancer screening policies 
(Leinonen et al., 2009). Actually only baseline results of large randomized controlled trials 
are available. 
Anttila et al., evaluated the impact of primary HPV-DNA screening plus conventional 
cytology triage of HPV-DNA positive women and compared this cohort with cytology-
based screening cohoort. The study incorporated the population enrolled in organised 
screening programme for cervical cancer in Finland (Anttila et al., 2010). The evaluation was 
based on the total number of CIN3+ cases detected within five years after the invitation. The 
study, adding longitudinal information based on cancer registry files, showed that a single 
round of HPV primary test has been able to reduce the number of cases of invasive cervical 
cancer. These data suggest that using HPV DNA testing in primary screening, followed by 
cytology to triage HPV-DNA positive women, would represent an approach more sensitive 
than that based on cytology alone, in identifying CIN2+ lesions. 
In Sweden Naucler et al., explored the efficacy of 11 different screening strategies based on 
HPV DNA testing alone, cytology alone, and HPV DNA testing combined with cytology 
(Naucler et al., 2009). They showed that using HPV DNA testing as primary screening 
followed by cytological triage and repeating HPV DNA testing on DNA-positive/ cytology 
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negative women after at least 1 year would be a feasible strategy in primary cervical 
screening. 
The Italian NTCC (New Technology for Cervical Cancer) randomized controlled trial 
compared Human Papillomavirus testing (HC2) alone with conventional cytology as the 
primary cervical cancer screening test, in a total of about 49,200 having a median age of 42 
years (Ronco et al., 2008). Among women aged 35-60 years, HPV testing did not show a 
statistically significant extent vs conventional cytology for the detection of CIN2+ lesion. 
Vice versa, increasing the cut-off for HPV-DNA positive results from 1 to 2 pg/ml, 
molecular testing arm showed a statistically significant increase in sensitivity, associated to 
a non statistically significant reduction of PPV. The sensitivity of HPV testing compared 
with conventional cytology was much larger among women aging 25-34 than among older 
women. Ronco et al., recommended the use of HPV testing as primary screening in women 
older than 35 years of age and a  preferable 2 pg/ml cut-off for HC2. In women aged less 
than 35 years, to avoid colposcopic overtreatment in HPV-positive/cytology negative 
patients, NTCC suggested 1 year molecular retesting (Figure 3). 
 
Fig. 3. Three different approaches to cervical cancer screening (Dillner J et al., BMJ 2008, 
modified) 
The consultation of the Medline database by formulating the queries “HPV testing”, 
“cervical cancer screening”, “cervical cancer”, “HPV testing in primary screening”, “HPV-
DNA screening test” allows to the following consideration: 
1. all the trials (except for NTCC) found that sensitivity of HPV-DNA testing was higher 
than that of cytology, in detecting CIN2+ lesion; 
2. all the trials state that NPP is higher for HPV testing than that for cytology. On the other 
hand, DNA testing is less specific than Pap test (89% vs 95%);  
3. HPV testing alone might induce an overtreatment, especially in the youngest 
population. The specificity for both HPV testing and cytology are clearly lower below 
30 years of age; 
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4. several studies showed that HPV-negativity alone or in combination with negative 
cytology triage would signify a longer disease interval against CIN2+ lesions than that 
being for cytology alone. In this context, it seems that a screening interval of five years, 
would be best choice. After five years, women testing DNA-negative would have a 
considerable lower risk for CIN2+ (0.25%) than woman having a normal Pap test 
(0.83%); 
5. cytology triage of HPV-DNA positive women, would be the best strategy for referring 
to colposcopy patients who were DNA-positive/cytology positive; 
6. it’s meaningless to perform cytology on DNA-negative women; in this case, double 
testing adds negligible protection compared to HPV testing alone; 
7. the better protection but the lower specificity of DNA testing implies that it should only 
be used in well-organized screening programs, in which the test is not used too 
frequently, or at too younger age (Dillner et al., 2008; Naucler et al., 2007; Naucler et al., 
2009).  
It’s our opinion that further evaluation of the risk of CIN2+ lesions with different 
combination of test and in relation to women’s age, would be the next step; then, it’s 
important to choose the best primary screening tool, taking in account costs and logistics of 
the single countries. 
The next step in research could be to improve the specificity of HPV-DNA testing by 
validating adjunctive markers, predictive of HPV persistence, in liquid-based cytology 
biobanks. 
10. New ways to use existing technologies 
From the meta-analyses summarised above, it is clear that HPV-DNA testing is substantially 
more sensitive than cytology at detecting CIN2+ lesions. However, molecular testing is 
rather less specific than cytology. The main problem with DNA testing is the high 
prevalence of HPV-DNA positivity among female population, compared with the low 
number of women with transient infection which spontaneously would regress. These 
considerations suggest that the more sensitive test should be applied firstly (i.e. DNA 
testing), while the more specific test should be used only in HPV-positive women, in order 
to establish the correct management strategy. 
The approach of using HPV-DNA test as the sole primary screening modality has several 
advantages: HPV-DNA detection assays is an objective and automatable test with a 
dichotomous result; his allows for better quality of screening. Cytology can thus to be 
reserved for the 5-15% of women who are DNA-positive. This protocol would obtain cost 
savings through reductions in staff numbers, would reduce turnaround time of diagnosis, 
would avoid overtreatment and could permit a longer screening interval. For DNA testing, 
the requirement for adequate specimen sampling is less rigorous, when compared to 
cytology. Several studies evaluated the diagnostic accuracy of self-collected cervico-vaginal 
specimens (Ogilvie et al., 2005). With an overall sensitivity of 74% and specificity of 84%, 
self-taken sampling appears to be favourable in settings where sensitivity of cytology is 
typically less than 70%. Göh M et al., found that women prefer self-sampling to a clinician 
taken-sampling (Gök et al., 2010). These results suggest that self-sampling for HPV-DNA 
testing could be a valuable screening method to recruit women who refuse to attend 
clinician-based screening, and to improve population coverage of screening.  
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11. Screening in low-resource settings: changing the paradigm of cervical 
cancer prevention and control 
In developing countries, it seems unrealistic to introduce cytological screening and 
histopathological follow-up because of financial, technical and human limitations. 
Alternative methods of screening that would surmount barriers consisting in the “three-visit 
cytology-based approach” are needed which accurately predict the presence of cervical 
cancer or precursors (Table). Three requisites are essential in effective screening program: 
screening diagnosis and treatment should be provided on-site or in clinics accessible to the 
vast majority of women at risk of developing cancer; reproducible, validated, low-cost 
screening test should be available; screening should ensure high participation of women at 
risk for cervical cancer, by using appropriate educational programmes direct towards both 
health workers and population. While the first two conditions are essential in low-resource 
settings, the third is an universal requirement.  
In low-resource settings, a wide number of tests have been investigated over the years, as 
alternative screening tests to cytology. The four most widely studied alternative approaches 
are VIA (visual inspection with acetic acid), VILI (visual inspection with Lugol’s iodine), 
self-sampling and HPV testing.  
 
Screening  
test 
Sensitivity* Specificity* Characteristics 
Conventional 
cytology 
44%-78% 91%-96% 
Requires adequate laboratory-based healthcare 
infrastructure, stringent training and quality 
control 
HPV testing 66%-100% 61%-96% 
High throughput, objective, reproducible and 
robust but currently expensive 
VIA 62%-80% 77%-84% Low cost, strict linkage to immediate treatment 
VILI 92% 85% Low cost, strict linkage to immediate treatment 
Colposcopy 44%-77% 85%-90% Expensive, inappropriate for low-resource settings 
Table. Ranges of sensitivity and specificity and characteristics of some screening methods. 
VIA: visual inspection with acetic acid; VILI: visual inspection with Lugol's iodine 
11.1 Visual inspection with acetic acid 
This technique involves the examination of the cervix with the naked eye and a bright light 
source, one minute after the application of 3-5% diluted acetic acid. Detection of well-
defined aceto-white areas close to the squamocolonnar junction, indicates a positive test. 
CIN and microinvasive cancer switch-on white following acetic acid application. Aceto-
whitening is essentially due to a reversible coagulation of intracellular proteins. The high 
concentration of intracellular proteins in neoplasia led to the dense aceto-whitening 
appearance. The main advantage of VIA is that it yields an immediate result, thus making it 
possible for treatment of abnormalities at the same visit (“screen-and-treat”approach). This 
method is also inexpensive and can be carried out by using modest  equipments, without 
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the need for laboratory infrastructures. Moreover, health workers can be rapidly trained to 
perform VIA (about ten days of courses duration). Several cross-sectional studies evaluated 
the accuracy of VIA in developing countries. Pooled estimates of the sensitivity of the test in 
detecting CIN2+ lesions vary from 62 to 80%, and the specificity from 77 to 84% (Arbyn et 
al., 2008; Gaffikin et al., 2008; Hovland et al., 2010). The greatest reduction in incidence and 
mortality rates are observed for the 30-39 years of age group. 
11.2 Visual inspection with Lugol’s iodine 
VILI involves the examination of the cervix the naked eye, in order to identify yellow areas 
after the application of Lugol’s iodine. A multi-centre study conducted in Africa and India 
showed a pooled sensitivity and specificity to detect CIN2+ lesions of 92% and 85% 
respectively, thus indicating a higher sensitivity than VIA but a similar specificity (Sarian et 
al., 2005).  
11.3 Self-sampling 
Self-sampling method using self-collected vaginal samples is another alternative approach 
for primary screening in developing countries. The aim would be to try to increase the 
coverage of population when women do not undergo a gynaecological examination and 
when cytology screening is not available. Prevalence of oncogenic HPV types on self-
sampled vaginal material is about 5-10%, lower than for cervical smear; sensitivity for 
detecting CIN is also decreased in respect to cytology (Bekkers et al., 2006). However, for 
women not participating in programs of screening, vaginal self-sampling could be a good 
alternative and could reduce the risk of cervical cancer. 
11.4 HPV-DNA testing 
Screening must be linked to treatment to ensure its efficacy. This can be done using the 
traditional approach (screen, diagnosis, confirm and treat), intermediate approach (screen, 
diagnose and treat, with post-treatment biopsy confirmation) or screen-and-treat approach 
(treatment is based on the result of screening alone). A number of studies have investigated 
the screen-and-treat approach, and its safety and feasibility has been always confirmed. Basing 
on these studies, primary screening with HPV testing was considered an attractive approach.  
The use of HPV-DNA testing may prove more practical, especially when incorporated into 
strategies less dependent on existing laboratory infrastructure, such as low-resource setting 
and developing countries.  This “single-visit HPV-DNA testing strategy” requires screening 
sites to run the test on the day in which the sample is received and to allow for treatment of 
cervical lesion during the same visit (Levin et al., 2010). “See and treat’ approach would 
reduce the number of non-compliance to treatment and improve the efficiency of the 
program.  
No HPV-DNA existing test was deemed appropriate for the use in low-resources settings. 
For this reason, PATH (Seattle, WA, USA) and Qiagen entered into collaborative agreement 
and developed a new rapid, simple and affordable HPV-DNA test, specifically designed for 
developing countries. CareHPVTM is a signal-amplification assay that detects 14 different 
carcinogenic HPV types (16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66 and 68) in 2-5-hrs 
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processing time. The assay needs only a footprint, no mains electricity or running water. The 
short time-consuming would permit a same-day diagnostic evaluation, with treatment in a 
second visit, or even screening and treatment in the same day. CareHPV  can be performed 
by inexperienced, newly trained and minimally educated technicians, under suboptimal 
condition of temperature, humidity, lightning and space.  CareHPV use would be associated 
to fewer visits and transportation costs, and would reduce loss to follow-up. The rapid 
HPV-DNA, with its lower cost per test and greater sensitivity than conventional cytology 
now dominates other screening methods in developing countries. Levin CE et al., showed 
that accuracy for the detection of CIN2+ lesions was higher for careHPV test than for VIA. 
No differences has been detected between CareHPV and HC2, when screening women 30 
years of age and older (Levin et al., 2010). 
With the availability of vaccine against HPV-16 and 18, there has been enthusiasm for 
vaccination of young adolescent girls, also in disadvantage settings. Although preadolescent 
vaccination offers great hope for future generation, there exist a number of uncertainties that 
will persist for the next decades, including the need for drastically lower vaccine prices and 
creative financing sources to support vaccination costs. For the older women, the best option 
to reduce deaths from cervical cancer will still be the secondary prevention. Rapid HPV-DNA 
testing, 3 time per lifetime, would have excellent potential to be and effective and cost-effective 
strategy. Particularly, the strategy of vaccinating targeting young adolescent and screening 
and treat older women, could address social, economic and political organization to contribute 
in reducing cervical cancer incidence and mortality in developing countries (Tsu et al., 2008).  
12. Molecular surrogate markers 
The sensitivity of HPV-DNA assays for the detection of CIN2+ is high, although they cannot 
discriminate transient infections from persistent infections, thus lacking in specificity. 
Consequently, there is motivation to evaluate more disease-specific biomarkers, able to 
identify women susceptible to progression. Ideally the candidate marker, defining the 
different stages (clearance, persistence, progression) of cellular changes associated with 
HPV infection, should give a high positive predictive value in predicting progression to 
cervical cancer. Recently, guidelines have been proposed for the development of biomarker-
based screening toll for early detection of cancer, which can be categorized into five phases: 
1) preclinical exploratory studies for marker discovery; 2) clinical assay development and 
validation; 3) retrospective longitudinal repository studies; 4) prospective screening; 5) 
cancer control studies, including cost-benefit analysis. 
Potential markers of progression include HPV viral load, DNA methylation, HPV-DNA 
sequences integrated into the host genome, over-expression of cell-cycle regulator proteins 
or proliferation markers, telomerase and messenger RNA for E6 and E7 oncoproteins. Here, 
we will restrict the discussion to the markers which have been evaluated in large clinical 
trials and reached some level of clinical applicability. 
12.1 HPV Viral load 
HR-HPV viral load has been suggested to be a useful marker in distinguishing infection of 
clinical relevance (48, 49). Among women with HPV-DNA positivity, cytological abnormalities 
are more common in those having high viral load (Lilli et al., 2005; Xi et al., 2011).  
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However, it is now clear that the liaison between viral load and cervical disease is more 
complex that it was previously thought. (De Oer et al., 2007). Many cross-sectional studies 
reported an increased viral load with growing disease severity, but others found no 
association (50). There are some probable reasons for these contradictions: HPV integrated 
status increases with enhancing of disease severity; integration status is characterized by a 
declined viral replication. Thus paradoxically, the risk of disease progression is not 
associated to the rate of viral replication but is sometimes just the opposite! (Denis et al., 
2008). In our retrospective longitudinal analysis, we did not observe a significant association 
between semi-quantitative value of viral load and low-grade cervical lesions outcome 
(Zappacosta R et al, data not shown). In addition, the relationship between viral load and 
cervical disease varies among oncogenic HPV types. Studies using quantitative type-specific 
PCR for HR-HPV 16, 18, 31, 33 and 45 and LR-HPV 6 and 11 showed that HPV-16 can reach 
a much higher viral load than the other above listed types and that only HPV-16 viral load 
might correlate with increased severity of cervical disease (Saunier et al., 2008). Then, all 
oncogenic HPV types but 16 are able to provoke cervical cancer, even when they are present 
at low levels (Boulet et al., 2008).  
12.2 DNA methylation markers 
More recently, epigenetic alteration of genome of HPV-infected cells have been considered 
as diagnostic marker for cervical cancer. Aberrant presence of CpG-rich DNA sequences (the 
so-called CpG islands) in the promoter region of tumor suppressor genes, represents one of 
the several epigenetic changes that contribute to carcinogenesis (Esteller et al., 2002). DNA 
methylation involves the covalent addition of a methyl (-CH3) group at the carbon-5 
position of a cytosine that precedes a guanosine. Usually, DNA methylation plays a role in 
maintaining genome stability and in regulating gene expression (Jung et al., 2011). However, 
global hypermethylation of CpG clusters located in the promoter region of multiples genes 
have been associated with malignancy (Ehrlich, 2002). Numerous clinical studies 
demonstrated that these epigenetic methylation changes are often present in a variety of 
cancer. In this framework, silencing of the Tumor Suppressor Lung Cancer 1 (TSLC1) gene 
by promoter hypermethylation may be a valuable biomarker to detect cervical lesions with 
high malignancy potential. TSLC1 was found to be silenced in 91% of cervical cancer cell 
lines, primarily resulting from promoter hypermethylation (Yang et al., 2006). Moreover, 
such hypermethylation was detected in 58% of cervical carcinomas and in 35% of CIN2+ 
lesions, but not in low-grade CIN or in normal cervix (Fenq et al., 2005). The high frequency 
of TSLC1 methylationin in cervical cancer was confirmed by studies of Li et al., (Li et al., 
2005) and Gustafson et al. (Gustafson et al., 2004). These data suggest that the analysis of 
methylation patterns of TSLC1 gene maight be a valuable tool in forthcoming screening 
programs; however, they appear more likely to play a role in detecting cervical cancer cell 
clones rather than cells in early initiating events of cervical carcinogenesis.   
12.3 Markers of viral DNA integration  
Viral integration often occurs at the E2 gene of the HPV genome. Disruption of the E2 gene 
is believed to result in more intensive transcription of the oncogenes E6 and E7. In the 
episomal state, E2 and E6 DNA are present in equal amounts, while in the integrated form, 
less intact E2 is present (zur Hausen, 2002). Then, a decrease in E2/E6 DNA ratio assessed 
with real-time PCR would be a valuable potential progression marker.  
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12.4 Ki-67 and other markers of proliferation or regulation of cell cycle  
Expression of  Ki-67 protein occurs in proliferating cells and its presence is normally 
confined to the basal or suprabasal epithelial cells layers. Expression of Ki-67 allows 
distinction of negative atrophic cells and positive neoplastic cells in menopausal women. 
Expression beyond the inner third of the cervical epithelium  is observed in case of CIN and 
cancer. Several authors have found a significant correlation between the presence/intensity 
of Ki-67 and the severity of cytological abnormality in cytological preparation (Luzzatto et 
al., 2004; Sahebali et al., 2003). However, deeper analysis did not confirm the initially 
hopeful results and showed that these markers did not have adequate sensitivity and 
specificity to supply the request of additive prognostic markers, in cytological screening 
(Wentzensen & von Knebel Doeberitz, 2007). 
Several other proteins are overexpressed in proliferating cells. So, certain cell progression 
regulators have been proposed as potential markers for cervical neoplasia: Proliferating Cell 
Nuclear Antigen (PCNA), Mcm5, Cdc6 and Cyclin E. Proliferation markers are 
physiologically present in basal and parabasal cells, and are an objective indicator of 
neoplasia when observed beyond the lower cell layers. In cervical smears, lacking 
architectural information, the presence of proliferation markers is less informative and can 
easily yield false-positive results.  
12.5 Telomerase 
Telomerase are repeated arrays of six nucleotides (TTAGGG) at the chromosome ends that 
protects chromosomes against degradation, aberrant fusion or recombination. They become 
progressively shorter as cells multiply, resulting in chromosomal instability and senescence 
when a critical short length is reached. The enzyme telomerase is a ribo-nucleoprotein 
composed of two parts: an RNA part (hRT) and a catalytic part (hTERT), which controls 
telomere length. hTERT is believed to play a role in cells immortalization. Its activity in 
increased in CIN and cancer (Barbosa et al., 2011).  The intensity of telomerase activity is 
reported to be correlated with the severity of the abnormality, both in cervical biopsies and 
cytology. However, reliable detection of hTR, hTERT and telomerase activity is still limited 
by analytical deficiencies (Xiang et al., 2011).   
12.6 p16 
INK4a
 
Cyclin-dependent kinases (CDKs), cyclins and CDK inhibitors are key molecules that control 
the cell cycle and coordinate DNA synthesis, chromosome separation and cell division. The 
cyclin-dependent kinase inhibitor p16 INK4a prevent the CDK4/6 interaction with cyclin D1, 
thus stopping progression of cell cycle through the G1/S checkpoint. Usually, HPV-E7 
oncoprotein is expressed only in terminally differentiated superficial cell layers of the cervical 
epithelium, Several factors, such as loss of cellular inhibiting factors and integration of HPV 
genome into the host genome, can lead to the expression of E7 in basal cell layers. The result is 
the cellular transformation and the massive accumulation of p16 ink4A into cells. Accumulation 
of p16 mRNA and related protein has been reported in response to inactivation of the 
retinoblastoma gene product (pRb), through binding with viral E7 oncoprotein. p16 is then 
overexpressed at very low levels in normal cells, while it is strongly over-expressed in cervical 
cancer cell lines, in which pRB has been inactivated by E7  (Lambert et al., 2006). 
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The usefulness of immunocytochemical detection of p16 overexpression in cervical samples 
has been shown in many trials and has been widely accepted, especially as reflex test for the 
triage of equivocal or mildly abnormal Pap cytologic results. In triaging ASC-US and LSIL 
cases, it has been shown that p16 immunocytochemical analyses might provide similar 
sensitivity for the detection of underlying CIN2+ lesions as HPV testing, but at significantly 
higher specificity level (Denton et al., 2010). A recent meta-analysis (Tsoumpou et al., 2009), 
showed a substantial variability in the literature regarding the cut-off for positive p16 
results; this variability was  probably due to the wide range of colorbased qualitative 
(nuclear or cytoplamatic positivity, staining intensity, etc.) and quantitative parameters (ie, 
number of immunoreactive cells), which singly or in combinations could be use for the 
evaluation of results. The purely colour-based approaches to identify abnormal cells in 
cervical smears using p16INK4a, is hampered by the fact that some normal endocervical, 
endometrial, intercalated, squamous metaplastic or atrophic cells may also display p16-
immunoreactivity. For this reason, it was proposed the evaluation of a score based on a 
four-tiered classification of nuclear abnormalities of p16-positive cells, to discriminate 
between no abnormal nuclei (score 1), slightly abnormal nuclei (score 2), clearly abnormal 
nuclei (score 3), and severely abnormal nuclei (score 4).  Nuclei from normal-intermediate 
cells or polymorphonuclear granulocytes were used as an internal size, shape, staining, and 
texture standard (Wentzenses et al., 2005). Despite NS classification, there are still 
disagreement in literature regarding the utility of p16 INK4a tool, both as locator of high-grade 
cervical cells-positive cell as well as interpreter, for the predictive assessment of potential 
abnormal cells. Disagreements are based on the common conviction about the poor 
feasibility of p16 INK4a  immunocytochemical assay. 
13. Novel approaches with prognostic significance in cervical cancer 
prevention 
13.1 p16/Ki-67 dual stain 
Under physiological conditions, the simultaneous expression of a protein with a tumor-
suppressive function (p16) and a proliferation marker (Ki-67) mutually excludes each other. 
Vice versa, simultaneous detection of p16 overexpression and expression of proliferation 
marker K1-67 within the same cervical epithelial cell indicates deregulation of the cell cycle. 
In this context, it has been proposed the use of the immunocytochemical evaluation of p16-
Ki-67 coexpression to identify esocervical cells with deregulated cell cycle, independently 
from morphology-based interpretation parameters (Galgano et al., 2010). The presence of 
one or more double-immunoreactive cell may be considered positive and indicative of 
underlying CIN2+ lesion (Schmidt D et al., 2011). The European Equivocal or Mildly 
Abnormal Papanicolaou Cytology Study (EEMAPS) evaluated the performance of the new 
immunocytochemical p16/Ki-67 dual-stain protocol (CINtec+ assay, mtm laboratories AG, 
Heidelberg, Germany) in the triage of ASC-US and LSIL lesions. Results from this study 
showed a high sensitivity of CINtec+ test for the detection of underlying CIN2+ lesions in 
women with ASC-US and LSIL cytology, comparable to sensitivity showed by HPV testing 
and p16 single-stain cytology. Particularly, Schmidt et al., showed that, in ASC-US triage, 
p16/Ki-67 dual-stain identified the same proportion of underlying CIN2+ lesions as HPV 
testing, but significantly reducing the number of women which would need referral to 
colposcopy, especially in younger population. Regarding  CINtec+ dual-stain specificity, 
this was significantly improved in comparison with that of p16 single-stain approach. 
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In a recent retrospective analysis, conducted within the regional organized screening 
program of Abruzzo region (Italy), in which Hybrid Capture 2 test is used in primary 
screening, we analyzed the diagnostic performances of p16INK4a/Ki67 dual-stained cytology 
in identifying CIN2+ lesion in 372 HPV-DNA positive women triaged for LSIL-or-worse 
(LSIL+) Pap cytology (unpublished data). Preliminary results showed that reflex CINtec+ 
test improved significantly sensitivity and NPV of cytology alone in triaging LSIL+ lesions 
(90.8% vs 62% and 77.2% vs 88.3%, respectively), but reduced triage cytology specificity and 
PPV (42.6% vs 79.6% and 49.4% vs 65.2%, respectively). In this context we believe that 
p16/Ki67 cytology, as a reflex test, may efficiently complement HPV-based screening 
programs to prevent cervical cancer, but follow-up studies are needed to assess its effective 
value in terms of predictive marker.  
13.2 Direct detection of cervical carcinogenesis: mRNA markers 
As previously described, one of the key consequences of HPV-induced chromosomal 
instability is the integration of HPV genome into the host-cell genome together with the 
continuous and deregulated expression of E6/E7 viral oncogenes. Then persistent 
expression of E6/E7 is a necessary step for HPV-induced carcinogenesis. 
E6 expression is regulated at transcriptional or post-transcriptional level. HPV-16 E6 ORF 
encodes for three different variants of E6 protein, which may have dissimilar roles in the 
viral cell cycle. These transcripts are either unspliced (full length-FL- E6 transcripts) or 
spliced (Figure 4). Interestingly, only FL E6 protein has been found to be powerfully bound 
to p53, thus promoting its degradation. Moreover, only the unspliced E6 form was found to 
be more strongly associated with tumorigenicity. Studies carried out on cervical cancer 
samples show that FL transcripts are always present (Wise-Draper, & Wells, 2008). These 
studies indicate FL transcripts as being the most important biomarkers for the carcinogenic 
process (Asadurian et al., 2007).  Then, tests for the detection of E6/E7 mRNA seems to be 
promising in increasing HPV testing specificity. 
 
Fig. 4. Full length E7 transcripts in relation to HPV life cycle 
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13.2.1 Nuclisens
®
 EasyQ HPV mRNA test and PreTect™ HPV- Proofer mRNA test 
Various in-house assays for E6/E7 mRNA detection have been described, most of which 
have employed a reverse transcription PCR approach, focusing on HPV-16 and -18. Now, 
two commercial RNA assays are available: the Nuclisens EasyQ HPV assay (biomérieux 
S.A., France), in certain countries distribuited as the PreTect HPV-Proofer® assay (Norchip 
AS, Klokkarstua, Noway), and the Aptima®  HPV Assay (Gen-Probe Incorporated, San 
Diego, CA) .  
Both assays are compatible with samples collected in cytology media. 
Nuclisens EasyQ HPV assay is a multiplex nucleic acid sequence amplification (NASBA) 
method, detecting FL transcripts of E6/E7 oncoproteins in a DNA background is 
commercially available from two companies; they are the and (Boulet et al., 2008). The test is 
based on the molecular beacon probe technology and on the real-time detection of five 
oncogenic HPV types (16, 18, 31, 33 and 45). Molecular beacons are oligonucleotide probes 
consisting of stem-loop structure and of two regions: loop region, is a single-stranded 18-30 
base pair sequence that is complementary to the target sequence; stem region, typically 
consists of 5-7 base pair long double-stranded sequences that lie on both arms of loop 
region; 5’ sequences are labeled with a fluorescent dye (fluorophore) while 3’ sequences are 
covalently labeled with a non-fluorescent quencher. In absence of a complementary target 
sequence, molecular beacon remains closed and in a nonhybridized state; in this situation, 
the quencher captures the fluorescent signal. When beacon unfolds the presence of the 
complementary target (E6/E7 mRNA), loop region hybridizes with this sequence, 
fluorophore separates itself from the quencher, and the fluorescent signal is transmitted 
(Figure 5). 
In Nuclisens procedure, two different labeled molecular beacon probes for each multiplex 
reaction are used. Fluorescein (FAM) is used as fluorophore for the detection of HPV-16, 31, 
and 33; Texas Red (TxR) as fluorophore for the detection of U1A gene, HPV-18, and HPV-45. 
U1A is a small nuclear specific ribonucleoprotein A included in HPV-Proofer kit to avoid 
false-negative results, and to monitor sample mRNA integrity. NASBA amplification is 
achieved through coordinated activities of three enzymes (Avian Myeloblastosis Virus 
Reverse Transcriptase, E.Coli Rnase H and T7 RNA polymerase) and two DNA 
oligonucleotide primers that are specific for the target sequence of interest. RNA 
amplification is performed for one hundred and fifty minutes at isothermal temperature of 
41 ºC. In presence of the target sequences, a fluorescent signal is observed. A fluorescent 
analyzer measures, in real-time, the emitted fluorescence from molecular beacon hybridized 
with amplified mRNA (Varnai et al., 2008). 
Cuschieri et al., carried out a follow-up study on 54 HPV-DNA positive samples obtained 
from 3,444 cytologically normal women. Samples which were PreTect HPV-Proofer-positive 
over 9 months (persistence), were proven to have CIN3 in most cases (Cuschieri et al., 2004). 
This study showed the strict correlation between E6/E7 mRNA expression and oncogenic 
HPV-DNA persistence, moreover detecting a mRNA test specificity higher (81%) than 
DNA-based methods (44%). Cuschieri concluded that mRNA test (PreTech or Nuclisens) 
would find persistent HPV infection and would reduce the need for follow-up or repeated 
test, that will be sometime necessary if DNA-based technology is used.  
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Fig. 5. NASBA technology. A – molecular beacon in absence of target sequence; B – 
molecular beacon unfolds the presence of the complementary target and transmits 
fluorescent  
The high clinical accuracy of E6/E7 mRNA test has been confirmed by a large cross-
sectional study, carried out on about 4,000 women older than 30 years assessed 
longitudinally for a minimum of 2 years, based on detection of HPV-DNA and E6/E7 
mRNA. Cytological and histological data related to follow-up were also included (Molden 
et al., 2005). DNA and RNA test showed identical sensitivity to detect CIN2+ lesion, but the 
specificity for RNA and DNA test was 85% and 50% respectively. Benevolo et al carried out  
a retrospective study to evaluate the performance of mRNA test as a triage test for cytology 
and HPV DNA testing. The study analyzed 1,201 women, 688 of whom had a colposcopy 
follow-up and 195 of whom had histology-confirmed CIN2+ lesion. Diagnostic accuracy for 
CIN2+ were determined for mRNA test in comparison to HPV-DNA test and cytology. 
Stratifying by cytological grades, mRNA test sensitivity ranged from 62% to 83%. The 
corresponding figures for DNA testing ranged from 91% to 96%. Specificity values  for 
mRNA test and DNA test ranged from 45% to 82% and from 4% to 29%, respectively. Used 
as a triage test for ASC-US and L-SIL, mRNA test reduced colposcopies by 69-79%, while 
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DNA testing reduced colposcopies by 15-38%. As a HPV-DNA positivity triage, mRNA test 
reduced colposcopies by 63%, whereas cytology at the ASC-US+ threshold reduced 
colposcopies by 23% (Benevolo et al., 2011). 
These data, combined with others 15 extensive studies carried out in many countries, show 
that mRNA test might reduce the number of ASCUS and LSIL cases to be followed by 
colposcopy-directed biopsies by more than 70% (Nakagawa et al., 2000). Then, 
overexpression of E6/E7 for carcinogenic HPV types might prove a specific and predictive 
marker of precancerous lesions that need clinical attention. At present, only the above listed 
five oncogenic HPV types are detectable by Nuclisens technology; at the first sight this may 
be considered a disadvantage in comparison with the available DNA genotyping strategies. 
However, studies carried out to find E6/E7 mRNA in cervical smears of women with 
cervical cancer, demonstrated a 100% coverage by these genotypes (Kraus et al., 2006; 
Skomedal et al., 2006).  
13.2.2 Aptima
®
 HPV mRNA test  
APTIMA®  HPV Assay (Gen-Probe Incorporated, San Diego, CA) is a target amplification 
nucleic acid probe test for the in vitro qualitative detection of E6/E7 mRNA from 14 
oncogenic HPV types (16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, 68), in LBC specimens. 
The assay provides a qualitative result (positive/negative) for the presence/absence of these 
oncogenic HPV types, but does not determine the specific HPV type present in the 
specimen.This technology amplifies target mRNAs using transcription-mediated 
amplification (TMA) and detects the amplification products using nucleic acid probes  
without specific distinction among the specific HPV types implicated. 
APTIMA HPV Assay involves three main steps, which take place in a single tube: capture, 
amplification and detection. To capture the target mRNA, HPV-specific capture oligomers 
and magnetic microparticles are used. Target mRNA is amplified by transcription-mediated 
amplifications (TMA) and using two enzymes: Moloney murine leukemia virus reverse 
transcriptase and T7 RNA polymerase. Targeted amplification is achieved using primers 
that hybridize to conserved regions of oncogenic E6/E7 mRNA.  The detection of the 
amplification products (amplicons) is carried out through dual kinetic assay . Specifically, 
analyte amplicons are detected using 2-methyl acridinium ester-labeled probes, which 
hybridized to conserved region of carcinogenic HPV types. An fluoro-acridium ester-labeled 
probe is used to detect internal control amplicon added to each reaction to verify the 
performance of each step of the assay.  
Positive and negative calibrators are used to determine the validity of the run and to 
establish the assay cut-off values for the internal control and analyte signals. 
Chemiluminescent signal observed for each reaction is measured using a luminometer, and 
compared to the cut-off values. Specimens with cut-off (S/CO) ratio ≥1.00 are considered 
positive. Samples with S/CO ratio <1.00 must have an internal control signal greater than or 
equal to the internal control cut-off value and may be considered a valid negative result. 
FASE (French APTIMA Screening Evaluation) study was the first trial comparing Aptima 
mRNA test with LBC and HC2 (Monsonego et al., 2011). Data from about 4,500 Parisian 
women have been analyzed. Results showed that the sensitivity of Aptima mRNA test for 
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detecting CIN2+ lesions was similar to that offered by HC2 test but is significantly higher 
than that of LBC. In addition, the specificity of Aptima was significantly higher than that of 
both HC2 and cytology.  
Actually, for its characteristics, Aptima test is considered to be the ideal assay for primary 
cervical cancer screening, offering good specificity without losing sensitivity. The use of 
APTIMA HPV Assay would reduce the number of false positive results compared to DNA 
assays, helping limit the number false positive results leading to inappropriate and costly 
diagnostic procedures, over-treatment and needless anxiety in women. 
On the other hand, PreTect HPV-Proofer/Nuclisens EasyQ HPV mRNA tests with their 
high specificity and PPV, is considered helpful in the clinical work-up of DNA-positive 
women, particularly of those with ASC-US/LSIL cervical abnormalities, also in 
consideration of its flexibility when used in LBC samples, stored at room temperature in 
cytological biobanks. 
Basing on these consideration, mRNA-based technology would certainly increase the 
diagnostic accuracy of cervical abnormalities, through a better identification of HPV 
infection which are more likely to persist and induce CIN2+ lesions in future, and by 
reducing psychological distress and costs for women who only have a transient infection. 
14. Conclusions 
Persistent HPV infection has proven to be important in predicting cell abnormalities. Hence, 
a supplementary method should reveal HPV persistence and preferentially give additional 
information about the outcome of the disease. The ideal test should then reveal optimal 
analytical and clinical accuracies. Analytical accuracy of a test merely refers to the ability of 
detection of an endpoint. Clinical accuracy is a parameter which is more related to medical 
practice: it expresses the ability of the test to detect a relevant phase of disease. 
Studies summarized above resulted in a long list of candidate tools which may improve Pap 
test in the early detection of cervical cancer. Most of these markers have not yet passed the 
first phases of validation but surely, their number is expected to expand, as more genomic 
and proteomic studies will appear in the near future. 
Before integrating the ideal marker into clinical practice, deeper clinical validation studies 
are needed, particularly longitudinal assessment to prospectively evaluate its clinical 
performances. At the moment, it is difficult to predict which of those markers or marker 
panels are ultimately the most promising candidates, also considering the shift to primary 
HPV screening. 
Currently, most national vaccination program are primarily aimed to preadolescents and 
adolescents. It is an extremely positive fact to hope in use of a vaccine capable to prevent a 
neoplasia with so strong social impact such as cervicocarcinoma. However, there are several 
issues that still need to be addressed before the fully appreciation of HPV vaccination in 
matter of overall potential and impact for public health (Psirry & Di Maio, 2008; Stanley et 
al., 2006). First, the duration of protection is unknown. Second, bivalent vaccination will 
only protect against HPV-16 and 18. Third, prophylactic vaccines are likely to provide 
limited benefits to women previously infected with oncogenic HPVs. Fourth, vaccines are 
relatively expensive and vaccine delivery in developing world is more difficult. Fifth, the 
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effects of vaccination on the female psychology could be dangerous: if vaccinated women 
will believe to be at no further risk of developing HPV-induced cancer and will leave 
screening programs, the last impact of vaccination on the incidence of cervicocarcinoma will 
be invalided (Welters et al., 2008). 
It is therefore important that both, women and healthcare professionals, do not perceive 
HPV vaccination as an immediate alternative to cervical cancer screening, because only 
integrating HPV vaccination into screening programs will maximize the benefits offered by 
vaccine and will lead to a greater reduction of cervical cancer prevalence, incidence, and 
mortality. It was recently reported that , if both HPV testing and vaccination are performed, 
the total number of annual number of Pap tests is predicted to be reduced by 43% (Logatto-
Filho & Schmitt, 2007). In this context, the nature of the screening and the management of 
women must to be adapted to the new technologies. 
In conclusion, moving the diagnostics from the cellular level into the molecular level allows 
not only to better identify cervical precancerous states, but also to prevent cervical 
pathology in the stage of molecular changes. In this context, the management of women 
with HPV infection would be based on risk categories rather than on specific assay results. 
This tailored cervical cancer risk assessment give hope for the improvement of effectiveness 
of cervical cancer prevention and for a significant reduction of screening costs.  
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1. Introduction 
The Papillomaviruses are small double-stranded DNA viruses that infect squamous 
epithelia. They display absolute species-specificity: human papillomavirus (HPV) only 
infect humans, rabbit papillomaviruses only infect rabbits and so forth. They are also 
exquisitely tissue tropic, undergoing a complete infectious cycle only in fully differentiating 
squamous epithelium (Stanley, 2010). Nearly 100 HPVs were described based on the 
isolation of complete genomes (de Villiers et al., 2004). The circular genome, whose size is 
close to 8.0 kilobases (kb), is enclosed in a protein shell made from the major (L1) and minor 
(L2) capsid proteins resulting in virions of approximately 55nm in diameter. It can be 
divided into 3 domains: a noncoding upstream regulatory region (URR), an early region 
with 6 genes (E6, E7, E1, E2, E4 and E5), and a late region encoding two genes (L1 and L2). 
The early genes are involved in DNA replication, transcriptional regulation and cellular 
transformation. The late genes encode capsid proteins and facilitate the entry of viral DNA 
into the cell (Tjalma et al., 2005). Approximately 35 HPV types are known to infect the 
human genital mucosa. They can be grouped as “high risk” (HR) or “low risk” (LR) based 
on their epidemiologic association with cancer. HR types such as HPV16 and HPV18 are 
associated with low and high-grade intraephitelial lesions and invasive cancer. The LR types 
such as HPV6 and HPV11 are associated with genital warts or condyloma acuminate, 
recurrent respiratory papillomatosis, and low-grade cervical intraepithelial lesions (LSIL) 
(Trottier and Franco, 2006). The recognition that infection with HPV is essential for the 
development of cervical cancer led to the development of cervical cancer prevention 
strategies which incorporate HPV testing.  
There are a variety of HPV tests in use worldwide and several of these may be adequate to 
use for cervical cancer screening and HPV vaccination. An ideal assay should have 
(Organization, 2009):  
1. good sensitivity and specificity as evaluated in internal proficiency testing; 
2. ease of transfer to laboratories with varying levels of experience and resources; 
3. affordable cost, to allow use in low-resource settings. 
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It is important that quality assurance programs are established, both in HPV serology and 
DNA typing, in order to evaluate laboratory performance as well as assay characteristics. 
The WHO global reference laboratory recommends proficiency panels composed of a series 
of validated samples, traceable to International Standards, sent to unknown challenges to 
HPV LabNet members. Results allow an evaluation of individual laboratory performances 
and an evaluation of whether assays platforms used by multiple laboratories are robust in 
terms of the generation of acceptable results. HPV cannot be easily propagated by standard 
in vitro culture systems, and in malignant tissue there are little or no infectious HPV 
particles (Organization, 2009). Other classical direct virological diagnosis techniques, such as 
electron microscopy and immunohistochemistry, lack the sensitivity and specificity for the 
routine detection of HPV (Poljak and Kocjan, 2010). For these reasons, the preferred assay 
formats are based on the detection of HPV nucleic acids.  
Molecular methods for HPV DNA detection can be grouped in two main categories: those 
that rely on signal amplification to detect the targets, and those that rely on target 
amplification; most of them are based on polymerase chain reaction (PCR). Results of HPV 
detection are strongly influenced by the technique, and comparison between assays is not 
always possible. This is why all HPV testing steps need careful standardization including 
sample collection, extraction and testing. Stability during transport and storage is very 
important for a good quality DNA. The viral nucleic acid must be preserved to avoid false 
negative results caused by degradation by endogenous endonucleases. To assess the 
integrity of genomic DNA in the specimen and its stability for molecular techniques it is 
crucial to use internal controls such as β-globin. There are several commercially available 
kits (PreservCyt, Cytyc Corp.) for sample transportation that adequately preserve nucleic 
acids for molecular diagnosis even after long periods of ambient temperature storage 
(Molijn et al., 2005, Chan et al., 2006). The choice of which DNA extraction method to use 
depends on the quality of the clinical material and the diagnostic test that will be executed.  
In this chapter, the paramount methods for screening and typing high risk HPV types will 
be described (Table 2). In particular, we describe molecular methods for the identification of 
HPVs based on signal amplified hybridization, polymerase chain reaction (PCR), DNA 
sequencing, type-specific probes, reverse line-blot hybridization, in situ hybridization, 
southern blot hybridization and immunological techniques, including ELISA and western-
blot. In addition, we give examples of commercially available kits, for each assay, and point 
out advantages and limitations of its use.  
2. Signal amplified hybridization assays 
Hybrid Capture to HPV detection was first introduced by Digene Corporation (Gaithesburg, 
MD,USA) in 1995.  This assay is a non radioactive amplification method, based on the 
hybridization of the target HPV-DNA to labeled RNA probes in solution. It captures the 
resulting hybrids detecting them by a specific monoclonal antibody and a chemiluminescent 
substrate, providing a semi-quantitative measurement of HPV-DNA. The second generation 
of hybrid capture assay - hc2 -  uses microtiter plate instead of tubes for the detection of 13 
high-risk HPV types: 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59 and 68, on liquid-based 
cervical specimens  (Clavel et al., 1999). Specimens containing the target DNA hybridize 
with a specific HPV RNA probe cocktail. The resultant RNA:DNA hybrids are captured 
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onto the surface of a microplate well coated with antibodies specific for RNA:DNA hybrids, 
and detected with a chemiluminiscent substrate. Several alkaline phosphatase molecules are 
conjugated to each antibody. Multiple conjugated antibodies bind to each captured hybrid 
resulting in substantial signal amplification. As the substrate is cleaved by the bound 
alkaline phosphatase, light is emitted being measured as relative light units (RLUs) on a 
luminometer (Figure 1). The intensity of the light emitted denotes the presence or absence of 
target DNA in the specimen. An RLU measurement equal to or greater than the Cutoff 
Value (CO) indicates the presence of high risk HPV DNA sequences in the specimen, 
whereas an RLU measurement lesst han the CO indicates the absence of the specific high 
risk HPV DNA sequences tested or HPV DNA levels below the detection limit of the assay 
(Digene, 2004). This assay has an excellent sensitivity (93% according to referral Kaiser 
Study population) since it can detect HPV16 DNA of a concentration down to 1pg/ml. It is 
considered the most reliable signal amplified hybridization assay and is a CE-IVD test. On 
the other hand, it does not detect all high risk HPV types or very low levels of infection. 
Cross hybridizations with low risk types 6 and 11 may happen (Castle et al., 2002, Seme et 
al., 2006). Despite the negative aspects, it is still the gold standard technique for HPV 
detection, highly recommended for comparative evaluations. The hc2 assay has been used in 
the majority of key randomized controlled and other clinical trials that have proved the 
clinical value of HPV testing (Cox, 2009, Meijer et al., 2009). For this reason it has been 
recommended that new HPV assays should show that they possess similar  characteristics 
as hc2 in the process of clinical validation of the test, before it can be used for cervical cancer 
screening purposes (Meijer et al., 2009).   
 
Fig. 1. Hybrid Capture2 test principle, adapted from 
www.papillomavirus.cz/eng/diagnosis_kits_hybrid.html 
The Cervista™ is another FDA approved qualitative test that detects the DNA from 14 high 
risk HPV types: 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66 and 68. The detection of DNA 
from targeted HPV types, with similar characteristics, is performed with three different 
probe mixtures. It uses the Invader® chemistry, a signal amplification method for the 
detection of specific nucleic acid sequences. This method uses two types of isothermal 
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reactions: a primary reaction that occurs on the targeted DNA sequence and a secondary 
reaction that produces a fluorescent signal. In the primary reaction, two types of sequence 
specific oligonucleotides – a probe oligonucleotide and an Invader oligonucleotide – bind to 
the DNA target sequence. When these oligonucleotides overlap by at least one base pair on 
the target sequence, an invasive structure forms that acts as a substrate for the Cleavase® 
enzyme. The enzyme cleaves the 5’ portion (flap) of the probe at the position of the overlap. 
The probes are present in large molar excess and cycle rapidly on and off the target 
sequence so that many cleaved 5’ flaps are generated per target sequence. The cleaved flaps 
then bind to a universal hairpin fluorescence resonance energy transfer (FRET) 
oligonucleotide creating another invasive structure that the Cleavase enzyme recognizes as 
a substrate. The enzyme cleaves the FRET oligonucleotides between the fluorophore and 
quencher and produces a fluorescence signal as the cleaved flaps cycle on and off. For each 
copy of target, the combined primary and secondary reactions result in 106 - 107 fold signal 
amplification per hour. The flap sequences and FRET oligonucleotides are universal since 
they are not complementary to the targeted sequence (Technologies, 2009). Oligonucleotides 
that bind to the human histone 2 gene (HIST2H2BE) are also present in all three 
oligonucleotides mixtures. This serves as an internal control, producing a semi-quantitative 
signal from cellular DNA present in the sample (Day et al., 2009). The Cervista™ HPV 16/18 
uses de same chemistry for the identification of the two most highly oncogenic and 
persistent HPV types. It does not allow the exact determination of HPV type(s) present in 
the clinical specimen, but rather express the result as negative or positive (Day et al., 2009, 
Poljak and Kocjan, 2010). Sensitivity of the Cervista HPV HR test for detection of ≥CIN2 
among women with ASCUS cytology was 92.8% (84.1-96.9) and the negative predictive 
value (NPV) was 99.1% (98.1-99.6). Sensitivity for detection of ≥CIN3 among women with 
ASCUS cytology was 100% (85.1-100) and the NPV was 100% (99.4-100). HPV 16/18 
genotyping test sensitivity of ≥CIN2 was 68.8 (56.6-78.8) and NPV was 96.0% (93.9-97.4). 
HPV 16/18 genotyping test sensitivity of ≥CIN3 was 77.3 (56.6-89.9) and NPV was 99.0% 
(97.7-99.6)(Einsteina et al., 2010). The reproducibility, tested at three different testing centers, 
resulted in an overall inter-run reproducibility agreement of 98.8% [1-sided 95% Confidence 
Lower Limit = 96.9%] and an overall inter-site reproducibility agreement of 98.7% [1-sided 
95% Confidence Lower Limit = 97.9%] (Day et al., 2009). The Cervista HPV HR test showed 
no cross-reactivity with DNA from seven non-oncogenic HPV types or 17 different 
infectious agents at up to 10 copies per reaction (Day et al., 2009). This assay uses standard 
laboratory equipment and instrumentation, such as thermal cyclers and fluorescence plate 
readers reducing the need for additional equipment. It has technology proficiency, due to 
common reaction conditions for all DNA targets, and the simple analysis yields objective 
results producing straightforward interpretation. It should be used in conjunction with 
clinical information derived from other diagnostics and screening tests, physical 
examinations, and full medical history in accordance with appropriate patient management 
procedures (Day et al., 2009). The limitations of Cervista includes: 1) Cervista HPV HR only  
detects 14 high-risk HPV types and the Cervista 16/18 only  detects 2 high risk types; 2) the 
Cervista HPV HR test shows cross-reactivity to two HPV types of unknown risk – HPV 
types 67 and 70 - while the Cervista 16/18 test shows cross-reactivity to high levels of high 
risk HPV 31 (an HPV16 positive result was observed with 107 copies/reaction of HPV31); 3) 
very low levels of infection may cause false negative results; 4) false-negatives can also take 
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place with cervical specimens contaminated with high-levels of contraceptive jelly and/or 
anti-fungal creams, when DNA was isolated with the Genfind™ DNA extraction kit; 5) the 
Cervista HPV HR and 16/18 have been validated only for use with cervical cytology 
specimens collected in Preserv Cyt® solution using a Rovers  Cervex® Brush, Wallach 
Papette® or endocervical Brush/Spatula; 6) performance of Cervista HPV HR and HPV 
16/18 were established exclusively using DNA extracted with the Genfind™ DNA 
extraction kit and using cervical cytology PreserveCyt® specimen processed on the 
ThinPrep 2000 processor; 7) the performance of the Cervista HPV HR and HPV 16/18 test 
has not been established for HPV vaccinated individuals (Technologies, 2009). 
AMPLICOR HPV is a CE-IVD PCR based test launched in 2003, by Roche, in America, and 
in 2004 in Europe. It is capable of detecting 13 HR HPV types with simultaneous assessment 
of the presence of the human β-globin gene as a positive control. It expresses the result of 
the test HR HPV in either negative or positive. The method involves the isolation of nucleic 
acids, PCR amplification, hybridization and absorbance detection. It makes use of a pool of 
PCR primers designed to amplify HPV DNA from 13 high risk genotypes: 16, 18, 31, 33, 35, 
39, 45, 51, 52, 56, 58, 59 and 68. Capture probe sequences are located in polymorphic regions 
of L1 bound by these primers. One additional primer set is used to amplify the human β-
globin gene to provide control for cell adequacy, extraction and amplification. After PCR 
amplification, the HPV amplicon and the β-globin amplicon are hybridized to the 
olinucleotide probles bound to the well of the microwell plate. This hybridization of 
amplicon to the probes increases the overall specificity of the test. Following the 
hybridization reaction the plate is washed to remove unbound material and avidin-
horseradish peroxidase conjugate binds to the biotin-labeled amplicon hybridized to the 
oligonucleotide probes bound to the microwell plate. The absorbance of the reaction mixture 
is measured at 450nm (Monsonego et al., 2005, van Ham et al., 2005). This test has shown 
high analytical sensitivity with an specificity (Poljak et al., 2005) and overall specificity of 
96.5% and sensitivity of 96.1% (Sun et al., 2005). It is comparable to hc2 assay in detecting 
high grade CIN among women examined for abnormal PAP test. This test sensitivity in 
detecting both CIN1 and CIN2-3 is practically identical with the sensitivity of colposcopy 
(with minor abnormality cutoff) but, such as hc2, AMPLICOR assay cannot compete with 
the specificity of cervical (LBC) cytology (Monsonego et al., 2005). The current version of 
Amplicor is not well suited for high throughput testing since it includes many manual steps. 
The recommended extraction of DNA using the AmpliLute liquid media extraction kit is 
especially time-consuming, labor intensive and prone to potential cross-contamination, 
especially when large numbers of samples are being processed. AMPLICOR HPV test does 
not detect HPV 26, 53, 66, 73 and 82, HPV types that have been classified as probably high 
risk types (26, 53, 66) or high risk (73 and 82) types in a large epidemiological study (Munoz 
et al., 2003). Although this test is sensitive, specific, feasible, and easy to handle in routine it 
does not provide specific genotype information.  
A new rapid screening test – careHPV (QIAGEN, Gaithersburg, MD, USA) – based on the 
simplified hc2 technology -  has been developed to detect 14 high-risk types of carcinogenic 
human Papillomavirus: 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66 and 68, in about 2.5 h 
(Qiao et al., 2008). This test is very promising as a primary “screen and treat strategy“due to 
the ability to obtain accurate HPV results in a few hours. This strategy is especially 
important for remote and low resource regions of the world where  follow-up is difficult 
(Qiagen, 2009). The advantages of the use of this test are: 1) it can be run in any setting (no 
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special needs of humidity, temperature, mains electricity or water are required) by a 
healthcare worker with minimum laboratory training; 2) cervical samples can be collected 
by a healthcare worker or can be self-collected by the patient herself; 3) the results are easily 
interpreted and are available in approximately 3 hours (Qiagen, 2009). Limitations include 
the low throughput with only 24-90 specimens processed manually. However, it is very 
promising for developing countries HPV screening strategies such as China (Levin et al., 
2010, Canfell et al., 2011, Shi et al., 2011) and Thailand (Trope et al., 2009). A cross sectional 
study assessed the clinical accuracy of careHPV, comparing it with the hc2, in two county 
hospitals in rural China. A sensitivity and specificity for CIN2+ of 90.0 and 84.2% while 
standard hc2 parameters were 97.1 and 85.6%, respectively (Qiao et al., 2008). 
3. Polymerase chain reaction (PCR) assays 
The polymerase chain reaction (PCR) is a molecular technique capable of amplifying 
selectively a particular DNA sequence several million-fold. It consists of repeated cycles of 
heating and cooling in which a heat stable enzyme (Taq polymerase) uses a denatured 
double strand DNA to synthesize new molecules of DNA. The starting point for DNA 
synthesis are the primers (forward and reverse), short strands of nucleic acid, which 
selectively recognise flanking regions of the DNA template. The sensitivity of this 
methodology is about 10-100 HPV viral genomes in a background of 100ng cellular DNA 
(Zaravinos et al., 2009). The sensitivity and specificity of PCR-based methods vary, 
depending on several aspects such as: DNA extraction procedures, site and type of clinical 
sample, sample transport and storage, primer sets,  size of the PCR product, reaction 
conditions and performance of the DNA polymerase used in the reaction and ability to 
detect multiple types (Garland and Tabrizi, 2006).  
3.1 Type-specific and consensus primer PCR methods 
HPV detection by PCR can be performed using either type-specific primers, which amplify a 
single HPV genotype, or consensus/general primers, which are usually directed to a highly 
conserved region of the L1 gene. Type-specific primers are designed to amplify exclusively a 
single HPV genotype and in order to detect the presence of HPV-DNA in a single sample, 
multiple type-specific PCR reactions must be performed separately (Molijn et al., 2005). The 
use of multiple type-specific PCR reactions has the disadvantages of being labor-intensive, 
costly, time consuming and  requiring the evaluation of the type-specificity of each PCR 
primer set  (Molijn et al., 2005, Zaravinos et al., 2009).  
The use of consensus primers (Table 1) is more convenient because they can amplify a 
broad-spectrum of HPV genotypes. Most laboratories use consensus primers targeting the 
L1 region,  since it is the most conserved part of the genome, referring to the assay as L1 
consensus PCR. Amplification of each of the primer sets will result in different size 
amplicons and consequently can result in a variation in sensitivity for detection of certain 
HPV types, particularly when samples contain multiple genotypes (Garland and Tabrizi, 
2006). There are numerous L1 consensus PCR primers that can be used. The first was 
described in 1989 by Manos and colleagues (Manos et al., 1989). This assay is a set of 
degenerated primers, MY09/MY11, designed with the intent of amplifying in a single 
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reaction all the included genotypes. It generates a 450pb amplicon ready for typing 
determination by subsequent molecular techniques such as restriction fragment length 
polymorphism and DNA sequencing (Manos et al., 1989). At the time that MY09/11 was 
described, only 5 of the 20 or more known HPV genotype sequences had been reported: 
HPV 6, 11, 16, 18, and 33 and the primer set was not entirely homologous even among 
these 5 genotypes. The intertypic sequence variation was compensated by introducing one 
or more degeneracies at the priming sites, resulting in a mixture of 24 unique 
oligonucleotide sequences (Gravitt et al., 2000). The disadvantage of this design is that the 
synthesis of oligonucleotides containing degeneracies is not highly reproducible and 
results in high batch-to-batch variation (Molijn et al., 2005). The degenerate MY09/11 
primers were afterwards replaced by a set of 18 defined primers, PGMY09/11, to improve 
specificity and sensitivity. This amplification system combines a number of distinct 
forward and reverse primers, aimed at the same position of the viral genome. They do not 
contain random degeneracy but may contain inosine, which matches any nucleotide.  
Gravitt (Gravitt et al., 2000) and colleagues grouped the virus types by sequence 
homology in each of the two primer binding regions: a set of 5 upstream oligonucleotides 
comprising the PGMY11 primer pool and a set of 13 downstream oligonucleotides 
comprising the PGMY09 (Gravitt et al., 2000) primer set. Using a defined mixture of non-
degenerate primers has the advantages that the oligonucleotides can be synthesized with 
high reproducibility and PCR is performed at optimal annealing temperatures (Molijn et 
al., 2005). 
Other example of consensus primers is the GP5/6, incorporating one forward and one 
reverse primer aimed at short regions of homology conserved amongst HPV types 1a, 6, 8, 
11, 13, 16, 18, 30, 31, 32 and 33 (Snijders et al., 1990). To improve efficiency, part of these 
sequences were used to elongate GP5 and GP6 at their 3’ ends to generate the primers 
GP5+/6+ (de Roda Husman et al., 1995). The GP5+/6+ primer set generates a 160pb 
amplicon and reveales an improved HPV detection, reflected by a 10 to 100 fold higher 
sensitivity, compared with the GP5/6. The mismatching between the primers and the non 
complementary HPV types (it was only 100% complementary to just a few HPV genotypes) 
is overcome by setting a low annealing temperature at the PCR reaction (Zaravinos et al., 
2009). Qu and colleagues (Qu et al., 1997) compared the MY09/11 and GP5+/6+ primer sets 
in a group of cervicovaginal samples and concluded that despite good agreement in the 
detection of HPV DNA –positive and –negative status, there is a significant difference in the 
detection of multiple types within samples. The MY-PCR primer set was more robust than 
the GP+-PCR method. The second was relatively inefficient in the amplification of HPV 
types 53 and 61 compared with the MY-PCR, which was inefficient in the amplification of 
HPV35.  Chan and colleagues (Chan et al., 2006) compared the 3 methods: PGMY09/11, 
MY09/11, GP5+/6+ in 2006 and concluded that PGMY09/11 showed higher sensitivity with 
a positive rate of 95.8% compared to 84.2% of the MY09/11 and GP5+/6+ methods. 
Regarding samples with multiple infection, PGMY09/11 primer set detected most of them 
(9/11, 81.8%), MY09/11 detected 2/11 (18.2%), whereas GP5+/6+ failed to detect any of 
these. 
General primers in the E1 region have also been described, and several other broad-
spectrum PCR primers were reported, but have not been extensively used in clinical 
situations (Molijn et al., 2005) and therefore will not be mentioned in this chapter. 
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Primer Sequence (5’-3’)a Amplimer 
length (bp) 
Targetb 
MY09/11 (MY09)CGT CCM ARR GGA WAC TGA TC 450 L1 
(MY11)GCM CAG GGW CAT AAY AAT GG 
PGMY09/
11 
(PGMY11)A GCA CAG GGA CAT AAC AAT GG 450 L1 
(PGMY11B)GCG CAG GGC CAC AAT AAT GG 
(PGMY11C )GCA CAG GGA CAT AAT AAT GG 
(PGMY11D)GCC CAG GGC CAC AAC AAT GG 
(PGMY11E)GCT CAG GGT TTA AAC AAT GG 
(PGMY09F)CGT CCC AAA GGA AAC TGA TC 
(PGMY09G)CGA CCT AAA GGA AAC TGA TC 
(PGMY09H)CGT CCA AAA GGA AAC TGA TC 
(PGMY09Ia)G CCA AGG GGA AAC TGA TC 
(PGMY09J)CGT CCC AAA GGA TAC TGA TC 
(PGMY09K)CGT CCA AGG GGA TAC TGA TC 
(PGMY09L)CGA CCT AAA GGG AAT TGA TC 
(PGMY09M)CGA CCT AGT GGA AAT TGA TC 
(PGMY09N)CGA CCA AGG GGA TAT TGA TC 
(PGMY09Pa)G CCC AAC GGA AAC TGA TC 
(PGMY09Q)CGA CCC AAG GGA AAC TGG TC 
(PGMY09R)CGT CCT AAA GGA AAC TGG TC 
(HMB01b) GCG ACC CAA TGC AAA TTG GT 
GP5/6 (GP5)TTT GTT ACT GTG GTA GAT AC 140-150 L1 
(GP6) TGA TTT ACA GTT TAT TTT TC 
GP5+/6+ (GP5+)TTT GTT ACT GTG GTA GAT ACT AC 160 L1 
(GP6+)GAA AAA TAA ACT GTA AAT CAT ATT 
C 
a M, A1C; R, A1G; S, G1C; W, A1T; Y, C1T. 
b L1, HPV late structural protein 1. 
Table 1. Specifications of oligonucleotides used as primers for general HPV detection by 
PCR 
3.2 Polymerase chain reaction-restriction fragment length polymorphisms assays 
(PCR-RFLP) 
PCR-RFLP assay is an alternative technique developed to identify and characterize species 
detecting variations at the DNA sequence level. It involves the digestion of the PCR product 
with specific restriction endonucleases to generate DNA profiles. Appropriate software such 
as Webcutter v2.0 (http://rna.lundberg.gu.se/cutter2/) is used in order to find the most 
suitable restriction site. The restriction enzymes will generate several fragments of variable 
lengths which can be resolved by gel electrophoresis, producing DNA fingerprinting 
patterns (Kado et al., 2001). This method depends on the availability of restriction enzymes 
capable of detecting specific mutations. In addition to several in-house genotyping protocols 
based on PCR-RFLP, there is one commercially available kit. The BIOTYPAP kit (Biotools, 
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Nave, Spain) allows the detection and identification of 31 HPV types: 6, 11, 13, 16, 18, 30-35, 
39, 40, 42-44, 51-54, 56-59, 61, 62, 64 and 66-69, and one subtype (subHPV-44 or subHPV-55). 
The kit consists of a multiplex amplification reaction, using two pairs of primers. One pair of 
primers (Pair1– GEN1 and GEN2) hybridizes with sequences common to all tested HPV 
genotypes (L1 and L2 genes), and therefore, indicates HPV presence. The second pair of 
primers (Pair 2 – ONC1 and ONC2) hybridizes with specific sequences for oncogenic HPV 
genotypes (E6 and E7 genes). The first pair of primers renders a band of approximately 450 
bp, while Pair 2 renders a product of approximately 250 bp. Amplification products are then 
subjected to a restriction fragment analysis, on which different restriction patterns will 
indicate presence of a given HPV genotype (Figure 2) (BIOTYPAP Kit, 2009). Mammas and 
colleagues (Mammas et al., 2010) used the kit for genotyping of HPV in four children with 
respiratory papillomatosis. The use of PCR-RFLP has been shown to be useful in the 
identification of multiple HPV infections as well as the detection of novel HPV types (Kay et 
al., 2002). 
1       2       3       4       5       M 
 
Fig. 2. Detection of HPV with BIOTYPAP Kit. Lane 1 and Lane 3: samples from healthy 
patients; Lane 2: patient infected with a generic HPV; Lane 4: patient infected with an 
oncogenic HPV; Lane 5: negative control; M: 100 bp Ladder, adapted from (BIOTYPAP Kit, 
2009). 
3.3 Polymerase chain reaction-restriction fragment mass polymorphism assay (PCR-
RFMP) 
The PCR-RFMP assay is based on PCR amplification, restriction enzyme digestion, and 
analysis by MALDI-TOF mass spectrometry. The precise sizing of oligonucleotides after 
genotype-specific base variation is detected by fragment scission using type IIS restriction 
enzymes (Lee et al., 2011). The use of a type IIS restriction enzyme makes the RFMP assay 
sequence independent and applicable to a wide variety of HPV genotypes, because these 
enzymes have cleavage sites at a fixed distance from their recognition sites. It is a simple 
and rapid protocol (4-4,5 h) and accurately detects and identifies at least 74 different HPV 
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genotypes (Hong et al., 2008). When Lee (Lee et al., 2011) and colleagues compared the assay 
with the well established automated direct sequencing, the PCR-RFMP had a higher 
analytical sensitivity - 92% and 84% respectively. 
3.4 Real-time polymerase chain reaction based assays (rtq-PCR) 
Real-time PCR reaction, also called quantitative real time PCR, is a technique capable of 
amplifying and simultaneously quantifying the target DNA molecules. At each PCR cycle 
it is possible to measure the amount of amplified product. The detection is performed 
using non-specific fluorescent dyes that intercalate with any double-stranded DNA or 
using sequence-specific DNA probes. The reaction is performed in a Real-time PCR 
thermocycler.  After each cycle, to estimate the DNA concentration, the fluorescence is 
measured with a detector and is compared with a control used as reference. Given its 
capacity to detect the presence and abundance of a specific DNA sequence, rtq-PCR 
techniques have been developed to quantify HPV-DNA in clinical samples. Type-specific 
probes can be combined with fluorescence probes although multiplexing several type-
specific primers within one reaction is technically difficult. Consensus primers are used in 
this technique but are less amenable to quantification than a type-specific system (Molijn 
et al., 2005). This methodology has the following advantages: 1) it is capable of detecting 
the viral load; 2) the reaction can be performed on multiplex, with the use of different 
fluorochromes which emit fluorescence as the PCR reaction proceeds; 3) using a 7-log 
dynamic range to extrapolate viral load/concentration in the standard curve, it is possible 
to detect nucleic acids at very small concentrations which would not be detectable by 
conventional PCR; 4) it is extremely reproducible, rapid and pertinent in a clinical setting 
(Zaravinos et al., 2009). 
Novel RT-PCR methods have been released and are capable of being used as high-
throughput screening tools. The GenoID (GenoID Ltd., Budapest, Hungary) is a molecular 
beacon-based one-step multiplex real-time PCR system which detects 15 high-risk HPV 
types: 16, 18, 26, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66 and 68) and 5 low-risk HPV types: 6, 
11, 42, 43 and 44. The optimized PCR reaction mixture contains 16 forward, 16 reverse 
primers and 20 type-specific molecular beacon probes targeted to a special sequence of the 
L1 gene, where a highly variable sequence is flanked by two conserved sequences. 
Molecular beacons detecting high-risk types are 5-FAM-3-DABCYL-labeled, molecular 
beacons for low-risk detection are 5-TET-3-DABCYL-labelled, while the internal control 
added before sample DNA extraction is detected by a 5-FAMTexasRed-3-DABCYL 
wavelength-shifting molecular beacon. Accordingly, fluorescent data for HPV detection are 
collected at 530 nm for high-risk types, 560 nm in case of low-risk types and the reaction 
internal control is detected at 610 nm on a Roche LightCycler 2.0 instrument (Takacs et al., 
2008). The sensitivity for detected types varies between 22 and 700 copies/reaction; the 
assay shows some cross-reactions, however without comprising the overall clinical 
applicability of the system.  
The Abbott Real Time High Risk HPV test (Abbott Molecular Inc., Des Plaines, IL, USA) is 
performed on the m2000rt real-time PCR instrument (Abbott Molecular) and is designed to 
individually genotype HPV16 and HPV18 and detect other 12 HPVs: 31, 33, 35, 39, 45, 51, 52, 
56, 58, 59, 66 and 68 using a modified GP5+/6+ primer mix consisting of three forward and 
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two reverse primers. The assay uses four channels for detecting fluorescent probes: one for 
detecting the internal control (human beta-globin), a second one for detecting HPV16, a 
third one for detecting HPV-18, and a fourth one for detecting the remaining 12 hr-HPV 
genotypes. The assay turnaround time is 6 to 8 hours for 96 samples and depends on the 
method used for DNA extraction. The fully automated high throughput m2000sp instrument 
(Abbott Molecular Inc.) or smaller m24sp instrument (Abbott Molecular Inc.) can be used for 
DNA extraction, or alternatively DNA can be prepared manually (Poljak et al., 2009). Halfon 
and colleagues (Halfon et al., 2010b) evaluated the clinical performance of the Abbott Real 
time HR HPV test, in comparison with biopsy, hybrid capture II and Linear Array, for 
detection of high-grade disease (CIN2+) in women with abnormal cytology who referred to 
undergo colposcopic evaluation. All tests had high sensitivity in detecting CIN2+ lesions: 
Abbott RT HR HPV had 90%, LA had 92% and HCII had 95%  and similar specificities: 50%, 
47% and 50% for Abbott RT HR HPV, LA, HCII respectively. The authors concluded that the 
Abbott RT HR HPV assay is good and closely correlated with the other two assays with the 
advantages of automation and ability to identify HPV16 and HPV18. Another study 
compared the performance of Abbott RT HR HPV test with that of Hybrid Capture II in 250 
liquid-based cervical cytology samples diagnosed with ASCUS, collected from Asian 
Screening Population. The two tests showed high concordance (absolute agreement: 90%; 
95% CI = 0.726–0.874). For detecting cases with underlying HSIL/CIN2+, both tests 
achieved 100% sensitivity and 100% NPV but Abbott provided higher specificity (20.83% vs 
12.50%). The RT-PCR assay is found to provide enhanced sensitivity and specificity for 
triage of ASCUS (Wong et al., 2011). This assay is also a reliable, sensitive and specific 
diagnostic tool for the detection and partial genotyping of targeted HPV genotypes in 
formalin-fixation and subsequent paraffin/paraplast embedding cervical cancer tissue 
specimens (Kocjan et al., 2011).  
The cobas 4800 HPV Test (Roche Molecular Diagnostics, Pleasanton, CA, USA) is a real-time 
PCR assay for the detection of 14 high-risk HPV types in a single analysis in patient 
specimens. The test specifically identifies HPV16 and HPV18 while concurrently detecting 
the rest of the high risk types: 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66 and 68. The cobas 4800 
System consists of the cobas x 480 instrument for fully automated sample preparation 
directly from primary sample tubes and the cobas z 480 analyser for real-time PCR based 
amplification and detection. The cobas x 480 instrument is an automated multi-channel 
pipetting instrument used to extract, purify, and prepare target nucleic acid for subsequent 
PCR testing on the cobas z 480 analyser. After completion of sample preparation the cobas x 
480 instrument automatically sets up the PCR in a microwell plate. The microwell plate with 
the PCR-ready samples is then manually unloaded, sealed, and transferred to the cobas z 
480 analyser for amplification and detection using real-time PCR (Figure 3) (cobas 4800, 
2010). When Castle and colleagues (Castle et al., 2009) described the cobas 4800 HPV DNA 
Test and compared its performance with the LA test, the percentage of total agreement was 
94.7% (95%CI, 92,5%-96%5%), in 531 tested samples. A study enrolling 47,208 women from 
61 clinical centers across USA (ATHENA study) evaluated the clinical performance of the 
cobas 4800 HPV DNA test. The clinical validation of the assay was achieved by determining 
its performance characteristics for the detection of CIN2+ or worse and CIN3 or worse and 
by comparing with hc2 test. Sensitivy rates for CIN 2 and CIN 3 were 90% (95%CI, 81.5%-
94.8%) and 93,5% (95%CI, 82.5%-97.8%), respectively. The specificity for high grade disease 
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detected by cobas 4800 HPV Test was also comparable with hc2: 70.5% (95%CI, 68.1%-
72.7%) vs 71.1% (95%CI, 68.8%-73.4%), respectively. The main advantage of the assay over 
hc2 is that it provides information on HPV16 and HPV18 separately (Stoler et al., 2011).  
 
Fig. 3. cobas 4800 HPV Test system overview, adapted from (cobas 4800, 2010) 
3.5 Reverse-transcription polymerase chain reaction assays (RT-PCR) 
Although the majority of HPV detection strategies are DNA based, it is possible to look for 
specific HPV viral RNA by incorporating a reverse transcriptase (RT) step before PCR 
amplification (Molijn et al., 2005). Reverse transcriptase is a DNA polymerase enzyme that 
transcribes single-stranded RNA into double-stranded DNA. In RT-PCR a specific mRNA is 
first ‘reverse transcribed’ into its DNA complement (cDNA) and then amplified using 
traditional PCR or rtq-PCR methods. The most relevant transcripts for diagnostic purposes 
are those encoding viral oncoproteins E6 and E7. The detection of viral mRNA can be done 
by reverse transcriptase PCR or by nucleic acid sequence-based amplification (NASBA) 
(Poljak and Kocjan, 2010). 
The Pretect HPV-Proofer (HPV-Proofer; NorChip, Klokkarstua, Norway) is based on real-
time multiplex NASBA and has the advantage of detection type-specific E6/E7 mRNA from 
the carcinogenic HPV types: 16, 18, 31, 33, and 45. Two primer and probe-sets are included 
in each reaction vessel. This assay can therefore be used in monitoring a persistent viral 
infection. Also, it is possible to detect the transforming potential of the infection, due to the 
oncogenic capacity of E6/E7 genes (Molden et al., 2007). The protocol of this assay is based 
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on isothermal RNA amplification, accomplished by the simultaneous enzymatic activity of 
avian myeloblastosis virus (AMV) reverse transcriptase, T7 RNA polymerase, and RNase H. 
For detection, two different types of probes are used, an ECL probe and a molecular beacon 
probe direct against E6/E7 mRNA (Figure 4). As performance control, to avoid false 
negatives due to degradation of nucleic acid,  a primer set and probe directed against the 
human U1 small nuclear ribonucleoprotein-specific A protein (U1A mRNA) is included. Two 
differently labeled molecular beacon probes are used in each multiplex reaction. Fluorescein 
(FAM) is used as a fluorophore for the detection of HPV16, 31 and 33; Texas Red (TxR) is used 
for the detection of U1A, HPV 18 and 45. All the molecular beacons contain the non-
fluorescent quencher Dabsyl CPG (1-dimethoxytrityloxy-3-[O-(N-4’-sulfonyl-4-
(dimethylamino)-azobenzene)-3-aminopropyl]-propyl-2-O-succinoyl-long chain alkylamino- 
CPG) (Kraus et al., 2004, Molden et al., 2007). The performance of HPV-Proofer requires 
standard laboratory equipment, the lambda FL600 fluorescence reader- NASBA platform 
(Bio-Tek, Wnooski, VT, USA) and PreTect Analysis software (NorChip) for analysis of the 
experimental data. The analytical sensitivity of the assay is less than 10 SiHA cells, 
equivalent to 20 copies of HPV16 and less than 1 HeLa cell equivalent to 25 copies of HPV18 
(Lie et al., 2005). All studies that have compared HPV-Proofer with hc2 or different in-house 
or commercial PCR-based HPV DNA assays, showed that HPV-Proofer has a lower clinical 
sensitivity for the detection of CIN2+ lesions than DNA-based assays, but a significantly 
higher clinical specificity (Kraus et al., 2004, Lie et al., 2005, Molden et al., 2007, Szarewski et 
al., 2008).  
 
Fig. 4. Schematic presentation of NASBA including molecular beacon detection, adapted 
from (Molden et al., 2007) 
The NucliSENS EasyQ HPV v1 (NucliSENS; bioMÉRIEUX) is a real-time nucleic acid 
amplification and multiplex detection assay for the qualitative determination of E6/E7 
mRNAs of the HPVs 16, 18, 31, 33 and 45. The assay utilizes the nucleic acid sequence-based 
amplification (NASBA) technology, detecting both viral and bacterial nucleic acids. 
NucliSENS EasyQ HPV version 1 was launched in 2007 and was based on the original 
PreTect Proofer assay, except for the NucliSENS hardware platform and the software for 
NASBA measurements and data analysis (NucliSENS Director software). The latest 
NucliSENS EasyQ HPV assay version 1 has recently been improved in the following ways: 
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taking into account the RNA nature of the HPV-specific targets, the five positive controls for 
the different subtypes and the U1A internal control were changed from single stranded 
DNA to RNA; also, in order to facilitate handling and to increase reproducibility of the 
assay, the positive controls are no longer provided in liquid phase but in freeze-dried 
accuspheres; aiming to improve and harmonize the sensitivity for the five HPV types 
covered by the assay, the concentrations of the primers and beacons for HPV16 and the U1A 
internal control were re-adjusted; the extraction protocol on NucliSENS EasyMAG® system 
was optimized; the HPV assay protocols were updated and the NucliSENtral ™ HPV 
software V1.1 introduced to further improve the convenience of operator use for results 
reporting (Jeantet et al., 2009). The calculated analytical sensitivity ranges from 2.3x102 to 
3.0x104 copies/mL, showing the highest sensitivity for HPV45 and the lowest for HPV31 
(Jeantet et al., 2009). Halfon and colleagues (Halfon et al., 2010a) compared this mRNA assay 
with the hc2 assay in a population of atypical cells of undetermined significance/low-grade 
squamous intraepithelial lesion/high-grade squamous intraepithelial lesion 
(ASCUS/LSIL/HSIL) patients. The clinical sensitivity of NucliSENS EasyQ HPV was 63% 
for the detection of CIN2+ or HSIL, significantly higher than the sensitivity of hc2 and LA 
(49% and 45%, respectively). The sensitivity of the assay is significantly lower than that of 
hc2 and LA (76% vs 95% ans 76% vs 92% respectively).  
The APTIMA HPV Assay (Gen-Probe Incorporated, San Diego, CA) is a multiplex nucleic 
acid test that detects HPV E6/E7 mRNA from 14 high-risk HPV types: 16, 18, 31, 33, 35, 39, 
45, 51, 52, 56, 58, 59, 66 and 68. The assay provides a qualitative result (positive/negative) 
for the presence/absence of these high-risk HPV types, but does not determine the specific 
HPV type present in the specimen. The APTIMA HPV Assay involves three main steps, 
which take place in a single tube: capture of the target mRNA using HPV-specific capture 
oligomers and magnetic microparticles; target mRNA amplification using transcription-
mediated amplification, and detect the amplification products (amplicons) using the 
Hybridization Protection Assay (Dockter et al., 2009a). An internal control transcript is 
added to each reaction to verify the performance of each step of the assay: capture, 
amplification and detection. One positive calibrator and one negative calibrator are used to 
determine the validity of the run and to establish the assay cutoff values for the internal 
control and analyse signals. A positive control and a negative control are also processed as 
separate samples and used to determine run validity. The assay can be performed on the 
semi-automated Direct TubeSampling (DTS) systems, or on the fully automated TIGRIS DTS 
system (Gen-Probe Incorporated, San Diego, CA). The throughput is approximately 180 
specimens for 1 operator in about 5 to 6 hours for the DTS systems and approximately 1000 
specimens in about 14 hours for the TIGRIS DTS system (Dockter et al., 2009a). The 
analytical sensitivity of the assay in the semi-automated DTS systems was between 38 and 
488 HPV mRNA copies and in fully automated TIGRIS DTS system was between 17 and 275 
HPV mRNA copies. The overall analytical specificity of the assay was equal to or greater 
than 99% in both systems. Dockter and colleagues (Dockter et al., 2009b) evaluated APTIMA 
HPV Assay performance for detection of high risk HPV and high-grade cervical 
intraepithelial neoplasia (CIN) compared to hc2. The mRNA based assay was found to be 
highly sensitive and specific for the detection of high-risk HPV in clinical samples, with a 
sensitivity of 92% and a specificity of 98%. The results obtained in the DTS and TIGRIS DTS 
systems were equivalent. Another study compared the sensitivity and specificity of several 
tests, including APTIMA HPV Assay, for the detection of high-grade CIN in a population 
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referred to colposcopy because of abnormal cytology (Szarewski et al., 2008). Four adjuvant 
tests had sensitivities greater than 95% for high-grade disease (CIN2+ and CIN3+ 
respectively): Amplicor (98.9% and 99.5%), Hybrid Capture II (99.6% and 99.5%), Linear 
Array (98.2% and 99.0%) and APTIMA (95.2% and 97.4%). Of these, APTIMA showed the 
highest specificity (42.2% and 38.8%). 
4. Sequencing reaction (GP6+) – big dye terminator cycle sequencing kit 
As previously mentioned, sequencing methods of PCR products are also now available for 
high throughput allowing its application to routine clinical analysis (Ekstrom et al., 2011). 
Nested PCR amplification of a conserved region of the HPV L1 gene, with the consensus 
GP5+/GP6+ primers, followed by genotyping with direct DNA sequencing (BigDye 
Terminators, Applied Biosystems) and alignment of the hypervariable region of the L1 gene 
against known HPV genotype sequences, stored in the GenBank database, usually 
determines the genotype of the HPV isolates detected (Molijn et al., 2005). LoTemp™ HiFi® 
DNA polymerase has shown to be 10 times more efficient, than other Taq DNA 
polymerases, in amplifying HPV plasmid DNA by MY09/MY11 PCR and about 100 to 1000 
times more efficient when the first amplification was followed by a GP5+/GP6+ nested PCR 
in tandem (Lee et al., 2007). The nested PCR technology described by Molijn et al. proved to 
be a sensitive method for the detection of 1-10 copies of purified genomic DNA of HPV 
types 16, 18 or 6B. However, 104 - 105 copies of genomic DNA were needed as PCR 
templates for UV visualization of a positive primer amplicon after electrophoresis. 
Reproducibility of this nested PCR assay was confirmed (Molijn et al., 2005).The exploitation 
of this method allows the identification of new HPV types given that it is not intended for 
the identification of specific types. Sequencing protocols, in particular the requirement for 
template purification, are too labor-intensive for routine applications. In the presence of 
samples infected with more than one genotype of HPV are unsuitable for HPV 
determination. Sequences which represent a minority species, in the total of the PCR 
product, may remain undetected underestimating the prevalence of infections with multiple 
HPV genotypes. After detecting a sample with multiple HPV infection the genotype can be 
deduced by two methods: 1) database homology search (BLAST) and 2) phylogenetic 
analyses (Kleter et al., 1999). In any case, it is time consuming and not totally reliable. Thus, 
this method is not readily adapted to routine diagnostic labs. 
5. Type-specific probe assays 
5.1 DNA Microarray genotyping assays 
The DNA microarray system has been largely used in HPV typing (Jacobs et al., 1997). A 
DNA microarray is a collection of microscopic DNA probes attached to a solid surface by a 
covalent bond. Each probe contains picomoles of a specific DNA sequence like a short 
section of a gene. The cDNA targets are fluorescently labelled and under high-stringency 
conditions hybridize with the probes on the surface of a chip. In each spot the fluorescent 
light is detected by excitation with monochromatic light and transformed in image by 
software. This technology can screen a high number of markers per individual and it is 
particularly suited for strategy using large populations. An example of this methodology is 
HPVDNAChip (Biomedlab, Seoul, South Korea) which contains 22 type-specific probes, 
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allowing identification of 15 high-risk types: 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, 68, 
69 and 7 low-risk types: 6, 11, 34, 40, 42, 43 and 44. In summary, target HPV DNA is 
amplified by PCR with hpv1/hpv2 primers and labeled utilizing Cy5-dCTP or Cy5-dUTP, 
with primers and conditions described by manufacturer. Secondly, the PCR product is 
hybridized onto the chip and, after washing, the hybridized signals are visualized with a 
DNA chip scanner (Seo et al., 2006). The HPVDNAChip test was successfully implemented 
in a population based study in Korea with 2.470 women (Hwang et al., 2004) and in a study 
that compared the performance of four HPV genotyping assays on a panel of 824 samples; 
the analytical sensitivity of the test was around 80% and specificity for the individual HPV 
types was above 94% (Klug et al., 2008). 
The GG HPVCHIP (GoodGene, Seoul, South Korea) allows the identification of 42 alpha-
HPV types; 15 high-risk types: 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 68, 69 and 70; Three 
probable high-risk types: 26, 53 and 66; 20 low-risk types:6, 7, 10, 11, 27, 32, 40, 42, 44, 54, 55, 
57, 61, 62, 72, 73, 91, CP8304/81, and MM7/83, MM8/84; and four undetermined-risk types: 
30, 34, 67 and MM4/82. The DNA chips collect multiple oligonucleotide probes of the 42 
HPV types and human β-globin gene. The DNA is amplified with Cy5-labelled primer for 
E6, E7 and L1 gene and the produced amplicons are applied onto the DNA chip, followed 
by hybridization and the genotypes of HPV within sample are identified by a fluorescent 
scanner (Kim et al., 2006). The performance of the GG DNACHIP was compared with PCR 
sequencing on 100 cervical cancer specimens and both methods detected 98% (98/100) high-
risk types of the samples tested (Kim et al., 2006). 
The HPV GenoArray Test Kit (GenoArray, HybriBio Limited, Hong Kong) uses both DNA 
amplification and Hybrio’s proprietary flowthrough hybridization technique to 
simultaneously identify 21 alpha-HPV types: 6, 11, 16, 18, 31, 33, 35, 39, 42-45, 51-53, 56, 58, 
59, 66, 68 and 81. The test employs a macroarray format with a nylon membrane onto which 
HPV genotype-specific oligonucleotides probes have been immobilized (Grisaru et al., 2008). 
Liu and colleagues (Liu et al., 2010) compared the HPV GenoArray test with Linear Array, 
revealing concordant or compatible results for 97,5% of the samples and discordant results 
for only eight samples (2,5%). The assay appears to be highly sensitive and specific for the 
genotyping of HPV and has the advantage that specifically detects HPV52, which 
overcomes a limitation of the Linear Array. 
Less frequent in peer-reviewed literature are the kits GeneTrack HPV DNA Chip 
(GeneTrack, Genomic Tree, Daejeon, South Korea) and GeneSQUARE HPV Microarray 
(Kurabo Industries, Osaka, Japan). The first identifies 28 HPV types: 6, 11, 16, 18, 31, 33, 35, 
39, 40, 42-45, 51, 52, 54, 56, 58, 59, 62, 66-72 and consists in the amplification of a 450 bp 
region of the L1 gene using MY09/11/HMB01 primers and of an internal control (portion of 
the human interferon-2 gene). To determine the HPV genotype, the amplicons are 
hybridized on a DNA chip with eight microarrays chambers, each containing a duplicate of 
the 28 type-specific probes and a replicate of a human cellular target-specific probe (Oh et 
al., 2004, Poljak and Kocjan, 2010). The GeneSQUARE HPV is a microarray system in 
development that utilizes a multiplex PCR to amplify and identify 23 alpha-HPVs: 6, 11, 16, 
18, 30, 31, 33-35, 39, 40, 42, 45, 51-54, 56, 58, 59, 61, 66 and 68. Type-specific primer pairs are 
used in the assay and the upstream primer in each pair is labeled with biotin at the 5’end. 
After hybridization, the microarray is washed, dried and scanned (Figure 5) (Ermel et al., 
2010, Matsushita et al., 2011). Ermel and colleagues (Ermel et al., 2010) compared the hc2, 
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Linear Array and GeneSQUARE methods and the sample proportion agreement was very 
good, particularly between Linear Array and GeneSQUARE. 
 
Fig. 5. Protocol for HPV-specific probe synthesis by oligonucleotide shuffling used in 
GeneTrack, adapted from (Oh et al., 2004) 
The Infiniti HPV assays (AutoGenomics, Carlsbad, CA, USA) are commercially available 
genotyping platforms for HPV genotyping that uses multiplex PCR, followed by automated 
processing for primer extension, hybridization and detection (Erali et al., 2009). It groups 
three assays: Infiniti HPV Genotyping Assay, Infiniti HPV-HR Quad assay and Infiniti HPV-
Quad Assay. The Infiniti HPV-Quad assay targets the E1 gene of the HPV genome and 
identifies five individual HPV types: 16, 18, 31, 33, and 45, five combinations of HPV types: 
35/68, 39/56, 58/52, 59/51, 6/11 and a β-globin internal control. When Erali and colleagues 
(Erali et al., 2009) compared this assay with Hybrid Capture II, the overall concordance of 
positive and negative results was 83% among the 197 specimens tested.  
The PANArray HPV Genotyping Chip (PANArray, PANAGENE, Daejeon, Korea) uses 
peptide nucleic acid probes for the identification of 31 HPV types: 6, 11, 16, 18, 26, 31-35, 39, 
40, 42-45, 51-54, 56, 58, 59, 62, 66, 68-70, 73, 81, 83 and one subtytpe, subHPV-44 or HPV-55. 
MY09/11 PCR products nested with GP5+/biotinylated-GP6+ primers are used for the 
genotyping (Poljak and Kocjan, 2010). A study comparing the genotyping results of 
PANArray to sequencing with MY09/11 PCR products showed excellent agreement except 
for samples reflecting multiple infections (Choi et al., 2009). 
Another illustration of this methodology is Clart HPV 2 assay (Genomica, Madrid, Spain), 
developed for the detection and genotyping of 35 HPV types: 6, 11, 16, 18, 26, 31, 33, 35, 39, 
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40, 42, 43, 44, 45, 51, 52, 53, 54, 56, 58, 59, 61, 62, 66, 68, 70, 71, 72, 73, 81, 82, 83, 84, 85 and 89. 
It uses biotinylated primers that amplify a 450bp fragment within L1 region. Co-
amplification of an 892 bp region of the CFTR gene and 1,202 bp fragment of a transformed 
plasmid provides a control to ensure DNA extraction and PCR efficiency (Pista et al., 2011). 
The performance of Clart HPV 2 requires standard laboratory equipment and the Clinical 
Arrays Processor (Genomica) for fully automated microarray processing and genotyping 
analysis (Poljak and Kocjan, 2010). A comparative evaluation of Clart HPV 2 with Hybrid 
Capture 2 Test on samples with cervical intraepithelial neoplasia grade 2 or worse showed a 
clinical sensitivity of 96.9% and specificity of 71.9% (Pista et al., 2011). When Galan-Sanchez 
and colleagues (Galan-Sanchez and Rodriguez-Iglesias, 2009) compared INNO-LIPA HPV 
Genotyping v2, Linear Arrays HPV Genotyping Test and Clart HPV 2 the results were 
absolutely concordant in 31 samples, compatible (some but not all genotypes) in 44 samples 
and discordant in only 3 samples; concluding that all the 3 methods are highly comparable 
and suitable for clinical and epidemiological studies. The advantages of this methodology, 
made a successful use in large-population-based study in Spain, where 2362 women from 
three different regions were investigated (Gomez-Roman et al., 2009). 
The PapilloCheck HPV-Screening Test (Greiner Bio-One GmbH, Frickenhausen, 
Germany) is one of the two most frequently used PCR-microarrays-based assays (Poljak 
and Kocjan, 2010). It is a PCR-based test using a consensus primer set targeting the E1 
HPV gene. HPV oligoprobes immobilized on a DNA chip allow for the identification of 24 
HPV types: 6, 11, 16, 18, 31, 33, 35, 39, 40, 42-45, 51-53, 56, 58, 59, 66, 68, 70, 73 and 82. Each 
PapilloCheck chip contains 12 wells defined by elevated rims, each of which contains one 
PapilloCheck array with 28 probes, each in 5 replicate spots (Dalstein et al., 2009). This 
test utilizes the amplification of 350 pb HPV DNA fragment as a new consensus primer 
set: each reverse primer was extended at 5’ end with a universal tag. Additionally, a 
region within the human ADAT1 gene is simultaneously amplified using fluorescent-
labeled primers with Cy5-dUTP. The amplicons hybridize to HPV specific oligoprobes 
immobilized on the DNA chip the readings are performed on a CheckScanner instrument 
(Dalstein et al., 2009). Several comparative evaluations of PapilloCheck with other HPV 
assays have been published (Halfon et al., 2010c, Hesselink et al., 2010, Iftner et al., 2010, 
Schopp et al., 2010, Kitchener et al., 2011). This genotyping test was compared with 
SPF10PCRLiPav and PGMY09/11 on Hybrid Capture2 pretested samples (Schopp et al., 
2010). From results of 826 cervical samples, the PapilloCheck found 100% sensitivity in 
HPV types 53, 56 and 33. The lowest detection rate was observed for type 35 (72,2%) and 
the detection rates for the identification of high-grade intraephitelial neoplasia (CIN2+) 
ranged from 93,7% (PGMY09/11 PCR) to 98,4% (PapilloCheck, SPF10 PCR, HC2), leading 
to the conclusion that the  PapilloCheck gives comparable results on established PCR 
methods (Schopp et al., 2010). Halfon and colleagues (Halfon et al., 2010c) compared 
PapilloCheck, Linear Array and hc2 in 239 women referred for colposcopy and histology, 
concluding that all tests showed a good sensitivity (greater than 90%) without statistically 
relevant differences between them.  
The application of microarray technology as a diagnostic toll shows great advantages, 
since microarray can discriminate HPV genotypes and identify multiple infections (Kim et 
al., 2003). Ideally, a larger number of HPV type-specific probes could be spotted on a chip, 
augmenting the quantity of HPVs genotyped by assay. Unfortunately this method 
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requires the presence of expensive equipment and therefore is not suitable for all the 
laboratories.  
5.2 Suspension array genotyping assays (HPV-SA) 
The HPV-SA provides a rapid and cost-effective method to simultaneously detect 
different HPV genotypes. This technology uses microspheres as array elements that carry 
appropriate receptor molecules such as DNA oligonucleotide probes, antibodies, or other 
proteins. Microspheres are readily suspendable in solution and possess distinct optical 
properties. Each bead can easily be differentiated based on variations and intensity of 
colour. The most common detection systems are light scatter or fluorescence from an 
internal dye. The Luminex xMAP system is a flexible analyzer based on the principle of 
flow cytometry. It incorporates a proprietary process to internally dye polystyrene beads 
with two spectrally distinct fluorochromes. Each bead set is usually coupled to a single 
oligonucleotide probe specific for one HPV type. Genotyping is done by reverse 
hybridization using biotinylated PCR amplicons. After denaturing and hybridization of 
target HPV sequences to the bead-bound probes, labeling of the hybridized biotinylated 
amplicons is done using R-phycoerythrin-labelled streptavidin, serving as a reporter 
fluorophore. The bead sets are then read and analysed on a Luminex analyser (Poljak and 
Kocjan, 2010).  
There are several in-house genotyping protocols based on xMAP technology. Jiang and 
colleagues (Jiang et al., 2006) developed a rapid high-throughput DNA suspension assay, 
capable of simultaneously typing 26 HPVs: 6, 11, 16, 18, 26, 31, 33-35, 39, 40, 42-45, 51-54, 
56, 58, 59, 66, 68, 73 and 82. The HPV-SA consists of 26 different microsphere sets with 
spectral addresses. Each microsphere set shows an HPV type-specific probe on its surface, 
and they can be combined allowing up to 26 different HPV targets to be measured 
simultaneously in a single reaction vessel (Figure 6). Another in-house SA protocol was 
developed by Oh and colleagues (Oh et al., 2007) combining PCR amplification with 
Luminex hybridization. The use of HPV type-specific probes and YBT L1/GP6-1 primers 
detects HPVs 6, 16, 18, 31, 35, 42, 51, 52, 55, 56, 58, 59, 66, 67 and 68. The authors compared 
the SA to the established HPV DNA microarray chip for PCR products derived from 53 
clinical samples. The evaluation showed excellent agreement as the SA was a very 
sensitive and reproducible technique for simultaneously genotyping of all clinically 
relevant genital HPV types (Oh et al., 2007). 
In addition, at least two commercial assays based on this technology are available at present. 
The Multiplex HPV Genotyping kit v1.0 (Progen/Multimetrix, Heidelberg, Germany) is a 
research use only (RUO) assay that allows detection and identification of 24 HPV types: 6, 
11, 16, 18, 26, 31, 33, 35, 39, 42-45, 51-53, 56, 58, 59, 66, 68, 70, 73 and 82. The sample is 
subjected to PCR amplification, using sets of biotinylated primers contained in the kit.  The 
amplicons are added to bead mix, containing 26 distinct bead populations coupled to 24 
HPV, one β-globin and one hybridization control specific oligonucleotide probe. The β-
globin control serves as quality control for genomic DNA in the PCR. After thermal 
denaturing and hybridization of target sequences to the bead-bound probes, labeling of the 
hybridized biotinylated PCR products is achieved by R-phycoerythrin labeled streptavidin. 
Schmitt and colleagues (Schmitt et al., 2006) compared the performance of Multiplex Human 
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Papillomavirus Genotyping assay to an estabilished reverse line blot assay on GP5+/6+ PCR 
products derived from 94 clinical samples. The evaluation showed an excellent agreement 
but also a higher sensitivity of the Multiplex assay.  
 
Fig. 6. Schematic representation of the HPV-SA. After HPV DNA extraction  (A), the 
template was amplified with the MY09/11 primer set (B). PCR products are transferred to a 
PCR tube containing the 26-plex HPV-SA and hybridized (C). After washing, the hybridized 
microspheres were incubated with streptavidin-R-phycoerythrin at room temperature for 30 
min (D). Finally, the mixture is analysed on the Luminex100 analyser (E), adapted from 
(Jiang et al., 2006). 
The digene HPV genotyping LQ Test RUO (Digene LQ Test; Qiagen) uses multiplex, bead-
based xMAP technology and an automated, high-throughput read-out by either the 
LiquidChip 200 workstation (Qiagen, Hilden, Germany) or Luminex 100 IS System 
(Luminex Corporation, Austin, TX, USA). The test was developed for identification of 18 
high-risk HPVs: 16, 18, 26, 31, 33, 35, 39, 45, 51-53, 56, 58, 59, 66, 68, 73 and 82 using 
GP5+/6+ PCR products. Read-out of this assay is expressed as the medium fluorescent 
intensity of the reporter fluorescence for each genotype (Geraets et al., 2009b). When 
compared with in-house GP5+/6+, the assay demonstrated high agreement for overall 
detection and type-specific identification (Geraets et al., 2009b).  
6. Reverse line-blot hybridization-based HPV genotyping assays 
It is the most common method used for HPV genotyping nowadays. In these types of assays 
a fragment of the HPV genome is first amplified by PCR, using biotinylated HPV-specific 
primers, and the resulting amplicons are then denatured and hybridized with HPV-specific 
oligonucleotide probes immobilized as parallel lines on nylon or a nitrocellulose membrane 
strip. After hybridization, streptavidin-conjugated alkaline phosphatase or horseradish 
peroxidase is added, which binds to any biotinilated hybrid formerly produced (Figure 7). 
Incubation with chromogenic substrates yields a colored precipitate at the probe positions 
where hybridization occurs. The genotyping strip is then visually interpreted by comparison 
with the test reference guide for each of the targeted HPV types. The principle of INNO-
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LiPA HPV Genotyping assay is based on the amplification of a 65bp region of the HPV L1 
gene, using biotinylated SPF10 primers, followed by the hybridization of the resulting 
amplicons with HPV specific oligonucleotide probes immobilized on a nitrocellulose strip. 
This is one of the most widely used HPV genotyping kits and there are several versions 
developed of which the first version, the INNO-LiPA25 HPV genotyping V1.0 (Labo 
Biomedical Products, Rijswick, The Netherlands) allowed the identification of 26 HPVs: 6, 
11, 16, 18, 31, 33, 34, 35, 39, 40, 42,43, 44, 45, 51, 52, 53, 54, 56, 58, 59, 66, 68, 70, 73 and 74 
(Kleter et al., 1999). More recent versions of this assay, the INNO-LiPA HPV Genotyping v2 
and INNO-LiPA HPV Genotyping CE Assays (Innogenetics) allowed the identification of 24 
and 17 individual types, respectively. The latest version, INNO-LiPA HPV Genotyping 
Extra, allows the simultaneous identification of 28 different HPV types: 6, 11, 16, 18, 26, 31, 
33, 35, 39, 40, 43, 44, 45, 51, 52, 53, 54, 56, 58, 59, 66, 68, 69/71, 70, 73, 74 and 82. The former 
assay contains an additional primer pair, in the amplification mix, for the amplification of 
the HLA-DPB1 gene to check for PCR inhibition, sample quality and DNA extraction, as well 
as an anticontamination system based on uracil-N-glycosylase (Poljak and Kocjan, 2010). 
Several evaluation studies have been performed in recent years. A recent study compared 
real-time multiplex HPV PCR assays with INNO-LiPA Genotyping Extra suggesting 
increased sensitivity of DNA HPV detection by type-specific multiplex HPV PCR assays 
(Else et al., 2011). Another interesting and important assessment was the comparative 
evaluation of different extraction methods for genotyping with INNO-LiPA and Linear 
array genotyping tests. This study suggests that the use of consistent protocols for DNA 
purification is a priority to guarantee intra-assay reproducibility over time (Dona et al., 
2011). INNO-LiPA HPV Genotyping Extra is also recommended for the use with paraffin-
embedded tissue. After comparison with Linear Array HPV Genotyping Test the INNO-
LiPA genotyping Extra revealed greater sensitivity for HPV genotyping from archival tissue 
(Tan et al., 2010). INNO-LiPA Extra has a sensitivity of 20-70 viral copies per assay 
(estimated for HPV-16, 18, 31, 45 and 52) (Seme et al., 2009). 
 
Fig. 7. INNO-LiPA HPV Genotyping test principle, adapted from INNO-LiPA brochure. 
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As with INNO-LiPA, Linear Array HPV Genotyping assay is based on the amplification of a 
region of the HPV L1 gene (450 bp). This genotyping test also amplifies a 268bp region of the 
human β-globin gene, using biotinylated primer sets PGM09/PGMY11 and PC04/GH20, 
respectively. Subsequent hybridization of the resulting amplicons is made onto a single-
typing nylon strip coated with HPV type specific and β-globin specific oligonucleotide 
probes. This test is one of the most commonly used HPV genotyping assays which combines 
PCR amplification and reverse line-blot hybridization for the identification of 36 HPV types: 
6, 11, 16, 18, 26, 31, 33, 35, 39, 40, 42, 44, 45, 51, 52, 53, 54, 56, 58, 59, 61, 62, 64, 66, 67, 68, 69, 
70, 71, 72, 73, 81, 82, 83, 84 and 89 and one subtype (subHPV-82 or IS39) (Poljak and Kocjan, 
2010). It is registered for use in the European Union (CE-IVD) but not available for use in the 
United States. Numerous comparative evaluations of Linear Array with other HPV 
genotyping assays have been performed. All studies reported high concordance amongst 
hybridization genotyping methods and suitability for clinical and epidemiological studies 
(Galan-Sanchez and Rodriguez-Iglesias, 2009). Linear Array has revealed good correlation 
and perfect agreement with hc2, with high sensitivity; 100% detection of cervical 
intraepithelial neoplasia (CIN) III was shown by both Linear array and hc2 (Paolini et al., 
2011). Comparison of this genotyping assay with real-time multiplex HPV PCR assays, 
holding as constant the DNA extraction method (Qiagen Spin blood kit), revealed that 
multiplex PCR assays detect more HPV-positive specimens for the 14 HPV types common to 
both than Linear Array HPV genotyping assay. Type-specific agreements between the 
assays were good but were often driven by negative agreement in HPV types with low 
prevalence, as evidenced by reduced proportions of positive agreement. An alternate DNA 
extraction technique (Qiagen MinElute kit) impacted subsequent HPV detection in both the 
multiplex PCR and Linear Array (Roberts et al., 2011). A comparative evaluation with 
INNO-LiPA has shown high concordance amongst both methods; however, when 
comparing individual HPV types, Linear Array was able to detect significantly more HPV-
16, 18, 39, 40, 42, 54, 58, 59, 66, 70 and 68/73, and fewer HPV-11, 31 and 52 than INNO-LiPA 
(Castle et al., 2008). Furthermore, INNO-LiPA was able to detect more multiple HPV 
infections and a greater number of HPV types per multiple infection (Castle et al., 2008). 
Linear array has shown a sensitivity of 98.2% and a specificity of 32.8% for the detection of 
CIN II+ lesions (Szarewski et al., 2008). 
The Digene HPV Genotyping RH Test RUO is a reverse line-blot assay designed for the 
detection and identification of 18 HPV types: 16, 18, 26, 31, 33, 35, 39, 45, 51, 52, 53, 56, 58, 59, 
66, 68, 73 and 82. As the previous genotyping tests it is based on the PCR amplification of a 
150bp region of the HPV L1 gene using biotinylated GP5+ and GP6+ primers, followed by 
the hybridization of the resulting amplicons onto a single-typing nitrocellulose strip 
containing 18 HPV type-specific probe lines (Geraets et al., 2009a). Digene HPV genotyping 
RH Test RUO was compared to INNO-LiPA genotyping test Extra showing comparable 
genotyping results. However, INNO-LiPA identified significantly more samples with 
multiple HPV types (Seme et al., 2009). Another evaluation study compared the Digene 
genotyping RH test with the in-house Reverse Line Blot (RLB) genotyping assay. Both 
genotyping assays demonstrated high concordance, in 493 HC2-positive samples, for overall 
HR HPV detection and type-specific identification of the 18 HR types. The Digene RH Test 
revealed positivity for one or more HR HPV type(s) in 86.6% of the HC2-positive women, 
and negativity was confirmed in 97.9% of the HC2-negative women. The Digene HPV 
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Genotyping RH Test revealed a high genotyping agreement with the established RLB assay 
on GP5+/6+ amplimers (Geraets et al., 2009a). It was reported recently another study 
encompassing the Digene HPV Genotyping RH test. The objective was to test whether the 
RH Test and LQ Test (XMap based) can be used as an universal hrHPV genotyping test. 
Self-collected 416 cervico-vaginal specimens from an epidemiologic study were analyzed 
with Amplicor. The amplimers obtained were also tested with the RH Test and LQ Test for 
identification of 18 HPV types, including the 13 hrHPVs targeted by Amplicor. 197 
specimens were positive by Amplicor, in which the RH Test and LQ Test identified one of 
the 13 hrHPVs in 94.4% and 98.0%, respectively. In 219 specimens remaining negative by 
Amplicor, the RH Test and LQ Test, performed on the Amplicor amplification products, still 
detected one of the 13 hrHPVs in 3.7% and 5.5% respectively, and include identification of 
HPV53, 66, and 82. Overall, the RH and LQ Tests demonstrated high concordance with 
Amplicor for hrHPV detection (κ=0.908 and κ=0.923, respectively). The authors suggest that 
the digene HPV Genotyping RH and LQ Tests can be directly used for amplimers generated 
by the Amplicor HPV Test (Geraets et al., 2011). The latest version of Digene RH test (v1.0) 
includes an additional primer pair for human β-globin gene amplification, serving as an 
internal control for PCR inhibition and adequate sample taking and DNA purification 
(Poljak and Kocjan, 2010). 
The EasyChip HPB Blot kit (HPV Blot kit; King Car, Taiwan) is a reverse dot-blot assay 
designed for the identification, in the latest version, of 39 types of HPV: 6, 11, 16, 18, 26, 31, 
32, 33, 35, 37, 39, 42, 43, 44, 45, 51, 52, 53, 54, 55, 56, 58, 59, 61, 62, 66, 67, 68, 69, 70, 72, 74, 82, 
CP8061, CP8304, L1AE5, MM4, MM7 and MM8. The biotinylated PCR amplicons of several 
HPV general primer sets or their combinations can be used for genotyping, including 
MY11/MY09, PGMY11/PGMY09, GP5+/GP6+, MY11/GP6+, MY11/GP6+ nested with 
GP5+/GP6+ and SPF1/GP6+. The latest version of this kit provides two standardized PCR 
amplification mixes: in the first, a modificed MY11/GP6+ primers set is used to amplify a 
190bp region of the HPV L1 gene; in the second, the quality of extracted DNA is validated 
by amplification of a 136bp region of the human GAPDH gene. The resulting amplicons 
from an individual DNA sample are genotyped together on a single-typing nylon 
membrane containing the 39 HPV type-specific and one GAPDH-specific oligonucleotide 
probe marked in duplicate (Poljak and Kocjan, 2010). The evaluation of the sensitivity, 
specificity, reliability and reproducibility of the EasyChip HPV blot for HPV genotyping 
was performed in two studies. In the first, type-specific sensitivity and specificity for the 39 
types of HPV were examined. The operating environment, reliability, reproducibility and 
blot interpretation were assessed by a quality assurance system. Each batch experiment 
contained samples from 89 cervical specimens and 7 extrinsic controls. Caski, HeLa and 
Jurkat cells, male human blood cell DNA and sterile water were used to assess reliability. 
Furthermore, pairs of sibling controls were used to assess reproducibility. The overall 
sensitivity of HPV detection was 1-50 copies of HPV genome equivalent. There was no 
cross-reactivity with amplicons of other HPV genotypes. One hundred batch experiments 
demonstrated that the reliability was excellent. The intra-batch and inter-batch 
reproducibility was 98 and 97%, respectively. The authors concluded that the EasyChip 
HPV blot is a highly sensitive, reliable and reproducible tool for detection and identification 
of HPV genotypes (Lin et al., 2007). The second study compared the efficacy of HPV 
detection and typing with a general PCR-based genotyping array with EasyChip HPV Blot. 
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The concordance of the two tests in determining HPV positivity was 96.8% (419/433), with a 
Cohen's kappa=0.93 (95% CI: 0.90-0.97) and McNemar's test of P=1.0, which indicates 
excellent agreement. The overall concordance of the two tests in the identification of type-
specific HPV was 91.0%. Sensitivity (90-100%), specificity (99.2-100%), and accuracy (98.6-
100%) rates of HPV Blot against the gold standard were satisfactory for HPV-16, 18, 58, 33, 
52, 39, 45, 31, 51, 70 while HPV-71 (63.6%) had suboptimal sensitivity. The authors conclude 
that the modified MY11/GP6+ PCR-based HPV Blot assay is accurate and sensitive for 
detection and genotyping of HPV in cervical swab samples (Lin et al., 2008). 
M&D REBA HPV-ID® is a molecular diagnostic kit for genotyping HPV; it  detects 15 high-
risk genotypes:16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 68, 53, 66 and 10 low-risk genotypes: 
6, 11, 42, 43, 44, 70, 72, 81, 84, 87 , simultaneously. Genetic target of REBA HPV-ID® is the 
HPV L1 gene, which is expressed at the late stage of infection cycles in the host cells. The kit 
is based on one-step nested PCR with biotinylated MY09/11 and GP5+/6+ primers and 
subsequent genotyping of the resulting amplicons with a single typing strip containing 23 
HPV type-specific probes and one HPVV universal probe. There are no evaluation studies 
about this kit in peer-reviewed literature (Inc, M&D, Poljak and Kocjan, 2010).  
The reverse hybridization methodology uses standard laboratory equipment and the 
methodology is both reproducible and rapid. The price per sample can limit its use.  
7. In situ hybridization assays (ISH) 
In situ hybridization allows the detection of intact viral DNA directly in tissues sections or 
cell preparations (in situ). The method is based on the recognition and following bond of the 
labelled probe with the complementary viral target.  The sample is fixed in fixative solution 
in order to preserve the tissue morphology and to prevent loss of genetic material (Carlson 
and Hu). The result of the hybridization reaction is evaluated microscopically and the 
appearance of a specific precipitate is indicative of infection (Huang et al., 1998, Poljak and 
Kocjan, 2010). Generally the assay is based on four steps: tissue fixation, permeabilization of 
tissue samples, hybridization of the sample with probes, and detection of the HPV positive 
cells. Critical points for a successful ISH test are the hybridization and post-hybridization 
treatment. Hybridization is performed by incubating the fixed tissue with the solution 
containing the hybridization probe and washing the tissue to remove the unbound probes. 
During these steps, many parameters play a crucial role. Different lengths of probes and 
different labelling conditions are an example (Montgomery, 2002). The ISH probe cocktails 
available in the market for HPV detection are several.  The latest generation probes utilize 
stacked antibodies to enhance the sensitivities and probes containing viral genomic DNA in 
double strand form (INFORM HPV III test). The target of the probes can be the viral DNA 
and mRNA sequences or viral mRNA transcript in human cells. ISH assay showed a low 
sensitivity (50%) but a significantly higher specificity (Caussy et al., 1988). The values can 
vary, depending on the commercially method utilized.  
INFORM HPV III test (Ventana, Tucson, AZ, USA) represents the last generation 
commercial kit for detecting HPV DNA in cytological and histological specimens. It utilizes 
stacked antibodies to enhance the sensitivity of the technique (Poljak and Kocjan, 2010). The 
antibody stacks consist of a primary antibody that binds the dinitro-phenol hapten linked to 
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the probe, a secondary antibody, a biotinylated tertiary antibody, and a streptavidin–
alkaline phosphatase conjugate that generate the final colour precipitates. Several are the 
probe cocktails available for low and high HPV risk detection. The probe B and C target 12 
HPVs: 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, and 66. 
GenPoint HPV Biotinylated DNA probe is the last generation ISH kit using the GenPoint 
Tyramide Signal Amplification System (Dako) (Glostrup, Denmark). It can be used in both 
cytological and histological specimens. The probe is biotin-labeled and consists of a viral 
genomic double-stranded DNA of 500 bp (Gebeyehu et al., 1987). Biotin can be detected by 
using enzyme conjugates of streptavidin to produce covalent bounds with tyramide 
substrates and chromogenic indicator dye diaminobenzidine (DAB) (Bobrow et al., 1989). 
DAB is oxidized by peroxidase enzymes to produce a dark brown precipitate that can be 
visualized on Dako Hybridizer and Autostainer Plus (Poljak and Kocjan, 2010). The probe 
cocktail recognises 13 HPVs: 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, and 68. In a 
comparative study of INFORM III, GenPoint, and HPV PCR evaluated on 58 tissue 
specimens, GenPoint showed the same specificity (100%) then INFORM III but lower 
sensitivity (Kong et al., 2007).  
ZytoFast HPV Probes (ZytoVision, Bremerhaven, Germany) are specific probes for the 
detection of viral DNA and mRNA of E6, E7, and L1 proteins. It can be used in both 
cytological and histological specimens. The probes are biotin or digoxigenin labelled and 
consist of HPV-type-specific oligonucleotides (Poljak and Kocjan, 2010).  The target is 
indirectly detected using an antidigoxigenin or antibiotin enzyme conjugated antibody. The 
use of a chromogenic substrate leads to the formation of a colour precipitate that is 
visualised by light microscopy. The ZytoFast HPV Kit is designed for the detection of low 
risk HPV types 6 and 11 and high risk types 16, 18, 31, and 33.  
HPV OncoTect Test Kit (OncoTect; IncellDx, El Camino Real Menlo Park, CA, USA; Invirion 
Diagnostics, Oak Brook, IL, USA) measures the number of transforming cells and the 
quantity of E6, E7 mRNA in each intact human cell. The kit works as indicator of disease 
activity. The percentage of tested cells that overexpress the viral mRNAs provides a specific 
indication about the risk of an HPV infection can turn into cervical cancer (IncellDx, 
2010)(IncellDx, 2010)(IncellDx, 2010)(IncellDx, 2010)(IncellDx, 2010, Bhat et al., 2007). 
Generally, HPV OncoTect Test is used in parallel with other HPV protocols (Poljak and 
Kocjan, 2010). The sensitivity and the specificity of the test are high (83.3% and 91.3% 
respectively) and is significantly increased (Narimatsu and Patterson, 2005). It is possible to 
detect 95% of infected cells in moderate dysplasia (HPV OncoTect™, 2010, Liu et al., 2007). 
The advantages and disadvantages of this technique depends on the methodologies and the 
kind of probe used (Feldman et al., 1997): double stranded DNA probes are easy to use but 
need reannealing during the hybridization (decreasing the probe availability); single 
stranded DNA probes does not need probe denaturation and no reannealing during 
hybridization but it is technically complex. RNA probes have high specific activity, no probe 
denaturation needed, no reannealing, but less tissue penetration.  Finally, oligonucleotide 
probes have stable good tissue penetration (small size), no self-hybridization, but lower 
specific activity, so less sensitive, less stable hybrids, and access to DNA synthesizer needed. 
The ISH based tests for HPV detection are insufficiently clinically validated. They are not 
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used in routine screening  because the methodology is too laborious and not sufficiently 
sensible (Poljak and Kocjan, 2010). 
 
Test name Test 
principle 
Nucleic 
acid target
Types Performance 
   Detected Genotyped Sensitivity Specificity 
hc2 Signal 
amplified 
hybr. 
DNA HPVs16, 18, 31, 
33, 35, 39, 45, 51, 
52, 56, 58, 59 and 
68. 
 - 93%  
Cervista™ Signal 
amplified 
hybr. 
DNA HPVs16, 18, 31, 
33, 35, 39, 45, 51, 
52, 56, 58, 59, 66 
and 68. 
-  92,8%  
Amplicor Signal 
amplified 
hybr. 
DNA HPVs16, 18, 31, 
33, 35, 39, 45, 51, 
52, 56, 58, 59 and 
68. 
- 96,1% 96,5% 
careHPV Signal 
amplified 
hybr. 
DNA HPVs16, 18, 31, 
33, 35, 39, 45, 51, 
52, 56, 58, 59, 66 
and 68. 
- 90,0% 84,2% 
GenoID rtq-PCR DNA HPVs16, 18, 26, 
31, 33, 35, 39, 45, 
51, 52, 56, 58, 59, 
66, 68, 6, 11, 42, 
43 and 44. 
-   
Abbott 
Real Time 
HR HPV 
test 
rtq-PCR DNA HPVs31, 33, 35, 
39, 45, 51, 52, 56, 
58, 59, 66 and 68.
HPV16 and 
HPV18. 
90,0% 50% 
Cobas4800 rtq-PCR DNA HPVs31, 33, 35, 
39, 45, 51, 52, 56, 
58, 59, 66 and 68.
HPV16 and 
HPV18. 
90,0% 70,5% 
Pretect 
HPV-
Proofer 
RT-PCR mRNA HPVs16, 18, 31, 
33 and 45. 
- 78,1% 75,5% 
NucliSENS 
EasyQ 
HPV v1 
RT-PCR mRNA HPVs16, 18, 31, 
33 and 45. 
- 63%  
APTIMA 
HPV Assay 
RT-PCR mRNA HPVs16, 18, 31, 
33, 35, 39, 45, 51, 
52, 56, 58, 59, 66 
and 68. 
- 92% 98% 
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Test name Test 
principle 
Nucleic 
acid target
Types Performance 
   Detected Genotyped Sensitivity Specificity 
HPVDNA 
chip 
DNA 
Microarray
DNA - HPVs16, 
18, 31, 33, 
35, 39, 45, 
51, 52, 56, 
58, 59, 66, 
68, 69, 6, 11, 
34, 40, 42, 
43 and 44.
80% 94% 
GG 
HPVCHIP 
DNA 
Microarray
DNA - HPVs16, 
18, 31, 33, 
35, 39, 45, 
51, 52, 56, 
58, 59, 68, 
69, 70, 26, 
53, 66, 6, 7, 
10, 11, 27, 
32, 40, 42, 
44, 54, 55, 
57, 61, 62, 
72, 73, 91, 
CP8304/81, 
MM7/83, 
MM8/84, 
30, 34, 67 
and 
MM4/82. 
 
HPV 
GenoArray 
Test Kit 
DNA 
Microarray
DNA HPVs6, 11, 
16, 18, 31, 
33, 35, 39, 
42-45, 51-
53, 56, 58, 
59, 66, 68 
and 81.
 
GeneTrack 
HPV DNA 
Chip 
DNA 
Microarray
DNA HPVs6, 11, 
16, 18, 31, 
33, 35, 39, 
40, 42-45, 
51, 52, 54, 
56, 58, 59, 
62 and 66-
72. 
 
Clart HPV2 DNA 
Microarray
DNA - HPVs6, 11, 
16, 18, 26, 
96,9% 71,9% 
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Test name Test 
principle 
Nucleic 
acid target
Types Performance 
   Detected Genotyped Sensitivity Specificity 
31, 33, 35, 
39, 40, 42, 
43, 44, 45, 
51, 52, 53, 
54, 56, 58, 
59, 61, 62, 
66, 68, 70, 
71, 72, 73, 
81, 82, 83, 
84, 85 and 
89. 
Multiplex 
HPV 
genotyping 
kit v1.0 
Suspension 
array 
DNA - HPVs6, 11, 
16, 18, 26, 
31, 33, 35, 
39, 42-45, 
51-53, 56, 
58, 59, 66, 
68, 70, 73 
and 82. 
  
digene 
HPV 
genotyping 
LQ Test  
Suspension 
array 
DNA - HPVs16, 
18, 26, 31, 
33, 35, 39, 
45, 51-53, 
56, 58, 59, 
66, 68, 73 
and 82. 
  
INNO-
LiPA v2 
Reverse 
line-blot 
DNA - HPVs6, 11, 
16, 18, 26, 
31, 33, 35, 
39, 40, 43, 
44, 45, 51, 
52, 53, 54, 
56, 58, 59, 
66, 68, 
69/71, 70, 
73, 74 and 
82.  
  
Linear 
Array HPV 
Reverse 
line-blot 
DNA - HPVs6, 11, 
16, 18, 26, 
31, 33, 35, 
39, 40, 42, 
44, 45, 51, 
98,2% 32,8% 
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Test name Test 
principle 
Nucleic 
acid target
Types Performance 
   Detected Genotyped Sensitivity Specificity 
52, 53, 54, 
56, 58, 59, 
61, 62, 64, 
66, 67, 68, 
69, 70, 71, 
72, 73, 81, 
82, 83, 84 
and 89. 
Digene 
HPV 
Genotypin
g 
Reverse 
line-blot 
DNA - HPVs16, 
18, 26, 31, 
33, 35, 39, 
45, 51, 52, 
53, 56, 58, 
59, 66, 68, 
73 and 82. 
  
EasyChip 
HPB Blot 
Reverse 
line-blot 
DNA - HPVs6, 11, 
16, 18, 26, 
31, 32, 33, 
35, 37, 39, 
42, 43, 44, 
45, 51, 52, 
53, 54, 55, 
56, 58, 59, 
61, 62, 66, 
67, 68, 69, 
70, 72, 74, 
82, CP8061, 
CP8304, 
L1AE5, 
MM4, 
MM7 and 
MM8.  
90,0% 99,2% 
INFORM 
HPV III 
In situ
hybridizati
on 
DNA HPVs16, 18, 31, 
33, 35, 39, 45, 51, 
52, 56, 58 and 66.
- ~50%  
GenPoint 
HPV 
Biotinylate
d DNA 
In situ
hybridizati
on 
DNA HPVs16, 18, 31, 
33, 35, 39, 45, 51, 
52, 56, 58, 59 and 
68. 
- - 100% 
 
 
Table 2. Most important commercially available assays for HPV detection and/or 
genotyping. 
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8. Southern blot hybridization assays 
Southern blot hybridization was the first assay used to detect integrated HPV (Cooper et al., 
1991) and is generally used to classify new viral types (Lorincz, 1996). In Southern blot 
hybridization, the genome is extracted and the DNA chain is broken using restriction 
enzymes. The products are integrated into a gel and separated by electrophoresis. The 
fragments are denatured in situ, transferred to a nitrocellulose membrane, and hybridized 
with cloned HPV genomic probes. The probes are then labelled, often using radioisotopes. 
The detection of the labelled DNA hybrids is visualized by autoradiography. The sensitivity 
and the specificity of the assay are high, ranging between 70% and 80% the first and 90% the 
second (Caussy et al., 1988).There are no commercial kits available; the method is entirely 
laboratory-based, with existing reagents and methodologies. Despite high sensibility, 
specificity and application to cells and biopsies, Southern Blot is not suitable for routine 
application: it is time consuming, labourious, expensive and requires large amount of 
purifying DNA and radio labeled probes.  
9. Immunological techniques  
9.1 Enzyme-linked immunosorbent (ELISA) assays 
ELISA, also known as an enzyme immunoassay (EIA), is a technique used to detect the 
presence of antigens or antibodies in wide variety biological samples. The basic steps of this 
technique are the immobilization of the antigen and its detection by a labeled antibody. The 
immobilization can be accomplished by direct adsorption to the assay plate or indirectly via 
a capture antibody that has been already attached to the solid phase. The detection can be 
performed either directly by a labeled primary antibody or indirectly by a labeled secondary 
antibody. The labeled antibody reacts with a colourless substrate to produce a coloured 
product. The most widely used ELISA methods for detecting antigens is the Sandwich 
system (Figure 8) (Baker et al., 2009) . In this format, the antigen is sandwiched between two 
similar or different antibodies: a capture antibody, already bond to the solid phase, and an 
enzyme-conjugated secondary antibody.The enzyme reacted with the substrate producing a 
colour reaction which can be observed visually or measured with a spectrophotometer. The 
enzyme activity is directly proportional with the amount of the test antigen. Sandwich 
ELISA is especially used when the concentration of antigens is low or in presence of 
contaminating protein, as its sensitivity is 2-5 times more than other Elisa assays (Baker et 
al., 2009). The assay is very specific and simple (Biosupply, 2010, Chung et al., 2010) and 
there is no need to purify the antigen prior to use. On the other hand, only monoclonal 
antibodies can be used as matched pairs. They detect different epitopes on the antigen 
without impeding each other’s binding (Biosupply, 2010). 
To detect specific antibodies, the most widely used ELISA systems are the “indirect” and 
“competitive” systems (Figure 8). In the indirect system the antigen is directly adsorbed 
onto a solid phase and the primary and the conjugate antibodies are added to the plate 
successively. The intensity of the colour development between substrate-conjugate enzyme 
indicates the amount of antigen present. In the indirect ELISA there are many binding sites 
for the antibody, consequently more enzyme can be detected. A large variety of enzyme-
linked secondary antibodies are commercially available. The method is sensitive and 
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versatile.  The same enzyme-linked secondary antibody can detect many primary antibodies 
in one species. A non-specific signal might occur if cross-reactivity happens with the 
secondary antibody and an extra incubation step is required in the procedure. 
“Competitive” system is useful for identification and quantification of either antigen or 
antibody. The antigen is first incubated in presence of the unlabeled antibody, forming 
antigen-antibody complex, and after add to an antigen-coated plate. The production of 
colour elicited by antibody-antigen-substrate complex will be inversely proportional to the 
amount of antigen in the sample. In competitive ELISA, the secondary antibody competes 
with the sample antigen which is associated with the primary antibody. The more antigen in 
the sample the less labelled antibody is retained in the plate and the weaker the signal.  It is 
possible to use impure samples (Biomaterials, 2007)(Biomaterials, 2007)(Biomaterials, 
2007)(Biomaterials, 2007) and the assay is precise, rapid, accurate, and reproducible (Zhou et 
al., 2002). The use of  monoclonal antibodies is not so adequate because they are more 
difficult to find and cost more. The sensitivity and specificity are lower than the sandwich 
assay (Chung et al., 2010).   
 
Fig. 8. Schematic representation of Sandwich and competitive ELISA. 
The ELISA methodology is widely used to detect HPV antigens (Gutierrez-Xicotencatl et al., 
2009). Several works are focused on antibodies against the viral HPV16L1 capsid protein 
and the viral HPV16E6 and HPV16E7 oncoproteins.  L1 is the major capsid protein and it 
represents 80%-90% of the total viral proteins(Favre et al., 1975). The most of the antibody-
mediated immune responses are directed against L1 antigen (Carter et al., 2000, Rocha-
Zavaleta et al., 2003). A high frequency of anti-16L1 antibodies was found in patients with 
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high-risk HPV-associated LSIL and with cervical cancer. While a low antibody response was 
found from women without evidence of HPV infection and with low-risk HPV-associated 
LSIL (Cason et al., 1992, Ghosh et al., 1993, Di Lonardo et al., 1994, Rocha-Zavaleta et al., 
2004, Leon et al., 2009). Furthermore, it is possible to discriminate between high-risk HPV 
and low-risk HPV types by using the epitopes of the L1 capsid protein. The viral oncogenes 
E6 and E7 are associated with cancer; they modify the cell cycle in order to favour the viral 
genome replication and consequent late gene expression (Munger and Howley, 2002).  Most 
HPV-positive cancer cells maintain the expression of E6 and E7 (Baker et al., 1987, Shirasawa 
et al., 1987).  A higher HPV16E6 and HPV16E7 seropositivity was observed in patients with 
cervical cancer compared to healthy or with subjects displaying  early lesions (Kanda et al., 
1992, Ghosh et al., 1993, Viscidi et al., 1993, Di Lonardo et al., 1994, Dillner et al., 1994, Fujii 
et al., 1995, Fisher et al., 1996). Hence, E6 and E7 oncoproteins might be used to monitor 
infected woman at the very late stage of the infection.  
Several studies were focused on biomarker identification for early stages of cervical cancer 
in order to perform an early diagnosis of woman at risk of infection. For this reason the 
detection of viral HPV16E2, HPV16E4, and HPV16E5 proteins were studied. The expression 
of the HPVE4 protein is linked to cellular differentiation status (Breitburd et al., 1987, Chow 
et al., 1987a, Chow et al., 1987b, Doorbar et al., 1989, Palefsky et al., 1991) playing important 
role in the viral life cycle (Doorbar et al., 1986, Jareborg and Burnett, 1991). HPVE2 is the 
first protein to be expressed. High E2 levels repress expression of the E6 and E7 
oncoproteins. When the HPV genome is integrated in its host, E2 function are disrupted, 
preventing repression of E6/E7 (Munger and Howley, 2002). In relation to the expression of 
HPV16E2 and HPV16E4 there are conflicting opinions. Some authors found elevated 
responses for E2 antigen in patients with cervical cancer. Others reported anti-E2 antibodies 
in normal subjects and in women with CIN lesions (Dillner, 1990, Dillner et al., 1994, Veress 
et al., 1994, Marais et al., 1997). A higher E4 seropositivity was observed in pre-cancerous 
and cancerous lesions as well as in healthy individuals (Jochmus-Kudielka et al., 1989, Crum 
et al., 1990, Kochel et al., 1991, Snyder et al., 1991, Kanda et al., 1992, Dillner et al., 1994, 
Muller et al., 1995), while other studies found a  frequency of E4 antibodies in cancer 
patients higher than in normal subjects (Suchankova et al., 1991, Ghosh et al., 1993, 
Gaarenstroom et al., 1994). Moreover, an expression of the E4 protein was observed in 
patients with high-risk and low-risk HPV-associated but not in patients with cervical cancer 
(Crum et al., 1990, Vazquez-Corzo et al., 2003).  HPV16E5 is a weakly oncogenic protein 
which potentiates the transforming activity of E7(Bouvard et al., 1994, Valle and Banks, 
1995), but its biological activity is mostly unknown. Chang et. al (Chang et al., 2001) studied 
the HPV-16 E5 protein and found its expression in the lower third of the epithelium in LSIL. 
ELISA assays are quick, convenient, and very accurate. The method can achieve high 
sensitivities and specificities, favorably comparable with other radioimmunoassay (Moore et 
al., 1999, Leng et al., 2008). It can be performed in a small laboratory and it has the 
advantage of automation and multiplexing (Leng et al., 2008, Adler et al., 2009). Moreover, 
ELISA assays need small volume of blood and do not use radioisotopes or a costly radiation 
system. It is suitable for large numbers of specimens. False positive results might happen if 
the blocking solution is ineffective and the enzyme/substrate reaction is short term and 
needs a rapid reading. It is a time-consuming methodology ( >1.5h), uses refrigerated 
 
Molecular Diagnosis of Human Papillomavirus 
 
235 
reagents and probe design is difficult, but many kits are available.Considering PCR as a 
reference, ELISA methods are less sensitive than PCR (81.8%, 53%, 72.2% vs. 100%) but more 
specific (100%, 99%, 92.2% vs. 78%) for invasive cervical cancer (Meschede et al., 1998, Lack 
et al., 2005, Zaghloul, 2011) . 
9.2 Detection of HPV antibodies - western blot 
Western blot (alternatively, protein immunoblot) is an analytical technique used to identify 
proteins based on their ability to bind a specific antibody. The analysis can detect the target 
from a mixture of a great number of proteins from tissue homogenate or extract. It uses gel 
electrophoresis to separate native or denatured proteins by the length of the polypeptide or 
by the 3-D structure of the protein (Towbin et al., 1979). The proteins are transferred to a 
membrane made of nitrocellulose or polyvinylidene difluoride (PVDF) to make the proteins 
accessible to antibody detection (Khan et al., 2005). The membrane is "probed" for the 
protein of interest with a modified antibody which is linked to a reporter enzyme. When the 
enzyme is exposed to an appropriate substrate drives a colorimetric reaction (Renart et al., 
1979).  
Several works based on Western Blot technique have studied the high correlation between 
the oncogene proteins and cervical cancer (Jochmus-Kudielka et al., 1989, Kochel et al., 1991, 
Suchankova et al., 1991, Fujii et al., 1995) and the possible role of the protein E4 in cancer 
disease (Jochmus-Kudielka et al., 1989, Ghosh et al., 1993, Pedroza-Saavedra et al., 2000, 
Middleton et al., 2003) but  the results were controversial. The sensitivity of the Western blot 
assay is 67%. The specificity increases to 78%(Pedroza-Saavedra et al., 2000). 
There are kits based on detection of antigens using horseradish peroxidase (HRP) 
conjugated antibodies and the chemiluminescent substrate luminol. Chemiluminescent 
system detects the protein target using the light produced by the catalysis of an enzyme 
substrate. It is rapid and allows accurate identification of samples. With this assay it is 
possible to detect the target protein from a mixture of antigens (Molijn et al., 2005); it is,  
nevertheless, expensive, demanding and complex and it is impossible to analyze a large 
number of samples simultaneously (Molijn et al., 2005). 
10. Conclusions 
There are two major purposes for the use of molecular HPV diagnosis. The first is to identify 
women at cervical cancer risk; these can be detected through community-based screening 
programs or through clinical counseling. In this scenario, the use of a highly sensitive assay 
will overestimate some HPV infections that would be cleared by the immune system in less 
than 24 months (Moscicki, 2007). If a less sensitive or even a quantitative assay is chosen, the 
efficacy in identifying women at risk of progression might be more effective. The other 
purpose includes vaccination trials, epidemiological and natural history studies (Molijn et 
al., 2005). In this case, contrarily to the clinical application, a highly sensitive and 
reproducible assay is required, and it should include the broadest spectrum of HPV types. 
The ideal HPV testing for both goals should be a single assay with adjustable cut-off for 
detection, linked to a genotyping method (Molijn et al., 2005). Unfortunately, such method 
does not exist and combined detection systems have to be used. The molecular assays are 
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the gold standard for HPV testing and there are specific characteristics that positively 
distinguish each method. For instance, the extremely high sensitivity and specificity of PCR 
assays and the need of only small amounts of DNA template, makes it the support of several 
other high-quality assays. Within the signal amplification assays, hc2 is considered the most 
reliable assay and is a CE-IVD test. On the other hand, Southern blot technique is more 
expensive, requires large amount of purifying DNA and it is difficult to apply in routine 
practice due to time consumption; in situ hybridization is not as sensitive as the PCR and 
hc2 methods. The sampling and HPV DNA detection assays bearing different sensitivity 
and specificity, as shown above, are the most accountable aspects for the heterogeneity of 
the results. To overcome such problems, a combined detection system, to detect the presence 
of the HPV, and an antibody profile against different viral antigens, to stage the infection, 
will improve the signaling of persistent infections and prevent cervical cancer. 
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1. Introduction  
Human papillomavirus (HPV) is a DNA virus which belongs to the newly named 
Papillomaviridae family (de Villiers et al., 2004). The papillomaviruses induce a variety of 
proliferative lesions in the skin and internal mucosa. Nearly half of the over 200 types of 
HPVs can infect the genital mucosa, producing benign epithelial lesions. However, a subset 
of these viruses is found in over 90% of malignant carcinomas of the genital tract, the 
majority of which contain the HPV16 and 18 types considered to be of "High Risk" (HR), as 
they help the progression into cervical cancer (Lorincz et al., 1992; Shah & Buscema, 1988). 
The mechanisms through which HPVs induce cell transformation have been intensively 
investigated in the last few years. The most abundant viral transcripts in tumor and tumor 
cell lines are produced from the E6 and E7 Open Reading Frames (ORFs) that are known to 
be oncogenic. These two genes from HPV are necessary and sufficient to induce HPV-
mediated transformation of murine cells (Yasumoto et al., 1986), transform human 
fibroblasts (Pirisi et al., 1987), and in cooperation with ras are capable of transforming baby 
rat kidney cells (Phelps et al., 1988) and primary human keratinocytes (Yoshida et al., 2008). 
The best evidence for the role of E6 and E7 proteins in malignancy comes from biochemical 
studies. E6 and E7 oncoproteins from the HR-HPV types have the ability to alter pathways 
involved in cell cycle control, interacting with and neutralizing the regulatory function of 
primarily two suppressor proteins, p53 and pRb respectively (Dyson et al., 1992; Werness et 
al., 1990). These effects produce genetic instability and accumulation of mutations that 
might contribute to the oncogenic process. Besides, several other target proteins for E6 and 
E7 oncoproteins have been identified and probably those interactions also promote cellular 
transformation. The latest oncogene identified from HPV was the E5 from HPV16. The E5 
oncoprotein showed to be capable of increasing the half-life of Epidermal Growth Factor 
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(EGF) and Platelet-Derived Growth Factor (PDGF) receptors (Leechanachai et al., 1992). 
Contrary to E6 and E7, the E5 oncogene is lost in the late stages of cervical cancer due to 
viral integration to the cellular genome. However, the close association with growth factor 
receptors could suggest that E5 has a key role in viral life cycle and may have an important 
function in the early development of the neoplasia. 
The oncogenes mentioned above codify for oncoproteins that have developed a plethora of 
strategies resulting in the alteration of cell cycle and apoptosis control by targeting the same 
or different cellular pathways, favoring viral persistence and leading to a strong synergism 
in promoting cellular transformation. Several studies have been performed to elucidate the 
mechanisms through which these HPV oncogenes allow the cellular transformation and the 
generation of the cervical cancer. Recently, the development of genomic and proteomic 
techniques has promoted the research of cervical cancer progression due to HPV infection, 
allowing the identification of protein interaction networks and the discovery of biomarkers 
useful for diagnostic and therapeutic systems. 
2. Organization and classification of human papillomaviruses 
HPV is a non enveloped DNA virus with icosahedral capsid that surrounds one copy of 
circular double stranded DNA close to 8 kb long. HPV genome codes for eight proteins 
classified as early (E) and late (L) proteins expressed from polycistronic mRNA by a positive 
DNA strand. Between E and L coding sequences is a Long Control Region (LCR) that has 
low conservation among members of the Papillomaviridae family. This region promotes and 
enhances the viral gene expression and it does not include ORFs (de Villiers et al., 2004; 
Syrjänen & Syrjänen, 1999). The HPVs maintain high fidelity of their genome as they use the 
host cell proofreading polymerases, generating mutations at similar rates as the host DNA 
genome. HPVs involve different genotypes, defined as a complete cloned genome whose L1 
ORF most conserved segment has a DNA sequence at least 10% different from any other 
HPV type (Bernard, 2005; de Villiers et al., 2004; Myers et al., 1996). HPV subtypes may be 
found (differences between 2-10% of homology) like HPV55 that is a subtype of HPV44. The 
HPV variants are defined as those that show differences of less than 2% of homology in 
nucleotide sequence in the coding regions and 5% in the non-coding regions from the 
original isolate (prototype) (Bernard et al., 1994; Bernard, 2005; de Villiers et al., 2004). Now 
at days, more than 200 suggested types have been detected and 100 types have been 
completely sequenced, all of them registered at the German Cancer Research Center in 
Heidelberg, Germany (Bernard, 2005; de Villiers et al., 2004). 
All HPV types are epitheliotropic and may be found in mucous tissue and/or in skin (de 
Villiers, 1989; Myers et al., 1996). Recently, the new taxonomy of papillomaviruses grouped 
them in 16 higher-order cluster groups (super-groups or major branches) named genus 
which share from 23 to 43% of identity. The genera are identified by Greek letters (alpha to 
pi) and divided in lower-order clusters named species that share 60-70% of identity within a 
genus and 71-89% within a species (de Villiers et al., 2004). Species are identified by 
numbers and group HPV types with common phylogenetical, biological and pathological 
properties (Bernard, 2005; de Villiers et al., 2004). HPVs are classified into five genera (alpha, 
beta, gamma, mu and nu) (Bernard et al., 2010). The alpha-papillomavirus genus contains all 
the clinically important HPVs associated with mucosal and genital lesions. While, the beta-
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papillomavirus genus includes all cutaneous HPV types involved in Epidermodysplasia 
verruciformis or skin cancer in immunosupressed subjects, the gamma-papillomavirus genus 
includes cutaneous HPV types distinguished by intracytoplasmic inclusion bodies in 
histological tests (Bernard, 2005; de Villiers, 1989; de Villiers et al., 2004). 
There are a limited number of variants for each HPV type, some of which are highly 
divergent, especially those taken from ethnic groups that evolved without geographical 
contact. Thus, it seems that each HPV type was not transferred from other species, has been 
with the human race since its origins, evolved together and spread as human ethnic groups 
arose and populated the world (Bernard, 2005). The HPV16 variants can be divided into six 
geographically clustered phylogenetic groups, the European (E), African 1 and 2 (Af1 and 
Af2, respectively), Asian (As), Asian-American (AA) and North American (NA) (Yamada et 
al., 1997). Clinically speaking, there is an interesting concern on the biological activity of 
HPV variants because some of them are more frequently detected (94%) in high-grade 
cervical lesions than the HPV16 prototype (6%) (Zehbe et al., 1998) and being associated to 
the development of cervical lesions grade 2-3 (Xi et al., 2002). However, more 
epidemiological and laboratory studies need to be performed to confirm these observations. 
Bravo and Alonso suggested an alternative classification system based on the nucleotide 
sequence of the E1 and E2 ORFs. Also, they proposed that concatenated E1-E2 proteins 
sequences can be incorporated as a suitable evolutionary standard for Papillomaviridae 
classification (Bravo & Alonso, 2007). Due to the increasing number of new sequences of 
Papillomaviruses (PVs), Bernard and coworkers proposed the expansion of the family 
Papillomaviridae. To accomplish this, the names of genera were extended to the end of the 
Greek alphabet (from Alphapapillomavirus to Omegapapillomavirus), followed by the prefix 
“Dyo” (i.e., “a second time”), omitting the designation from Dyoalphapapillomavirus to 
Dyogammapapillomavirus because the Alpha, Beta and Gamma genera include the most 
common and medically important HPVs. Also, they named the rest of PVs genera waiting 
for classification as Rho to Omega, assigning the terms “Dyodelta-PVs”, “Dyoepsilon-PVs” and 
so on, for the new PV genus (Bernard et al., 2010). 
Phylogenetical analysis of the E5, E6 and E7 gene sequences have revealed that only E6 and 
E7 genes from the alpha genus are highly conserved (>75% and >65% homology, 
respectively). However, when only the HR-HPV types of the alpha genus are considered the 
homologies go up to 80% for E6 and up to 70% for E7 sequences. The less conserved viral 
sequences from the alpha genus are those from the E5 gene, since the homology in this 
genus is only of 25% and 40% when only the HR-HPV types are considered. Few years ago, 
Bravo and Alonso (2004) described the evolutionary characteristics of the E5 proteins and 
compared them with the E6 and E7 oncogenic proteins and with the structural proteins L1 
and L2. They showed that there is a clear pattern of divergence from late to early genes at 
the protein level, which increased in the progression L1 < L2 < E6 ≈ E7 < E5. Among the E5 
proteins from the alpha genus it was clear that there was not an evident sequence similarity 
and that the evolutionary divergence between present proteins rises to 80% (Bravo & 
Alonso, 2004). The few common characteristics for the alpha genus E5 proteins are the high 
hydrophobicity, the high Ile+Leu+Val content and the presence of transmembranal regions. 
Taking into consideration these characteristics of the E5 protein, Bravo and Alonso (2004) 
identified 4 groups of E5 proteins in the alpha genus (E5α, E5β, E5γ and E5δ) and proposed 
that besides of the phylogenetic characteristics, the chemical part of the proteins have to be 
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taken into consideration to have a more specific classification, as it has been suggested that 
the protein chemistry is an important restriction for protein evolution (Babbit & Gerlt, 1997).  
On the other hand, Wang and coworkers (2010) showed that the Canine Papillomavirus 
type 2 (CPV2) encodes an E7 protein that has Ser substituted for Cys at the LXCXE motif, 
important in the E7 proteins from the alpha genus, to bind and degrade the pRb protein. 
This mutation in the CVP2 E7 protein abrogates pRb binding at this site; however a new 
domain with a binding site for pRb was identified at the C-terminal region of canine E7, and 
was able to degrade the pRb protein. At the same time, these researchers demonstrated that 
the HPV4 E7 protein also binds pRb in a similar way as CPV2 E7 protein and by screening 
of HPV genome sequences identified that the LXSXE motif of the CPV2 E7 protein was also 
present in the gamma HPV genus (Wang et al., 2010).  
Altogether these data show that phylogenetic sequence analysis is important to trace the 
papillomaviruses evolution and define ancestors, but also showed that when chemical and 
biological characteristics of the oncogenic HPV proteins are integrated into the analysis, 
there is a better classification of HPVs within the genus, as subgroups were identified. 
However, more work needs to be done before this type of integrative analysis can be used to 
give some light between clinical manifestations and the development of cancer associated to 
HPV. 
3. Viral cycle and HPV integration into the genome of host cell 
During HPV infection, the different viral proteins are expressed sequentially (Middleton et 
al., 2003; Peh et al., 2002). The HPV infection starts in the basal cell layer of the cervix since 
these cells express the specific receptors for viral entry and also because are the only cells in 
the squamous epithelium capable of dividing. Molecules like heparan sulfate and 
glycosaminoglycans seem to mediate the attachment of the virions via interaction of the 
major capsid protein, L1, to the basal membrane of human keratinocytes. The internalization 
of some HPV types is a slow process mediated by clathrin-coated vesicles, or the caveolae-
dependent route (Bousarghin et al., 2003; Horvath et al., 2010). Once the virus has 
penetrated the cell, disassembly of HPV particles occurs in cytoplasmic vesicles, followed by 
the delivery of the viral DNA into the nucleus mediated by L2 (Day et al., 2004). After 
infection, HPV genomes are established as autonomous replicating extra-chromosomal 
elements or episomes and start a low expression level of the E6 and E7 genes (Middleton et 
al., 2003; Moody & Laimins, 2010). The E6 and E7 gene expression is achieved by cellular 
transcription factors that interact with the LCR, a region where the E2 protein interacts to 
repress or to activate viral transcription. The promoter region from HPVs contains TATA 
boxes for binding cellular transcriptional factors like TFIID and an epithelial cell-specific 
enhancer, which holds binding sites for transcription factors like Sp-1 and AP-1, among 
others (Butz & Hoppe-Seyler, 1993; Doorbar, 2005; Middleton et al., 2003; Tan et al., 1994). 
The expression of E6 leads mainly to the ubiquitin-dependent proteolysis of p53 (Farthing & 
Vousden, 1994; Münger et al., 1992; Rapp & Chen, 1998), preventing cell growth inhibition 
in both undifferentiated and differentiated cells (Moody & Laimins, 2010) and the E7 
expression to the liberation of the transcription factor E2F by sequestration of pRb (Münger 
et al., 1992), effects that promote cellular proliferation and genome instability throughout 
the infected tissue. 
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While the basal HPV infected cell migrates to upper layers and differentiates, the viral cycle 
continues with the E1, E2, E4 and E5 protein expression and viral DNA replication (Doorbar, 
2005; Longworth & Laimins, 2004; Middleton et al., 2003; Peh et al., 2002). First, the E1 
protein hexamerizes to recruit the cellular DNA polymerase and replication accessory 
proteins, while it displaces Histone H1 and functions as a helicase/ATPase to start the viral 
genome replication (Hughes & Romanos, 1993; Lambert, 1991; Swindle & Engler, 1998). It 
has been observed that the E1 and E2 expression is auto-regulated and activated by 
replication. The E2 protein modulates E1 expression and E6 splicing differentially regulates 
E1 and E2 expression (Hubert & Laimins, 2002). Once the viral replication has finished, E2 
levels raise and repress the E6 and E7 expression by binding to the HPV early promoter as a 
dimmer and promoting the liberation of cellular transcriptional activator factors (Tan et al., 
1994).  
On the other hand, the E4 protein is translated from a spliced E1^E4 transcript to form a 
fusion protein that contains the first 5 amino acids (aa) from the E1 protein and the E4 ORF. 
In warts, E4 exists as multiple species that are formed from a combination of progressive 
proteolysis of the N-terminal residues, oligomerization, and phosphorylation. The species 
resulting from proteolysis are the 17 kDa species in the parabasal cell layer of epithelium 
and this is coincident with viral genome amplification. The E4 16, 11 and 10 kDa species are 
accumulated in superficial keratinocytes, where capsid proteins expression and assembly 
occurs (Doorbar et al., 1988; Middleton et al., 2003). It is known that E4 binds to zinc, 
cytoskeleton and cytokeratins (Roberts et al., 1994; Wang et al., 2004). Therefore, it is 
suggested that E4 may alter the normal keratinization process to benefit the viral cycle 
progress and generate a cytoskeleton collapse (Gaillard et al., 1992) inducing apoptosis 
through alteration of mitochondrial function (Raj et al., 2004) and favoring the viral particle 
liberation (Gaillard et al., 1992). However, in natural infections only a limited amount of 
keratin collapse has been observed (Doorbar et al., 1996). The E4 protein sequesters the 
CDK1/Cyc B1 complex (CDK, Cyclin dependent kinase and Cyc, Cyclin) onto the 
cytokeratin network, preventing their nuclear accumulation and therefore inducing 
inhibition of the G2/M transition of the cell cycle (Davy et al., 2002; Nakahara et al., 2002) 
and allowing viral and genomic DNA replication. The HPV16 E4 coding region possesses a 
splicing enhancer element required for the early viral mRNA splicing (Rush et al., 2005), 
especially for the expression of late viral transcripts of E1^E2, E1, E4 and E5, thus regulating 
the viral DNA amplification (Wilson et al., 2005). 
Other protein suggested to be expressed at the same time as E4 is E5, both of which may 
contribute to viral genome amplification (Doorbar, 2006; Syrjänen & Syrjänen, 1999). A 
polycistronic mRNA containing the E5 sequence is the most abundant transcript in HPV 
positive cervical carcinomas in situ (Stoler et al., 1992). E5 transcripts expression is very low 
in undifferentiated cells (Reagan & Laimins, 2008). The E5 mRNA and protein are mainly 
present in the lower third of the epithelium of Low Grade Squamous Intraepithelial Lesions 
(LSILs), and might contribute to neoplastic proliferation during the early stages of infection 
(Chang et al., 2001; Stoler et al., 1992), or to be essential for malignant transformation 
(Stoppler et al., 1996). The gene encoding the viral E5 protein is frequently disrupted or lost 
when viral DNA is integrated into human genome (Pater & Pater, 1985). Even though, E5 
protein expression pattern in cervical epithelia has not been accomplished yet, it has been 
observed that E5 function is needed to maintain the cell proliferation stimuli driven by the 
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EGF Receptor (EGFR) signaling pathway at this stage (Syrjänen & Syrjänen, 1999). In this 
way, the E5 function complements the E7 and E6 functions, to generate and maintain the 
transformed phenotype (Stöppler et al., 1996). 
A special characteristic of the viral cycle is that the last stages take place in terminally 
differentiated keratinocytes (Schiller et al., 2010). In this stage, viral particles are generated 
when the expression of capsid proteins (L1 and L2) starts by a promoter localized in the late 
region of the HPV genome. The L1 and L2 proteins polymerize into icosahedral capsids in a 
thermodynamic stable and spontaneous process that involves the binding of the HPV DNA to 
the N-terminal sequence of the L2 protein (Hagensee et al., 1993; Zhou et al., 1994). During 
their formation, HPV capsids require maturation (formation of intermolecular disulfide bonds 
in L1), event that leads to stability and virions liberation in the external surface of the 
squamous epithelium by cellular death (Buck et al., 2005; Syrjänen & Syrjänen, 1999). Up to 
now, it is still unknown if encapsidation of the viral genome takes place during or after capsid 
assembly (Conway & Meyers, 2009; Holmgren et al., 2005), but it has been suggested that L2 
uses E2 to recruit the viral genome to the site of virion assembly (Holmgren et al., 2005). 
During HPV productive infections that lead to cervical lesions, the viral genome is episomal 
with a great copy number that depends on differentiated cells. Throughout the HPV 
persistent infection, there is a gradual deregulation in the expression of E6 and E7 proteins 
that may lead to the development of low-grade cervical lesions, where one third of the 
epithelium is formed by E6/E7 expressing basal cells. The progression from High Grade 
Squamous Intraepithelial Lesions (HSILs) to cancer usually occurs in lesions that contain 
integrated copies of the viral genome. This event leads to an abortive infection (Farthing & 
Vousden, 1994; Münger et al., 2004; Peitsaro et al., 2002) and cells cannot longer produce 
new viral particles (Matlashewski, 2006). It has been observed that the viral integration 
occurs mainly between E1-E2 ORFs, event that produces the loss of E2 and E4 genes 
expression. Thus, the loss of E2 and E4 genes generates a down-replication of the viral 
genome, G2 arrest, and E6 and E7 over-expression (Jeon & Lambert, 1995; Wilson et al., 
2005). Thus, the integration of the HPV DNA in the host genome represents an important 
event in cervical carcinogenesis (Pett & Coleman, 2007), as this may cause cellular 
immortalization (Band et al., 1990; Jeon & Lambert, 1995; Münger et al., 1992; zur Hausen, 
2000), reduction of cellular differentiation, cellular dysplasia and TNF-α non-responder cells 
(TNF, Tumor Necrosis Factor) (Syrjänen & Syrjänen, 1999; zur Hausen, 2000).  
Besides increasing the transcript stability and protein expression of the viral E6 and E7 
oncoproteins, integration of the viral genome may cause chromosomal rearrangements (Jeon & 
Lambert, 1995) and influences cancer progression through interaction with hTERT, p53 and 
pRB (Raibould et al., 2011). The integration of HPV sequences in the host genome occurs 
randomly, although in invasive genital carcinomas or cervical cancer-derived cell lines, HPV 
genome has been found frequently integrated near fragile sites, like translocation breakpoints 
(Koopman et al., 1999; Mammas et al., 2008), or modifying proto-oncogenes sequences either 
by rearrangement or amplification as has been observed for myc genes (Ocadiz et al., 1987; 
Sastre-Garau et al., 2000). Disruption or deregulation of defined critical cellular gene functions 
by insertional mutagenesis of HPV genome fragments has been hypothesized as the major 
promoting factor in the pathogenesis of HPV-associated cancers (Wentzensen et al., 2004). 
Further investigation on early integration events needs to be done to describe the mechanism 
by which viral infection is aborted and cell transformation is generated. 
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4. Role and function of HPV oncoproteins 
4.1 E5 oncoprotein 
4.1.1 E5 biochemical properties 
The E5 oncoproteins are small highly hydrophobic proteins important in the carcinogenic 
process and recently have been identified as potential oncogenes, although their role is not 
well understood (Bouvard et al., 1994). The E5 proteins from both animal and human 
sources can transform mammalian cells with different degrees of efficiency (Bouvard et al., 
1994; Horwitz et al., 1989; Straight et al., 1993). Both BPV-1 (bovine papillomavirus) and 
HPV E5 proteins are transmembrane proteins localized in Golgi and endosomes, but they 
have also been found in plasmatic membrane and endoplasmic reticulum (ER) (Cartin & 
Alonso, 2003; Conrad et al., 1993; Disbrow et al., 2005; Lewis et al., 2008). The E5 
oncoprotein from HPV16 has 83 aa residues with an estimated molecular weight of 10 kDa. 
The E5 protein presents three transmembranal helices and short hydrophilic regions at the 
C- and N-terminus (Alonso & Reed, 2002; Ullman et al., 1994; Yang et al., 2003), being the 
first hydrophobic region important for cellular localization of E5 (Fig. 1) (Cortese et al., 2010; 
Lewis et al., 2008). In HaCat cells (immortalized human keratinocytes) this region confers 
anchorage-independent growth and is associated with the capacity of these cells to invade 
extracellular matrix in organotypic “raft” assays (Barbaresi et al., 2010; Lewis et al., 2008).  
It has been demonstrated that E5 proteins contribute to cellular transformation by  
increasing the mitogenic signal from growth factor receptors to the nucleus (Leechanachai et 
al., 1992).  
4.1.2 E5 functional properties 
A proposed mechanism for E5 transforming activity is through increasing the half-life of the 
tyrosine kinase-containing growth factor receptors like EGFR, the phosphorylation state of 
this receptor or both (Genther-Williams et al., 2005; Straight et al., 1993, 1995; Tomakidi et 
al., 2000). It has been also proposed that HPV E5 proteins interact with the 16 kDa subunit of 
the protonic ATPase, inhibiting the acidification of endosomes and retarding the receptor 
degradation (Andresson et al., 1995; Briggs et al., 2001; Conrad et al., 1993; Straight et al., 
1995). At the same time, E5 induces a number of functional effects like causing alkalinization 
of endocellular pH, tyrosinase activation, melanin deposition and modulation of sensitivity 
to dopamine mimetic drugs as it has been shown in melanocytes that express E5 from 
HPV16 (Di Domenico et al., 2009). The second and third transmembranal domains cooperate 
to bind the protonic ATPase-16 kDa subunit (Adam et al., 2000; Rodriguez et al., 2000). 
However, some contradictory studies indicate that E5 proteins bind, but do not disturb the 
activity of the vacuolar protonic ATPase (Adam et al., 2000; Ashby et al., 2001; Rodriguez et 
al., 2000), and it has been shown that the final effect is due to a perturbation of the endocytic 
trafficking (S.L. Chen et al., 1996c). In contrast, it has been demonstrated that HPV16 E5 
stimulates the EGFR-mediated signal transduction by inhibiting the interaction with c-Cbl 
and decreasing the receptor degradation pathway (B. Zhang et al., 2005a) (Fig. 2). Recently, 
it was shown that HPV16 E5 down-modulates the KGFR/FGFR2b (keratinocyte growth 
factor receptor) by interference of the endocytic receptor pathway and perturbing the 
differentiation process (Belleudi et al., 2011). 
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Fig. 1. Biochemical characteristics of the HPV16 E5 oncoprotein. (A) The E5 protein with 83 
amino acid residues has an estimated molecular weight of 10 kDa. (B) E5 is divided in three 
hydrophobic regions as estimated by the Kyte-Doolittle Hydropathy Plot.  (C) The first 
region (aa 1-30) is important for membrane localization and for anchorage-independent 
growth. The second (aa 41-54) and third (aa 54-78) hydrophobic regions contain the domains 
for binding to the protonic ATPase-16 kDa subunit. 
The expression of E5 protein has been associated with the expression of other members of 
the EGFR family (i.e. ErbB1, ErbB4) as well as the activity of ErbB2 (Crusius et al., 1998) and 
components of the EGF signaling pathway, like MAPKs (ERK1/2) (Crusius et al., 1997; S.H. 
Kim et al., 2006). The activation of members of the MAPK pathway may lead to regulation 
of other set of genes implicated in growth, as was observed that HPV16 E5 favors the over-
expression of transcriptional factors such as c-Fos and c-Jun that form the AP-1 complex 
(S.L. Chen et al., 1995, 1996a, 1996b), and stimulates transcription of genes involved in cell 
growth. During the cell cycle the E5 proteins from HPV11 and 16 have shown to be able to 
modulate cell proliferation, due to repression of p21Waf1 gene expression through c-jun 
activation (Tsao et al., 1996). In addition, our laboratory has identified that HPV16 E5 
increases the down-regulation of p27Kip1 CDK inhibitor in an EGFR dependent pathway, 
allowing the cells to stay for longer time into the cell cycle due to an increment in the S-
phase (Pedroza-Saavedra et al., 2010) (Fig. 2). Also, HPV16 E5 is able to activate other type 
of transcriptional factors like NF-κB and leading to COX-2 expression (S.H. Kim et al., 2009) 
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(Fig. 2). More recently, it has been suggested that HPV16 E5 protein can act independently 
of the EGFR through the PLCγ1 (Crusius et al., 1999) and on MAPKs (ERK1/2 and p38) 
activities, when the cells are placed under stress conditions (Crusius et al., 2000). On the 
other hand, E5 is also able to induce the expression of other type of receptors like the EP4 
subtype of prostaglandin E2 receptor, which increases the colony-forming efficiency and the 
Vascular Endothelial Growth Factor (VEGF) secretion in cervical cancer cells, both of which 
are required for tumor growth, angiogenesis and metastasis (Oh et al., 2009). 
 
Fig. 2. Important functions of HPV16 E5 in the cell. E5 can modify the half-life of the EGFR 
through binding with the protonic ATPase-16 kDa subunit, avoiding acidification of 
endosomes and favoring the recycling of receptors and perturbing the endocytic trafficking. 
E5 targets molecular components of the MAPKs cascade that have incidence on the 
progression of the cell cycle. E5 decreases the level of the CDK inhibitor p21Waf1 and 
modulates p27Kip1 protein levels allowing deregulation of the cell cycle, by increasing the S-
phase of the cell cycle and promoting cellular transformation. 
Other important activity observed for E5 proteins is the ability to keep the major 
histocompatibility complex (MHC) class I in Golgi, preventing its transport to the cell 
surface. In the case of HPV16 E5, this blockage is rescued by treatment with interferon. 
Unlike BPV E5, HPV16 E5 does not affect the synthesis of HLA class I heavy chains, but 
rather interferes with the transporter associated with antigen processing (TAP). The absence 
of cell surface HLA class I molecules in E5 expressing cells may allow the HPV to establish 
an infection by avoiding immune clearance of virus-infected cells by CTLs (Araibi et al., 
2004; Ashrafi et al., 2005; Marchetti  et al., 2002, 2006). In this context, Gill and coworkers 
(1998) observed that women with increasingly severe HPV16-associated lesions have 
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decreasing T cell HPV16 E5-specific proliferative responses. At the same time, HPV16 E5 
impairs TRAIL- and FasL-mediated apoptosis in HaCat cells possibly as a mechanism to 
escape immune surveillance that otherwise would be likely to detect infected cells at an 
early stage in the viral life cycle (Kabsch et al., 2004). 
Finally, the close association of E5 with growth factors and their receptors, and the fact that 
the E5 ORF is lost in cervical carcinoma cells, suggest that E5 may play a critical role in the 
genesis of cervical cancer as an initiator of the transformation process, as it has been shown 
to happen with the Ras oncoprotein in colorectal cancer (Gryfe et al., 1997; Takami et al., 
1995). Additionally, these findings support the idea that the E5 protein could be an early 
predictor marker of cervical cancer (Gill et al., 1998; Hsieh et al., 2000; Kell et al., 1994). 
4.2 E6 oncoprotein 
4.2.1 E6 biochemical properties 
E6 proteins from HPVs comprise molecules between 151 and 158 amino acids that are 
usually localized within the cell nucleus (Nomine et al., 2006; Rapp & Chen, 1998). It has 
been difficult to study E6 proteins because they are expressed at very low levels in HPV 
infected cells and are difficult to purify in a stable folded form as they tend to aggregate in 
complexes of misfolded molecules when over-expressed in bacteria (Nominé et al., 2001; 
Ristriani et al., 2002).  
In general, the E6 proteins contain two Cys-Xaa2-Cys-Xaa29-30-Cys-Xaa2-Cys zinc binding 
domains located at the N- and C-terminal parts of the molecule. These domains are novel 
types of zinc-binding structures characterized by αβαβ secondary structures separated by 29 
to 30 residues (Ullman et al., 1996). The E6 C-terminal domain is a DNA binding site that 
consists of 3-stranded β-sheet (S1, S2 and S3) with two short helices (H1 and H2) packed on 
one of its sides, a peripheric zinc binding site that protrudes away from the β sheet and that 
involves the long loop (L2) connecting H1 and H2 with a short C-terminal helix (H3). E6 has 
a main hydrophobic core (conserved among HPVs) between the β-sheet and helices H1 and 
H2, that it is not exposed to water in the full-length E6 protein. This part of the E6 protein 
has a mostly positive charge potential, except for a neutral area at the top of H1 and H2 
corresponding to the hydrophobic patch. Conserved amino acids are on the surface of the 
N- and C-terminal zinc binding motifs of E6 protein in all HPV species. Some may 
participate in generic functions shared by all HPVs E6 proteins like trans-activation, 
transformation, and protein-protein interactions, while others may have a structural role. In 
this sense, it seems that specific amino acids located at the hydrophilic sites in high- and 
low-risk HPVs, allow certain physicochemical characteristics which confer them the ability 
to recognize different subsets of cellular molecules. An example is the C-terminal region 
from HPV16 E6, which displays a strong positive charge at the nucleic acid binding site and 
the highest surface potential (Nominé et al., 2006).  
The HPV16 E6 full-length protein is composed of 151 amino acids (Rapp & Chen, 1998), 
with a calculated molecular weight of 18 kDa and with a bimodal half-life in SiHa cells of 30 
min and 4 h that seem to be related to E6 interactions with target proteins (Androphy et al., 
1987). HPV16 E6 protein C-terminal region has an IEP of 10.6 (IEP, Isoelectric Point) and it is 
the part of the molecule necessary for binding to p53, while the N-terminal region contains 
the binding site for E6AP (LxxφLsh motif) important for p53 degradation (Howie et al., 2009; 
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Thomas et al., 1999). These LxxφLsh motifs (where xx is a dipeptide and one of the residues 
is Asp, Glu, Asn or Gln; φ is a hydrophobic residue; s is a small amino acid; h is an amino 
acid capable of accepting hydrogen bonds) are Leucine-rich amphipathic helices and 
binding through these motifs is a conserved property of the E6 proteins from HPVs from the 
alpha genus. In this sense, the minimal segment still functional for p53 degradation 
comprises residues 1-142 and coordinates with two Zn+2 ions (Beerheide et al., 1999; Lipari 
et al., 2001) by means of conserved cysteine residues 30, 33, 63 and 66 at the N-terminal and 
residues 103, 106, 136 and 139 at the C-terminal (Nominé et al., 2001), where the loss of the 
Zn+2 at the C-terminal domain leads to loss of tertiary structure and protein aggregation (Y. 
Liu et al., 2009). Other proteins like E6AP, E6BP, IRF3, Paxilin and MCM7 are also able to 
bind E6 through these LxxφLsh motifs, interaction that appears to regulate the activity of 
different subset of proteins (J.J. Chen et al., 1998; Elston et al., 1998; Tong & Howley, 1997).  
Besides, the E6 proteins from oncogenic HPV types have a motif designated XT/SXV at their 
C-terminal motifs that mediates binding to specific domains known as PDZ (Howie et al., 
2009). The PDZ domains are approximately 90 amino acid stretches. The PDZ proteins 
known to bind E6 are hDlg1 and 4, tumor suppressor proteins (Kiyono et al., 1997; S.S. Lee 
et al., 1997), MAGI-1, -2 and -3, Membrane Associated Guanylate kinase homolog proteins 
(Thomas et al., 2001), MUPP-1 a multi PDZ protein (S.S. Lee et al., 2000), hScrib (Nakagawa 
& Huibregtse 2000) and PTPN3, both tyrosine phosphatase proteins (Jing et al., 2007). These 
proteins bind to E6 by the PDZ domain (aa 141-151) (Pim et al., 2009; Storrs & Silverstein, 
2007; Y. Zhang et al., 2007), acting as an adaptor to link the ubiquitin ligase to the target for 
ubiquitination by means of its C-terminal region (Pim et al., 2009). Moreover, differences in 
binding PDZs by different HPV E6 proteins have been associated with the pathogenicity of 
HPV types as a single amino acid substitution in this binding motif among HR-HPV E6 
proteins has a profound effect upon its binding to PDZ bearing target proteins (Thomas et 
al., 2001).  
E6 protein may be found full length and C-terminally truncated (E6*) expressed from a subset 
of spliced transcripts, differing in number depending on the HPV type (HPV16 E6 presents 4 
species, while HPV18 E6 only one). The E6* protein of HPV18 has the first 44 amino acids of 
the full-length protein and thereafter is composed by 13 unique amino acids derived from E6 
intronic sequences. One of these sequences results in an E6* protein of 7 kDa able to bind to 
E6AP, but not p53. This interference with the p53-mediated E6 degradation by E6* re-activates 
the p53-dependent growth arrest and apoptotic functions (Pim et al., 2009). In this sense, the 
presence of E6 over E6* may lead to aggressive cancers as E6* is present at low levels in Asian-
American HPV16 variant, the one detected in the most aggressive cancers, and at high levels in 
African variant, together with higher levels of p53 (Filippova et al., 2009). 
4.2.2 E6 functional properties 
The HR-HPV E6 proteins are distributed in the cytoplasm and the nucleus, and its 
expression leads to the transformation of NIH3T3 cells as well as the immortalization of 
human mammary epithelial cells (Holt et al., 1996). The first function associated to E6 
protein was its anti-apoptotic activity due to the ability to mediate the p53 degradation 
through the E6/E6AP complex, allowing the regulation of expression of proteins controlling 
the cell cycle, being the most important the CDK inhibitor p21Waf1 (Cooper et al., 2003). The 
p73 protein, homologue in structure and function to p53, also binds to E6 but its 
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degradation is not promoted by the oncoprotein (Das et al., 2003). However, in HPV18 
transformed cells there is an abrogation of p53 degradation due to the Pitx2a protein that 
binds to E6 and interferes with the E6/E6AP complex, leading to the accumulation of 
functional p53 protein (Wei, 2005). In this case, the anti-apoptotic effect of E6 is carried out 
through the interference of the p53/PUMA/Bax cascade (M. Vogt et al., 2006).  
On the other hand, E6 is able to transactivate the survivin promoter and along with E7, 
transactivate the c-IAP-2 promoter and confer resistance to apoptosis (Yuan et al., 2005). 
Isoforms of E6 regulate the extrinsic apoptosis in a concentration-dependent manner. When 
low levels of large (E6) and short E6 (E6*) proteins are expressed, the cells become resistant to 
TNF. On the other hand, with moderate and high levels of expression, there is a sensitization 
to TNF aided by the E6 protein ability to form complexes with each other. In this sense, the 
cellular response to TNF depends on the ratio of the two E6 isoforms, being high levels of large 
E6 responsible for the low response to TNF and E6* reverting the E6 effect (Filippova et al., 
2009). The resistance to TNF-mediated apoptosis is related to high levels of E6 and low levels 
of E6*. Other ways by which E6 protein regulates cell death pathways is by inhibiting the 
transactivation action of IRF3 (Ronco et al., 1998) and by inhibiting TLR9 transcription 
generating functional loss of TLR9-regulated pathways (Hasan et al., 2007). 
In contrast, the capacity of E6/E6AP-mediated p53 degradation favors the accumulation of 
genetic alterations. A possible explanation is that E6 alters molecules implicated in DNA-
repairing such as degradation of MGMT (Srivenugopal & Ali-Osman, 2002) and MCM7 
proteins, producing chromosomal abnormalities (Kühne & Banks, 1998; Kukimoto et al., 
1998). Also E6 from the HR-HPVs increases cellular telomerase activity via transcriptional 
activation of the telomerase catalytic subunit, hTERT (X. Liu et al., 2005) and degradation of 
the telomerase inhibitor NFX1-91 (Gewin et al., 2004), events that lead to reconstitution of 
telomerase activity allowing the immortalization process in the cells (J.P. Liu, 1999; 
Longworth & Laimins, 2004).  
Recent studies have demonstrated that HR-HPV E6 proteins have a PDZ-binding motif, 
which probably mediates the disruption of signal transduction where PDZ proteins are 
implicated (Watson et al., 2003). It has been reported that E6 binds PDZ proteins and 
promotes their ubiquitination and further degradation as observed for hDlg (Grm & Banks, 
2004), MUPP-1 (S.S. Lee et al., 2000; Massimi et al., 2004), h-SCRIB (Thomas et al., 2005), 
MAGI-1, -2 and -3 (Thomas et al., 2001, 2002). The MAGUK family protein MAGI-2 interacts 
with PTEN tumor suppressor (Wu et al., 2000), which inactivates IP3. Thus, PKB remains 
activated promoting cell survival and proliferation. Additionally, HPV E6 oncoprotein has 
been linked to the MAPK signaling pathway by increasing the levels of MAPK1/2, MEK 
1/2, and BRaf specially the E6 variant in amino acid 83, promoting cell proliferation by 
another pathway (Chakrabarti et al., 2004). 
Other molecules that bind E6 proteins (in some cases with its concomitant degradation) are 
the Rap GTPase-activating protein E6TP1 (Gao et al., 1999; L. Singh et al., 2003), the CDK 
inhibitor p16INK4a (Malanchi et al., 2004), the regulator of insulin signaling pathway tuberin 
(Lu et al., 2004), the regulator TRIP-Br1 for the E2F/DP1/pRb complex during cell-cycle 
(Gupta et al., 2003), the extracellular matrix Ca+2-binding protein fibulin-1 (Du et al., 2002) 
and the putative Ca+2 binding protein E6BP (J.J. Chen et al., 1995). Viral oncoproteins induce 
mislocation of select PDZ proteins allowing disruption of tight junctions and cause polarity 
defects in epithelial cells. The development of human cancers is frequently associated with a 
Molecular Bases of Human Papillomavirus 
Pathogenesis in the Development of Cervical Cancer 261 
failure of epithelial cells to form tight junctions and to establish proper apicobasal polarity 
and this is probably another pathway that E6 follows to disrupt the cellular system (Latorre 
et al., 2005). On the other hand, E6 interacts and promotes the degradation of NHERF-1, a 
PDZ domain containing protein leading to the activation of the PI3K/AKT signaling 
pathway (Accardi et al., 2011), and promoting cellular proliferation also by this mechanism. 
Furthermore, E6 protein participates in the up-regulation of SGLT1 promoting the glucose 
intake in tumor cells (Leiprecht et al., 2011). 
4.3 E7 oncoprotein 
4.3.1 E7 biochemical properties 
The nucleotide sequence of E7 oncogenes are highly conserved among different HPV types. 
The E7 ORF encodes for a small acidic phosphoprotein of 98 amino acids. The predicted 
molecular weight of this E7 protein is 11 kDa and 14 kDa when phosphorylated in vitro, 
characteristics that are observed in the E7 protein from HPV16 (Armstrong & Roman, 1993). 
However, the electrophoretic mobility of HPV16 E7 protein observed when analyzed by 
SDS-PAGE is approximately 17 kDa and this molecular weight is not affected by in vitro 
phosphorylation by CKII (Armstrong & Roman, 1992; Gage et al., 1990). Heck and 
coworkers (1992) showed that the anomalous behavior of the HPV16 E7 protein resides 
within the amino-terminal residues that confer a net negative charge to the protein.  
The E7 proteins of different HPV types are highly similar among them and share 3 regions 
of homology with the Adenovirus E1A protein and with the SV40 large T antigen (Fig. 3) 
(Barbosa et al., 1990; Brokaw et al., 1994). The amino-terminal portion of E7 protein contains 
the CR1 (Consensus Region 1) between amino acids 1-20 important for DNA synthesis and 
cellular transformation (Gulliver et al., 1997). The CR2 (aa 21-43) contains the binding site 
for pRb (aa 21-26), the phosphorylation sites for CKII (aa 31 and 32) and the site for binding 
the cyclin A-E2F complex (Barbosa et al., 1990; Gulliver et al., 1997; Münger et al., 1989). 
Although the C-terminal region of the HPV16 E7 (aa 44-98) does not contain an extensive 
amino acid homology with the CR3 of E1A, it consists of a metal binding domain composed 
of two CXXC motifs separated by 29 amino acids (Fig. 3) (Brokaw et al., 1994; Phelps et al., 
1988). The E7 proteins from HPV16 and 18 are able to bind Zn+2 with the CXXC motifs, sites 
that are important for dimerization and intracellular stabilization of the molecule 
(Clemmens et al., 1995). This region also contains a low affinity pRb binding site and is 
involved in the disruption of the E2F/pRb1 complex (Braspenning et al., 1998). 
Different molecular weights for E7 have been reported and suggested that the negative 
charge and the N-terminal region of the protein are related to these changes. Pulse-chase 
experiments by Smotkin and Wettstein (1987) with HPV16 were unable to detect changes in 
the E7 protein mobility in SDS-PAGE, suggesting that no other modifications were present. 
However, other groups have reported the presence of two E7 species in HPV6, 16 and 18 
(Gage et al., 1990; Greenfield et al., 1991; Sato et al., 1990; Selvey et al., 1994), but neither the 
origin or the biological significance have been explained. The presence of phosphorylated 
species of E7 can explain some of the different molecular weights, although treatment of E7 
protein with alkaline phosphatase suggests the presence of other posttranslational 
modifications (Selvey et al., 1994). Differences in cellular localization also exist for the E7 
protein, some groups have reported this protein as cytoplasmic, but others have found it in 
nucleus (Kanda et al., 1991; Sato et al., 1990; Selvey et al., 1994).  
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Fig. 3. Biochemical characteristics of HPV16 E7 protein. The HPV16 E7 protein has been 
reported with different eletrophoretical molecular weights (from 14-21 kDa), differences that 
have been partially explained by the net negative charge of the protein. E7 shares 3 
homology regions with the Adenovirus E1A protein and with the SV40 large T antigen 
denoted as CR1, 2 and 3. Mutational analysis of the E7 protein has shown that CR1 is 
important for cellular transformation; CR2 contains the high affinity binding site (LXCXE) 
for pRb and the phosphorylation sites for CKII (aa 31 and 32); CR3 contains two binding 
motifs (CXXC) for Zn+2 important for the protein stability and DNA binding.  
The HPV16 E7 is able to translocate through the nuclear pores via a non-classical Ran-
dependent pathway, independent of the main cytosolic Kap beta import receptors (Angeline 
et al., 2003), and it possesses two NLSs and one NES domains to shuttle between nucleus 
and cytoplasm (Knapp et al., 2009). Recently, our group identified 3 isoforms of E7 from 
HPV16 present in CasKi cells, E7a1 (17.5 kDa and IEP of 4.68), E7a (17 kDa and IEP of 6.18) 
and E7b (16 kDa and IEP of 6.96). The processing of the E7 protein was followed up by 
pulse-chase experiments and found that the first isoform synthesized was a 17 kDa protein 
and after approximately 1 h, it was processed to a faster moving band of 16 kDa with a short 
half-life (Valdovinos-Torres et al., 2008). A broad phosphorylated band of a calculated 
molecular weight of 17.5 kDa was also identified, and this could be the 17 kDa protein that 
due to the change in charge because phosphorylation is retarded in the SDS-PAGE. 
However, the lower molecular weight band of 16 kDa could not be explained by 
phosphorylation and it is suggested that an unidentified posttranslational modification 
could exist and generated the E7b isoform (Valdovinos-Torres et al., 2008). Until now, the 
only posttranslational modification identified for E7 has been the phosphorylation. 
However, immunofluorescence experiments in our laboratory have shown that a fraction of 
E7 is present in ER and Golgi apparatus (Fig. 4 and Valdovinos-Torres et al., 2008). This 
suggests that during the processing and transit of E7 through the different cell 
compartments, the protein could be posttranslationally modified.  
According with the amino acid sequence of the HPV16 E7 protein, it contains putative 
posttranslational modification sites such as the Asp 29 that can be glycosylated, or modified 
by sulphation at Tyr 23 and 26, and phosphorylated in four other residues apart from the 
already known Ser residues 31 and 32. Until now, it is unknown if all these posttranslational 
modifications apply to E7 protein, but some of them could explain the different molecular 
weights found and their presence in different cell compartments. 
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Fig. 4. Immunolocalization of HPV16 E7 protein. Cos-7 cells were transiently transfected 
with the pcDNA-E7 plasmid and chased for different times (0, 16, 24 and 48 h). Cells were 
fixed (4% p-formaldehyde) and permeabilized with 0.2% saponine. Cell preparations were 
tested with different anti-E7 antibodies produced in our laboratory (Valdovinos-Torres et 
al., 2008). (A) Cells were tested with D11 anti-E7 monoclonal antibody and with anti-
calnexin polyclonal antibody as marker for ER. (B) Cells were tested with B4 anti-E7 
monoclonal antibody and calnexin as in A. Secondary fluorescent antibodies were anti-
rabbit IgG conjugated with Alexa 488 (green) or anti-mouse IgG conjugated with Alexa 594 
(red). Images were taken at a magnification of 1000X using Confocal Microscope. The results 
showed that E7 protein is recognized by different antibodies in different cell compartments 
as the B4 monoclonal antibody recognized the E7 protein at the ER (co-localized with 
calnexin), while the D11 monoclonal antibody recognized a different isoform of E7 as no co-
localization with calnexin was observed. 
4.3.2 E7 functional properties 
The E7 proteins are the major oncoproteins of HPVs that do not have known intrinsic 
enzymatic activities. Expression of HR-HPVs E6 and E7 genes in primary human  
keratinocytes is necessary for immortalization (Hawley-Nelson et al., 1989; Münger et al., 
1989). The HPV16 E7 gene encodes a multifunctional oncoprotein that can subvert multiple 
cellular regulatory pathways. Studies on mucosal HPV types showed that E7 deregulates 
the cell cycle mainly by binding to and promoting degradation of the tumor suppressor pRb 
protein (Caldeira et al., 2005; Collins et al., 2005), resulting in the dissociation of pRb from 
E2F transcription factors and the premature cell progression into the S-phase of the cell 
cycle. This activity is mediated by the LXCXE motif and the CR3 zinc binding domain of the 
E7 protein (Singh et al., 2005). However, E7 from HR-HPVs can also bind E2F1 and activates 
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E2F1-driven transcription independent of pRb (Hwang et al., 2002). It has been postulated 
that E7 binds and activates µ-calpain (Darnell et al., 2007) to target pRb, that in turn is 
poliubiquitinated by cullin 2 (Huh et al., 2007) and degraded by the 26S proteasome through 
the interaction of E7 with the subunit 4 of the proteasome (Berezutskaya & Bagchi, 1997). In 
a similar way, E7 affects the pRb-related pocket proteins p107, p130 (Davies et al., 1993; B. 
Zhang et al., 2006) and the retinoblastoma protein associated factor p600 (Huh et al., 2005). 
However, cells try to defend themselves from the HPV infection through the expression or 
activation of molecules such as the transglutaminase 2 that inhibits pRb binding to HPV18 
E7, by incorporating polyamine (J.H. Jeon et al., 2003) and PAI-2, and regulating ARF 
protein expression, which in turn protects pRb from the accelerated degradation mediated 
by E7 (Darnell et al., 2003). At the same time, the E7 oncoprotein is able to modulate the 
G2/M phase of the cell cycle by regulating the kinase of the histone H1 through a complex 
with the p107 protein, effect that allows progression of the viral cycle (Davies et al., 1993). It 
has also been shown that HPV16 E7 associates mainly with the cyclin A-E2F complex, or to 
cyclin E retaining their CDK2-associated kinase activity (Ghittoni et al., 2010; He et al., 2003). 
On the contrary, E7 inhibits the activity of CDK inhibitors p21Waf1 (Funk et al., 1997; Jones et 
al., 1997), p27Kip1 (Zerfass et al., 1996) and indirectly the p16INK4a (Giarrè et al., 2001). The 
regulation of all these cell cycle proteins by E7 may allow the activation of a subset of 
substrates important for the completion of the viral life cycle. 
Apart from the already described E7-protein interactions, there are other groups of E7-target 
proteins that allow the modification of several different pathways such as metabolism, 
metastasis, transcription, apoptosis among others, and these subsets of E7-target proteins 
have been summarized in Table 1.  
Finally, E7 has evolved to escape the immune-response by interfering with cytokines 
signaling pathways: abrogates the immune surveillance by binding to IRF-1 and preventing 
activation of the INFα and β promoters (Barnard & McMillan, 1999; Park et al., 2000), as well 
as represses the TGF-β2 promoter by releasing E2F from pRb (Lee et al., 2002b; Murvai et al., 
2004). The cytotoxic response against HPV is also evaded by E7 through the down-
regulation of TAP1, a key protein for peptide transportation from cytosol into the ER, 
reducing MHC I-dependent antigen presentation, impairing in this way a specific CTL 
response (Vambutas et al., 2001).  
Cellular differentiation–dependent HPV life cycle has been difficult to study due to the lack 
of an in vitro culture system to differentiate epithelial cells efficiently. The recently 
development of xenographs and raft cultures have allowed the replication of HPV under in 
vitro conditions (Chow & Broker, 1997). And now, it is important that the activity of the 
oncogenic viral proteins be examined in their proper physiological contexts with complete 
viral genomes rather than relying on over-expression assays in different cell types. 
5. Proteomics and genomics in the study of HPV  
Recent advances in proteomics and genomics have allowed the study of modifications of 
profiles of cellular proteins and gene transcripts involved in a particular phenomenon 
compared to a normal status. In this way, Lee and coworkers (2004) identified a group of 
modulators regulated by E7 oncogene using proteomics and genomics technology. By using 
MALDI-TOF MS, 47 spots were identified in a HPV-negative cervical cancer cell line (C33A) 
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stably transfected with HPV16 E7. Proteins like disulfide isomerase A3, integrase interactor 
1 protein, glutathione S-transferase P and vav proto-oncogene were down-regulated, 
whereas HSP60, Ku70 binding protein, 26S proteosome subunit were up-regulated. In the 
genomic approach using DNA microarrays the researchers showed that IL-12Rβ, 
cytochrome c and TNF II were induced by E7 oncogene (K.A. Lee et al., 2004).  
 
Activity Pathways 
subgroups 
Proteins Modulated by 
HPV E7 References 
1) Metabolism-related Pyruvate kinase 
α-glucosidase Zwerschke et al.,1999, 2000 
2) Metastasis suppressors Nm23-H1 Nm23-H2 Mileo et al., 2006 
3) Transcription factors 
TBP 
TAF-110 
AP-1 family factors 
MPP2 
SMAD3 
MYC 
p48 from ISGF3 complex 
Massimi et al., 1996 
Mazzarelli et al., 1995 
Antinore et al., 1996 
Lüscher-Firzlaff et al., 1999 
D.K. Lee et al., 2002b 
Y.W. Wang et al., 2007 
Barnard & McMillan, 1999 
4) Transcriptional 
coactivators 
pCAF acetyltransferase 
FHL2 
Skip 
IRF1 
SRC-1 
p300 
TAF9 
Avvakumov et al., 2003 
Campo-Fernández et al., 2007 
Prathapam et al., 2001 
Park et al., 2000 
Baldwin et al., 2006 
Bernat et al., 2003 
Enzenauer et al., 1998 
5) Transcriptional 
repressors E2F6 McLaughlin-Drubin et al., 2008 
6) DNA modifying 
enzymes 
DNMT1 
BRG-1 from SW1/SNF 
complex 
Burgers et al., 2007 
D. Lee et al., 2002a 
7) Histone-related Mi2β from NURD complex Brehm et al., 1999 
8) Tumor suppressor BRCA1 hTid1-TNF-α modulator 
Y. Zhang et al., 2005b 
Schilling et al., 1998 
9) Senescence regulators DEK PML 
Wise-Draper et al., 2005 
Bischof et al., 2005 
10) Anti-apoptotic Mcl-1 Y.W. Cheng et al., 2008 
11) Pro-apoptotic 
PP2A 
Siva-1 
IGFBP-3 
Pim et al., 2005 
Severino et al., 2007 
Mannhardt et al., 2000 
12) Miscellaneous 
TAP-1 
γ-tubulin 
IkB kinase complex 
F-actin 
Vambutas et al., 2001 
Nguyen et al., 2007 
Spitkovsky et al., 2002 
Rey et al., 2000 
Table 1. Subsets of E7-target proteins according to activity pathways.  
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On the other hand, Yim and coworkers (2004b) analyzed the genomic and proteomic 
expression patterns in 2 different HPV16 E6 transfected human carcinoma cell lines. They 
reported that among 1024 known genes and expressed sequence tags (ESTs) tested by cDNA 
microarray and by performing two dimensional gel electrophoresis and MALDI-TOF-MS, 
the authors found that only the genes and proteins of CDK5, Bak, and I-TRAF matched in 
both systems, the cDNA microarray and the proteomics. In addition, proteomic profiling of 
altered proteins by anti-cancer drugs on cervical cancer cells may contribute to provide the 
fundamental resources for investigation of disease-specific target proteins, elucidation of the 
novel mechanisms of action and development of new drugs (Yim & Park, 2006) as it has 
been analyzed with the 5-fluorouracil (5FU) drug (Yim et al.,  2004a).  
Other study with a genomic approach carried on by Garner-Hamrick and coworkers (2004), 
analyzed the mRNA from primary human keratinocytes infected with retroviruses that 
expressed the HPV18 E6 and E7 genes and used to generate probes for querying Affymetrix 
U95A microarrays, which contain >12,500 human gene sequences. The results showed that 
HPV18 E6/E7 expression significantly altered the expression of 1,381 genes. A large increase 
of transcripts associated with DNA and RNA metabolism was observed, with major 
increases noted for transcription factors, splicing factors and DNA replication elements, 
among others. Multiple genes associated with protein translation were down-regulated. In 
addition, major alterations were found in transcripts associated with the cell cycle and cell 
differentiation. 
This review does not include an exhaustive search of all gene transcripts or proteins which 
expression pattern is altered in each report. In Tables 2 and 3 were summarized only those 
important genes or proteins that were strongly associated to the phenomenon studied.  
 
HPV 
Gene 
Research 
Focused on Concluding Remarks 
Refe-
rence 
HPV16 
E6/E7 Anti-tumor immunity Down-regulated: MCP-1, osteopontin and midkine. 
Smahel et 
al., 2005b 
E6/E7 Chromosome alterations 
HPV16-negative tumors had loss  
at 18q12.1–23 but gain in HPV16-positive  
tumors. 
Smeets et 
al., 2006 
E6/E7 Chromosome amplifications
Duplication of chromosome 5q and 20q and 
macrodeletions in chromosomes 6q and 20q. 
Ramirez 
et al., 
2004 
E6, E7 Chromosome amplifications
Genes (DNA metabolism) up-regulated: 6 in 
chromosome 20q and 25 in chromosome 5. 
Klingelhu
tz et al., 
2005 
E6/E7 Differenti-ation 
Blocked or delayed differentiation. Alteration in TGFβ 
expression /TGFβ inducible genes. 
Nees et 
al., 2000 
E6/E7 Differenti-ation 
Altered expression of 80 cellular genes: INF-responsive 
genes, NF-kB stimulated genes, cell cycle progression 
and DNA synthesis. 
Nees et 
al., 2001 
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HPV 
Gene 
Research 
Focused on Concluding Remarks 
Refe-
rence 
E7 
Effect of E7 
on p53 
stability 
E7 can modulate normal turnover of p53. No 
transcriptional consequences on p53 targets. 
Eichten et 
al.,  2002 
E6/E7 Episome integration 
53 genes up-regulated: IFN modulators, EGFR, 
cytoskeleton proteins, and 32 genes down-regulated 
during episomal integration. 
Alazawi 
et al., 
2002 
E6/E7 
Episome loss 
and 
integration 
Activation of antiviral response genes MX1, MX2, OAS1, 
TRIM22, GIP3 and IRF7. 
Pett et al., 
2006 
E6 Gene expression 
Up- or down-regulated genes: 85 in RKO and 70 in A549 
cells. Genes and proteins matched: CDK5, Bak and I-
TRAF. 
Yim et al., 
2004b 
E6/E7 Gene expression 
Expression of 13 genes from HPV16-positive cell lines is 
down-regulated. 
Ruutu et 
al., 2005 
E7 
Host cell 
effectors 
interaction 
E7 interacts with Siva-1 factor. 
Severino 
et al., 
2007 
E6/E7 Immorta-lization 
Over-expression of IGFBP-3 is a late event after E6/E7 
expression in the infected cells. 
Berger et 
al., 2002 
E6/E7 
 
Immorta-
lization and 
progression
HPV immortalized EGFR null cells have elevated levels 
of mRNAs of p21Waf1 and insulin-like growth factor-
binding protein-2 (IGFBP2). 
Woodwor
th et al., 
2000 
E7 Immuno-surveillance Induction of IL12Rβ1, cytochrome c and TNFR type II. 
K.A. Lee 
et al., 2004 
E6, E7 miRNA in carcinoma 
Up-regulation of miR-363 and down-regulation of miR-
181a, mR-218, and miR-29a. 
Wald et 
al., 2011 
E6/E7 
Oncogenicity 
and 
metastases 
Down-regulation of CKIs (p57 and p16) and up-
regulation of S100 proteins (A6, A10) might be involved 
in the increase of oncogenicity. 
Smahel et 
al., 2005a 
E6/E7, 
E7 
Regulation of 
cellular genes
54 up- or down-regulated genes involved in DNA 
damage, differentiation, signal transduction, immune 
response, cell-cycle. 
Duffy et 
al., 2003 
E7 Senescence Associated genes: BRAK, DOC1 and IGFBP-3 but down-regulated in immortalization. 
Schwarze 
et al., 
2002 
E6/E7 Tumor angiogenesis
Down-regulation thrombospondin-1, maspin and up-
regulation of IL-8 and VEGF. 
Toussaint 
et al., 
2004 
 
HPV 18 
E6 
Effects of E6 
gene 
knockdown
359 genes up- or down-regulated. Cell cycle: p21; 
apoptosis: CASP4, CASP6, IGFBP3; ubiquitin proteolysis 
pathway: UBE3A; differentiation: KRT4, KRT6E, KRT18; 
anti-oncogenes RECK, VEL. 
Min et al., 
2009 
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HPV 
Gene 
Research 
Focused on Concluding Remarks 
Refe-
rence 
E6/E7 E2-induced senescence 
E2 induces senescence by up-regulating 10 genes (p21) 
and down-regulating 24. 
Wells et 
al., 2003 
E6/E7 Gene expression 
Affects DNA synthesis genes: MCM, cdc6, cdc7, PCNA. 
Regulators: cdk 1-2, CycB, Wee1, CycE. Centrosome 
abnormalities: Bub1, TTK. 
Garner et 
al., 2004 
Table 2. Genomics in HPV research. 
 
HPV 
Protein 
Research Focused 
on Concluding Remarks Reference 
HPV 16
E6 Chemotherapeutic agents sensitization
Cdc2 is the most dramatically up-
regulated protein. 
Z.G. Liu et al., 
2007 
E5 
Early cervical cancer 
markers related to 
E5 
Both EGFR and TfR assays detected HSIL 
with very high accuracy (100% and 
96.3%, respectively). 
Keesee et al., 
2002 
E6/E7**** Expression levels for  protein features 
This large-scale analysis provides a 
framework for understanding the 
cooperation between oncoproteins in 
HPV-driven carcinogenesis. 
Merkley et al., 
2009 
E5 */** Expression of membrane proteins
Decreased amount of calnexin and 
increased hsp70 expression, both 
associated to MHC-I processing. 
Leykauf et al., 
2004 
E5/E6/E
7 
HPV proteins 
immunogenicity 
E7 proteins of HR-HPV types are more 
reactive in cancer patients and 
discriminating between cancer and HSIL 
or LSIL patients. 
Luevano et al., 
2010 
E7 */*** Immunosurveillance
36 proteins down-regulated and 11 up-
regulated including Ku-70 binding 
protein involved in DNA metabolism 
and hsp60 KD protein 1. 
K.A. Lee et al., 
2004 
E6 */*** Protein expression 
In RKO and A539 cells: 26 up- and down-
regulated proteins. Only three proteins 
matched with its corresponding gene: 
CDK5, Bak and I-TRAF. 
Yim et al., 
2004b 
 
E7*/*** Proteins modulated by E7 
Two down-regulated proteins: actin and 
leukocyte elastase inhibitor and 26 
proteins up-regulated, amongst these: 
catalase and peroxiredoxin.
K.A. Lee et al., 
2005 
E6/E7 
*/*** 
Proteins modulated 
by E6, E7 or E6/E7 
Annexin III, gp96, transaldolase 1, 
elongation factor 1, proteasome 26S were 
up-regulated and have been confirmed at 
the transcriptional level. 
Ciotti et al., 
2009 
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HPV 
Protein 
Research Focused 
on Concluding Remarks Reference 
E7 */*** 
Resistance to 
oxidative stress-
induced apoptosis 
E7 induces higher resistance to ROS-
induced cell injury, probably via the 
modulation anti-oxidant enzymes, 
including catalase and peroxiredoxin. 
Shim et al.,  
2005 
 
HPV 18 
E6/E7 
*/*** 
Anti-cancer effect of 
5-fluorouracil 
treatment 
22 proteins up-regulated (CIDE-B, 
caspase-3, caspase-8, Apo-1/CD95 (Fas) 
and 12 proteins down-regulated (BUB3, 
c-myc protein, src substrate cortactin, 
transforming protein p21A, among 
others). 
Yim & Park 
2006; Yim et 
al.,  2004a 
E6/E7 
*/*** 
Anti-cancer effect of 
paclitaxel treatment
Paclitaxel showed anti- proliferative 
activity through the (DR)-mediated 
apoptotic pathway with TRAIL-
dependent caspase-8 activation and the 
mitochondrial-mediated pathway with 
down-regulation of bcl-2 by cytochrome 
c release. 
K.H. Lee et al., 
2005; Yim & 
Park 2006 
Used systems: * 2-DE: two-dimensional electrophoresis; ** nanoESI-MS: nanoelectrospray ionization 
mass spectrometry; *** MALDI-TOF-MS: matrix-assisted laser desorption/ionization time of flight mass 
spectrometry; ****2D-DIGE: two-dimensional difference gel electrophoresis. 
Table 3. Proteomics in HPV research. 
Working with genomics and proteomics is a great challenge as the following issues must be 
overcome: 1) The use of a standard genomic chip or an appropriate cell line has not been 
achieved, leading to results not easily comparable between different laboratories; 2) Many 
genes can be down-regulated or up-regulated during transcriptional profile analysis of a 
particular phenomenon, but this may not correspond necessarily at all with the proteomic 
profile; 3) Only a lesser number of proteins actually are modified as consequence of an 
alteration in the expression of the related gene; 4) Changes in gene expression may predict 
changes in protein expression, but not necessarily changes in functionality that in most cases 
is related to protein posttranslational modifications; 5) There are many human genes in data 
banks that codify for hypothetical proteins which activity or function are not yet known. 
Therefore, the expression of selected genes needs to be confirmed by means of other kind of 
procedures like real-time RT-PCR and the corresponding protein analysis by Western blot or 
in functional assays. In this regard, only two reports showed that some of the proteins 
studied with altered gene expression matched with the altered protein expression levels 
(Ciotti et al., 2009; Yim et al., 2004b). More remains to be done in genomics and proteomics, 
because once all the proteins modified in their expression have been characterized, the 
researchers need to investigate the way by which the proteins interact with each other, the 
sequence in which those interactions take place, and finally to establish the mechanism 
through which cervical cancer develops. This information is of great value when anti-cancer 
drugs are assayed to attack tumor cells, because the identification of the cellular targets of 
Human Papillomavirus and Related Diseases 
– From Bench to Bedside – Research Aspects 270 
the drug will help to design better molecules to induce specific malignant cell death. In the 
case of HPV, these studies are focused on the research of the proteins or genes that are 
altered by the presence of HR-HPV in the cell. In this sense, the identification of a biomarker 
to design chips would be useful in high-throughput screening test for uterine cervical cancer 
(Kim et al., 2006; Steinau et al., 2005), early diagnosis and prediction of response to therapy. 
6. Conclusions 
Intense work has been done to elucidate the molecular mechanisms through which the HPV 
E5, E6 and E7 oncoproteins generate cellular transformation. At the same time, it has 
became clear that the HPV oncoproteins use and modify different signal pathways, specially 
those related to cell growth, differentiation and apoptosis. The study of the transformation 
process associated to HPV has given some light about target proteins and disturbed 
mechanisms that could be considered for the design of drugs, which in the future would be 
specifically generated for the treatment of HPV associated cancers.  
Early detection remains one of the most important issues in cervical cancer research. 
Therefore, intensive screening to search for biomarkers (genes and/or proteins) particularly 
sensitive to differences between early and late stage cancer patients is the main target of the 
new technology. The development of the genomics and proteomics in cervical cancer 
associated to HPV infection will help in the identification of most accurate biomarkers for an 
automated early detection of this kind of cancer, as this approach allows the correlation of 
changes in host gene expression with the biological functions of viral genes. Although 
proteomics and genomics have simplified the analysis of a great quantity of genes or 
proteins that are modulated by the presence of HPV oncoproteins in a cell, a major concern 
has always existed as to whether the discovered biomarkers and the derived multivariate 
models are truly associated with the disease process. There is still much to do regarding to 
how these genes or its codified proteins are interconnected and which of them are actually 
important to the carcinogenic process. 
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1. Introduction 
Cancer is a disease in which uncontrolled cell division begins, cell integrity and 
transmission collapse. Cervical cancer is the second most common cancer among women 
worldwide. The oncogenic human papillomavirus (HPV) types are the most significant risk 
factors in its aetiology. HPV causes deformation of genomic integrity, control of cell cycle, 
cell adhesion and apoptosis by suppressing tumor suppressor genes and interacting with 
cellular proteins via various proteins on carcinogenesis process. While doing all these 
functions, HPV undoubtedly interacts with the members of cytoskeleton which enable 
cellular motility and integrity. This causes deformation of intercellular junction and tissue 
integrity. Formation of “koilos” which is created by HPV in cells and has an important place 
in the diagnosis of virus in gynecologic and non-gynecologic samples can be thought as the 
result of interaction of HPV-cytoskeleton. In this chapter the relation between HPV proteins 
and members of cytoskeleton will be studied through tumor suppressor genes. First of all 
HPV genomic structure and HPV proteins will be mentioned generally, then cytoskeleton 
and its members will be explained together with HPV proteins which they are in interaction 
with.  
2. HPV genomic structure and function  
Human papillomaviruses (HPVs) are small, nonenveloped, icosahedral, double-stranded 
circular DNA viruses belong to the Papovaviridae family. HPVs specifically infect keratinized 
stratified epithelia. The circular DNA approximetely 8,000 bp in size, contained within a 
spherical protein capsid, composed of 72 capsomers. The viral capsid has developed to 
complete several roles that are crucial to establish viral infection. The HPV genome is 
enclosed by an icosahedral capsid (T=7) of 55 nm in diameter composed by two structural 
proteins, the major protein L1 and the minor capsid protein L2 (Horvath et al., 2010; Howley 
1996; Longworth & Laimins, 2004; Prétet et al., 2007). To date, over 100 different viral types 
have been recognized and new types are regularly added to this list. These viruses can be 
classified into mucosal and cutaneous subtypes. Within each of these HPV groups, 
individual viruses are designated high risk or low risk according to their oncologic 
potential: high risk viruses such as HPV16,18 are frequently found in carcinomas. Low-risk 
types are responsible for benign lesions or condylomas (Blachon & Demeret, 2003, Howley 
1996; Longworth & Laimins, 2004; Mu¨nger et al,, 2004, Prétet et al., 2007). 
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HPV types belong to four of those genera, i.e., Alphapapillomavirus, Gammapapillomavirus, 
Mupapillomavirus and Nupapillomavirus have been associated with cutaneous warts, 
especially foot and hand warts (Koning et al., 2011). Genitally transmitted HPV types are 
contained within genus Alfapapillomavirus and viruses from this group, such as HPV 6 and 
11, are major sexually transmitted pathogens (Brentijens et al., 2002; de Villiers et al., 2004, 
Myers et al., 1994 as cited in Doorbar, 2005). These viruses are associated with benign 
papillomas. Contrary, the high-risk viruses from supergroup A, such as HPV16 and 18, 
cause mucosal lesions that can progress in some individuals to high-grade neoplasia and 
cancer (Bosch et al., 2002; Walboomers et al., 1999 as cited in Doorbar, 2005). The second 
major group of human papillomaviruses (also known as Beta papillomaviruses) are 
contained within supergroup B such as HPV5. This virus causes inapparent or latent 
infections in the general population (de Villiers et al., 2004; Myers et al., 1994; Ramoz et al., 
2002, as cited in Doorbar 2005). The third major group of human papillomaviruses (also 
known as Gammapapillomaviruses) are gamma papillomaviruses such as HPV4. This virus 
cause cutaneous warts in the general population that can superficially resemble those 
caused by supergroup A papillomaviruses such as HPV2. The remaining group of HPVs are 
contained within supergroup E (also classified as Mu and Nu-papillomaviruses (de Villiers 
et al., 2004, Myers et al., 1994 as cited in Doorbar, 2005). Only three human members from 
this group are known, and all cause cutaneous papillomas in the general population. HPV1 
is the most well studied member of this group, and like HPV2 in supergroup A, causes 
verrucas and palmar warts (Doorbar, 2005). 
The HPV genome includes several open reading frames (late and early gene regions and the 
non-coding long control region (LCR) that encode proteins involved in viral DNA 
replication (E1 and E2), viral gene expression regulation (E2), virus assembly (E4) and the  
immortalisation and transformation of infected epithelial cells (E5, E6 and E7; high-risk HPV 
only). These proteins play a role in genome organization, regulation of gene expression, and 
cellular transport. HPV proteins and their functions were documented in Table 1. The open 
reading frames L1 and L2 encode the two capsid proteins (Howley 1996; Prétet et al., 2007). 
These proteins are expressed in the upper layers of infected tissue (Ozbun & Meyers, 1998, 
as cited in Doorbar, 2005). HPVs L1 and L2 capsid proteins form the structure of the virion 
and facilitate viral DNA packaging and maturation.   
The papillomavirus E1 and E2 proteins play significant roles in viral genome replication. 
(Munger et al., 2004). The E1 protein also exhibits DNA helicase/ATPase activity (Hughes & 
Romanos 1993, Longworth & Laimins, 2004). E1 proteins bind to specific DNA elements in 
the viral origin of replication and assemble into hexameric helicases with the assist of a 
second viral protein, E2 (Wilson et al., 2002). The viral E2 protein is also crucial for the viral 
origin of replication (Dao et al., 2006). E2 plays a role in regulating viral transcription from 
the early promoter and viral genome segregation during cell division (Haugen et al., 1987 as 
cited in Longworth & Laimins, 2004, Munger et al., 2004). 
E6 and E7 oncoproteins, encoded by the oncogenic HPV types, are responsible for malignant 
transformation. These proteins disrupt normal cell growth and proliferation by binding to 
tumor suppressors proteins such as p53 and retinoblastoma (pRb) (Burd, 2003, Gammoh et 
al., 2006). High risk HPV E6 protein interacts with many significant cellular protein. To 
examplify these cellular protein, EF-hand calcium-binding protein E6-BP (reticulocalbin 2), 
the interferon regulatory factor IRF-3, and the focal adhesion protein paxillin (Munger et al.,  
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Table 1. HPV proteins and their functions.  
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2004). E6 also binds the p53 as part of a trimeric complex with the cellular ubiquitin ligase, 
E6AP, leading to the rapid turnover of p53 (Scheffner et al., 1990; Werness et al., 1990 as 
cited in Longworth & Laimins, 2004). 
HPV E7 proteins are low-molecular-weight proteins of approximately 100 amino acids. This 
oncoprotein encoded by small DNA tumor viruses, they associate with and adjust the 
functions of cellular protein complexes. The HPV E7 proteins interact with the 
retinoblastoma (Rb) family of tumor suppressors protein and the related “pocket proteins” 
p107 and p130. The proteins control the activities of the E2F family of transcription factors 
that regulate multiple cell cycle transitions as well as other cellular activities (Munger et al., 
2004). E7 also binds to other proteins such as  p130, p21, p27, cyclin A, cyclin E, the cyclin 
dependent kinase inhibitor (CKI), TBP,P300/CBP, MPP2,IGFBP-3, Mi2, NuMA (nuclear 
mitotic apparatus protein 1), p600. and a cellular protein kinase activity (Dyson et al., 1989 
as cited in Longworth & Laimins, 2004; Jones and Munger, 1996; Pim and Banks, 2010).  
HPV-16 may not only inactivate the tumor suppressor proteins p53 and pRB with its E6 and 
E7 oncoproteins, respectively, but could also alter other cellular functions through E7 
interaction with the cytoskeleton or associated proteins (Rey et al.,2000). Causing both 
benign and malignant lesions, HPV must first infect the divisible basal cell to induce 
papilloma formation (Burd, 2003; Flores et al., 2000; Howley 1996; Stanley, 2001). Viral 
replication occurs concomitantly with epithelial cell differentiation. Entering the basal cell, 
HPV replicates simultaneously with epithelial cell differentiation and reaches the 
keratinized cell (Andersson et al., 2005; Burd, 2003; Flores et al., 2000; Hoory et al., 2008; 
Howley 1996; Stanley, 2001).  
The E4 protein is the most abundantly expressed HPV protein. HPV E1^E4 accumulates in 
differentiating cells of the upper epithelial layers. It is synthesized from a spliced mRNA, 
E1^E4, which encodes five amino acids from the E1 ORF spliced to the protein encoded by 
the E4 ORF (Chow et al.,1987, Doorbar et al., 1990, Nasseri et al., 1987 as cited in Raj et al., 
2004). The first activity described for the 10-kDa HPV type 16 (HPV16) E1^E4 protein was 
its ability to bind and collapse the cytokeratin network (Doorbar et al., 1991 as cited in  Raj et 
al., 2004). Although all of the role of HPV16 E1^E4 is unclear, previous work has revealed 
that HPV16 E1^E4 can interact with keratins and cause the reorganization of the keratin 
intermediate-filament network (Doorbar et al., 1991 as cited in Wang et al., 2004). The HPV 
16 E1^E4 protein binds to keratins directly and interacts strongly with keratin 18, a member 
of the type I intermediate-filament family. By contrast, HPV16 E1^E4 bound only weakly to 
keratin 8, a type II intermediate-filament protein, and showed no detectable affinity for the 
type III protein, vimentin (Wang et al., 2004). 
The product of the E5 oncogene in HPVs contributes to cellular transformation. HPV16 E5 is 
a highly hydrophobic protein. It found mainly at the Golgi apparatus and internal 
membranes (Conrad et al., 1993 as cited in Alonso and Reed, 2002). Little is known about the 
biological activities of the HPV16 E5 protein or the source of its oncogenicity. It has been 
shown that E5 is able to regulate epidermal growth factor receptor (EGFR) activation in the 
presence or absence of ligand, and that expression of the protein in human keratinocytes 
results in altered gap junction-mediated cell–cell communication (Alonso and Reed, 2002). 
HPV E5 is also known to interact with growth factor receptors and gap junction proteins 
and is believed to play a role during the initiation of neoplasia (Yang et al., 2003). 
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Most benign and low-grade cervical lesions contain HPV DNA in an extrachromosomal 
state (Durst et al., 1985 as cited in Martineza 2007). However, in most cases of cervical 
carcinomas the HPV DNA is usually found integrated into the host chromosomes, 
frequently disrupting the E1 and E2 genes (zur hausen, 2000, 2002; Durst et al., 1985; 
Meissner et al., 1989 as cited in Martinez 2007). This process result in increased expression of 
the viral E6 and E7 oncogenes (Yee et al., 1985 as cited in Martinez 2007).  
A common feature of Human papillomavirus infection is the appearance of koilocytosis in 
the differentiated layers of squamous epithelium. Koilocytosis is the most common 
cytopathic effect and is considered by pathologists to be the major histopathological aspect 
for determination of HPV infection. Koilocytosis is composed of the presence of abnormal 
koilocytes. The greatest change caused by HPV in the epithelial cell cytoplasm is called 
koilos. Koilos means “hollow” in Greek. These koilocytes are squamous epithelial cells that 
may contain an acentric hyperchromatic nucleus and large clear perinuclear halos that 
usually occupy a greater volume than that of the cytoplasm (Fornatora et al., 1996; 
Krawczyk et al., 2008; Miyahara et al., 2011, Safi Oz et al., 2009, Safi Oz, 2010). The multiple 
nuclei of koilocytes are in fact multilobation of a single nucleus, and this phenomenon is 
associated with upregulation of gene products related to the G2 chectpoint. On restoration 
of 3D confocal images, the multinucleated feature of koilocytes was revealed to be 
multilobation of a single nucleus, as opposed to true multinucleation (Cho, 2005, 2006). 
HPV causes various changes through its structural proteins in the cytoplasms and nuclei of 
the cells and tissues it infects (Krawczyk et al., 2008, Safi Oz et al., 2009, Safi Oz, 2010, 
Fornatora et al. 1996 as cited in Miyahara et al., 2011). The formation of koilos is influenced 
by the structural proteins of the virus, cell skeletal filaments, and tumour suppressor genes. 
Modifications of the cytoskeleton as a result of viral protein expression have been associated 
with oncogenic transformation by papillomaviruses. HPV proteins are interacted with cell 
skeletal filaments. Some of these proteins are E6 (HPV16,18), E7 (HPV16,18,38), E5 (high and 
low risk HPV types), E1^E4 (HPV16), E4 proteins (Lee & Dominguez, 2010; McIntosh et al., 
2010; Nguyen 2008; Rey et al., 2000, Safi Oz, 2010; Stanley, 2001; Uribe & Jay., 2009; Yue et 
al., 2011). 
3. HPV proteins in relation with cytoskeletal filaments and interaction 
mechanisms 
Malignant transformation occurs with the alteration of cytoskeleton (Ben-Ze’ev 1997 as cited 
in Akgul et al., 2009). All these chances occur in different stages of cell cycle. Disruption of 
cytoskeleton not only means disruption of cytoskeletal organization but also disruption of 
many cellular functions. In this section, first of all cytoskeleton, its members and functions 
will be mentioned briefly. Then HPV proteins which are known and thought to have 
relation with cytoskeleton due to studies carried out until today will be explained. HPV 
proteins and cellular molecules interacted with cytoskeletal filament disruption were 
documented in Table 2)  
The cytoskeleton is a network of fibers throughout the cell's cytoplasm that helps the cell 
maintain its shape and gives support to the cell. In addition to providing support for the 
cell, the cytoskeleton is also involved in cellular motility and in moving vesicles within a 
cell, as well as assisting in the formation of food vacuoles in the cell. A variety of cellular 
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organelles are held in place by the cytoskeleton. The cytoskeleton is made up of three 
different types of protein filaments: microtubules, actin filaments (microfilament) and 
intermediate filaments. Each type of filament has different mechanical possestions and 
dynamics, but certain fundamental principles are common to them all (Alberts et al.,2002; 
http://biology.about.com/od/cellanatomy/a/aa013108a.htm). 
Actin filaments determine the shape of the cell’s surface and are necessary for whole cell 
locomadation. The actin cytoskeleton is a critical part of the cellular activities such as cell 
shape, cell division, motility, contraction, focal adhesion, phagocytosis, protein sorting and 
signal transduction (Lee & Dominguez 2010; Uribe & Jay 2009). Actin filament’s usefullness 
to the cell depends on a large number of accessory proteins that link the filaments to other 
cell component. These proteins are essential for the control assembly of the cytoskeletal 
filaments in particular locations (Alberts et al., 2002). Cell movement is an important 
phenomenon in embryonic morphogenesis, immune surveillance, angiogenesis and tissue 
repair and regeneration (Hussey et al., 2006; Itoh and Yumura, 2007; McMahon and Gallop, 
2005; Puppo et al., 2008; Yamaguchi and Condeelis, 2007 as cited in Lee & Dominguez, 
2010). Two transition types (monomeric or G actin and filamentous or F actin) of actin 
filaments are in cells (Uribe & Jay 2009). Schematic representation of monomeric and 
filamentous actin were seen in Figure. 1. 
The actin filament is asymmetric; actin monomers join the barbed (or +) fast growing end of 
the filament in the ATP-bound state and depart the filament preferentially from the pointed 
(or -) end primarily in the ADP state, giving rise to a process known as actin filament 
threadmilling. The transition between two types of actin is tighty regulated in cells by a 
large number of Actin-Binding Proteins (ABPs)  (Lee & Dominguez, 2010; Uribe & Jay 2009). 
ABPs carry out a wide range of functions, including actin filament nucleation, elongation, 
severing, capping, and crosslinking and actin monomer sequestration (Lee & Dominguez 
2010). The reorganization of the actin cytoskeleton is regulated in time and space by 
multiple factor, most notably Rho family GTPases that act as GTP-dependent molecular 
switches (Raftopoulou and Hall, 2004 as cited in Lee & Dominguez 2010). Among the small 
GTPases of the Rho family, Cdc42, Rac, and Rho are recognized as the most important 
regulators of actin assembly, controlling respectively the formation of filopodia, 
lamellipodia, and stress fibers (Etienne- Manneville and Hall, 2002 as cited in Lee & 
Dominguez 2010). Signals transmitted through these GTPases lead to localized actin 
cytoskeleton assembly/disassembly at the plasma membrane, with the actin filaments 
acting to push the cellular membrane (Hall, 1994 as cited in Lee & Dominguez 2010).  
By interacting with paxillin, E6 protein facilites transformation by disrupting the normal 
links between paxillin and the actin cytoskeleton by displacing paxillin-LD motif-binding 
proteins, disrupts the actin filament formation and the regulation of cytoskeleton (Cooper et 
al., 2007; Safi Oz et al., 2009, Rapp & Chen, 1998, Turner, CE., 2000). In the light of this 
information, the disruption of actin filament formation and thus, cytoskeleton disruption are 
believed to affect the formation of koilos around the nucleus (Safi Oz et al., 2009, Rapp & 
Chen, 1998, Cooper et al., 2007). With HPV disrupting actin filament formation, it is thought 
that cell shape and division, motility, contraction, focal adhesion and phagocytosis may be 
influenced.  
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Fig. 1. Schematic representation of monomeric and filamentous actin  
The bovine papillomavirus (BPV) E6 oncoprotein also interacts with paxillin and disrupt the 
actin cytoskeleton. HPV16 E6 binding to paxillin may contribute to the carcinogenic 
potential of the human papillomavirus (HPV). The association of HPV16 E6 with paxillin 
was affected by depolymerization of the actin fiber network. Disruption of the actin 
cytoskeleton is a characteristic of many transformed cells. (Tong & Howley, 1997). 
HPVE6 interacted with numerous proteins involved in adhesion, cell architecture and 
polarity. hDLG (the mammalian homologue of the Dropsophila discs large tomour 
suppressor protein), hScrib and MUPP control cell polarity and cellular scaffolds, and their 
interaction with E6 would lead to deregulation of cytoskeletal organization and cell–cell 
interactions (Campo, 2005). E6 also interact with the calcium binding protein ERC 55 and the 
paxillin, interactions that could lead to the disruption of the actin cytoskeleton and cell 
matrix interactions. Paxillin is a protein associated with focal adhesion kinase (FAK), a 
kinase that plays a regulatory role in cell migration, and vinculin and involved in the 
regulation of the cytoskeleton. Paxillin takes role in the regulation of actin cytoskeleton by 
interacting with other adhesion proteins in the cell such as actopaxin and vinculin. When 
Human Papillomavirus E6 protein is associated with paxillin, interaction of paxillin with 
other adhesion proteins therefore formation of actin cytoskeleton is disrupted. (Table 2) 
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HPV proteins Cellular molecules 
Types of 
cytoskeletal 
filamets
Effects 
HPV 16 E5 
Golgi apparatus
Endoplasmic reticulum 
Cellular membrane  
 
 
 
 
 
 
 
 
Actin filament 
 
 
 
 
Inhibits 
endocytotic 
activity 
HPV 16 E6 
Paxillin
(disrupt paxillin and vinculin, 
actopaxin interaction) 
Disruption of 
actin filament 
ERC55 (calcium binding 
protein)
hDLG (the mammalian 
homologue of the 
Dropsophila discs large 
tomour suppressor protein) 
hScrib  
MUPP
Tight junction complex
HPV 16 E7 
Unknown Disruption of actin filament HPV 38 E7 
HPV 16 E7 
Microtubule network
(attaches to microtubule 
network via the motor 
protein complex dynein) 
NuMA ( Nuclear Mitotic 
Apparatus Protein 1) /dynein 
network
Microtubule 
Disruption of 
microtubule 
motors and HPV 
associated 
tumorigenesis. 
Mitotic errors 
HPV 16 L2 
Microtubule network
(attaches to microtubule 
network via the motor 
protein complex dynein)
Disruption of 
microtubule 
motors 
HPV E4 Cytokeratin
Intermediate 
filament 
Total collapse of 
the cytokeratin 
matrix HPV E1^E4 
Cytokeratin 
DEAD-BAX protein 
Table 2. HPV proteins and cellular molecules interacted with cytoskeletal filament disruption 
HPVE6, specifically targets p53 for inactivation in order to promote cell growth and 
transformation and tumor supressors such as MAGI-1 and SAP97/hDlg for degradation. 
HPVE6 also targets numerous cellular proteins involved in a variety of cellular processes 
such as calcium signaling, cell adhesion, transcriptional control, DNA synthesis, apoptosis, 
cell cycle control, DNA repair, and small G-protein signaling. (Das et al., 2000, Degenhardt 
& Silverstein, 2001, Filippova et al, 2002, Gao et al., 1999, Gao et al., 2000, Iftner et al., 2002, 
Kuhne & Banks, 1998 Tong and Howley, 1997 as cited in Zhang  et al., 2007). Cellular targets 
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for the E6 proteins from high-low risk HPV types are Bak, myc, E6AP, E6BP⁄ERC55, P300 
⁄CBP, PDZ proteins, hTERT, Tyk2, hAda3 (Pim and Banks, 2010). HPV E6 interacts with 
tight junction complex (Zhang et al., 2007). Tight junction acts as an impermeable barrier 
that divides epithelial cells into functionally distinct apical and basolateral membrane 
domains (Yeaman et al., 1999 as cited in Zhang., 2007). Tight junctions consist of several 
transmembrane proteins (occludin, claudins, and junctional adhesion molecule). All these 
proteins are associated with at least one of the Zonula occludens proteins (ZOPs). ZOPs 
bind to the junctional transmembrane proteins linking them to the actin cytoskeleton. So, 
ZOPs establish a link between the junction site and the cytoskeleton by interacting directly 
with actin filaments (Fanning et al., 1998, Itoh et al., 1997, Wittchen et al., 1999 as cited in 
Traweger et al., 2003). ZOPs currently comprising ZO-1, ZO-2, and ZO-3, belong to the 
family of membrane-associated guanylate kinase homologue (MAGUK) proteins. MAGUK 
proteins are involved in the organization of epithelial and endothelial intercellular junctions 
(Traweger et al., 2003 as cited in Bauer et al., 2010). HPV E6 polypeptide binds to MAGUK 
Proteins (Zhang et al., 2007). The ZO-2 protein is targeted by HPVE6. ZO-2, a 160-kDa 
phosphoprotein and was found to co-precipitate with ZO-1 in epithelial cells (Gumbiner et 
al., 1991, Jesaitis and Goodenough, 1994 as cited in Traweger et al., 2003). 
ZOPs not only associate with each other but also with components of adherens junctions 
and gap junctions in cells lacking (Gumbiner et al., 1991, Howarth and Stevenson, 1995 as 
cited in Traweger et al., 2003). Adherens junction is responsible for cell-cell adhesion 
(Gumbiner, 1996 as cited in Zhang., 2007). The disruption of adherens junction decreases the 
phosphorylation of E-cadherin by protein kinase CK2, and this process of downregulation is 
treated as a common event in carcinogenesis (Serres et al., 2000 as cited in Zhang., 2007). 
Tight junction disruption and apobasical activity directly contribute to carcinogenesis by 
deregulating normal proliferation and differentiation programs in epithelial cells (Matter & 
Balda et al., 2003 as cited in Zhang., 2007). It is also thought that the damage caused by HPV 
on E6 proteins and tight junctions on carcinogenesis process is important.  
HPV-16 may not only inactivate the tumor suppressor proteins p53 and pRB with its E6 and 
E7 oncoproteins, respectively, but could also alter other cellular functions through E7 
interaction with the cytoskeleton or associated proteins. The E7 oncoprotein of Human 
Papillomavirus type 16 interacts with F-Actin in vitro and in vivo. F-actin is part of cellular 
structures such as microfilaments and the cell cortex and interacts with several structural 
and regulatory components. F-actin modifications resulting from viral protein expression 
will not only affect cytoskeletal organization but can also disrupt several cellular functions 
(Rey et al, 2000).  
Yue et al. showed that HPV38 E7 induces actin stress fiber disruption, and this phenomenon 
correlates with its ability to down-regulate Rho activity. In addition, HPV38 E7 is able to 
induce actin fiber disruption by directly binding to the eukaryotic elongation factor 1A 
(eEF1A) and abolishing its effects on actin fiber formation. Their data support the conclusion 
that HPV38 E7 promotes keratinocyte proliferation in part by negatively regulating actin 
cytoskeleton fiber formation and by binding to eEF1A and inhibiting its effects on actin 
cytoskeleton remodeling (Yue et al., 2011). 
The second type of cytoskeletal filament is the microtubule. Microtubules determine the 
positions of membrane-enclosed organelles and direct intracellular transport. Microtubules 
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are formed from protein subunits of tubulin (alpha-tubulin and beta-tubulin)  (Alberts et al., 
2002). Construction of microtubules was seen in Figure 2.  
 
Fig. 2. Construction of microtubules from α and β tubulins 
Romani et al. showed that the effect of HPV transformation on cellular cytoarchitecture. 
Cells from laryngeal papillomas and normal epithelium were cultured in vitro. Cytoskeletal 
components of both types of cells were visualized by immunofluorescence, to determine 
whether there were any differences in the structure or distribution of the cytoskeleton. The 
intermediate filaments and actin filaments are altered in the papilloma cells but there isn’t 
significant change in microtubules (Romani et al., 1987). (Table 2) Most of the studies carried 
out up-to-now are about HPV proteins and motor proteins. HPV16 E7 expresion leads to an 
increased population of mitotic cells with dynein, a minus end–directed microtubule motor 
protein, delocalized from the mitotic spindle. Dynein is composed of several subunits. The 
dynein motor complex aids in the positioning of the Golgi complex and mitochondria, along 
with other organelles, and transports cargo from the endoplasmic reticulum, endosomes, 
and lysosomes. It is possible that the disruption of microtubule motors by high-risk HPV 
may contribute to HPV associated tumorigenesis (Nguyen et al., 2008). The other type of 
motor protein is kinesin. Kinesin uses the energy of ATP hydrolysis to move along a 
microtubule. These proteins have legs and feet that change conformations by binding and 
hydrolyzing ATP to walk along the microtubules.  
Also HPV16 L2 protein attaches to microtubule network via the motor protein complex 
dynein (Florin et al., 2006; Schneider et al., 2011). The viral capsid play a critical role in the 
establishment of the viral infection. The L2 protein is an internally located multifunctinal 
protein with roles in genome encapsidation (Schelhaas et al., 2008, Holmgren et al., 2005 as 
cited in Horvath et al., 2010). Papillomaviruses enter cells via endocytosis. After endocytic 
cell entry and egress from endosomes, HPV16L2 goes along with the viral DNA to the 
nucleus. HPV16 L2 protein may be involved in the intracytoplasmic transport of the viral 
genome (Florin et al., 2006; Schneider et al., 2011).  
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The high-risk HPV16 E7 expression leads to the delocalization of dynein from mitotic 
spindles via an association with Nuclear Mitotic Apparatus Protein 1 (NuMA). The 
disruption of the NuMA/dynein network may result in mitotic errors (Nguyen, 2008, 2009). 
It is hypothesized that these event may important role in chromosome alignment and viral 
persistance (Nguyen &  Munger.,  2009). 
The third type of cytoskeletal filament is the intermediate filament. Intermediate filaments 
(IFs) provide mechanical strenght and resistance to share stres (Alberts et al., 2002). 
Intermediate filament-associated diseases clearly represent a significant group of human 
pathologies, and these pathologies that have given us the best clues to the function of this 
type of cytoskeleton component (Penky & Lane, 2007). Intermediate filaments are composed 
of smaller subunits that are themselves elongated and fibrous, but actin filaments and 
microtubules are made of compact and globular subunits (Alberts et al., 2002).  
IFs is a highly elongated, rod-like dimer based on an α-helical coiled-coil structure. 
Assembly of cytoplasmic IF proteins, such as vimentin, begins with a lateral association of 
dimers into tetramers and gradually into the so-called unit-length filaments (ULFs)  
(Strelkov et al., 2003). The molecular organisation of the intermediate filaments is specific for 
the cell type, the developmental stage and the type of differentiation (McIntosh et al., 2010). 
Major types of intermediate filament proteins in vertebrate cell are nuclear, vimentin-like, 
epithelial and axonal IF. Nuclear IF are composed of lamin A, B and C. The nuclear lamins 
are filamentous proteins, providing the nucleus with a putative skeleton for chromatin 
attachment (Alberts et al., 2002, Carmo-Fonseca &David-Ferreira , 1990). 
Different families of intermediate filaments are keratins, neurofilaments, vimentin-like 
filaments. Neurofilaments are found in concentrations along the axons of vertebrate 
neurons. Neurofilament proteins are NF-L, NF-M, NF-H. The vimentin-like filaments are 
found in muscle, glial cells, many cells of mesenchymal origin and some neurons (Alberts et 
al., 2002). The most diverse intermediate filament family is that of the keratins. Keratins are 
major structural proteins in epithelial cells and form the cytoplasmic network of 
intermediate filaments (Fuchs et al., 1998 as cited in Wang et al., 2004). Every keratin 
filament is made up of type I (acidic) and type II (neutral/basic) keratin chains (Alberts et 
al., 2002). The keratin IF network of epidermal keratinocytes provides a protective barrier 
against mechanical insult, it is also a major player in absorbing stress in these cells  
(McIntosh et al., 2010). They contain at least 20 members, called keratin 1 (K1) to K20, which 
are divided into two types according to the sequence and isoelectric point (pI). K9 to K20 are 
type I (acidic) keratins. The type II keratins, K1 to K8, are neutral or basic. Type I and type II 
keratins form noncovalent heteropolymers at a 1:1 ratio (Moll et al., 1998 as cited in Wang et 
al., 2004). Recently, several new functions of keratins have emerged. K8 and K18 prevent 
Fas- and possibly tumor necrosis factor-induced apoptosis (Caulin et al., 1998, Gilbert et al., 
2001, Inada et al., 2001, Ku et al., 2003 as cited in Wang et al., 2004). Keratin intermediate 
filaments are highly dynamic structures and are reorganized during cellular events such as 
mitosis and apoptosis (Wang et al., 2004). Diversity of keratins is clinically useful in the 
diagnosis of epithelial carcinomas, as the particular set of keratins expressed gives an 
indication of the epithelial tissue in which the cancer originated and thus can help to guide 
to choise of treatment (Alberts et al., 2002). HPVE4 interacts with the keratin cytoskeleton 
and intermediate filaments (Campo, 2005). Recent studies have introduced a new protein 
named E1^E4 of HPV16 that could disrupt the epithelial cytoskeleton. This protein is 
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encoded by spliced mRNAs that fuse the two early genes, E1 and E4, which encodes five 
amino acids from the E1 ORF spliced to the protein encoded by the E4 ORF , and is the most 
abundantly expressed viral protein in HPV-infected epithelia (Doorbar et al., 1991 as cited in 
Ohta & Nishiyama, 2011). It has been reported that this protein degrades the cytoskeleton by 
interacting with epithelial cell proteins (Davy et al., 2002, Nakahara et al.,2002 ). (Table 2) 
Doorbar et al showed that expression of the HPV-16 E1^E4 protein in human keratinocytes 
(the natural host cell for HPV infection) results in the total collapse of the cytokeratin matrix. 
Tubulin and actin networks are unaffected by E1-E4, as are the nuclear lamins  (Doorbar et 
al., 1991). The human HPV16 E1^E4 protein is associate with and reorganise the keratin IF 
network in cells in culture. HPV16 E1^E4 was found to effect a dramatic cessation of keratin 
IF network dynamics by associating with both soluble and insoluble keratin. These 
observations shed new light on the mechanism of keratin IF network reorganisation 
mediated by HPV16 E1^E4 (McIntosh et al., 2010). E1^E4 also translocates to mitokondria 
via an N-terminal leucine-rich region and induces the detachment of mitocondria from 
microtubules. The detached mitochondria then aggregate adjacent to the nucleus (Ohta & 
Nishiyama, 2011). 
HPV16 E1^E4 protein is the most abundantly expressed viral protein in HPV infected 
epithelia. HPV E1^E4 possesses the ability to bind to the cytokeratin network by interacting 
directly with cytokeratins and to DEAD-box proteins. Keratin association leads to the 
eventual  reorganization of the cytokeratin network in vivo as well as in vitro (Wang et al., 
2004 as cited in Raj  et al., 2004). Interestingly, the collapse of the network appears to initiate 
from the plasma membrane. Once collapsed, the cytokeratin appears as a cluster beside the 
nucleus. 
HPV16 E1^E4 is also able to prevent the progression of cells into mitosis by arresting them 
in the G2 phase of the cell cycle.  
HPV16 E1^E4 protein binds to mitochondria after binding to and collapsing the cytokeratin 
network and induces the detachment of mitochondria from microtubules, causing the 
organelles to form a single large cluster adjacent to the nucleus. This is followed by a severe 
reduction in the mitochondrial membrane potential and an induction of apoptosis (Raj et al., 
2004). 
In addition to the proteins mentioned above, it is expressed that HPV E5 protein contributes 
to the formation of koilocytes together with E6. The HPV E5 proteins are small (83 amino 
acids) hydrophobic proteins whose biological functions remain unresolved. These proteins 
are localized to endosomal membranes and the Golgi but on occasion are found in the 
cellular membranes (Longworth & Laimins, 2004). This protein associates with Golgi 
apparatus, endoplasmic reticulum and cellular membrane and inhibits endocytic activity by 
linking actin cytoskeleton. Although the role of HPV E5 in the cell-cycle is not known 
completely, it was shown with studies carried out on rodents that it shows low oncogenic 
activity in addition to major oncoproteins E6 and E7 (Kabsch & Alonso, 2002; Suprynowicz 
et al., 2008; Yang et al., 2003 as cited in Safi Oz., 2010). E6 protein in low and high risk HPV 
types aims at p53 and PDZ protein which organizes membrane transport in polarized 
epithelial cell membrane and may be damaging cell cytoskeleton (Safi Oz 2009, Krawczyk et 
al., 2008). HPV E5 – cell cytoskeleton association is an issue which requires more detailed 
biochemical and cellular studies.  
 
The Interactıon between Human Papillomavirus Proteins and Cytoskeletal Filaments 
 
303 
4. Conclusion 
Here, I summarize recent progress in my understanding of the interaction between Human 
papillomavirus proteins and their ability to disrupt cytoskeletal filaments. Disruption of cell 
cytoskeleton causes the occurrence of some important diseases such as cancer. Disruption of 
cell cytoskeleton both causes the disruption of cellular motility and cellular integrity and 
failure of important biological events such as cell division, contraction and phagocytosis. 
Association of various viruses with cell cytoskeleton is a study issue which has been gaining 
importance in recent years. HPV is included in this group of virus. In the studies of cell 
cytoskeleton – HPV, HPV16 and 18 which are among the risky group in the sense of cancer 
formation, become prominent. E6 protein of HPV16 and 18, E5 protein of HPV 16 and E7 
protein of HPV38 associate with the members of actin cell cytoskeleton and damages cell 
cytoskeleton. Moreover, HPV E6 associates through MAGUK (membrane-associated 
guanylate kinase homologue) proteins with tight junctions which form impermeable barrier 
between apical and basal membrane domains. Although studies show that actin and 
intermediate filaments in papilloma cells alter but there are no significant alterations in 
microtubules; more detailed studies are required on this subject. In association of HPV – 
microtubule, some studies have been shown in which HPV16 minor capsid protein L2 and 
E7 link with microtubule network via motor protein dynein. Moreover it was stated that 
HPV16 E7 causes dynein delocalization via Nuclear mitotic apparatus (NuMa). I am of the 
opinion that there are few studies upon HPV and kinesine from motor proteins; 
enlightenment of this subject will direct the association of HPV–microtubule. 
Comprehensive understanding of HPV-cytoskeleton interaction will offer new insights into 
the HPV life cycle as well as karcinogenesis. This virus- cytoskeleton interaction will also 
provide a paradigm for investigating other DNA tumor viruses that share a similar 
mechanism for interacting with cytokeratin filaments.  
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1. Introduction 
Worldwide, cervical cancer is an important health issue leading to high morbidity and 
mortality rates. The HPV virus plays an essential in the development of this disease. Of the 
more than 100 different HPV types identified, 40 are known to infect the genital tract 
(Woodman et al., 2007). These mucosal HPV types are classified as “low-risk” and “high-
risk” types based on the prevalence ratio in cervical cancer and its precursors. Low-risk 
HPV types, such as 6 and 11, induce benign lesions with minimum risk of progression to 
malignancy. In contrast, high-risk HPVs have higher oncogenic potential (Fehrmann & 
Laimins, 2003). Approximately 99% of cervical cancers contain HPV DNA of high-risk types, 
with type HPV16 being the most prevalent, followed by types 18, 31, 33, and 45. Cervical 
HPV infection is one of the most common sexually transmitted infections (Walboomers et al. 
1999; Woodman et al., 2007). 
HPVs are obligatory intracellular parasites that must deliver their genome and accessory 
proteins into host cells and subsequently make use of the biosynthetic cellular machinery for 
viral replication. The journey of a HPV particle from the cell surface to the cytosol and 
nucleus consists of a series of consecutive steps that move it closer to its site of replication 
(Day & Schiller, 2006; Marsh & Helenius, 2006). Host cell entry of HPV is initiated by 
binding of the virus particle to cell surface receptors followed by internalization. Since HPV 
replication and assembly requires infected basal keratinocytes to undergo the stepwise 
differentiation program of the epithelium, HPV propagation in cell culture is a major 
challenge. This has prompted many researchers to study the HPV-host cell interactions by 
generating VLPs, PsVs and QVs. Because of many difficulties, including viral particle 
heterogeneity due to the maturity state of the “artificial” viral particles used in many 
studies, data concerning the HPV entry mechanisms are contradictory and still a subject of 
scientific debate (Horvath et al., 2010).  
To prevent and cure HPV infections and its complications, it is important to identify the 
viral infection mechanisms by means of investigating the viral biology. Viral attachment and 
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internalization are first fundamental steps in the infection process and therefore, the ideal 
points to interfere with the progression of the viral life cycle. Identifying HPV uptake 
mechanisms may lead to a more specific pharmacological control of viral processing hereby 
improving therapeutic and prevention strategies.      
The design of a tool to study HPV internalization is the important goal in this research 
project. HPVs are small, non-enveloped DNA viruses that generally enter through clathrin-
coated endocytic vesicles or via the clathrin-independent caveolae system (Day et al., 2003). 
To date, most of the studies proved that different types of HPVs entered cells in distinct 
pathways, including clathrin-mediated endocytosis, caveolar endocytosis and clathrin- and 
caveolae-independent uptake mechanisms, although it was found that clathrin-mediated 
endocytosis was the major cellular entry route (Horvath et al., 2010). Therefore, it is 
important to design an experimental model to study the exact role of clathrin-mediated 
endocytosis in the uptake of HPV.  
The use of molecular tools with such precise specificity to individual cellular functions 
allows the defined examination of endocytic pathways (Day et al., 2006). In an experimental 
setting, it is challenging to identify a particular endocytotic pathway that is unique for the 
uptake of a specific ligand. It is important that the internalization route of interest is 
exclusively suppressed without affecting other endocytotic pathways. Chemical inhibitors 
like cholesterol extracting or sequestrating drugs such as cyclodextrins, filipin and nystatin 
not only disrupt caveolae/lipid rafts, but also lead to the destabilization of CCPs (Rodal et 
al., 1999; Subtil et al., 1999). The development of molecular inhibitors in the form of 
dominant negative molecules has surpassed the use of these pharmacological inhibitors in 
terms of decreasing non-specific effects (Day et al., 2003). Different accessory proteins such 
as dynamin, amphiphysin and Eps15 have been subjected to dominant negative 
overexpression (Benmerah et al., 1998; Benmerah et al., 1999; Yao et al., 2005).  
Targeting viral mRNA is one of the most active areas of research and development. Several 
strategies have emerged over the years such as antisense-oligonucleotides, ribozymes and 
RNA interference (RNAi). All these strategies share the features of conceptual simplicity, 
straightforward drug design and quick route to identify drug leads  (Le Calvez et al., 2004). 
RNA interference is the inhibition of expression of specific genes by double-stranded RNAs 
(dsRNAs). It is becoming the method of choice to knockdown gene expression rapidly and 
robustly in mammalian cells. Comparing to the traditional antisense method, RNAi 
technology has the advantage of significantly enhanced potency, therefore, only lower 
concentrations may be needed to achieve the same level of gene knockdown. RNAi gained 
rapid acceptance by researchers after Tuschl et al. discovered that in vitro synthesized small 
interfering RNAs (siRNAs) of 21 to 23 nucleotides in length can effectively silence targeted 
genes in mammalian cells without triggering interferon production (Le Calvez et al., 2004; 
Tuschl et al., 1999).  
The transient nature of siRNA, due to the short lifespan of synthetic RNA molecules and the 
absence of a RNA-dependent RNA polymerase in mammalian cells, limits its applications 
(Dykxhoorn et al., 2008; Kim & Rossi, 2007; Rao et al., 2009). To overcome these limitations, a 
vector-based production of short hairpin RNA (shRNA) is used, hereby mediating a long-
term and stable knockdown of the target transcripts for as long as transcription of the 
shRNAs takes place (Brummelkamp et al., 2002, Kim & Rossi, 2007; Paddison et al., 2002).    
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As described above, epsin is an essential accessory protein involved in clathrin-mediated 
endocytosis. Therefore, epsin is the target protein to generate a shRNA-based knockdown 
construct to investigate the role of clathrin-mediated endocytosis in the uptake of HPV.  
Another approach to investigate the role of clathrin-mediated endocytosis in the uptake of 
HPV, is the use of dominant-negative inhibitors of Eps15. Eps15 (epidermal growth factor 
pathway substrate 15) is a protein that is associated with clathrin-mediated endocytosis and 
consists of three different domains. The N-terminal region contains three copies of the 
conserved Eps15 homology domain (EH-domain). The central region of the protein is 
important in the homodimerization/oligodimerization of Eps15 and the C-terminal region 
contains binding sites for AP2. Overexpression of the C-terminal region (GFP-Eps15 DIII 
mutant) has a strong inhibitory effect on the uptake of the clathrin markers transferrin and 
epidermal growth factor receptor (EGFR) (figure 1) (Benmerah et al., 1998). Another Eps15 
mutant (GFP-Eps15 EΔ95/295), missing the second and third EH-domain in its N-terminal 
region has a negative influence on clathrin-mediated internalization (figure 1) (Benmerah et al., 
1999). Both vectors, in combination with a control plasmid (GFP-Eps15 D3Δ2), can be used in 
order to study the involvement of clathrin-mediated endocytosis in the uptake of HPV.  
 
Fig. 1. Eps15 mutants  
The EH29 mutant was generated by deleting 537 nucleotides (+288/+825) resulting in a 
construct length of 2163 nucleotides versus 2700 for wild type Eps15. This construct has 
been cloned between the BamHI/XbaI sites of the EGFP-C2 vector.  
The DIII construct corresponds to the C-terminal domain of Eps15 (+1587/+2700) resulting 
in a construct length of 1200 bp. The D3D2 construct corresponds to DIII from which AP-2 
binding sites has been removed (+1863/+2217) resulting in a 760 nucleotides long insert 
(Benmerah et al,, 1998; Benmerah et al., 1999). 
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2. Materials & methods  
2.1 Cell culture  
The human cervical cell line HeLa (ATCC CCL-2), which contains 10-50 copies of integrated 
HPV-18 and the human keratinocyte cell line HaCaT (Prof. Boukamp, Deutsches 
Krebsforschungszentrum (DKFZ), German Cancer Research Centre, Heidelberg, Germany), 
were grown under a humidified carbon dioxide atmosphere in Dulbecco’s Modified Eagle’s 
Medium (DMEM) supplemented with 10% fetal bovine serum, 200mM L-glutamin, 50mg/L 
penicillin/streptomycin, 50mg/L gentamicin, non-essential amino acids (Gibco, Carlsbad, 
CA, USA) and 50mg/L amphotericin (Sigma-Aldrich, Milan, Italy). 
Human intestinal colon carcinoma cells, Caco-2 cells (ATCC HTB-37) were cultured in 
Modified Eagle’s Medium (MEM) supplemented with 10% fetal bovine serum, non essential 
amino acids, 50mg/L penicillin/streptomycin, 50mg/L gentamicin, 55mg/L sodium 
pyruvate (Gibco, Carlsbad, CA, USA) and 1mg/L amphotericin (Sigma-Aldrich, Milan, 
Italy).   
2.2 RNAi selection and plasmid preparation 
Based on the primary sequences of the different epsin isoforms a multiple alignment and 
homology search was performed using ClustalW (searchlauncher.bcm.tmc.edu/multi-
align/.html). A stretch of 21 nucleotides was selected from the conserved ENTH region 
located <0.2 kb after the start codon, according to the guidelines and parameters (Tuschl et 
al., 1999). (table 1).  
pRNATin-H1.2/Neo is a siRNA inducible expression vector (GenScript). The H1.2 promotor 
is an engineered inducible H1 promotor (RNA polIII) containing a tetracycline operator 
(TetO1). The tetracycline operator itself has no effect on expression. When the tetracycline 
repressor (TetR) is present, it effectively binds the TetO1 and blocks the transcription. In the 
presence of tetracycline or doxycycline, the inducer binds TetR and causes the TetR protein 
to release the TetO1 site, and derepressing the transcription from the H1 promotor. The 
pRNATin-H1.2/Neo vector is designed for mammalian transfection and carries a neomycin 
resistance gene which can be used for establishing stable cell lines and a cGFP (coral GFP) 
marker under CMV promotor control to track the transfection efficiency. The insert is cloned 
after the H1 promotor and transcribed into short double stranded RNA (dsRNA) with a 
hairpin structure.  
The parental plasmid was digested with BamH1 and HindIII, separated on a 1% agarose gel 
and purified using the Qiagen Extraction kit. The shRNA insert was designed by using 
siRNA construct builder (GenScript; http://www.genscript.com/rnai.html). The shRNA 
sequences (table 1) were allowed to anneal and ligated into the digested vector using Ready-
to-Go T4 ligase. In parallel, a functional non-targeting shRNA, a sequence with no matching 
mRNA (scrambled sequence) (table 1), was ligated into the same vector.   
Correct insertion of the construct was confirmed by sequencing (data not shown). After 
transformation of E.coli, ampicillin recombinant strains were selected by using Fast-Media® 
Amp XGal Agar. Bacterial cells were grown in medium supplemented with 5µl/ml 
ampicillin and plasmids were purified using the PureYield Plasmid Midiprep System 
(Promega, Madison, WI, USA). Transformation and purification for the Eps15 mutant 
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vectors was performed in a similar way, hereby selecting recombinant strains by using 
kanamycin selection.     
 
Name Sequence (5‘→3’) 
 
siRNA 
epsin  
 
siRNA 
scrambled 
 
 
Forward: GAAGAACATCGTCCACAACTA 
Reverse: CTTCTTGTAGCAGGTGTTGAT 
 
Forward: GCATATGTGCGTACCTAGCAT 
Reverse: CGTATACACGCATGGATCGTA 
shRNA 
epsin 
GGATCCCGAAGAACATCGTGCACAACTATTCAAGAGATAGTTGTGC
ACGATGTTCTTCTTTTTTCCAAAAGCTT 
 
shRNA  
scrambled  
 
GGATCCCGCATATGTGCGTACCTAGCATTTCAAGAGAATGCTAGGTA
CGCACATATGCTTTTTTCCAAAAGCTT 
Table 1. siRNA and shRNA sequences  
2.3 Transfection and selection 
Liposomal transfection using Lipofectamine2000 (Invitrogen, San Diego, CA, USA) was 
performed according to the manufacture’s protocol. In brief, 4 µg plasmid DNA was added 
to 250µl OptiMEM and gently mixed, 5µl Lipofectamine2000 was suspended in 250µl 
OptiMEM, both mixtures were combined after a 5 minute incubation at room temperature 
and added to HeLa and HaCaT cells, with a 90-95% cell density, in a 6-well plate.  
HeLa and HaCaT cells were trypsinized 24h after transfection and seeded into a selection 
medium containing 100 µg/ml G418 as a starting point. A kill curve was created by 
doubling the G418 concentration with each medium change eventually culturing the HeLa 
and HaCaT cells in selection medium containing 1500 µg/ml G418. 
To estimate the transfection efficiency through GFP expression, cells were grown in MatTek 
glass bottom dishes (MatTek Corp., Ashland, MA, USA), fixed with 4% paraformaldehyde 
for 30 min at RT and mounted in Citifluor. Confocal fluorescence microscopy (Zeiss CLSM 
510) was used to discriminate between transfected and non-transfected cells. GFP-positive 
cells were counted by fluorescence microscopy and expressed as the percentage of the total 
amount of cells visualized by light microscopy.  
2.4 Real-time RT-PCR 
The effect of shRNA against epsin was evaluated by monitoring the epsin mRNA expression 
level.  
Total RNA was isolated using the reagent-based method TRIzol® (Invitrogen, Carlsbad, CA, 
USA) and RNA concentration and purity were monitored by UV-spectrophotometry. Prior 
to cDNA synthesis, DNA was removed from the total RNA extracts. An amount of 12µl 
DNase-treated total RNA was reversed transcribed in a 20µl reaction volume using the 
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Transcriptor First Strand cDNA synthesis kit (Roche Applied Science, Indianapolis, IN, 
USA) according to the manufacturer’s instructions.  
Real-time RT-PCR analyses were performed using the LightCycler system based on the 
TaqMan methodology (Roche Applied Science, Indianapolis, IN, USA). PCR-efficiencies (E) 
were tested for hypoxanthine phosphoribosyltransferase (HPRT) and epsin (EPN), ranging 
from 92%-132%. Specific primers and probes for these genes were designed using Primer 
Express 2.0 software (Applied Biosystems, Foster City, CA, USA) (table 2). 
For the LightCycler reaction a Mastermix of the following reaction components was 
prepared to the indicated end-volume (20µl): 7µl PCR-H2O, 1µl forward primer (0.5µM), 1µl 
reverse primer (0.5µM), 2µl probe (0.2µM), 4µl LightCycler Mastermix (LightCycler TaqMan 
Master kit; Roche Applied Science, IN, USA) was filled in the LightCycler glass capillaries 
and 5µl cDNA was added as PCR template. The following protocol was used: denaturation 
program (95°C for 10min), amplification and quantification program repeated 50 cycles 
(95°C for 10s, 58°C for 10s, 72°C for 10s with a single fluorescence measurement), melting 
curve program (55-95°C, with a heating step of 0.1°C per second and a continuous 
fluorescence measurement) and finally a cooling step to 40°C. 
 
Name Sequence 5’→3’ 
 
EPN 
Forward: ACTTCCAGTACGTGGACCGC 
Reverse: GCTGCTTAGCTTTCTCACGCA 
TaqMan probe: FAM-ACGGCAAGGACCAGGGCGTGA-Dabcyl 
 
HPRT 
Forward: GGCAGTATAATCCAAAGATGGTCA A 
Reverse: GTCTGGCTTATATCCAACACTTCGT 
TaqMan probe: FAM-CAAGCTTGCTGGTGAAAAGGACCCC-Dabcyl 
Table 2: Epsin and HPRT primer and probe sequences 
2.5 Western blotting 
Cells were lysed 60 min on ice in standard lysis buffer (50 mM NaCl, 10 mM HEPES, 3 mM 
MgCl2, 300 mM sucrose and 0.5% Triton X-100) supplemented with Complete Mini EDTA-
free protease inhibitor (Roche). Lysates were centrifuged at 15,000xg for 20 min at 4°C and 
supernatans was collected.  
Protein A/G agarose beads were coated with goat-anti-epsin polyclonal antibodies (Santa 
Cruz Biotechnology, 1:1000) and incubated overnight with the cell lysate on ice. After 
centrifugation at 15,000xg for 5 min at 4°C, the sediment was suspended in NuPAGE LDS 
Sample Buffer (Invitrogen), heat denaturated for 10 min at 95°C and loaded on a NuPAGE 
12% bis-tris polyacrylamide gel (Invitrogen). After electrophoresis in NuPAGE MOPS SDS 
running buffer using the NOVEX XCell II unit (40 min, 200V, 120mA), proteins were 
transferred to Immun-Blot® I PVDF membranes (Bio-Rad) (1h, 30V, 170mA). Membranes 
were blocked in Tris buffered saline containing 0.05% Tween-20 (TBST) and 5% non-fat dry 
milk for 1h. After blocking, membranes were probed overnight at 4°C with polyclonal goat-
anti-epsin in TBST containing 5% dry non-fat milk. Membranes were washed five times with 
TBST during 5 minutes and incubated with TBST containing 5% dry non-fat milk and mouse 
anti-goat peroxidase conjugated antibody (Calbiochem, 1:2500) for 2h at room temperature. 
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After several washing steps, 5 times for 5 minutes, immunoblots were detected using the 
ECL® Plus Western blot detection system by the ChemiGenius2.         
3. Results 
3.1 Transfection efficiency 
Efficiency of transfection with pRNATin-H1.2/Neo was measured by confocal fluorescence 
microscopy and the amount of GFP-positive cells were counted by fluorescence microscopy 
and expressed as the percentage of the total amount of cells visualized by light microscopy. 
Figure 2 shows the efficiency of transfection with pRNATin-H1.2/Neo in HeLa cells which 
amounted to 81%. 
 
Fig. 2. Efficiency of transfection with pRNATin-H1.2/Neo in HeLa cells. The amount of 
transfected cells was determined by counting GFP-positive cells versus the total amount of 
cells, determined by fluorescence (A) and light microscopy (B)  respectively  
3.2 Real-time RT-PCR and western blotting 
3.2.1 Synthetic siRNA 
The synthetic siRNA (table 3) reduced the epsin expression with a factor >10³ (figure 3 A) 
without affecting expression profiles of the housekeeping gene. In negative controls (HeLa 
scrambled) the expression of epsin was barely affected, an indication that the transfection 
procedure did not elicit non-specific effects (figure 3 A).   
Western blot analysis shows a reduction of the epsin protein in HeLa epsin deficient cells 
(HeLa eps-; figure 3 B) compared to HeLa control and HeLa scrambled.  
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Fig. 3. A. The synthetic siRNA reduced the epsin expression with a factor >10³. B. Western blot 
analysis shows a reduction of the epsin protein in HeLa epsin deficient cells (HeLa eps-). 
3.2.2 Plasmid transfection shRNA 
The extent of siRNA-mediated silencing of epsin expression in HeLa cells (both control and 
transfected cells) by using a shRNA-based knockdown construct, was controlled by means 
of real-time RT-PCR and Western blotting (figure 4-5).  
Real-time RT-PCR for epsin and HPRT expression was performed on HeLa control cells and 
on HeLa cells transfected with a vector expressing siRNA against epsin (HeLa eps-) and a 
scrambled sequence (HeLa scrambled). In order to exclude secondary transfection effects, 
the expression profile of a housekeeping gene HPRT was compared in both transfected cells 
and control cells. The real time RT-PCR curves of HeLa control, HeLa scrambled and HeLa 
eps- nearly coincided, resulting in almost identical CP values. These data reveal that neither 
the carbohydrate nor nucleic acid metabolism were compromised by the transfection 
procedure, an essential requisite for application of siRNA-induced silencing of specific 
target genes (figure 4 A). However, the same results were obtained for epsin, indicating that 
there is no suppression of epsin in cells transfected with the vector expressing siRNA 
against epsin (figure 4 B).  
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A 
 
B 
 
Fig. 4. The extent of siRNA-mediated silencing of epsin expression in HeLa control and 
transfected cells (HeLa scrambled/HeLa eps-) by using a shRNA-based knockdown 
construct, control by means of real-time RT-PCR. Real-time RT-PCR was performed on 
HeLa control cells and cells transfected with a vector expressing siRNA against epsin and a 
scrambled sequence. Total RNA was isolated and used for real-time RT-PCR with primers 
against the housekeeping gene HPRT (A) and against epsin (B).  
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In order to evaluate expression of epsin at the protein level, Western blotting was 
performed. These results revealed that there was no reduction of cellular epsin in 
transfected HeLa cells versus controls (figure 5).     
 
Fig. 5. Western blotting was performed on HeLa control and transfected cells. Caco-2 cells 
were used as a positive control. Densitometric scans of the protein bands were performed 
and normalized. There was no reduction of epsin at the protein level measured.    
4. Discussion  
Despite the significant advances and the emergence of a general picture of the infectious 
HPV entry pathway, many details remain to be clarified. This study intended to design an 
experimental model to study the exact role of clathrin-mediated endocytosis in the uptake of 
HPV, hereby exploiting the technique of RNAi. Because proteins as clathrin heavy chain 
(CHC) and AP2 suffer from cross reaction phenomena with other endocytotic pathways 
(Hinrichsen et al., 2003), the essential accessory protein of clathrin-mediated endocytosis, 
epsin was used as the target protein to generate a shRNA-based knockdown construct. 
CHC is inherently specific for clathrin-mediated endocytosis, although it is not unique for 
internalization at the plasma membrane, because of its involvement in vesicular transport at 
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the trans-Golgi network (TGN) (Alberts et al., 2002). AP2 has an important function in the 
recognition of certain cargo motifs, although it is not recognized by all cargo molecules that 
are internalized via coated pits. Moreover, coated pits can be formed independently of AP2 
interaction with cargo (Nesterov et al., 1999; Rappoport et al., 2004). To date, for epsin there 
are no specific restrictions in specificity for clathrin-mediated endocytosis at the plasma 
membrane reported.  
It is important to know that complete inhibition of clathrin-mediated uptake would 
undoubtedly lead to induction of apoptosis, hence partial blocking of clathrin-mediated 
endocytosis has the advantage that cell viability is not significantly reduced. Hinrichsen et 
al., have shown that a reduction of clathrin to 20% is the absolute limit to ensure cell 
viability (Hinrichsen et al., 2003). In addition, it has been reported that the uptake of the 
transferrin receptor, which is an important marker for clathrin-mediated endocytosis, can 
never be abolished completely in living cells (Iversen et al., 2003).    
In this study, a inducible shRNA-based epsin knockdown construct was used. Transient or 
constitutive expression of either siRNA or shRNA results in temporal or persistent 
inhibition of gene expression, respectively. A tightly regulated and reversibly inducible 
RNAi-mediated gene silencing approach could conditionally control gene expression in a 
temporal or spatial manner that provides an extremely useful tool for studying gene 
function. It provides an ideal genetic switcher allowing the inducible and reversible control 
of specific gene activity in mammalian cells (Wu et al., 2007). Moreover, it is less likely that 
the use of such a system would compromise cell viability.     
In our experiments, there was no reduction of the epsin expression in HeLa cells on both 
mRNA and protein level. However, Vanden Broeck et al., showed a highly specific reduction 
of epsin in Caco-2 cells using a constitutive shRNA-based knockdown construct. Epsin 
expression at the protein level was reduced by ~75%, resulting in an equal inhibition of 
clathrin-mediated endocytosis  (Vanden Broeck & De Wolf, 2006).  
There are different reasons to explain to obtained results in this study. First of all there 
might be some cell type specific differences that could clarify these data. Different cells 
express different genes and feature different cellular pathways. It is likely that different cell 
types will reveal different results. Moreover, certain cell types could have more profound 
off-target effect compared to other cell types. Although HeLa cells are probably the most 
frequently used cell type in published RNA studies, Koller et al., showed that in general, 
higher concentration of siRNA were needed to see effects in HeLa cells compared to other 
cell types (Koller et al., 2006).  
Furthermore, the copy number of the plasmid could be too low in transfected HeLa cells or 
the reduction of epsin is detrimental to the cells, leading to the selection against those with 
reduced levels of expression (counter-selection of knockdown cells). Although we have used 
high concentration of antibiotics in our experiments, even much higher concentrations of 
antibiotics may lead to survival of those cells with higher integration numbers and therefore 
probably more knockdown efficiency.  
5. Future perspectives 
To prevent and cure HPV infections and its complications, it is important to identify the 
viral infection mechanisms by means of investigating the viral biology. Viral attachment and 
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internalization are first fundamental steps in the infection process and therefore, the ideal 
points to interfere with the progression of the viral life cycle.  
The use of molecular tools with such precise specificity to individual cellular functions 
allows the defined examination of endocytic pathways. The use of an inducible vector 
system, expressing shRNA against pathway-specific markers is an important step in 
achieving this goal. This study used such an inducible system in order to knockdown epsin 
in HeLa, herby interfering with clathrin-mediated endocytosis. Although no reduction of 
epsin has been achieved, it is important to adjust and optimize the experimental setting, 
hereby using different vector systems and multiple cell types.  
The use of live cell imaging and single virus tracking are important means to dissect 
multiple infection pathways and multiple infection steps.  
Finally, it is important to note that cultured cells are simplified model system. A complete 
understanding of viral infection would greatly benefit from in vivo experiments. It is 
therefore particularly exciting to track virus particles in live tissues and animals to see how 
viruses break host defence barriers to reach target cells for infection. 
6. References 
Alberts, B., Johnson, A., Lewis, J., Raff, M., Roberts, K. & Walter, P. (2002). Intracellular 
vesicular traffic, In Molecular Biology of the Cell, Alberts, B., pp.711-766. Garland 
Science, ISBN 9780815332183, New York. 
Benmerah, A., Bayrou M., Cerf-Bensussan N. & Dautry-Varsat A. (1999). Inhibition of 
clatrhin-coated pit assembly by an Eps15 mutant. Jounral of Cell Science, Vol.112 
No.9, (May 1999), pp.1303-1311, ISSN 0021-9533. 
Benmerah, A., Lamaze, C., Bègue, B., Scmid, S.L., Dautry-Varsat, A. & Cerf-Bensussan, N. 
(1998). AP-2/Eps15 interaction is required for receptor-mediated endocytosis. The 
Journal of Cell Biology, Vol.140 No.5, (March 1998), pp.1055-1062, ISSN 0021-9525. 
Brummelkamp, T.R., Bernards, R. & Agami, R. (2002). A system for stable expression of 
short interfering RNAs in mammalian cells. Science, Vol.296 No.5567, (April 2002), 
pp.550-553, ISSN 0036-8075. 
Day, P.M. & Schiller, J.T. (2006). Early events in the papillomavirus life cycle, In: 
Papillomavirus research: from natural history to vaccines and beyond, Campo, S.M., 
pp.175-192, Caister Academic Press, ISBN 9781904455042, Norfolk. 
Day, P.M., Lowy, D.R. & Schiller, J.T. (2003). Papillomaviruses infect cells via a clathrin-
dependent pathway. Virology, Vol.307 No.1, (March 2003), pp.1-11, ISSN 0042-6822. 
Dykxhoorn, D.M., Chowdhury, D. & Lieberman, J. (2008). RNA interference and cancer: 
endogenous pathways and therapeutic approaches. Advances in Experimental 
Medicine and Biology, Vol.615, pp.299-329, ISSN 0065-2598. 
Fehrmann, F. & Laimins, L.A. (2003). Human papillomaviruses: targeting differentiating 
epithelial cells for malignant transformation. Oncogene, Vol.22 No.33, (August 
2003), pp.5201-5207, ISSN 0950-9232.  
Hinrichsen, L., Harborth, J., Andrees, L., Weber, K. & Ungewickell, E.J. (2003). Effect of 
clatrhin heavy chain- and α-adaptin-specific small inhibitory RNAs on endocytic 
accessory proteins and receptor trafficking in HeLa cells. The Journal of Biological 
Chemistry, Vol.278 No.46, (November 2003), pp.45160-45170, ISSN 0021-9258. 
 
A Functional RNAi-Based Knockdown System: A Tool to Investigate HPV Entry? 
 
323 
Horvath, C.A., Boulet, G.A., Renoux, V.M., Delvenne, P.O. & Bogers, J.J. Mechanisms of cell 
entry by human papillomaviruses: an overview. Virology Journal, Vol.7, (January 
2010), 11, ISSN 0022-538X. 
Iversen, T.G., Skretting, G., Van Deurs, B. & Sandvig, K. (2003). Clathrin-coated pits with 
long, dynamin-wrapped necks upon expression of a clathrin antisense RNA. 
Proceedings of the National Academy of Sciences of the United States of America, Vol.100 
No.9, (April 2003), pp.5175-5180, ISSN 0027-8424. 
Kim, D.H. & Rossi, J.J. (2007). Strategies for silencing human diseases using RNA 
interference. Nature Reviews. Genetics, Vol.8 No.3, (March 2007), pp.173-184, ISSN 
1471-0056. 
Koller, E., Propp, S., Murray, H., Lima, W., Bhat, B., Thaza, P.P., Allerson, C.R., Swayze, E.E., 
Marcusson, E.G. & Dean, N.M. (2006). Competiotion for RISC binding predicts in 
vitro potency of siRNA. Nucleic Acids Research, Vol.34 No.16, (August 2006), 
pp.4467-4476, ISSN 0305-1048. 
Le Calvez, H., Yu, M. & Fang, F. (2004). Biochemical prevention and treatment of viral 
infections – a new paradigm in medicine for infectious treatment. Virology Journal, 
Vol.1, (November 2004), 12, ISSN 0022-538X. 
Marsh, M. & Helenius, A. (2006). Virus entry: open sesame. Cell, Vol.124 No.4, (February 
2006), pp.729-740, ISSN 0092-8674. 
Nesterov, A., Carter, R.E., Sorina, T., Gill, G.N. & Sorkin, A. (1999). Inhibition of the 
receptor-binding function of clathrin adaptor protein AP-2 by dominant-negative 
mutant mu2 subunit and its effects on endocytosis. The EMBO Journal, Vol.18 No.9, 
(May 1999), pp.2489-2499, ISSN 0261-4189. 
Paddison, P.J., Caudy, A.A., Berstein, E., Hannon, G.J. & Conklin, D.S. Short hairpin RNAs 
(shRNAs) induce sequence-specific silencing in mammalian cells. (2002). Genes & 
Development, Vol.16 No.8, (April 2002), pp.948-958, ISSN 0890-9369. 
Rao, D.D., Vorhies, J.S., Senzer, N. & Nemunaitis, J. (2009). SiRNA vs. shRNA: similarities 
and differences. Advanced Drug Delivery Reviews, Vol.61 No.9, (July2009), pp.746-
759, ISSN 0169-409X. 
Rappoport, J.Z., Simon, S.M. & Benmerah, A. (2004). Understanding living clathrin-coated 
pits. Traffic, Vol.5 No.5, (May 2004), pp.327-337, ISSN 1398-9219. 
Rodal, S.K., Skretting, G., Garred, O., Vilhardt, F., van Deurs, B. & Sandvig, K. (1999). 
Extraction of cholesterol with metyl-beta-cyclodextrin perturbs formation of 
clathrin-coated endocytic vesicles. Molecular Biology of the Cell,Vol.10 No.4, (April 
1999), pp.961-974, ISSN 1059-1524. 
Subtil, A., Gaidarov, I., Kobylarz, K., Lampson, M.A., Keen, J.H. & McGraw, T.E. (1999). 
Acute cholesterol depletion inhibits clathrin-coated pit budding. Proceedings of the  
National Academy of Sciences of the United States of America, Vol.96 No.12, (June 1999), 
pp.6775-6780, ISSN 0027-8424. 
Tuschl, T., Zamore, P.D., Lehmann, R., Bartel, D.P. & Sharp, P.A.. (1999). Targeted mRNA 
degradation by double-stranded RNA in vitro. Genes & Development, Vol.12 No.24, 
(December 1999)pp.3191-3197, ISSN 0890-9369. 
Vanden Broeck, D. & De Wolf, M. (2006). Selective blocking of clathrin-mediated 
endocytosis by RNA interference: epsin as target protein. Biotechniques, Vol.41 
No.4, (October 2006), pp.475-484, ISSN 0736-6205. 
Human Papillomavirus and Related Diseases 
– From Bench to Bedside – Research Aspects 
 
324 
Walboomers, J.M.M., Jacobs, M.V., Manos, M.M., Bosch, F.X., Kummer, J.A., Shah, K.V., 
Snijders, P.J.F., Peto, J., Meijer, C.J.L.M. & Muñoz, N. (1999). Human 
papillomavirus is a necessary cause of invasive cervical cancer worldwide. Journal 
of Pathology, Vol.189 No.1, (September 1999), pp.12-19, ISSN 1096-9896. 
Woodman, C.B.J., Collins, S.I. & Young, L.S. (2007). The natural history of cervical HPV 
infection: unresolved issues. Nature Reviews. Cancer, Vol.7 No.1, (January 2007), 
pp.11-22, ISSN 1474-175X. 
Wu, R.H., Cheng, T.L., Lo, S.R., Hsu, H.C. , Hung, C.F., Teng, C.F., Wu, M.P., Tsai, W.H. & 
Chang, W.T. (2007). A tightly regulated and reversibly inducible siRNA expression 
system for conditional RNAi-mediated gene silencing in mammalian cells. Journal 
of Gene Medicine, Vol.9 No.7, (July 2007), pp.620-634, ISSN 1099-498X. 
Yao Q, Chen J, Cao H, Orth JD, McCaffery JM, Stan RV & McGiven MA. (2005). Caveolin-1 
interacts directly with dynamin-2. Journal of Molecular Biology, Vol.348 No.2, (April 
2005), pp.491-501, ISSN 0022-2836. 
13 
Molecular Events Towards Wnt Pathway 
Activation in Cervical Cancer: Changing the 
Balance on NKD/DVL Signals  
Carlos Pérez-Plasencia1,2,3, Patricia Piña-Sánchez4, Felipe Vaca-Paniagua1,2, 
Verónica Fragoso-Ontiveros1,2, Nadia Jacobo-Herrera5,  
César López-Camarillo6 and Omar Vargas-Hernández1,2 
1Universidad Nacional Autónoma de México UNAM, FES-Iztacala, 
UBIMED Tlalnepantla, Estado de México 
2Instituto Nacional de Cancerología, Laboratorio de Genómica  
3Instituto Nacional de Cancerología, Unidad de Genómica y Secuenciación  
Masiva (UGESEM-INCan). Tlalpan, D. F. 
4Instituto Mexicano del Seguro Social, CMNSXXI, UIMEO. Cuauhtemoc, D. F.  
5INCMNSZ, Unidad de Bioquímica. Tlalpan, D. F.  
6UACM, Posgrado en Ciencias Genómicas. Benito Juárez, D. F. 
México 
1. Introduction 
The Wnt signaling pathway is a key regulator of developmental and homeostatic processes, 
including embryogenesis, stem cell maintenance, cell fate specification, cell polarity, 
migration, and, when is aberrantly activated, cancer progression. The Wnt pathway is a 
highly conserved mechanism during evolution, hence homologues of this via can be found 
in metazoan organisms, showing a crucial role in the developmental processes of metazoan 
body (Pang et al., 2010). 
The aim of the current chapter is to review and analyze recent data pointing to specific 
alterations in Wnt pathway components occurring during Cervical Cancer (CC) progression. 
We address an overall discussion about the feasible role of E6/E7 proteins as chromatin 
remodelers, hence turning off by promoter silencing or turning on, by recruiting co-
activators and transcription factors to genes that promote malignant progression. We also 
present our results, highlighting Wnt aberrant activation in cervical biopsies. Therefore, we 
propose that cervical neoplasms caused by high-risk human papillomavirus (HPV) activate 
the Wnt/beta-catenin pathway in order to establish and progress.  
2. HPV viral cycle and cervical cancer development 
Epidemiological and molecular studies have shown a causal relationship between high-risk 
HPV infection and CC development (Walboomers et al., 1999). However, HPV is a necessary 
agent, but not sufficient cause of cervical intraepithelial neoplasia and CC. The above 
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mentioned arises from epidemiological studies that demonstrated that HPV is one of the 
most common sexually transmitted agents with prevalence between 10-40 percent in women 
who have no cytological abnormalities (Jacobs et al., 2000; Molano et al., 2002). There is 
enough evidence suggesting that is very likely that most of people could have an HPV sub-
clinical infection, especially increasing the risk at juvenile ages (younger than 25 years old). 
This is due to many factors, for instance, in the case of older women could be the acquired 
immunity to HPV from previous exposures, likewise the alcohol consumption and the 
number of sexual partners can increase specific risk (Burk et al., 1996;  Kjaer et al., 1997;  Ho 
et al., 1998;  Lazcano-Ponce et al., 2001.). 
Moreover, other cohort and multi-center studies have shown that the presence of the viral 
sequence can reach up to 85% in women who have no cytological abnormalities detected by 
pap-smear (Roteli-Martins et al., 2011). Apparently the median duration of HPV infection is 
around eight months with a high consistence between different populations (Ho et al., 1998; 
Franco et al., 1999.; Molano et al., 2002.). Thus, we can conclude that in the CC multistep 
carcinogenesis process HPV persistent infection is the initial step, however, other factors are 
involved towards the development of malignant phenotype.  
Regarding HPV molecular events towards carcinogenesis, there are three key events during 
HPV course of infection associated with cancer: 1) viral DNA integration to host genome; 2) 
expression of viral proteins (namely E1, E2, E4, E5, E6 and E7), and 3) the complex 
interactions between E2, E6/E7 and cellular proteins (Figure 1). Cervical cancer is a complex 
disease elicited by the interaction of viral, host, and environmental factors, exerting an 
influence on the risk of disease progression from early cervical abnormalities to invasive 
cancer; thus the proper identification of involved factors will lead us to a better knowledge 
of the natural history of HPV infection.  
Once HPV has infected basal cells, the viral genome is actively replicated as episome and early 
genes (E1–E7) are expressed. E1 and E2 are essential proteins for viral genome replication and 
viral cycle completion (Matsukura et al., 1989). E1 is an ATP-dependent DNA helicase which 
unwinds the double-stranded viral DNA and interacts with the -primase subunit of the DNA 
polymerase, to recruit the replication complex to the viral replication origin (Masterson et al., 
1998; Conger et al., 1999). E1 also interacts with multiple cyclins and is phosphorylated by 
cyclin/CDK complexes (Dalton et al., 1995; Cueille et al., 1998.). These interactions require the 
consensus RxL cyclin binding motif, present in the amino-terminal domain of the E1 protein. 
Moreover, mutation of RxL motif severely compromises replication of viral genome (Ma et al., 
1999), suggesting that E1 is regulating HPV genome replication through interaction with 
cyclins and CDKs complexes (Deng et al., 2004).  
The full-lenght E2 protein is a sequence-specific transcription factor that functions as an 
activator or repressor to tightly regulate the transcriptional activity of all HPV genes. This is 
achieved through four consensus E2-binding sites (E2-BSs), ACCGN4CGGT, whose 
locations within the upstream regulatory region (URR) are highly conserved among genital 
HPVs (Fig. 1; Hedge, 2002; Hou et al., 2002). It has also been seen that E2 participates in viral 
DNA replication via interaction with the protein E1 (Chiang et al., 1992). Hence, the versatile 
role of E2 protein functioning as a transcriptional repressor/activator and promoting 
genome DNA replication could be explained by E2-BSs occupancy in a context-dependent 
fashion. In this respect, E2 binding to E2-BS4 can especifically up-regulate viral early gene 
expression, including the expression of oncogenes E6 and E7. In contrast, E2 binding at the 
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promoter-proximal sites E2-BS1 and E2-BS2 leads to transcriptional repression of the early 
genes, including E6 and E7, whereas the E2-BS3 site is important for viral DNA replication 
(Steger & Corbach, 1997; Stubenrauch & Pfister, 1994; Stubenrauch et al., 1998). In this way, 
E2 contributes to the cell cycle control by regulating the expression of E6 and E7. Repression 
of HPV-early genes mediated by E2 appears to involve the displacement of cellular 
transcription factors from the viral promoter (Tan et al., 1994). Therefore, viral DNA 
replication and viral gene expression reflect the relative occupancy of different E2 binding 
sites, finely modulated by the concentration of the E2 protein (Figure 2A). 
 
Fig. 1. HPV viral cycle and cervical cancer development.  
Human papillomavirus infect epithelial basal cells through mechanical microabrassions or by 
infecting the transformation zone, an abrupt transition from a columnar to a squamous 
epithelium (Phase 1). Infected cells actively express the early genes E1, E2, E4 and E5 (Phase 2). 
E6 and E7 are expressed in limited amounts due to transcriptional modulation exert by E2, 
which permits to cells have a higher cell cycle rate. Infected basal cells migrate to the lumen as 
they differentiate expressing the late capside genes L1 and L2 (Phase 3). Viral genome is 
replicated as an episome in sub-clinical infections or low grade intra-epithelial-lesions (LGSIL), 
and is encapsidated in the nucleus of the upper layer epithelium (Phase 4). Shed viral particles 
then can infect new zones of epithelium or be sexually transmitted. Only a limited number of 
infections progress to high grade intra-epithelial-lesions (HGSIL) and cervical carcinoma (CC). 
The progression of LGSIL to CC is associated with the integration of the HPV genome into the 
host genome and the loss of transcriptional repression exerted by E2. 
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However, E2 is not only a transcription factor, but can also induce apoptosis in absence of 
any other HPV open reading frame by its association to the DED motif of caspase-8. HPV-18 
E2 protein induces caspase oligomerization through its amino-terminus motif containing a 
27 amino-acid -helix (Demeret et al., 2003; Thierry & Demeret C., 2008). In this context, HPV-
16 E2 protein induces apoptosis by means of the binding to p53; this interaction has 
important implications in the viral cycle. Fo example, it has been reported elsewhere that 
p53-E2 heterodimer can down-regulate HPV-16 DNA replication (Webster et al., 2000; 
Brown et al., 2008). It is known that E2 regulates the cell cycle progression through two main 
mechanisms: a) by means of apoptosis either p53-dependent or caspase induction pathway; 
and by b) balancing the expression/repression of oncoviral proteins E6 an E7. That balance 
executed by E2 is broken upon HPV integration onto the host genome.  
HPV genome replicates as episome or extrachromosomic molecule in benign cervical 
precursor lesions. However, cancer tissues can contain both episomal and integrated HPV 
DNA that has been covalently incorporated into the host cell chromosomal DNA (Cullen et al., 
1991; Hudelist et al., 2008). Because the HPV genome is a ring molecule, it requires to be open 
in order to be integrated; this process involves a breakage in the E1–E2 open reading frames 
region and deletion of E2 and adjacent regions E2–E4, E5, and L2, after integration. Hence, as 
we discussed above the fine tune on the expression levels of E6 and E7 exerted by E2 is lost 
and viral oncogenes E6 and E7 are actively expressed in CC tissue (Ueda et al., 2003). It has 
been suggested that common sites of viral integration are cellular genes that could contribute 
essentially to the enhanced progression risk of HPV-induced premalignant lesions to 
neoplastic lesions. Thus, it has been reported that frequent integration sites are near to MYC, 
NR4A2, hTERT, APM-1, FANCC, and TNFAIP2 (reviewed by Wentzensen et al., 2004).  
2.1 Effect of protein-protein interactions of E6 and E7 with nuclear proteins in the 
regulation of transcription 
The active expression of E6 and E7 is required to increase the proliferation capacity of 
malignant cells and uncoupling differentiation through targeting prominent regulators of 
cell cycle control progression. E6 and E7 epithelial expression and its interactions with 
cellular proteins have been at the center of the HPV biomedical research scenario probably 
for the past 20 years. The central core of the classic E6/E7 model is the binding and 
inactivation of tumour suppressor proteins p53 and pRb, respectively; which was 
established between the late 1980’s and the early 1990’s (Dyson et al., 1989; Scheffner et al., 
1990). Currently, it is well-known that E6 and E7 interact with a plethora of cellular proteins, 
in the nucleus and in the cytoplasm, that participate in molecular pathways involved in the 
activation and establishment of the malignant phenotype. We will not discuss about the 
cytoplasmic interactions between E6/E7 with cellular proteins but there are some available 
reviews previously published that are highly recommended, with extensive and 
comprehensive content (Moody & Laimins, 2010; Lavia et al., 2003). 
It has been well described that E6 and E7 do not posses DNA-binding domains (Mallon et 
al., 1987; Grossman et al., 1988). However, in the nucleus these viral products interact with 
chromatin remodeling proteins, such as the histone acetyl transferase CREB-binding protein 
CBP/P300; with transcriptional coactivators, such as hADA3; with transcription factors, 
such as AP1, IRF3, E2F1, TBP, MPP2, SRC-1 and pCAF; DNA-methyl transferases, and the 
telomerase (Antinore et al., 1996;  Phillips & Vousden, 1997; Ronco et al., 1998; Lüscher-
Firzlaff et al., 1999;  Huang & McCance, 2002;  Hwang et al., 2002; Maldonado et al., 2002; 
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Baldwin et al., 2006; ; Burgers et al., 2007; Liu et al., 2009.). These protein-protein interactions 
may conduct important changes in transcriptional regulation by the direct action of these 
viral oncoproteins upon specific genes. For instance, E6 and E7 recruit c-Jun, c-Fos and 
CBP/p300, and also inhibit the binding of the repressive histone deacetylase NCoR to the 
promoter of COX-2. This corepressor/coactivator exchange caused by E6 and E7 induce the 
expression of this target gene (Subbaramaiah and Dannenberg, 2007; Haertel-Wiesmann et 
al., 2000; Howe et al., 1999). In addition, the over-expression of COX-2 could accentuate the 
malignant phenotype induced by Wnt hyper-activation and correlates with the progression 
of cervical epithelial lesions and lymph node metastasis in cervical cancer patients (Liu et al., 
2011; Balan et al., 2011). Likewise, the interaction between E6 and E7 with CBP/p300 has 
been described in the context of the promoters of TP53 and the proinflammatory IL-8. This 
event inhibits the histone acetylation of TP53 promoter region and prevents the interaction 
between CBP/p300 with NFkappa-B and SRC-1 in the promoter of IL-8, which results in the 
inhibition of the expression of p53 and IL-8 (Bernat et al., 2003). Altogether, this aberrant 
repression contributes to hinder apoptosis, induce malignant transformation and could 
compromise the immune response against HPV. Aditionally, the E6-hADA3 interaction 
prevents the transactivation of TP53 and the transcriptional induction mediated by the 
retinoic X receptor (Hu et al,. 2009; Zeng et al., 2002, Kumar et al., 2002). Moreover, the 
binding between E7 and DNMT1 stimulate the methyltransferase activity of this enzyme, 
producing an aberrant hypermethylation state, which could lead to the silencing of tumour 
suppressor genes and cellular transformation (Burgers et al., 2007). Similarly, the promoter 
of the catalytic subunit of hTERT has E6 and cellular transcription factor Myc consensus 
sequences both actively participating in the induction of this gene (Sekaric et al., 2008). This 
effect is consistent with the increased hTERT activity observed in primary epithelial cells 
transfected with E6 and provides a molecular basis for the immortalization of these cells 
(Klingelhutz et al., 1996). Furthermore, E6 can interact directly with hTERT, this interaction 
upregulates the activity of hTERT which could be determinant for cellular immortalization 
and progression to cancer (Liu et al., 2009). 
As we have described above, E2 has a functional DNA-binding domain and regulates viral 
gene expression. In addition, E2 can also regulate the expression of relevant cellular genes. 
In this regard, E2 binds to and transactivates the promoter of the splicing factor SF2/ASF. 
SF2/ASF participates in the regulation of the alternative splicing, and its overexpression 
mediated by E2 could be related to the production of the viral alternative transcripts of L1 
and L2 in the replicative cycle (Mole et al., 2009). E2 also interacts with the transcription 
factor Sp1 in the promoter of hTERT to repress its expression (Lee et al., 2002). This fact is 
consistent with the increased hTERT transcription observed in cells that have lost E2 as a 
result of viral genome integration, and is independent of E6 co-activation of the hTERT 
promoter (Lee et al., 2002; Sekaric et al., 2008). Additionaly, E2 can interact with C/EBP to 
promote keratinocyte differentiation (Hadaschick et al., 2003). Altogether, these findings 
illustrate mechanisms that participate in differentiation, growth inhibition and senescence 
induction, which are associated to E2 function (Dowhanick et al., 1995). 
These findings reveal that the interaction of E6, E7 and E2 with nuclear proteins could 
constitute a hallmark of transcriptional regulation. This direct trans regulation exerted by 
the presence in situ of these viral proteins in human promoters, in the form of co-regulatory 
complexes (E6 and E7) or by direct binding to DNA (E2), could occur at a global, genomic 
level. These events provide new molecular mechanisms of aberrant phenotype 
development, where E2 and E6/E7 have counteracting forces. Therefore, the new horizon in 
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the comprehension of the molecular pathology of HPV must address this complex nuclear 
scenario, in which cellular and viral proteins are partners in the promotion of the malignant 
phenotype (Figure 2B).   
 
 
Fig 2. Molecular mechanisms induced by HPV early-expressed proteins. 
A. Meanwhile HPV is maintained as episome, E1 and E2 are actively expressed, which are 
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essential proteins for viral genome replication and viral cycle completion. E2 is a sequence-
specific transcription factor which regulates the E6 and E7 rate of expression; depending on 
E2-BSs occupancy sites. 
B. Human papilloma virus E6 and E7 interact with nuclear proteins such as transcription 
factors, chromatin remodelers, co-activators and DNA methyl-transferases to influence gene 
expression and cellular processes towards malignant phenotype and tumoral progression. 
In the late stage of the infection E2 expression is reduced with a concomitant increase in 
hTERT expression and reduction of differentiation, therefore the oncogenic activity of E6 
and E7 are up-regulated (for details see text). 
3. Wnt cell signalling pathway 
One of the most relevant signaling pathways in tumourigenesis that has been proposed as a 
hallmark of CC initiation and progression is the Wnt/beta catenin pathway (Uren et al., 
2005; Kloth, 2005; Pérez-Plasencia et al., 2007; Pérez-Plasencia et al., 2008). The proto-
oncogenic effects of Wnt were discovered almost 30 years ago in C3H mice bearing 
mammary tumours induced by a viral agent, the mouse mammary tumour virus (MMTV), 
which genomic sequences were integrated in the host genome. After this seminal work it 
was clear that common sites of MMTV integration were int- called sequences, which were 
transcriptionally activated in C3H mice breast tumours and inactivated in their normal 
counterparts (Nusse et al., 1984). Since then, a wealth of evidence has put in the scene the 
significance of Wnt activation during neoplasm progression in a vast majority of tumour 
types. The activity of Wnt proteins encompass the regulation of three pathways: 1) the 
planar cell polarity (PCP) pathway, which controls the polarization and differentiation of 
cells within a plane of an epithelium and is essential in the neural tube closure and 
alignment of the neurosensory hair cells of the cochlea (Curtin et al., 2003;  Quian et al., 
2007.); 2) the Wnt/Ca+2 pathway that regulates cell movement and adhesion (Kuhl et al., 
2000); and 3) the Wnt/beta-catenin or “canonical” pathway, which we will further discuss in 
this chapter, and that is involved in the regulation of proliferation and that is considered as 
a hallmark of cancer as well (Ying & Tao, 2009; Hu & Li, 2010; Morris et al., 2010.).  
Wnt glycoproteins are extracellular ligands found in many species, ranging from the 
ctenophore Mnemiopsis leidyi to humans (Pang et al., 2010). In mammals, Wnt signalling 
regulates the establishment of the anterior-posterior (A-P) axis, which was demonstrated by 
gene depletion in mouse (Zeng et al., 1997). In the adult body, Wnts are involved in the 
regulation of several biological processes, for instance, cell fate specification, proliferation, 
migration, cell adhesion, cell polarity, tissue architecture, organogenesis, and angiogenesis, 
among other. (Wodarz et al., 1988; Peifer et al., 2000;  Ross et al., 2000; Gong et al., 2001; 
Goodwin et al., 2002.). 
In tumours, the Wnt/beta-catenin pathway is activated and regulates the expression of genes 
involved in cell cycle progression, such as cyclin D1 (Tetsu & McCormick, 1999); transcription 
factors, such as cMyc, that enhance the shift to aberrant tumoural metabolism towards aerobic 
glycolisis (He et al., 1998); antiapoptotic proteins, such as survivin (Zhang et al., 2001a); 
proangiogenic factors including VEGF (Zhang et al., 2001b); and metalloproteinases related to 
tumour progression, invasion and metastasis (Brabletz et al., 1999; Crawford et al., 1999). The 
alterations in Wnt canonical pathway have been well characterized in colorectal cancer, in 
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which the via is activated in 80% of cases due to a high rate of mutations in the negative 
regulators, including axin, APC and GSKb1 and activating mutations on -catenin (Miyoshi et 
al., 1992; Bienz & Clevers, 2000; Segditsas & Tomlinson, 2009)(Figure 3).  
 
Fig. 3. Wnt canonical signaling pathway.  
A. WNT Pathway not active. 
When the wnt signaling pathway is not active, β-catenin binds to the degradation complex 
composed by APC, axin, and the serine/theronine kinases CK1 and GSK3. The main role of 
the degradation complex is to phosphorylate β-catenin leading to its degradation by means 
of the proteasome-ubiquitin pathway. βTrCp1 functions as an ubiquiting-ligase protein. The 
pathway can be regulated by several proteins that operate at the receptor-ligand level; such 
as, Cer1, DKK, WIF1 and sFRP, whose function is to modulate positive signals induced by 
Wnts. Planar Cell Polarity pathway (PCP) is regulated by NKD genes which interacts to 
DVL and degrade it by ubiquitination. 
B. WNT Pathway activated.  
The contact of wnt with its receptors leads to the stabilization of β-catenin and its 
accumulation in cytoplasm and nucleus. β-catenin displaces the transcriptional repressor 
groucho from the LEF/TCF complex, leading to the activation of target genes, such as c-myc 
and cyclinD1, which are involved in cell proliferation and cell cycle progression.  
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Wnt binds to and activate the seven-transmembrane domain specific receptors denominated 
Frizzled (FZD). The secretion and post-translational modification of Wnt proteins are 
attained by accompaning molecules, such as porcupine and Wntless (WIs), a process needed 
to the optimal release and Wnt binding to their receptors and co-receptors (reviewed at 
Coudreuse & Korswagen, 2007). The broad range of cellular processes regulated by the Wnt 
pathway can be explained -at least in part- by the high diversity between Wnt proteins and 
FZD receptors: nineteen members of Wnt family and ten FZD genes have been identified in 
higher vertebrates (Wordaz & Nusse R, 1988). Besides, interactions between Wnt proteins 
and their receptors show an important rate of promiscuity (Bahnot et al., 1996). The 
interaction between Wnt and Fzd requires the cooperation of LRP-5/6 co-receptors, which 
are long single-pass transmembrane proteins (Wehrli et al., 2000). In this light, mutational 
studies have shown that both genes are involved in developmental processes; for instance, 
dorsal thalamic development, skeletal and neural tube abnormalities, decrease in osteoblast 
proliferation, osteopenia, and persistent embryonic eye vascularization (Kokubu et al., 2004; 
Zhou et al., 2004; Lindvall, 2006.).  
Another level of regulation operating on the interaction between LRP5/6, FZDs, and Wnts is 
achieved by secreted proteins acting as antagonists such as the secreted frizzled-related 
protein (sFRP), Dickkopf (Dkk), Cerberus1 (Cer1), and KLOTHO, which can inhibit Wnt 
signaling through direct binding to Wnt or co-receptor molecules. Dkk binds to LDL 
receptor-related protein (LRP) with other transmembrane proteins, the Kremens (Krm); thus 
promoting LRP internalization and inactivation (Mao et al., 2002; Pinson et al., 2000). It has 
been observed that the lack of expression of the sFRP1 is common in cervical, breast, ovary 
and kidney neoplasms, by mechanisms that include the loss of the sFRP1 locus in 
chromosome 8p21 and promoter hipermethylation; moreover, sFRP1 downregulation is 
associtated with tumour progression and invasion (Klopocki et al., 2004; Ko et al., 2002; 
Ugolini et al., 2001). Similarly, in primary colorectal carcinomas it has been detected a high 
frequency of hypermethylation on sFRP1, sFRP2, sFRP4 and sFRP5 promoters, which 
correlates to a reduced expression of these genes (Suzuki et al., 2002). In addition, in vitro 
experiments showed that Dkk-3 has reduced expression in immortalized and tumour cells 
and it is frequently downregulated in non-smal cell lung cancer (Tsuji et al., 2000). 
After Wnt binds to their receptor co-receptor complex, FZD recruits Disheveled (Dvl), which 
transduces the Wnt signal into the cell through interaction with several pathway 
components. Indeed, Dvl has a key role in the Wnt signal routing and amplification through 
pathway-specific effectors, by its interaction with axin, which performs a scaffolding 
function in the Wnt pathway by its association with key proteins for β-catenin 
phosphorylation and poly-ubiquitination, including GSK-3β, CK1, APC, and β-catenin itself 
(Zeng et al., 2005; Davidson et al., 2005; McDonald et al., 2009). The consequence of axin 
phosphorylation is inactivation of “degradation complex” and the subsequent activation of 
β-catenin (Xing et al., 2003). Degradation complex is a multi-protein assembly activated in 
the absence of Wnt signaling, whose main task is to add ubiquitins to β-catenin resulting in 
its inactivation by means of the ubiquitin-proteasome pathway (Peifer & Polakis, 2000). A 
key component of the degradation complex is APC. When β-catenin binds to APC, it 
displaces the bound to axin because the binding affinity of β-catenin increases dramatically 
upon phosphorylation and because the binding motifs of APC to axin and β-catenin overlap. 
Most colorectal tumours contain truncating mutations on APC, which leads to an inability to 
bind Axin or degrade β-catenin (Kinzler & Vogelstein, 1996; Xing et al., 2003). 
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Finally, stabilized non-phosphorylated β-catenin tends to accumulate in the cytoplasm 
leading to its nuclear translocation, where it is associated with lymphoid enhancer-binding 
factor 1/Tcell-specific transcription factor (LEF/TCF) and transcriptional activator Pygopus 
(Pygo). Pygo contains a PHD domain, which is shared by many nuclear proteins with a role 
in chromatin remodeling and transcriptional co-activation (Belenkaya et al., 2002). Several 
genes activated by the Wnt signaling pathway, which are involved in cell proliferation and 
differentiation processes have been identified (Daniels & Weis, 2005) (Figure 3).  
The Naked cuticle (Nkd) protein family (NKD1,2), whose activity is required to restrict Wnt 
signaling during Drosophila embryonic segmentation, thus establishing a negative-feedback 
loop and ameliorating canonical Wnt signaling by binding and destabilizing Dsh/Dvl 
proteins (Rousset et al., 2001). NKD was the first Wnt antagonist found to be induced by the 
Wnt pathway (Zeng et al., 2000). Besides, Naked cuticle is proposed to function as a switch, 
acting to restrict classical Wnt signaling and to activate a second Wnt signaling pathway that 
controls planar cell polarity (PCP) during gastrulation movements in vertebrates (Wharton 
et al., 2001). Recently, it has been shown mutations in NKD1 in a subset of DNA mismatch 
repair-deficient colorectal tumours that are not known to harbor mutations in other Wnt-
pathway genes. The mutant Nkd1 proteins were defective at inhibiting Wnt signaling; in 
addition, the mutant Nkd1 proteins stabilize β-catenin and promote cell proliferation, in 
part due to a reduced ability of each mutant Nkd1 protein to bind and destabilize Dvl 
proteins (Guo et al., 2009). Those results suggest that NKD1 is a negative regulator of Wnt 
and an important target of mutations during the carcinogenesis process. 
3.1 Wnt pathway and Cervical Carcinoma 
Wnt/-catenin pathway activation is an established hallmark of cancer; hence, mutations in 
distinct components of this pathway have been studied and identified in nearly all human 
cancers. In contrast to what is observed in other tumours, Wnt canonical pathway activation 
caused by mutations is meaningless in CC. In this regard, cervical high grade lesions have 
an increased expression and nuclear localization of β-catenin with no mutations of CTNNB1 
nor Axin (Shinohara et al., 2001; Pereira-Suárez et al., 2002; Su et al., 2003). Thus, in CC it is 
possible that activation of β-catenin occurs independently of activating mutations by an 
upstream level mechanism, which could be accomplished by the inactivation of negative 
regulators. It is well-known that during carcinogenesis aberrant CpG island methylation 
inactivates distinct tumour suppressor genes, a mechanism that could be explained by 
means of an increase in DNA methyltransferase (DNMT) activity (Robertson, 2001). In this 
context HPV16/E7 has the capacity to bind and increase the DNMT1 activity, (Burgers et al., 
2007); thus, it is feasible that negative Wnt/β catenin-pathway regulators are inactivated by 
methylation. In this respect, sFRPs, axin, DICKKOPF (Dkk), KLOTHO and APC genes have 
enriched CpG islands in their promoters which can be found as hypermethylated in CC 
(Mikheev et al., 2004; Chung et al., 2009a; Chung et al., 2009b; Lee et al., 2009; Okino et al., 
2003; Lee et al., 2010; Song et al., 2009). Therefore, it is probable that inactivation of these 
genes by promoter hypermethylation induce activation of Wnt canonical pathway during 
cervical carcinogenesis. 
On the other hand, respecting the upstream activation of Wnt/β-catenin pathway, the over-
expression of pathway activators such as Wnt ligands, frizzled receptors, and disheveled 
has been described. There is evidence showing over-expression of WNT10B, -14, FZD10, and 
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DVL-1 in cervical cell lines (Kirikoshi & Katoh, 2002; Kirikoshi et al., 2001; Koike et al., 1999; 
Okino et al., 2003); nonetheless, this has not been explored in pathological specimens. 
 
Fig. 4. NKD and DVL are over-expressed from early staged lesions.  
Levels of Wnt regulators were assessed in cervical epithelial lesions by means of Immune-
histochemistry. Unexpectedly NKD1 and 2 were over-expressed showing an aberrant 
nuclear staining. As expected, DVL is over-expressed in cervical lesions. 
We have reported by genome-wide expression analysis in HPV16 CC tissues that one of the 
most altered pathways is Wnt/β-catenin. In our study, we observed a significant increment 
of Wnt4, -8a, Fzd2, GSK3β, and β-catenin in tumours. In addition, genes also belonging to 
this pathway are actively expressed in normal cervical epithelia, such as sFRP4, PPP2C, and 
FZD7 (Pérez-Plasencia et al., 2007). This evidence demonstrates two important facts: first, 
the deregulation in specific genes belonging to Wnt/β-catenin pathway could play an 
important role in cervical carcinogenesis, and second, the presence of some Wnt/β-catenin-
related genes in normal tissues suggests that this pathway is involved in cervical epithelial 
differentiation. Interestingly, gene components of the planar cell polarity (PCP) pathway 
were actively expressed in normal cervices, indicating that this branch of Wnt signaling is 
down regulated in CC. In vertebrates, PCP is considered as any process affecting cell 
polarity within an epithelial plane and involving one or more core PCP genes. PCP has 
shown to be an important developmental and adult tissue differentiation process (Wang & 
Nathans, 2007). To our knowledge, there are no previous reports showing active PCP genes 
in normal cervical epithelia. This result demonstrates that during the carcinogenesis process, 
infected cervical cells turn off the PCP pathway, activating the canonical pathway with a 
concurrent increase of genes participating in it, for instance, Wnt4, -8A, FZD2, CTNNB1, 
among others. The activation of the canonical pathway leads to the upregulation of target 
genes such as MYC, JUN, FOS, and RRAS, which are related to growth promotion (Pérez-
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Plasencia et al., 2007). Notwithstanding, NKD1 and NKD2 expression in CC specimens 
show an increased expression and aberrant nuclear localization as an early event, occurring 
from low grade squamous intraepithelial lesions to carcinoma (Figure 4). Apparently, the 
aberrant localization is due to a lack of 300 bp in transcripts sequence (Pérez-Plasencia 
unpublished results), indicating a key role of NKD genes in Wnt pathway regulation on CC 
tumour progression.  
Additionaly, some experiments in vitro have shown that high-risk HPV16 E6 oncoprotein 
was capable of activate Wnt/beta-catenin pathway in an E6AP dependent fashion (Lichtig et 
al., 2010). Altogether, these data are in concordance with the fact that human genital 
keratinocytes immortalized with high-risk HPV need the activation of Wnt canonical 
pathway to be transformed and suggest that this event is essential in the cervical 
tumourigenesis (Uren et al., 2005). 
4. Conclusions 
The extensive use of the Papanicolau smear and colposcopy examination have significantly 
decreased the CC mortality rates; however, this neoplasm still remains as the second cause 
of death in women worldwide. Concordantly, HPV presence has been found in more than 
99% of CC, hence HPV infection is considered as the most important etiologic factor in 
cervical carcinogenesis. Even though HPV infection is very common among the young 
sexually active population, only a small fraction of infected individuals develop cervical 
carcinoma later in life. Thus, HPV is considered only as an initial hit in the multistep 
carcinogenesis that leads to the development of CC. The molecular pathways involved in 
the progression of HPV-infected cells to CC have not been accurately identified. Here, we 
reviewed the role of Wnt/β-catenin pathway over-activation and the inactivation of planar 
cell polarity pathway in CC cells as a second hit to develop CC; moreover, one key regulator 
of PCP, NKD, is aberrantly localized in nucleus and overexpressed in CC. In this regard, 
many reports have described that Wnt/β-catenin pathway is aberrantly active in CC, where 
common tumour-causing mutations on the genes of this pathway, such as APC, Axin and 
CTNNB1 have not been found. Thus Wnt/β-catenin pathway over-activation could be 
caused by disregulation in upstream modulators, by means of negative regulators 
inactivation or over-expression of activators. On the other hand, an additional branch in 
Wnt signaling pathway, that could be determinant during CC pathogenesis, is the planar 
cell polarity (PCP) pathway, which is involved in cellular differentiation. PCP is a key via in 
differentiation and the morphogenetic process involved in development of epithelia. In 
normal cervical epithelia, cells are polarized and migrate from basal to the luminal space as 
they differentiate. Interestingly, PCP component genes are repressed in CC, indicating that 
this pathway could be abated prior the establishment of the neoplasia. From the diagnostic 
point of view, this fact could be of great importance because the possibility to reveal PCP 
downregulation as an early tumourigenic process could provide for potential methods of 
early molecular markers detection in patients who have HPV and will develop CC. 
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1. Introduction 
For close to a century, researchers have known that Papillomavirus infections in humans 
cause a variety of benign proliferations including warts, epithelial cysts, intraepithelial 
neoplasias, oral laryngeal, pharyngeal papillomas and other types of hyperkeratosis. 
However the molecular mechanisms involved are far from understood. HPV has been 
detected in more than 90% of cervical cancers and therefore implicated as the main 
etiological agents in cervical cancer. The pathogenesis of cervical cancer is well-known to 
involve a multi-step process that includes the transformation of normal cervical epithelium 
to pre-neoplastic cervical intraepithelial neoplasia that is subsequently transformed to 
invasive cervical cancer. Although the causal relationship between high-risk human 
papillomavirus (HPV) infection and cervical cancer has been well-documented in 
epidemiologic and functional studies, HPV infection alone is not sufficient to induce the 
malignant transformation of HPV-infected cells. Hence, other unidentified genetic 
alterations, such as microRNAs the master switches, are required. A class of molecules 
discovered quite recently, microRNAs (miRNAs), appear to play a significant role in cell 
proliferation and differentiation, and aberrant miRNAs are associated with several cancers. 
An new era focusing on micro RNAs, and the studies on HPV and host miRNA interactions 
will continue shedding more light on understanding of the HPV life cycle and the 
mechanistic underpinnings of HPV-induced oncogenesis. 
These small non-coding RNAs can contribute to the repertoire of host pathogen interactions 
during viral infection. This interplay has important consequences, both for the virus and the 
host. There has been reported evidence of host-cellular miRNAs modulating expression of 
various viral genes, thereby playing a pivotal role in the host–pathogen interaction network. 
In the hide-and-seek game between the pathogens and the infected host, viruses have 
evolved highly sophisticated gene-silencing mechanisms to evade host-immune response. 
Recent reports indicate that virus also encode miRNAs that protect them against cellular 
antiviral response. Furthermore, they may exploit the cellular miRNA pathway to their own 
advantage. This chapter aims to summarize our current knowledge about miRNA profiles in 
cervical cancer cell lines and tissues as well as recapitulate recent updates on miRNA-
induced gene-silencing mechanism; modulating host–virus interactions of HPV integrated 
Cervical Carcinomas. 
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2. Human papillomaviruses and cervical cancer 
Cervical cancer is the second most common life-threatening cancer among women 
worldwide, with 493,243 new cases and nearly 273,505 deaths per year (Parkin et al., 2005, 
2006). In 2010, there were an estimated 12,200 new cases and an associated 4,210 deaths, 
accounting for approximately 1% of cancer deaths in women (Jemal et al., 2010). In 1995 the 
World Health Organization (WHO) declared HPV as a known carcinogen for causing factor 
for cervical cancer, because DNA of mucosal high-risk HPV types could be detected in 
almost all cervical cancers (Walboomers et al., 1999). Persistent infection with oncogenic 
high-risk subtypes of human papillomavirus (HPV) leads to cervical cancer (zur Hausen 
2002) and over 50% of the cases are HPV-16 (Walboomers et al., 1999). In cancer 
development, HPV-16 early proteins E6 and E7 are often believed to act as oncoproteins as 
both are crucial for immortalization and transformation of cervical keratinocytes (Munger et 
al., 2004). The E6 and E7 oncogenes work synergistically to deregulate cell cycle controls 
through a variety of mechanisms. The E6 oncogene promotes ubiquitination and 
proteasomal degradation of the tumor suppressor protein p53 and also deregulates the cell 
cycle (Thomas et al., 1999). The E7 protein binds to and inactivates the function of 
retinoblastoma protein Rb and the related tumor suppressor proteins p107 and p130. It 
disrupts the complex between Rb and the E2F transcription factor family, which controls the 
expression of genes involved in cell-cycle progression. Thus, destabilization of p53 and 
hypophosphorylated pRb by the expression of two viral oncoproteins E6 and E7 promotes 
chromosomal instability, foreign DNA integration, and other mutagenic events in the cell.  
2.1 HPV Oncoproteins 
HPVs encode two major oncoproteins, E6 and E7, which are consistently expressed in 
cervical carcinomas. E6 and E7 lack intrinsic enzymatic activities and transform cells by 
stimulating cell growth and inactivating tumor suppressor pathways. Expression of HPV16 
E6/E7 oncoproteins in primary human epithelial cells causes genomic instability.  
2.1.1 E6 protein 
The E6 protein of HPV is a 18 kDa phosphoprotein, which is localized in the nucleus and in 
non-nuclear membranes.  E6 is a critical factor in tumor formation and acts to destabilize the 
tumor suppressor p53. The p53 tumor suppressor protein, in turn, regulates the 
transcription of several genes that keep cell proliferation in check by inducing cell cycle 
arrest, DNA repair, or apoptosis. The E6 protein forms a complex with p53 and the cellular 
ubiquitin ligase causing a  deregulation of the cell cycle control at the G1/S and G2/M check 
points, an important step for the replication of HPV, because a productive infection cycle is 
only possible in cells, which are in the S-phase of the cell cycle. However, this cell cycle 
manipulation can lead to activation of oncogenes or inactivation of tumor suppressors and 
consequent DNA damage cannot be repaired. This leads to genetic instability and to 
malignant transformation of high-risk HPV-infected cells (Fehrmann and Laimins 2003). 
Another important way how E6 proteins of genital HPV contribute to transformation is the 
activation of the human telomerase reverse transcriptase promoter, which controls the 
transcription of the catalytic telomerase subunit. E6 proteins of cutaneous HPV do not 
 
Interplay between HPV Oncoproteins and MicroRNAs in Cervical Cancer 
 
349 
interact with p53 or E6-AP and do not degrade p53 (Elbel et al. 1997). Furthermore E6 
proteins of both cutaneous and anogenital HPV are able to target the proapoptotic protein 
for ubiquitin-dependent degradation by assembling E6-AP, thereby inhibiting apoptosis.  
2.1.2 E7 protein 
E7 is a 11 kDa protein with a zinc finger motif. It acts as an oncogene in genital high risk 
HPV and is able to immortalize primary foreskin keratinocytes. The major part of the 
transforming potential of E7 is due to binding and induction of ubiquitin-dependent 
degradation of the tumor suppressor retinoblastoma protein (Rb) (Berezutskaya and Bagchi 
1997). The competitive binding of E7 to Rb and its degradation lead to segregation of the 
transcription factor E2F. In the G1-phase, E2F is inactivated in a complex with Rb. After 
segregation, E2F can induce the expression of genes, which are important for DNA synthesis 
and cell cycle control. Additionally E7 can bind the inhibitors of cyclin dependent kinases 
p21CIP1 and p27KIP1 and inhibit their functions (Münger et al.2001). Both events direct the 
cell into the S-phase and enable the viral replication.  
3. MicroRNA biology 
One of the most significant recent advances in biomedical research has been the discovery of 
∼22-nt-long class of noncoding RNAs designated as microRNAs (miRNAs). MicroRNAs are 
small, non-coding RNAs that regulate gene expression (Ambros et al., 2003) it function by 
binding to the 3’ UTRs of their target messenger RNA (mRNA), whereby they induce 
mRNA degradation or repression of translation. The functions of miRNAs are still largely 
unknown but they appear to be integral to modulation of gene expression and cell behavior. 
These regulatory RNAs provide a unique level of posttranscriptional gene regulation that 
modulates a range of fundamental cellular processes.  
MiRNAs were first discovered in C. elegans (Lee et al., 1993). They have since been found to 
be conserved across many species, and may regulate thousands of targets via the RNAi 
pathway (Lewis et al., 2005). Most miRNAs are transcribed by RNA polymerase II, have a 
Cap, and are polyadenylated (Cai et al., 2004). They are often processed from polycistronic 
transcripts (Lee et al., 2002). Following transcription, the large primarymiRNA transcripts 
are processed into precursor-miRNAs by the protein Drosha . Pre-miRNAs are hairpin-like 
structures with characteristic 2 nt 3’ overhangs (Figure.1). They are exported to the 
cytoplasm by exportin 5 (Lund et al., 2004), where further processing into miRNA duplexes 
by the protein Dicer. MicroRNA duplexes associate with the RISC complex but only one 
strand, the mature miRNA; remains associated with it and are delivered to its target 
(Schwarz et al., 2003; Khvorova et al., 2003). The fate of target mRNAs depends on the 
degree of complementarity with the miRNA. Commonly, the 5’ 2-8 nt of the miRNA (called 
the seed sequence) is complementary to the target, and the remaining miRNA contains 
many mismatches. A low degree of complementarity results in translational repression, 
whereas a high degree of complementarity results in cleavage of the mRNA followed by its 
eventual destruction (Kim, 2005).  
To date, more than 10,000 miRNAs have been annotated in 96 species, including over 700 
human miRNAs (miRBase v14.0). More than 50% of miRNA genes are located in cancer 
associated genomic regions or in fragile sites, suggesting that miRNAs should be important 
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in cancer formation (Calin et al., 2004). Some recent studies show that miRNAs control many 
crucial biological activities, including cellular proliferation, differentiation and apoptosis 
(Esquela-Kerscher and Slack, 2006; Zhang et al., 2007). The main function of miRNA is to 
repress the expression of target mRNA by cleavage or translational silencing, which 
depends on their complementation with the 3’-untranslated region (3’UTR) of target 
mRNAs (Calin and Croce, 2006; Esquela-Kerscher and Slack, 2006; Garzon et al., 2005). By 
using highthroughput miRNA microarray analysis, compared with the adjacent normal 
tissues, deregulation of the expression of miRNAs has been reported in different kinds of 
human cancer (Zhang et al., 2007; Lee et al., 2008), including cervical cancer (Lui et al., 2007; 
Lee et al., 2008). The aberrant expression of miRNA in cancer indicates the possible function 
of miRNAs in cancer development (Calin and Croce, 2006). Current evidence indicates that 
viruses use these miRNAs to manipulate both cellular and viral gene expression. 
Furthermore, viral infection can exert a profound impact on the cellular miRNA expression 
profile.  
 
Fig. 1. Biogenesis of MicroRNA 
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3.1 MicroRNA and cancer 
Many studies showed that miRNAs are aberrantly expressed in cancer, suggesting their role 
as a novel class of oncogenes or tumor suppressor genes. Many studies have been 
performed to investigate the contribution of miRNAs to carcinogenesis.  The findings that 
miRNAs have a role in cancer are supported by the fact that about 50% of miRNA genes are 
localized in cancer-associated genomic regions or in fragile sites or integration sites of high-
risk HPVs (Calin et al., 2004). Integration may alter miRNA expression via deletion, 
amplification, or genomic rearrangement. In a recent study, Lu et al., (2005) profiled miRNA 
expression patterns of human cancers and found differential expression for each cancer 
type. Depending on the nature of their targets, miRNAs can function as either tumor 
suppressor genes or oncogenes. For example, overexpression of miRNAs that target 
oncogenes can lead to increased destruction of these oncogenes and therefore tumor 
suppression. Conversely, overexpression of miRNAs that target tumor suppressors can 
result in increased oncogenic activity and tumor formation. Regulation mediated by these 
genes has possibly a large impact on gene expression because, according to computational 
predictions, a single miRNA can target dozens of genes. MicroRNAs have been shown to 
regulate the oncogenes Bcl 2 and Ras, as well as the tumor suppressor pRb. MiR-15 and 
miR-16 were the first miRNAs shown to be associated with cancer; they are underexpressed 
in chronic lymphocytic leukemia (CLL) (Calin et al., 2002). They regulate the Bcl-2 oncogene, 
which is overexpressed in many cancers (Cimmino   et al., 2005). The let-7 family of miRNAs 
regulates the Ras oncogenes, which contain activating mutations in about 15-30% of cancers 
(Johnson SM,  et al., 2005) and down regulation of the let-7 family of miRNAs results in the 
up regulation of Ras, which is most pronounced in lung cancers (Takamizawa J, et al., 2004). 
3.2 Altered microRNA signatures in cervical cancer 
Many authors have reported that each cancer tissue has a specific microRNA signature and 
microRNA based cancer classification is a very effective and potential tool (Lu et al., 2005).It 
is interesting to speculate that miRNA expression signatures have been shown to be 
promising biomarkers for Cervical Cancer prognosis (Xiaoxia Hu et al.,2010). Thus miRNA 
expression patterns may serve as potential biomarkers of pre-invasive cervical disease and 
potential therapeutic targets. Keeping in view the immense impact of microRNAs 
expressional profile in cancer biology, conducted surveys on expressional patterns of 
miRNAs in cervical cancer suggested that beyond HPV, microRNAs play a major role in 
cervical cancer pathogenesis and progression (Reshmi and Pillai 2008). Micro-RNA 
expression profile in cervical cancer cell lines found that of 174 miRNAs which could be 
grouped into 46 different miRNA species, miR-21, miR-24, miR-27a, and miR-205 were most 
abundant in cervical cancer or cervical intraepithelial neoplasia derived cell lines (Wang et 
al., 2008). MicroRNA array analyses for age-matched normal cervix and cervical cancer 
tissues, in combination with Northern blot verification identified deregulated miRNAs in 
cervical cancer tissues. Down regulation of with miR-126, miR-143, and miR-145, miR-218, 
and miR-424 and up regulation of miR-15b, miR-16, miR-146a, and miR- 155 had shown in 
Table 1 and 2 respectively. Functional studies showed that both miR-143 and miR-145 are 
suppressive to cell growth. When introduced into cell lines, miR-146a was found to promote 
cell proliferation. Another study suggested that overexpression of miR-17-5p, miR-20a, miR-
21, miR-92, miR-106a, and miR-155 could be considered a miRNA signature of solid tumors 
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(Volinia et al., 2006). Eighteen miRNAs were upregulated in solid tumors where 15 were 
downregulated in cervical cancer tissues. The increased expression of miR-15b, miR-16, 
miR-146a, miR-155, and miR-223 observed in cervical cancer tissues has also been implicated 
in the development of other human cancers. Another study suggests that altered miRNA 
expression patterns seen in early stage invasive squamous cell carcinomas (ISCCs) and 
normal epithelial tissues of the cervix and findings suggest that miR-127 may be a marker 
for lymph node metastasis of ISCCs and that miR-199a may be a potential therapeutic target 
for future cervical cancer therapy (Lee et al., 2008). 
 
 
miRNA Chromosome Putative Function 
hsa-miR-210 11 oncogenic 
hsa-miR-182 07 og/tsg 
hsa-miR-183 08 og/tsg 
hsa-miR-200c 12 tumour suppressor 
hsa-miR-203 14 og/tsg 
hsa-miR-193b 16 oncogenic 
hsa-miR-34a 01 og/tsg 
hsa-miR-31 11 og/tsg 
hsa-miR-210 11 og/tsg 
hsa-miR-27a 19 og/tsg 
hsa-miR-503 X og/tsg 
hsa-miR-27b 09 og/tsg 
hsa-miR-199a 19 og/tsg 
hsa-miR-199b 09 og/tsg 
hsa-miR-146a 05 og/tsg 
hsa-miR-133a 18 og/tsg 
hsa-miR-133b 06 og/tsg 
hsa-miR-214 01 og/tsg 
hsa-miR-127 14 og/tsg 
og-oncogene; tsg-tumor suppressor gene 
 
Table 1. MicroRNAs overexpressed in cervical cancer cell lines. 
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miRNA Chromosome Putative function 
hsa-miR-126 09 og/tsg 
hsa-miR-145 05 og/tsg 
hsa-miR-451 17 og/tsg 
hsa-miR-195 19 og/tsg 
hsa-miR-143 05 og/tsg 
hsa-miR-199b 09 og/tsg 
hsa-miR-1 01 og/tsg 
hsa-miR-495 14 og/tsg 
hsa-miR-497 17 og/tsg 
hsa-miR-133b 06 og/tsg 
hsa-miR-223 X og/tsg 
hsa-miR-126-AS 09 og/tsg 
hsa-miR-150 19 og/tsg 
hsa-miR-376a 14 og/tsg 
hsa-miR-214 01 og/tsg 
hsa-miR-487b 14 og/tsg 
hsa-miR-10b 02 og/tsg 
hsa-miR-218 04 og/tsg 
hsa-miR-149 02 og/tsg 
hsa-miR-203 14 og/tsg 
og-oncogene; tsg-tumor suppressor gene 
Table 2. MicroRNAs underexpressed in cervical cancer cell lines. 
3.3 Modulation of cellular microRNA regulation by HPV oncoproteins 
Deletions or mutations in miRNA genes, as well as aberrant expression of oncogenic or 
tumor-suppressive miRNAs, are common in human cancers (Calin and Croce 2006; Wang et 
al. 2008), but the causes for their aberrant expression are poorly understood. Although many 
human viruses produce their own viral miRNAs in the course of virus infection (Tang S et 
al., 2008 & Umbach et al. 2008), but recently various studies  reported on viral proteins 
regulation of cellular miRNA expression. Deregulation of oncogenic and tumor suppressive 
miRNAs in human cervical cancer is associated High-risk human papillomavirus (HPV) 
integration. Cervical cancer represents a unique tumor model for understanding how viral 
E6 and E7 oncoproteins deregulate the expression of the microRNA clusters via downstream 
targets of the transcription factors (Figure.2). It is well recognized that cellular miRNAs play 
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important roles in the regulation of cellular genes. Recent data designate that cellular 
miRNAs can also target the genetic material of invading viruses. Moreover, Latest host viral 
interaction studies of HPV integrated cervical cancer samples supports the evidence of 
interplay between the viral oncoproteins and microRNA expressions in oncogenic HPV-
infected cells. 
3.3.1 hsa-miR-34a 
Recently, miR-34a was identified as a direct transcriptional target of cellular transcription 
factor p53 (He et al. 2007; Raver-Shapira et al. 2007). This transactivation of miR-34a 
expression is triggered by the binding of p53 to a consensus p53 binding site identified in 
the miR-34a promoter region. Since HPV E6 oncoprotein destabilizes p53 during virus 
infection, one may assume a down-regulation of miR-34a expression in most cervical cancer 
tissues with oncogenic HPV infection. Interestingly, Wang et al discovery shows that at all 
stages of pathogenesis induced by the high-risk HPV types, the E6 destabilization of the 
tumor suppressor p53 down-regulates the tumor-suppressive miR-34a, leading to the 
elevated expression of cell cycle regulators and cell proliferation (Wang et al., 2009). These 
intimate interplays among viral E6, p53, miR-34a, and E7 place miR-34a in a central role in a 
well-known viral oncoprotein–tumor suppressor network. 
3.3.2 hsa-miR-23b 
Au Yeung et al., suggesting miR-23b is often downregulated in HPV-associated cervical 
cancer. Interestingly, urokinase-type plasminogen activator (uPA), the miR-23b target, is 
detected in cervical cancer, but not in normal cervical tissues. Thus, the importance of miR-
23b and uPA in HPV-associated cervical cancer development is investigated. HPV-16 E6 
oncoprotein was found to decrease the expression of miR-23b, increase the expression of 
uPA, and thus induce the migration of human cervical carcinoma SiHa and CaSki cells. uPA 
is the target gene for miR-23b as the miR repressed uPA expression and interacted with the 
3′-untranslated region of uPA mRNA. From the above, miR-23b/uPA are confirmed to be 
involved in HPV-16 E6-associated cervical cancer development ( Au Yeung et al., 2011). 
3.3.3 hsa-miR-218 
MicroRNA-218 (miR- 218) is specifically underexpressed in cell lines, cervical lesions and 
cancer tissues containing integrated HPV-16 DNA compared to the normal cervix. Martinez 
et al., studies revealed that exogenous expression of the HPV-16 E6 oncogene reduced miR-
218 expression, and conversely, RNA interference of E6/E7 oncogenes in an HPV-16 
positive cell line increased miR-218 expression. Exogenous expression of miR-218 in HPV-16 
positive cell lines decreased expression of the epithelial-specific gene LAMB3, which is 
involved in cell migration and tumorigenicity (Martinez et al., 2008) 
3.3.4 hsa-mir-29 
Yang et al established a putative HPV-associated miRNA–mRNA regulatory network, 
showing that miR-29 is the most highly enriched. Studies found that YY1 and CDK6 were 
both positively correlated with E6/E7 RNA expression and targeted by tumour-suppressive 
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miR-29 (Yang et al., 2011). Evidence of miR-29 involvement in HPV infection was further 
verified in patient samples and by various experimental approaches suggests that HPVs 
have oncogenic properties at least in part by reshaping the milieu of cellular miRNAs. miR-
29 restrains cell cycle progression and induces apoptosis via YY1 and CDK6 promoting 
malignant transformation induced by HPV, although the abnormality of miR-29 in HPV-
infected cells might be regulated in an indirect way. 
 
Fig. 2. Interaction of HPV oncoproteins and regulation of MicroRNAs in Cervical Carcinoma 
3.3.5 hsa-miR-203 
Recent studies indicated that the HPV E7 protein interferes with the normal upregulation of 
miR-203 expression upon differentiation, which may occur through the mitogen-activated 
protein (MAP) kinase/protein kinase C (PKC) pathway. Interestingly, the MAPK pathways 
induce all these transcription factors (Melar et al., 2010). Several downstream targets of p63, 
CARM-1, p21, and Bax, were also increased in E7-expressing cells, and their levels were 
inversely correlated with amounts of miR-203.Since the MAPK/protein kinase C (PKC) 
pathway is also implicated in regulating keratinocyte differentiation, studies suggests that 
miR-203 levels were affected by the MAPK/PKC pathway signaling and if HPV E7 
interfered with the activation of this pathway. 
Recent studies indicate that human cellular miRNAs can also target the genetic material of 
invading HPV viruses. It also gives the virus an opportunity to modulate the host to suite its 
needs. Thus the range of interactions possible through miRNA-mRNA cross-talk at the host-
pathogen interface is large. These interactions can be further fine-tuned in the host by 
changes in gene expression, mutations and polymorphisms. In the pathogen, the high rate of 
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mutations adds to the complexity of the interaction network. Though evidence regarding 
microRNA mediated cross-talk in viral infections is just emerging, it offers an immense 
chance not only to understand the intricacies of host-pathogen interactions but also to 
develop novel biomarkers and therapeutics. 
4. Conclusion 
On the basis of these observations, we suggest a new dimension to HPV-initiated 
carcinogenesis. HPV modulates the expression of numerous cellular microRNAs that are to 
likely contribute to viral pathogenesis. Surprisingly, recent studies have led to the 
identification of cellular microRNA regulation by HPV oncoproteins and viral regulation of 
expression of a tumor suppressor miRNAs. The known data provides evidence that this 
intimate interplay of oncoproteins and microRNAs could disclose new ways for cancer 
diagnosis, prognosis evaluator and therapy.  
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1. Introduction 
Cervical cancer is the second most common cancer among women in the worldwide.  
Especially, in many regions of developing countries, cervical cancer is the most common 
among women. Infection with human papillomavirus (HPV) is a necessary event 
preceding the development of premalignant lesions in the cervical epithelium, which can 
partially progress to cancer. HPV DNA can be identified in almost all specimens of 
patients with invasive cervical cancer (Chen & Hunter, 2005; Munoz et al., 2003; Tindle, 
2002). Molecular epidemiological studies have demonstrated that specific subtypes of 
HPV are closely associated with cervical cancer, although the risk of cervical cancer varies 
with HPV types (Bosch et al., 2002; Chen & Hunter, 2005; International Agency for 
Research on Cancer [IARC] Working Group, 2007; 2011; Munoz et al., 2003; Sisk & 
Robertson, 2002; Tindle, 2002). IARC has classified several types of high-risk HPV, 
including HPV-16 and HPV-18, to be carcinogenic to humans (group 1) (IARC Working 
Group, 2007; 2011).  
The molecular mechanisms of HPV-induced carcinogenesis have been extensively 
investigated by focusing on HPV oncoproteins, E6 and E7 (Yugawa & Kiyono, 2009).  E6 
and E7 genes are invariably expressed in HPV-positive cervical cancer cells.  E6 protein 
forms a ubiquitin ligase complex with E6-associated protein (E6AP) and promotes the 
degradation of p53 protein, a tumor suppressor gene product involved in apoptosis, cell 
cycle arrest and DNA repair. The E6/E6AP complex also induces the transcription of the 
catalytic subunit of human telomerase reverse transcriptase (hTERT) via degradation of 
the repressor NFX1-91, leading to cell immortalization (Xu et al., 2008).  E7 oncoprotein 
binds and degrades retinoblastoma protein (RB), a major negative regulator of the cell 
cycle, and the related family members (Duensing & Munger, 2004). Recent studies 
demonstrated that E7-mediated degradation of RB requires the calcium-activated calpain, 
a cysteine protease (Darnell et al., 2007) and involves the interaction with p600, an RB-
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associated factor (Huh et al., 2005). E7 also inactivates the cyclin-dependent kinase (CDK) 
inhibitors, p21 and p27 (Duensing & Munger, 2004).  E7-induced RB degradation leads to 
the release of the transcription factor E2F from the RB/E2F transcriptional repressor 
complex (von Knebel Doeberitz, 2002).  Activation of E2F mediates gene transcription 
with increased expression of cyclin E and cyclin A and aberrant CDK2 activity (Duensing 
& Munger, 2004).  In addition, these oncoproteins cause genomic instability (Duensing & 
Munger, 2004).  E6 and E7 cooperatively induce numerical centrosome aberrations and 
eventual aneuploidy in cells overexpressing these oncoproteins (Duensing et al., 2000). E7 
protein of high-risk type HPV induced chromosome overduplication associated with 
aberrant multipolar spindle pole formation, while E6 had no immediate effects on 
centrosome numbers but potentiated mitotic disturbance (Duensing et al., 2000). On the 
basis of these numerous studies, E6 and E7 oncoproteins are considered to participate in 
cervical carcinogenesis by inducing cell immortalization, dysregulation of cell 
proliferation and chromosomal instability.   
However, it has been reported that these oncoproteins are insufficient to transform human 
cells, and additional cellular events are required for cervical carcinogenesis (Duensing & 
Munger, 2004).  The activation of Ha-ras in HPV16-immortalized human cervical cells 
resulted in malignancy, while transfection of HPV-16 DNA alone into cervical cells did not 
(DiPaolo et al., 1989).  Human protooncogenes, including the c-Ha-ras gene, can be activated 
via oxygen radical–induced DNA damage (Du et al., 1994).  HPV oncoprotein-expressing 
cells have an impaired ability to respond to DNA damage (Kessis et al., 1993; Song et al., 
1998).  These findings raise the possibility that additional factors other than HPV infection 
mediate DNA damage and participate in carcinogenesis.  Recent epidemiological and 
experimental studies have demonstrated that chronic inflammation contributes to cervical 
carcinogenesis as described in the following section. In this review, the role of inflammation 
and resulting DNA damage in cervical carcinogenesis and the molecular mechanisms will 
be discussed. 
2. Involvement of chronic inflammation in cervical carcinogenesis 
In 19th century, Rudolf Virchow noted leucocytes in neoplastic tissues and suggested that 
the “lymphoreticular infiltrate” reflected the origin of cancer at sites of chronic inflammation 
(Balkwill & Mantovani, 2001).  Since then, there has been a growing research interest in the 
link between chronic inflammation and carcinogenesis.  Actually, many malignancies arise 
from areas of infection and inflammation (Balkwill & Mantovani, 2001; Coussens & Werb, 
2002).  Epidemiological and experimental studies have provided evidence indicating that 
chronic infection and inflammatory conditions contribute to a substantial part of 
environmental carcinogenesis (Coussens & Werb, 2002; IARC, 2003). A recent review has 
estimated that chronic inflammation accounts for approximately 25 % of human cancers (S. 
P.  Hussain & Harris, 2007). Infection with bacteria, viruses and parasites contributes to a 
substantial part of chronic inflammation.  IARC has estimated that infectious diseases 
account for approximately 18 % of cancer cases worldwide, which are largely attributed to 
infection with oncogenic viruses, including HPV (IARC, 2003) (Table 1). Cervical cancer 
mediated by HPV accounts for approximately 6 % of cancer cases, and the largest part of 
infection-related carcinogenesis. 
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Infectious agents* Cancer site Number of cancer cases 
% of cancer 
cases 
worldwide 
Bacterial infection 
Helicobacter pylori Stomach 490,000 5.4 
Viral infection 
Human papillomavirus (HPV)
(especially high-risk types) Cervix and other sites 550,000 6.1 
Hepatitis B virus 
Hepatitis C virus Liver 390,000 4.3 
Epstein-Barr virus (EBV) Lymphoma and nasopharynx 99,000 1.1 
Human T-cell lymphotropic 
virus (HTLV-1) Leukemia 9,000 0.1 
Parasitic infection 
Schistosoma haematobium Bladder 2,700 0.1 
Opisthorchis viverrini
(Liver fluke) Intra- and extrahepatic bile duct 800  
 Total infection-related cancers Total cancers in 1995 
1,600,000 
9,000,000 
17.7 
100 
*The pathogens listed here have been evaluated as group 1 carcinogens (carcinogenic to humans) by 
IARC. 
Table 1. Burden of infection-related cancer worldwide [Adapted and modified from (IARC, 
2003)] 
2.1 Epidemiological studies on chronic inflammation and cervical carcinogenesis 
Recent epidemiological and experimental studies have revealed that chronic inflammation is 
associated with HPV-induced cervical carcinogenesis, although it is still unclear whether 
HPV infection alone or co-infection with HPV and other pathogens induces inflammatory 
conditions.  An epidemiological study in Costa Rica revealed that there was a positive trend 
of increasing cervical inflammation associated with high-grade lesions in oncogenic HPV-
infected women, and proposed a possibility that cervical inflammation is a cofactor for 
HPV-induced carcinogenesis (Castle & Giuliano, 2003; Castle et al., 2001).  Several 
epidemiological studies have suggested that other pathogens act in conjunction with HPV 
infection to increase the risk of cervical cancer.  Chlamydia trachomatis infection increased the 
risk of squamous cervical cancer among HPV-positive women in Brazil and the Philippines 
(Smith et al., 2002b).  Among the HPV DNA-positive women, seropositivity of herpes 
simplex virus-2 was associated with increased risks of squamous-cell carcinoma and adeno- 
or adenosquamous-cell carcinoma (Smith et al., 2002a).  In a study using cervical smears, the 
relative risk of high grade squamous intraepithelial lesions was significantly higher in 
patients infected with Gardinerella vaginalis and Chramydia and with dysbacteriosis and non-
specific inflammatory changes (leucocytosis) compared with normal subjects (Roeters et al., 
2010).  In addition, there is a study showing that biopsy specimens of women infected with 
carcinogenic HPV type had greater inflammation in the epithelium compared with those of 
women positive for noncarcinogenic HPV type and negative for HPV, although cervical 
inflammation varies with HPV cofactors, type of HPV infection, and risk of persistence and 
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progression (Kovacic et al., 2008). Recently, meta-analysis showed that bacterial vaginosis is 
significantly and positively associated with cervical HPV infection (Gillet, et al., 2011), 
supporting the hypothesis that cervical inflammation is involved in the pathogenesis of 
HPV-induced cancer.  
2.2 Molecular epidemiological studies on cervical carcinogenesis 
The expression of inflammation-related molecules in cervical tissues and the association with 
HPV-induced carcinogenesis have been extensively investigated.  Activation of the 
transcription factor nuclear factor (NF)-κB has been observed in cervical tissues of patients 
with squamous intraepithelial lesions.  In normal cervical tissue and low-grade squamous 
intraepithelial lesions, NF-κB subunits, p50 and p65, and inhibitor IκBα (IκBα) were mainly 
localized in the cytosol, whereas in high-grade lesions and squamous cell carcinomas, the p50-
p65 heterodimer was translocated into the nucleus and the expression of IκBα protein was 
concurrently decreased (A. Nair et al., 2003).  NF-κB is a key player in inflammation and 
regulates the expression of various genes involved in controlling the inflammatory response, 
including inducible nitric oxide synthase (iNOS), cyclooxygenase-2 (COX-2), interleukin (IL)-
1β and tumor necrosis factor (TNF)-α (Karin, 2006; Kundu & Surh, 2008).  NF-κB also 
participates in the promotion and progression of inflammation-related cancer (Karin, 2006; 
Pikarsky et al., 2004).  NF-κB mediates the expression of matrix metalloprotease (MMP) 9 and 
the angiogenic factor, vascular endothelial growth factor (VEGF) (Karin, 2006), which are 
considered to participate in tumor progression and metastasis. 
COX-2 mediates cancer development via various pathogenic events, including 
inflammatory responses, apoptosis inhibition and angiogenesis (Chun & Surh, 2004; Warner 
& Mitchell, 2004; Williams et al., 2000).  Molecular epidemiological studies have shown the 
overexpression of COX-2 in cervical cancer (Kim et al., 2004; Kulkarni et al., 2001).  Patients 
positive for both COX-2 and epidermal growth factor receptor (EGFR) had a higher 
likelihood of locoregional recurrence and worse prognosis than those negative for one or 
both proteins (Kim et al., 2004).   
In biopsy specimens of cervical intraepithelial neoplasia (CIN) 3 patients, activation of signal 
transducer and activator of transcription (STAT) 3 and coexpression of MMP9 have been 
detected in perivascular inflammatory cells.  STAT3 induced the expression of the 
chemokine CCL2, followed by MMP9 expression in tumor-instructed monocytes (Schroer et 
al., 2011).  Recently, it has been reported that the plasma levels of cytokines, especially IL-6, 
IL-8, TNF-α and macrophage inflammatory protein-1α (MIP-1α), were significantly 
increased in HPV-positive women relative to HPV-negative controls (Kemp et al., 2010).  
Therefore, the evidence for the participation of inflammatory responses in cervical 
carcinogenesis has been accumulating, although further studies are required to clarify the 
precise molecular mechanism. 
3. DNA damage mediated by reactive species under inflammatory conditions  
DNA damage is a key molecular event causing genetic instability involved in induction of 
human carcinogenesis.  Under inflammatory conditions, reactive oxygen species (ROS) and 
reactive nitrogen species (RNS), including nitric oxide (NO), are generated from 
inflammatory and epithelial cells.  These species are highly reactive and capable of causing 
oxidative and nitrative DNA damage, which may contribute to carcinogenesis (S. P. Hussain 
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et al., 2003; J. Nair et al., 2006; Ohshima et al., 2003).  ROS can induce the formation of 
various oxidative DNA lesions, including mutagenic 8-oxo-7,8-dihydro-2'-deoxyguanosine 
(8-oxodG) (Kawanishi et al., 2001; Tazawa et al., 2003; Wiseman & Halliwell, 1996).  If 8-
oxodG is not correctly repaired, adenine is preferentially incorporated opposite 8-oxodG 
during DNA synthesis, leading to G → T transversion (David et al., 2007; Shibutani et al., 
1991). Accumulation of 8-oxodG in human body has been demonstrated in patients with 
cancer and cancer-prone diseases.  A significant increase in urinary 8-oxodG levels has been 
observed in patients with various types of cancer compared with those in control subjects 
(Erhola et al., 1997; Tagesson et al., 1995; Thanan et al., 2008).  The content of 8-oxodG in 
cervical cells significantly increased with the grade of squamous intraepithelial lesion 
(Romano et al., 2000), raising the possibility that oxidative DNA damage participates in 
cervical carcinogenesis.   
Whereas ROS are generated from multiple sources, including not only inflammatory cells 
but also carcinogenic chemicals and electron transport chain in mitochondria, RNS are 
primarily generated under inflammatory conditions (Kawanishi & Hiraku, 2006).  Therefore, 
RNS-mediated DNA lesions may play an important role in inflammation-related 
carcinogenesis, and are expected as potential biomarkers to evaluate the cancer risk.  8-
Nitroguanine is a nitrative DNA lesion, formed under inflammatory conditions.  NO and 
superoxide (O2•-) are generated from inflammatory and epithelial cells, and react with each 
other to form peroxynitrite (ONOO-), a highly reactive species causing nitrative and 
oxidative DNA damage.  In vitro experiments revealed that the interaction of guanine with 
ONOO- led to the formation of 8-nitroguanine (Yermilov et al., 1995a), in addition to 8-
oxodG (Inoue & Kawanishi, 1995) (Figure 1).  In an in vivo experiment, 8-nitroguanine was 
formed via inflammation in the lung tissues of mice with viral pneumonia (Akaike et al., 
2003).  
8-Nitroguanine formed in DNA is chemically unstable, and can be spontaneously released, 
resulting in the formation of an apurinic site (Yermilov et al., 1995b).  Adenine is 
preferentially incorporated opposite an apurinic site during DNA synthesis, leading to G → 
T transversion (Loeb & Preston, 1986). Translesion DNA synthesis is the process in which 
error-prone DNA polymerases bypass unrepaired DNA lesions or insert nucleotides 
opposite the lesions.  Cells deficient in subunits of DNA polymerase ζ, were hypersensitive 
to NO, and translesion DNA synthesis past apurinic site mediated by this polymerase might 
contribute to extensive point mutations (Wu et al., 2006).  It has also been reported that 
adenine is preferentially incorporated opposite 8-nitroguanine during DNA synthesis 
mediated by DNA polymerase η and κ, leading to G → T transversion (Suzuki et al., 2005).  
Therefore, 8-nitroguanine is a potentially mutagenic DNA lesion, which may contribute to 
inflammation-related carcinogenesis.  In the ONOO--treated supF shuttle vector plasmid, 
which was then replicated in Escherichia coli, the majority of mutations occurred at G:C base 
pairs, predominantly involving G → T transversions (Juedes & Wogan, 1996; M.Y. Kim et 
al., 2005).  Indeed, this type of mutation occurred in vivo in the ras gene (Bos, 1988) and the 
p53 tumor suppressor gene in lung and liver cancer (Hsu et al., 1991; Takahashi et al., 1989).  
G → T transversions were most prominently detected in the omentum of asbestos-exposed 
rats (Unfried et al., 2002).  These findings imply that DNA damage mediated by 
inflammatory reactions may participate in carcinogenesis via activation of protooncogenes 
and inactivation of tumor suppressor genes.   
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Fig. 1. Proposed mechanism of 8-nitroguanine formation and mutation under inflammatory 
conditions. 
4. Nitrative DNA damage during cervical carcinogenesis 
4.1 DNA damage in cervical tissues of CIN patients 
To clarify the role of inflammation-mediated DNA damage in cervical carcinogenesis, we 
performed immunofluorescence staining to examine the formation of 8-nitroguanine and 8-
oxodG in biopsy specimens obtained from CIN patients.  To detect 8-nitroguanine, we 
produced a specific antibody and used for experiments (Hiraku & Kawanishi, 2009; Pinlaor 
et al., 2004a).  We compared the fluorescent intensity of these DNA lesions in cervical tissues 
of patients with different stages of CIN caused by high-risk HPV and condyloma 
acuminatum, benign cervical warts caused by low-risk HPV.  In biopsy specimens of CIN 
patients, 8-nitroguanine formation was observed in the nuclei of atypical cells (Figure 2), 
and 8-oxodG showed a similar staining pattern to 8-nitroguanine.  Their staining intensity 
tended to increase with CIN grades.  Statistical analysis revealed that the immunoreactivity 
of 8-nitroguanine in cervical epithelium was significantly increased in the order of 
condyloma acuminatum < CIN1 < CIN2-3, while there was no significant difference in 8-
oxodG formation (Table 2).  iNOS expression was also observed in the cytoplasm of both 
cervical epithelial cells and infiltrating stromal inflammatory cells in CIN patients.  8-
Nitroguanine formation was observed in the majority of iNOS-positive epithelial cells.  On 
the other hand, no or weak 8-nitroguanine formation occurred in cervical tissues from 
patients with condyloma acuminatum. These results raise the possibility that 8-nitroguanine 
can be used a potential biomarker to evaluate the risk of cervical carcinogenesis. 
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Fig. 2. 8-Nitroguanine formation and histopathological changes in cervical biopsy 
specimens.  8-Nitroguanine formation was assessed by immunofluorescence staining, and 
histopathological changes were examined by hematoxylin and eosin (HE) stain.  Paraffin 
sections were incubated with the primary antibody (rabbit polyclonal anti-8-nitroguanine 
antibody) and then with the secondary antibody (Alexa 594-labeled goat anti-rabbit IgG 
antibody).  8-Nitroguanine formation was observed in the nuclei of atypical epithelial cells.  
In the patients with condyloma acuminatum, no or weak 8-nitroguanine formation 
occurred.  Scale bar = 50 µm. 
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Biomarkers Immunoreactivity Grading* 
Number of cases 
Condyloma 
(n = 5) 
CIN1 
(n = 9) 
CIN2-3 
(n = 16) 
8-Nitroguanine 
- 
+ 
++ 
+++ 
4 
1 
0 
0 
4 
2 
3 
0 
2 
7 
4 
3 
P 
Kruskal-Wallis** 0.024# 
Scheffe 
      
 0.396    
      
  0.030#   
      
   0.359  
      
8-oxodG 
- 
+ 
++ 
+++ 
4 
1 
0 
0 
4 
4 
1 
0 
7 
3 
3 
3 
P Kruskal-Wallis 0.232 
p16 
- 
+ 
++ 
+++ 
1 
3 
1 
0 
1 
6 
1 
1 
2 
5 
8 
1 
P Kruskal-Wallis 0.332 
*The immunoreactivity for each specimen was scored as follows: (-) no or few cells were positive, (+) 
>25% of the cells were positive, (++) >50% of the cells were moderately positive, and (+++) >75% of the 
cells were strongly positive.  
**The statistical difference in immunoreactivities was analyzed by Kruskal-Wallis test, and if there was 
a statistical significance, Scheffe’s multiple comparison was performed.  #P < 0.05. 
Table 2. Difference in immunoreactivies of DNA lesions and p16 in cervical epithelial cells of 
biopsy specimens obtained from patients with CIN and condyloma acuminatum 
The formation of nitrative DNA lesion in relation to cervical carcinogenesis has been 
supported by a recent study.  NO exposure induced DNA damage and increased mutation 
rates in HPV-positive human cervical epithelial cell lines established from CIN patients (Wei 
et al., 2009).  In addition, NO exposure increased the expression of E6 and E7 genes, 
resulting in decreased p53 and RB protein levels in these cells (Wei et al., 2009), although 
precise molecular mechanism has not been understood.  These findings raise the possibility 
that NO serves as a molecular cofactor with HPV infection, and resulting DNA damage and 
the expression of viral oncoproteins cooperatively contribute to HPV-mediated cervical 
carcinogenesis.  Therefore, modification of local NO concentration in cervical tissues and 
related molecular events may constitute a strategy to prevent HPV-related cancer. 
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4.2 Comparison of 8-nitroguanine formation and p16 expression in CIN patients 
There are several reports showing that the cyclin-dependent kinase inhibitor p16 is 
overexpressed in cervical neoplasia (Gupta et al., 2010; Klaes et al., 2001; Sano et al., 1998; 
von Knebel Doeberitz, 2002; J. L. Wang et al., 2004), and proposed as a potential biomarker 
of cervical carcinogenesis. The expression of p16 was significantly higher in CIN and 
squamous cell cancer than in normal or inflammation of the cervix, and p16-positive 
patients had significantly shorter interval for disease progression from initial biopsy to CIN 
3 or invasive cancer than p16-negative patients (J. L. Wang et al., 2004).  E7 oncoprotein 
binds to RB, leading to the release of the transcription factor E2F from the RB/E2F complex 
(von Knebel Doeberitz, 2002). E2F accumulation leads to the expression of p16-related 
transcript, although the molecular mechanism remains to be clarified (Khleif et al., 1996).   
 
Fig. 3. 8-Nitroguanine formation and p16 expression in cervical biopsy specimens.  8-
Nitroguanine formation and p16 expression were assessed by immunofluorescence staining.  
Paraffin sections were incubated with the primary antibodies (rabbit polyclonal anti-8-
nitroguanine and mouse monoclonal anti-p16 antibodies), and then with the secondary 
antibodies (Alexa 594-labeled goat anti-rabbit IgG and Alexa 488-labeled goat anti-mouse 
IgG antibodies).  Strong p16 expression (green) was observed in cervical epithelial cells of 
CIN2 patients and showed a similar pattern to 8-nitroguanine formation (red).  In patients 
with condyloma acuminatum and cervicitis (HPV-16-positive), p16 expression was observed 
in the basal layer but no or weak 8-nitroguanine formation was detected.  Ep, epithelium.  
St, stroma.  Scale bar = 50 µm. 
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We performed immunohistochemistry to compare 8-nitroguanine formation and p16 
expression in cervical biopsy specimens of HPV-infected patients.  Strong p16 expression was 
observed in cervical epithelial cells of CIN patients and showed a similar pattern to 8-
nitroguanine (Figure 3).  However, in cervical tissues of patients with condyloma acuminatum 
and HPV-positive cervicitis, p16 expression was observed in the basal layer, whereas no or 
weak 8-nitroguanine formation was detected.  Statistical analysis revealed that no significant 
difference in p16 expression was observed among condyloma and CIN groups, whereas there 
was significant difference in 8-nitroguanine formation as described above (Table 2). These 
results suggest that p16 is simply a marker to reflect HPV infection, and that 8-nitroguanine is 
more suitable marker to discriminate high-risk and low-risk cervical lesions. 
5. Role of nitrative DNA damage in inflammation-related carcinogenesis 
5.1 8-Nitroguanine formation in inflammation-related carcinogenesis 
In addition to cervical cancer, we have investigated 8-nitroguanine formation in tissues of 
patients and animal models of a wide variety of inflammation-related cancer and cancer-
prone diseases by immunohistochemical analysis. We first demonstrated that this DNA 
lesion was formed at the site of carcinogenesis induced by bacterial, viral, and parasitic 
infections (Hiraku, 2010; Kawanishi & Hiraku, 2006; Kawanishi et al., 2006).  The studies on 
8-nitroguanine formation in relation to inflammation-related carcinogenesis are summarized 
in Table 3. 
Infectious diseases 
Cause Site of DNA damage Species References 
Helicobacter pyroli Gastric epithelium Human (Ma et al., 2004) 
Human papillomavirus 
(HPV) Cervical epithelium Human (Hiraku et al., 2007) 
Hepatitis C virus Hepatocyte Human (Horiike et al., 2005) 
Epstein-Barr virus (EBV) 
Nasopharyngeal 
epithelium 
and tumor tissue 
Human (Ma et al., 2008) 
Liver fluke 
(Opisthorchis viverrini) 
 
Bile duct epithelium 
 
 
Tumor tissue 
 
Hamster 
 
 
Human 
(Pinlaor et al., 2004a) 
(Pinlaor et al., 2004b) 
(Pinlaor et al., 2006) 
 
(Pinlaor et al., 2005) 
Inflammatory diseases and conditions 
Cause Site of DNA damage Species References 
Inflammatory bowel disease Colon epithelium Mouse (Ding et al., 2005) 
Oral licken planus Oral epithelium Human (Chaiyarit et al., 2005) 
Oral leukoplakia Oral epithelium Human (Ma et al., 2006) 
Soft tissue tumor 
(Malignant histiocytoma) Tumor tissue Human 
(Hoki et al., 2007a) 
(Hoki et al., 2007b) 
Asbestos Bronchial epithelium Mouse (Hiraku et al., 2010) 
Table 3.  8-Nitroguanine formation in humans and animals in relation to inflammation-
related carcinogenesis 
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We found that 8-nitroguanine was formed in epithelial cells of intrahepatic bile duct using 
an animal model infected with the liver fluke Opisthorchis viverrini, endemic in northeastern 
Thailand (Pinlaor et al., 2004a; Pinlaor et al., 2004b; Pinlaor et al., 2003).  Administration of 
the antiparasitic drug praziquantel and the antioxidant curcumin significantly reduced 
oxidative and nitrative DNA damage (Pinlaor et al., 2006; Prakobwong et al., 2011).  We 
have also demonstrated that 8-nitroguanine was formed in the gastric gland epithelial cells 
from gastritis patients with Helicobacter pylori infection (Ma et al., 2004), in the hepatocytes of 
patients with chronic hepatitis C (Horiike et al., 2005) and in the nasopharyngeal epithelial 
cells and tumor tissues of patients infected with Epstein-Barr virus (EBV) (Ma et al., 2008).  
These results suggest that 8-nitroguanine is a promising biomarker providing an assessment 
of the risk of inflammation-mediated carcinogenesis at the precancerous stage.  Moreover, in 
EBV-infected patients, the staining intensity of 8-nirtroguanine was significantly stronger in 
nasopharyngeal cancer cells than in epithelial cells of chronic nasopharyngitis patients, 
suggesting that 8-nitroguanine accumulates during the development of chronic 
inflammation to cancer (Ma et al., 2008).  In addition, 8-nitroguanine formation was 
observed under inflammatory conditions independent of infection.  This DNA lesion was 
seen in colon epithelial cells of a mouse model of inflammatory bowel disease (Ding et al., 
2005), in oral epithelial cells of patients with oral premalignant lesions (Chaiyarit et al., 2005; 
Ma et al., 2006) and in bronchial epithelial cells of asbestos-exposed mice (Hiraku et al., 
2010). 
Several studies have raised a possibility that DNA damage is involved in tumor 
progression.  In patients with inhrahepatic cholongiocarcinoma, oxidative and nitrative 
DNA damage in tumor and adjacent tissues was associated with tumor invasion (Pinlaor 
et al., 2005)  8-Nitroguanine staining was observed in tumor tissues of patients with 
malignant fibrous histiocytoma, a soft tissue tumor, which is proposed to be accompanied 
with inflammatory responses. The statistical analysis using the Kaplan-Meier method 
revealed that strong 8-nitroguanine formation was significantly associated with a poor 
prognosis of the patients (Hoki et al., 2007a).  These findings indicate that this DNA lesion 
contributes to not only tumor initiation but also tumor progression and poor prognosis of 
cancer patients. 
5.2 Mechanism of inflammation-related carcinogenesis and the role of DNA damage  
On the basis of our previous studies, possible mechanism of inflammation-related 
carcinogenesis and tumor development via DNA damage is shown in Figure 4.  Various 
infectious agents, including bacteria, viruses and parasites, inflammatory diseases and 
environmental factors can induce inflammatory responses and the production of ROS and 
RNS from inflammatory and epithelial cells.  A wide variety of inflammatory cytokines 
mediate the activation of transcription factors, including NF-κB and STATs.  NF-κB 
regulates the expression of a wide variety of inflammation-related molecules including 
iNOS (Karin, 2006; Kundu & Surh, 2008) and participates in multiple steps of carcinogenesis 
(Karin, 2006; Pikarsky et al., 2004).  RNS can induce the activation of NF-κB under certain 
circumstances (Janssen-Heininger et al., 2000).  Therefore, reciprocal and positive regulation 
between RNS and NF-κB may lead to persistent inflammatory reactions and nitrative DNA 
damage, contributing to carcinogenesis. 
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Fig. 4. Possible mechanism of inflammation-related carcinogenesis and tumor progression 
via 8-nitroguanine formation. 
STAT1 and STAT3 are known to mediate the expression of iNOS (Lo et al., 2005; Tedeschi et 
al., 2003).  STAT3 interacts with EGFR in the nucleus to form a complex, which mediates 
transcriptional activation of iNOS (Lo et al., 2005).  Actually, phosphorylated STAT3 (active 
form) and EGFR were strongly expressed and colocalized in the nucleus of cancer cells of 
nasopharyngeal cancer patients (Ma et al., 2008).  A recent study has demonstrated that 
excess ONOO- mediates the activation of JAK/STAT signalling pathway in experimental 
animals (H. Wang et al., 2009).  These findings imply that a positive loop between STATs 
and iNOS may exist.  
Hypoxia-inducible factor (HIF)-1α is an oxygen-sensing transcription factor, which is 
upregulated in a hypoxic environment during tumor growth.  HIF-1α mediates the 
transcription of various genes, including iNOS and VEGF (Harris, 2002).  An increase in 
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iNOS-catalyzed NO production induces the accumulation and activation of HIF-1α (Mateo 
et al., 2003; Thomas et al., 2004).  HIF-1α and 8-nitroguanine were colocalized and associated 
with poor prognosis of cancer patients (Hoki et al., 2007b).  Therefore, reciprocal activation 
of HIF-1α and iNOS may lead to persistent DNA damage in tumor tissues, contributing to 
poor prognosis of cancer patients.  A recent study has demonstrated that IκB kinase (IKK)-β, 
involved in NF-κB activation, is required for HIF-1α protein accumulation under hypoxia in 
cultured cells and animals (Rius et al., 2008), whereas NF-κB bas been reported to be 
regulated under hypoxia in an HIF-1α-dependent manner (Walmsley et al., 2005).  Thus, 
HIF-1α and NF-κB may positively regulate each other and participate in tumor progression. 
 
Fig. 5. Possible mechanism of HPV-induced cervical carcinogenesis mediated by chronic 
inflammation. 
Collectively, molecular events mediated by various pathogens converge to nitrative stress, 
and resulting DNA damage contributes to the accumulation of genetic alterations in tissues 
throughout the carcinogenic process. In particular, 8-nitroguanine formation may 
participate in inflammation-related carcinogenesis as a common mechanism, regardless of 
etiology.  Therefore, 8-nitroguanine could be used as a potential biomarker to evaluate the 
cancer risk and predict the prognosis of cancer patients. In addition, certain pathogens 
possess unique molecules mediating abnormal cell proliferation and survival, such as E6 
and E7 proteins of HPV as described below.  Therefore, 8-nitroguanine formation may 
contribute to carcinogenesis in cooperation with pathogen-specific molecular events. 
A recent study has demonstrated that 8-nitro-cGMP, formed by the reaction of RNS with 
cGMP, regulates the redox-sensor signaling proteins, via S-guanylation of cysteine 
sulphydrils, and mediates an adaptive response against oxidative and nitrative stress (Sawa 
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et al., 2007). S-Nitrosylated proteins, formed via reaction of thiols with NO or its reactive 
metabolites, possess cytoprotective properties (Ishima et al., 2007).  In inflammation-related 
carcinogenesis, nitrated or nitrosylated molecules may participate in protection of initiated 
cells bearing genetic alterations due to oxidative and nitrative DNA damage, and contribute 
to tumor development. 
5.3 Mechanism of HPV-mediated cervical carcinogenesis via inflammatory reactions 
A possible mechanism of HPV-induced cervical carcinogenesis involving inflammatory 
reactions is shown in Figure 5.  We have demonstrated that inflammation-mediated DNA 
lesions were formed in cervical tissues of CIN patients (Hiraku et al., 2007).  To date, no 
evidence suggesting that HPV infection alone induces inflammatory states has been 
provided.  Therefore, it is speculated that inflammatory reactions are derived from HPV 
infection and co-infection with other pathogens, although the precise mechanism remains to 
be clarified.  DNA damage mediated by inflammatory reactions would play a substantial 
role in tumor initiation and also the following steps of carcinogenesis.  In addition, HPV 
oncoproteins E6 and E7 mediate cell immortalization, dysregulation of cell proliferation and 
chromosomal abnormalities by interacting with numerous target proteins.  The molecular 
events mediated by these oncoproteins may promote the proliferation and transformation of 
cells initiated by oxidative and nitrative DNA damage, and contribute to tumor promotion 
and progression. 
In addition, several studies have demonstrated that HPV oncoproteins mediate 
inflammatory responses.  The expression of E6 and E7 oncoproteins derived from highly 
carcinogenic HPV-16 enhanced the release of IL-1α from cultures of normal cervical 
keratinocytes, and E7 proteins that strongly bound to RB protein (high risk types HPV-16 
and HPV-18) induced more IL-1α release than those that bound poorly (low-risk type HPV-
6) (Iglesias et al., 1998).  A recent study has shown that E7 expression increased the 
promotor activity of COX-2 and the downstream molecule IL-32 in HPV-positive cervical 
cancer cell lines (Lee et al., 2011).  IL-32 induces the expression of various inflammatory 
cytokines, including IL-1β, IL-6, TNF-α and chemokines (S.H. Kim et al., 2005).  IL-32 
expression was detected in cervical tissues of patients with squamous cell carcinoma and 
increased with the tumor stage (Lee et al., 2011).  Therefore, these HPV oncoproteins may 
participate in inflammatory responses in cervical tissues and contribute to carcinogenesis.  
In addition, a recent study has shown that NO treatment mediates the expression of E6 and 
E7 in cultured cells (Wei et al., 2009).  A COX-2-selective inhibitor suppressed the expression 
of E7 in cultured cervical cancer cells (Lee et al., 2011).  Inflammatory reactions may 
reciprocally mediate the expression of HPV oncoproteins, resulting in the persistence of 
inflammation-related DNA damage and dysregulated cell proliferation, contributing to 
tumor progression. 
6. Conclusion and future perspective 
Chronic infection and inflammation are known to contribute to a substantial part of 
environmental carcinogenesis.  Cervical cancer is the second most common cancer among 
women, and HPV infection is involved in almost all cases.  Recent epidemiological studies 
revealed that chronic inflammation participates in cervical carcinogenesis.  Under 
Role of Chronic Inflammation and Resulting DNA Damage 
in Cervical Carcinogenesis Induced by Human Papillomavirus 
 
373 
inflammatory conditions, reactive oxygen and nitrogen species are generated, and resulting 
DNA damage may play an important role in carcinogenesis.  We performed 
immunohistochemical analysis and demonstrated that 8-nitroguanine, a mutagenic DNA 
lesion formed during inflammation, was formed in cervical epithelial cells in CIN patients, 
and its immunoreactivity was significantly increased with CIN grades.  The comparison of 
8-nitroguanine formation and p16 expression revealed that 8-nitroguanine is more suitable 
to detect cervical lesions mediated by high-risk types of HPV.  Taken together with this and 
previous studies, it is concluded that 8-nitroguanine can be used as a potential biomarker to 
evaluate the risk of inflammation-related carcinogenesis, including cervical carcinogenesis.  
In addition, HPV oncoproteins E6 and E7 are known to mediate cell immortalization, 
dysregulated cell proliferation and chromosomal instability.  Several studies have suggested 
that these oncoproteins crosstalk with signalling pathways related to inflammatory 
responses.  Therefore, oxidative and nitrative DNA damage mediated by inflammatory 
reactions and oncoprotein-mediated molecular events may cooperatively contribute to 
cervical carcinogenesis. 
Establishment of methods for quantitative analysis of 8-nitroguanine in biological samples, 
such as blood and urine, would be useful for evaluation of the risk of inflammation-related 
carcinogenesis.  8-Nitroguanine formed in DNA is chemically unstable, and is likely to be 
released from DNA.  Thus, this property may hamper the quantitative analysis.  An attempt 
has been made to utilize free 8-nitroguanine in urine for quantitative analysis using high-
performance liquid chromatography coupled with electrochemical detection and 
immunoaffinity purification (Sawa et al., 2006).  8-Nitroguanine has also been measured by 
liquid chromatography with mass spectrometry and glyoxal derivatization (Ishii et al., 
2007).   
Moreover, the development of therapeutics targeting inflammation-related molecules may 
contribute to prevention of cervical carcinogenesis and improvement of prognosis of cancer 
patients.  Animal experiments demonstrated that iNOS inhibitors suppress inflammatory 
responses and effectively reduce inflammation-related carcinogenesis, although evidence 
has not yet been provided for their inhibitory effect on cervical carcinogenesis.  ONO-1714, 
an iNOS-specific inhibitor, significantly decreased the degree of cholangitis and reduced the 
incidence of intrahepatic biliary tumors in bilioenterostomized hamsters (Mishima et al., 
2009).  Another iNOS inhibitor, 1400W, reduced tumorigenesis in the mammary glands of γ-
irradiated mice treated with diethylstilbestrol (Inano & Onoda, 2005).  Moreover, 
administration of the antioxidant curcumin significantly reduced the incidence of liver 
fluke-induced carcinogenesis via suppression of oxidative and nitrative DNA damage 
(Prakobwong et al., 2011).  To develop a strategy for prevention of HPV-mediated cervical 
cancer, further studies are needed to clarify the precise molecular mechanisms and the role 
of chronic inflammation. 
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1. Introduction
The human papillomavirus (HPV) has been proved to be a many-sided virus. Up to date, over
200 types of HPV have been reported, while ongoing research studies constantly discover new
types of the virus. Recently, certain HPV types have been associated with the development
of several cancer types (Parkin, 2006), including anal, vaginal, penile, oral, and pharyngeal
cancer.
The cervical cancer is currently the most prominent case of association between HPV and
cancer. The persistent infection of the anogenital tract by a group of HPV types has been
proved to be the main causal factor of cervical cancer (Bosch et al., 2002; Walboomers et al.,
1999). This group of cervical cancer related types currently includes 30 to 40 types. However,
not all the types in the group induce the same risk for the development of cervical cancer.
In fact, virologists have classiﬁed the aforementioned types with respect to their oncogenic
activity as low-risk, high-risk, and potentially high-risk (Muñoz et al., 2003), while other HPV
types remain unclassiﬁed.
Focusing on the case of cervical cancer, the statistics are overwhelming: With 500.000 cases
diagnosed every year (Greenblatt, 2005), it is the second leading cause of cancer related
deaths after breast cancer for women between 20 and 39 years old (Landis et al., 1999) and
one of the leading cancer types affecting women worldwide (Moore, 2006). When the above
facts are combined with the variability of oncogenic activity among HPV types, the need for
specifying not only whether a patient has been infected by HPV but also the exact infecting
types becomes evident. The task of identifying the speciﬁc HPV type(s) that have infected a
patient based on their genotypic characteristics is called HPV genotyping or – more simply –
HPV typing.
In the domain of cervical cancer, HPV typing provides valuable and sometimes critical
information to the practitioner of a female patient with respect to her risk for developing
cervical cancer. However, it should be noted that as soon as the relation of HPV with other
cancer types becomes fully understood, it is highly probable that HPV typing will acquire
similar importance in those cancer domains as well. Moreover, HPV typing is also performed
for epidemiological purposes, i.e., to determine the frequency and type distribution of the
virus in various populations.
The need for HPV typing has given birth to a variety of molecular biology methods and
associated assays/kits for carrying out this task. The main objectives that are important when
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comparing these diagnostic tools are (i) the diagnosis accuracy, (ii) the diagnosis cost, and
(iii) the automation level of the diagnostic procedure. Although many solutions are currently
available – they will be brieﬂy described in the following section – none stands out when
compared to its counterparts. In this chapter, we will present a novel diagnostic tool for HPV
typing that attempts to optimize all the aforementioned objectives. This tool is HPVTyper,
a freely-available software application that processes images resulting from the PCR-RFLP
examination of tissue samples (see Section 2.1) and automatically infers the HPV type(s)
that have infected the samples. The novel HPV typing methodology that is employed by
HPVTyper has been introduced and extensively validated in a series of recent publications.
2. HPV typing methods
As we have already mentioned, owing to the signiﬁcance of the task, plenty of molecular
diagnostic methods for HPV typing have emerged during the last decades. The majority of
them is based on detecting type-speciﬁc DNA in an investigated tissue sample (DNA testing
methods). The most prominent DNA testing methods are outlined in Section 2.1. The method
that is employed by HPVTyper is described separately in Section 2.2.
2.1 Methods overview
Four categories of HPV typing methods are presented in this section. For each category,
we provide a short description of the corresponding generic method and comment on its
advantages/drawbacks with respect to the other categories.
PCR-based assays. The methods of this category employ the polymerase chain reaction
(PCR) to amplify a speciﬁc part of the viral DNA. Typing is achieved through the use
of type-speciﬁc pairs of primers that bound the DNA region to be ampliﬁed. Gel
electrophoresis of the PCR products is employed to visualize the typing results. The
PCR-based methods have been among the ﬁrst HPV typing methods to be employed
and, consequently, many applications of them have been reported (Fontaine et al., 2007;
Husnjak et al., 2000; Karlsen et al., 1996; Walboomers et al., 1999).
The main drawback of these methods is the need of a different pair of primers for each
type that is considered in the typing process, which, of course, increases the cost of the
diagnosis. Moreover, in the case of newly-discovered types appropriate sets of primers
have to be designed de novo.
Hybridization assays. These methods are based on the hybridization of oligonucleotide
probes, where each probe is associated with a speciﬁc type of the virus. There are several
variants of the hybridization method, namely dot blot (Greer Jr et al., 1990), reverse line
blot (Kleter et al., 1999; van den Brule et al., 2002), enzyme immunoassay (Jacobs et al.,
1997), etc. These methods employ PCR with general primers in their ﬁrst stages and their
results can be read directly from the assay.
The hybridization methods are less laborious than the PCR-based ones, since they do not
require the application of multiple PCRs. However, the previously discussed drawback
of the PCR-based methods applies here as well: A different oligonucleotide must be
produced – and possibly designed – for each HPV type that needs to be identiﬁed.
DNA microarrays. This category of methods shares its conception principle with the
hybridization assays (i.e., typing is performed through type-speciﬁc oligonucleotide
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probes) but additionally employs the microarray technology. More speciﬁcally, the
oligonucleotide probes are “printed” on a two-dimensional array structure and the
outcome is usually digitized with the help of a microarray scanner.
The DNA microarray assays have been proved to be very popular during the last decade
(Gheit et al., 2006; Hwang et al., 2003; Kim et al., 2003; Klaassen et al., 2004) owing to
their accuracy and ease of use. However, being mostly industrial products, the set of HPV
types that can be typed by a particular microarray is hardwired into the assay and the
expansion to new types necessitates redesigning the assay. Moreover, their consumable
nature imposes an additional component to their diagnosis cost.
DNA sequencing. This method discriminates among the HPV types by discovering the exact
nucleotide sequence of a small region in the viral DNA. This is the golden standard of virus
typing in terms of accuracy since it is able to reveal the viral DNA information to its fullest
extent. Since the establishment of the method, several DNA sequencing techniques have
been applied on the task of HPV typing (Barzon et al., 2011; Gharizadeh et al., 2001; 2005;
Vernon et al., 2000).
The early DNA sequencing techniques have been characterized by low throughput
(leading to expensive typing examinations) and could be easily confused in the case of
multiple infections. However, the recent introduction of massively parallel sequencing
assays (next-generation sequencing) has shown promise to minimize the examination cost
and revolutionize DNA sequencing as an HPV typing method (Jordan, 2010; Liu, 2008).
2.2 PCR-RFLP gel electrophoresis
The method of interest for this chapter, i.e., the method that is employed by HPVTyper, is
called PCR-RFLP gel electrophoresis. The standard protocol for performing HPV typing via the
aforementioned method is described in detail in the present section. The protocol involves a
series of operations that process the examined tissue sample by means of several established
molecular biology techniques and a ﬁnal step that requires the expertise of a molecular
biologist. The involved steps are outlined in Fig. 1(a).
Restriction
Fragment Length
Polymorphism
Polymerase Chain
Reaction
Gel
Electrophoresis
Image
Acquisition
tissue
sample
PCR-RFLP
image
(a)
ladder ladderlane lane
band
band
(b)
Fig. 1. HPV typing via PCR-RFLP gel electrophoresis. (a) The steps involved in the standard
HPV typing protocol. (b) The outcome of a typical PCR-RFLP gel electrophoresis
examination; samples of lanes, bands and ladders are enclosed in rectangles.
First, an organic sample is collected from the tissue of interest and the contained DNA is
isolated. Then, the PCR (Tagu & Moussard, 2006, Ch. 24) ampliﬁes a highly preserved region
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of the hypothesized1 viral DNA with the help of a general-purpose primer set. After that,
a restriction enzyme cleaves the ampliﬁed HPV DNA at sites that are characterized by a
speciﬁc nucleotide sequence (restriction sites). This procedure, which is called restriction
fragment length polymorphism (RFLP) analysis (Tagu & Moussard, 2006, Ch. 50), produces
for each HPV genotype a set of DNA fragments that is known a priori; the RFLP analysis is the
cornerstone of the discussed method.
Let us elaborate on this. If we assume that the ampliﬁed DNA sequence of an HPV genotype
of interest is known, then we can predict the sites that will be cleaved by a speciﬁc restriction
enzyme and, thus, we can infer the set of DNA fragments that are produced after digestion by
this restriction enzyme. This set of DNA fragments or fragment length pattern (FLP) serves as
the signature of this particular HPV genotype and is the means for successfully carrying out
the HPV typing.
Following the RFLP analysis, a solution of the digested PCR product is being injected into
an individual well at the front end of a gel matrix. Then, in the presence of an electric ﬁeld,
the negatively-charged DNA fragments are forced to move with different mobilities (i.e., drift
velocities) towards the anode in the direction opposite to that of the electric ﬁeld. During
the gel electrophoresis (Tagu & Moussard, 2006, Ch. 5), the large molecules remain close to
the well, while the more agile smaller molecules cover a much larger distance. This way,
one lane starting from each well is formed; each lane contains concentrations of DNA of the
same length that are shaped as bands perpendicular to the electric ﬁeld direction. One or more
among the wells of a gel matrix are reserved to include DNA ladders, i.e., DNA molecules of
known lengths. These reference ladders assist the biologists in estimating the unknown length
of the DNA that forms the bands of the other lanes during the last step of the protocol.
After the electrophoresis is completed, the viral DNA molecules are stained by soaking the gel
in a solution of a certain ﬂuorescent dye. For this purpose one can employ either the highly
mutagenic yet still common ethidium bromide or, preferably, some other less hazardous
ﬂuorescent substance (SYBR Safe, DAPI, etc). Then, an appropriate light source (usually ultra
violet or blue) is used momentarily to excite the dye, which ﬂuoresces to make the viral DNA
visible. At that moment, a digitized image of the gel matrix is acquired (see Fig.1(b) for an
example).
In the ﬁnal step, the acquired image is analyzed by a molecular biologist in order to reach
a typing decision. This analysis includes two stages. First, the biologist estimates the DNA
fragment lengths corresponding to the bands that are observed on a lane of interest; this is
achieved by interpolating the bands of the image’s ladder(s). Then, the biologist “manually”
compares the set of estimated fragment lengths from the investigated lane with the FLPs
of all the considered HPV genotypes in order to decide which genotype or combination of
genotypes has produced the observed band pattern.
From the previous description, one can realize that HPV typing via PCR-RFLP gel
electrophoresis suffers from several shortcomings. First of all, it falls short with respect
to the other methods in terms of accuracy, since it does not employ type-speciﬁc probes
or primers. Moreover, it might require a considerable amount of intellectual effort by the
molecular biologist to come to a typing conclusion, while typing by the other methods is
1 We use the word hypothesized because the sample can be HPV-free.
386
Human Papillomavirus and Related Diseases
– From Bench to Bedside – Research Aspects
HPVTyper: A Software Application for Automatic HPV Typing via PCR-RFLP Gel Electrophoresis 5
essentially straightforward. Finally, the typing procedure becomes even more complicated
and error-prone in cases of multiple infections.
Despite the aforementioned shortcomings, PCR-RFLP gel electrophoresis has been used
extensively over the past two decades as a method for HPV typing (Lungu et al., 1992; Nobre
et al., 2008; Santiago et al., 2006) and remains today the method of choice for a signiﬁcant
percentage of molecular biology laboratories worldwide. This is because the method also
demonstrates a series of noteworthy advantages over its counterparts. It does not require the
use of overspecialized devices, expensive consumables and type-speciﬁc agents. This way it is
relatively inexpensive and can be carried out in every moderately equipped molecular biology
laboratory. Moreover, owing to its lack of attachment to type-speciﬁc entities, the method can
easily be exploited for identifying new HPV types, possibly without even the need to repeat
the in vitro examination of the sample.
3. The employed HPV typing methodology
HPVTyper builds upon a novel HPV typing methodology (Maramis et al., 2010; 2011), which
tackles the main shortcomings of typing via the PCR-RFLP method. This methodology is
capable of producing very accurate typing decisions – even in complex cases of multiple
infections – in an entirely automatic manner. The methodology’s performance has been
extensively evaluated through a series of experiments (Maramis et al., 2011) on a well-sized
set of real HPV data 2.
The discussed methodology is founded on a novel observation model that describes formally
the mechanism by which a set of molecular biology parameters (e.g., the concentrations of
several HPV genotypes) generates the observed outcome of a PCR-RFLP gel electrophoresis
examination (i.e., an image similar to the one depicted in Fig. 1(b)). The observation model is
presented in Section 3.1.
Once the observation model has been established, we proceed with describing the employed
methodology. This involves three phases, which are outlined in Fig. 2. In the ﬁrst phase,
the acquired image is preprocessed (Section 3.2). This is a necessary condition for the
successful exploitation of the observation model. Then, based on the observation model,
accurate information regarding the viral DNA fragments that have resulted from the RFLP
analysis is automatically extracted (Section 3.3). The extracted fragment information is fed
to a novel HPV typing algorithm (Section 3.4) that identiﬁes – entirely automatically – those
HPV genotype(s) that are most probable to have infected the examined sample.
3.1 Observation model
The introduced observation model consists of a set of formulas which associate the visual
outcome of a PCR-RFLP gel electrophoresis examination with the underlying parameters of
the HPV genotype(s) that have infected the examined sample. In other words, it describes
with quantitative terms the mechanism by which the image of such an examination is
generated from the infecting HPV genotypes.
In order to present the observation model, let us imagine the following situation: The sample
that we are examining has been infected by type T of HPV. After the application of PCR, the
2 The employed dataset can be accessed via the internet at http://olympus.ee.auth.gr/
~chmaramis/virusTyping.
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Fig. 2. Outline of the employed HPV typing methodology. The main operations are
presented as blocks and the operation sequence is indicated by arrows.
concentration of T in the PCR product is cT . The digestion of the ampliﬁed DNA sequence of
T by the employed restriction enzyme yields K DNA fragments, whose lengths in base pairs
(bp) are contained in the FLP l = [l1, l2, . . . , lK ]. At the end of gel electrophoresis, the digested
DNA fragments have formed K bands on the sample’s lane – this might look like Fig. 3(a)
assuming that K = 4.
x
p(x)
x
p(x)
140 40240 260 160 60
(a)
(c)
(d)
(f)
(e)(b)
Fig. 3. Illustration of the employed observation model via two examples. (a) Lane image with
4 bands. This corresponds to a sample infected by HPV 53 (GenBank ID X7448) after
ampliﬁcation by MY09/11 (primers) and digestion by HpyCH4V (restriction enzyme). (b)
The intensity proﬁle that is extracted from the above lane. The depicted peaks correspond to
fragment lengths 171, 151, 83, and 44 bp (left to right). (c) The 20-bp marker that depicts the
position-length relation for the above image/proﬁle. (d) Lane image involving triple HPV
infection. This corresponds to a sample infected by HPV 30, 62, and 72 (GenBank IDs X74474,
AY395706, and X94164) after ampliﬁcation by MY09/11 and digestion by HpyCH4V. (e) The
intensity proﬁle that is extracted from the above lane (blue/dash-dotted line). The
contributions of the three infecting types are also displayed with various colors/grayscale
levels. (f) The 20-bp marker that depicts the position-length relation for the above
image/proﬁle.
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Due to the one-dimensional nature of the involved electrophoresis procedure, the information
that is conveyed by a lane image lies exclusively in the electrophoresis direction (the X axis in
Fig. 3(b)). This means that any two horizontal slices of the lane image are practically replicas
of each other. Thus, instead of dealing with the entire lane image, we might as well take a
single horizontal slice of it. The resulting one-dimensional intensity curve is called intensity
proﬁle and is depicted in Fig. 3(b). The intensity proﬁle consists of K bell-shaped peaks, whose
centers on axis X are aligned with the positions of the band middles in the lane image.
For a given gel electrophoresis conﬁguration (i.e., ﬁxed gel viscosity, electrophoresis voltage,
etc.) the distance that has been covered at the end of the experiment by a certain DNA
fragment, and consequently its position, x, on axis X depends only on the length, l, of the
fragment. In the described observation model this position-length relation is provided by the
following fragment mobility function:
x = d(l;π) = π1 + π2 log(π3 + π4l + l2) , (1)
where the vector π = [π1,π2,π3,π4] aggregates the parameters of the fragment mobility
function.
If we assume that π is known and recall that the ith peak in the intensity proﬁle of Fig. 3(b)
is formed by DNA fragments of length li, we conclude that the observed peak centers,
x1, x2, . . . , xK , are given by the expression
xi = d(li;π) i = 1, 2, . . . ,K . (2)
Moreover, it has been observed that, during gel electrophoresis, a moving population
consisting of DNA fragments of some length tends to constantly lose some of its members,
i.e., its concentration attenuates continuously as the population moves. This phenomenon is
taken into account by the described observation model by means of the residual function
r(x) = φx+ 1 x ∈ [0, E] . (3)
This function expresses the percentage of DNA fragments that have not abandoned the
moving population when its mean position is x.
In our example we have assumed that the concentration of the PCR product of T is cT . The
PCR product is digested to form K DNA fragment populations that correspond to lengths
l1, l2, . . . , lK and are concentrated in the lane’s well before the beginning of the electrophoresis.
Thus, the concentrations of these populations at the well will also be:
cT , cT , . . . , cT︸ ︷︷ ︸
K
.
However, due to the aforementioned concentration attenuation, at the end of the
electrophoresis, the fragment populations that form the peaks of the intensity proﬁle in
Fig. 3(b) will have the following reduced concentrations:
r(x1)cT , r(x2)cT , . . . , r(xK)cT︸ ︷︷ ︸
K
.
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The image intensity that is produced by a DNA molecule is determined by the number
of ﬂuorescent molecules that are bound to it. Since this number is proportional to the
fragment length, the employed observation model computes the contribution of each of the
aforementioned K fragment populations to the intensity of the proﬁle as follows:
f · l1r(x1)cT , f · l2r(x2)cT , . . . , f · lKr(xK)cT︸ ︷︷ ︸
K
,
where f denotes the contribution of a single-bp DNA fragment to the proﬁle intensity.
Regarding the peak shape, it has been proved (Maramis & Delopoulos, 2010b) that any
intensity proﬁle peak corresponding to fragments of length l0 can be accurately modeled by
the integrated Weibull function,
w(x; β,γ, x0) =
γ
2γ1/γβΓ(1/γ)
exp
(
− 1
γ
| x− x0
β
|
γ)
, (4)
where (i) Γ(·) is the complete gamma function, (ii) the parameters β and γ determine the peak
shape, and (iii) x0 is the mean distance covered by the fragments of length l0, i.e., x0 = d(l0;π).
Finally, the described observation model superimposes K integrated Weibull functions to
model the entire intensity proﬁle of the investigated lane as follows:
i(x) = f · cT
K
∑
i=1
li · r(xi) · w
(
x; βi,γi, xi)
)
, (5)
where i(·) denotes the intensity proﬁle model. In order to derive (5) we have taken into
account the previously computed contributions of the DNA fragment populations to the
proﬁle intensity.
3.2 Image preprocessing
The ﬁrst phase of the employed HPV typing methodology deals with the preprocessing of the
acquired PCR-RFLP image in order to extract the intensity proﬁles of all the depicted lanes.
The processing operations of this phase presume that the image at hand passes certain quality
checks (see Fig. 1(b) for a positive example):
1. The image depicts the lane areas exclusively.
2. The bands appear bright on darker background.
3. The vertical axis of the image identiﬁes with the electrophoresis axis.
Assuming that the image at hand passes these checks – as we will see in Section 4, this might
require the application of a few manually-guided image processing operations – the employed
methodology detects the boundaries of the lanes that are depicted. Then, with the help of the
inter-lane regions it models the background intensity of the image as a polynomial of the
image coordinates. Next, it removes the background intensity from the lane areas to keep
only the intensity component of the acquired image that is induced by the viral material. All
these operations are performed automatically and have been documented in detail elsewhere
(Maramis & Delopoulos, 2010a).
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This produces a set of background-corrected lane images like the one depicted in Fig. 3(a).
The extraction of the intensity proﬁle, p(·), of each lane image concludes this phase. However,
due to the presence of noise in the image, instead of taking a single slice of the lane image we
aggregate the intensity information along the axis that is perpendicular to electrophoresis (let
this be denoted by Y). Thus, if I(·) is the background-corrected image of a lane and D is the
image size along axis X, the intensity proﬁle of the lane is given by the expression:
p(x) = median
y
{I(x, y)} x = 1, 2, . . . , D . (6)
3.3 Fragment information extraction
The objective of this phase is to estimate certain properties of the DNA fragments that are
contained in the lane of a sample. More speciﬁcally, we refer to an initial estimation of the
fragment lengths and concentrations that are associated with the molecule populations on the
lane. For this purpose, the employed methodology makes use of the previously extracted
intensity proﬁles and the observation model of Section 3.1. The steps of this phase are
described in the following sections.
3.3.1 Peak area detection
This step has not been described in the introductory papers of the employed methodology
(Maramis et al., 2010; 2011). It is applied on every intensity proﬁle that has been extracted in
Section 3.2 and its objective is to determine (i) the number and approximate positions of the
peaks in the intensity proﬁle, and (ii) the set of datapoints that constitute the body of each
peak. The latter information is utilized by all the subsequent steps of the methodology that
involve curve ﬁtting (Sections 3.3.2 and 3.4.2).
First, the rolling disk technique (Mikhailyuk & Razzhivin, 2003) is applied to eliminate from
the proﬁle any possible background intensity residuals. The disk radius (parameter θ1)
controls the sensitivity of the aforementioned technique to intensity variations in the proﬁle.
After that, the intensity proﬁle is smoothed (θ2 denotes the order of the smoothing ﬁlter)
and the watershed algorithm (Vincent & Soille, 1991) detects the local maxima (i.e., peaks)
of the intensity proﬁle curve. In order to eliminate possible false peaks (i.e., peaks that do
not correspond to real HPV-related bands), a thresholding procedure is employed to rule out
peaks lower than a certain multiple (parameter θ3  1) of the median value of the intensity
proﬁle. Next, the watershed algorithm is applied for the second time to detect the pair of
the proﬁle’s local minima that are adjacent to both sides of each proﬁle peak. Each pair of
local minima deﬁnes a sequence of proﬁle points which includes the corresponding peak. The
central part of this sequence (“representing” the peak’s body) will be employed for ﬁtting
purposes in the rest of the typing process. The parameter θ4 speciﬁes the percentage of proﬁle
points that are selected for ﬁtting. The selected proﬁle points from all the peaks are aggregated
into the set, XF, of the proﬁle’s ﬁtting points.
The parameters θ1 to θ4 are going to be revisited in the description of HPVTyper in Section 4.
3.3.2 Initial intensity proﬁle ﬁtting
In this step, a simpliﬁed model originating from the observation model is employed for
each intensity proﬁle that has been extracted – this applies to both the image’s ladders and
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HPV-related lanes. This model deliberately ignores the – unknown at this point – correlation
of the intensity proﬁle peaks through the FLPs of the infecting HPV types. For a lane with K
peaks the simpliﬁed intensity proﬁle model, pm(·), is given by the formula
pm(x;ρ) =
K
∑
i=1
Ai · exp
(
− 1
γi
| x− xi
βi
|
γi)
x = 1, 2, . . . , D , (7)
where ρ = [A1, β1,γ1, x1, . . . , AK , βK ,γK , xK ].
The above model is ﬁtted to the extracted intensity proﬁle using the least squares optimization
criterion. Formally, this involves ﬁnding the parameter vector ρopt that satisﬁes the following
equation:
ρopt = argmin
ρ
∑
x∈XF
(
p(x)− pm(x;ρ)
)2 . (8)
This optimization procedure is called initial intensity proﬁle ﬁtting and is carried out once for
each lane of the examined image by means of an established optimization algorithm.
3.3.3 Fragment mobility calibration
This step applies only to the ladders of the image and aims to calibrate the fragment
mobility function, d(·), of the observation model. In other words, it attempts to calculate
the parameter vector π (see Section 3.1) that optimally describes the position-length relation
of the DNA fragments in the image at hand. Although ideally this relation should be a
constant characteristic of the image, the presence of noise and the approximate nature of the
fragment mobility function justify the use of all the available ladders to estimate as accurately
as possible the position-length relation for various regions of the image.
Focusing on a ladder that includes K peaks, the positions of the peak centers in the intensity
proﬁle have been estimated in the previous step; let these be denoted by x∗i for i = 1, 2, . . . ,K.
Moreover, the ladder speciﬁcations provide the molecular lengths that correspond to the
aforementioned peaks; let these be expressed as l∗i for i = 1, 2, . . . ,K. Then, the optimal
parameter vector πopt is given by the expression
πopt = argmin
π
K
∑
i=1
(
x∗i − d(l∗i ;π)
)2 . (9)
The described fragment mobility calibration is performed for each ladder of the image by means
of an established optimization algorithm.
3.3.4 Fragment properties estimation
The fragment lengths and concentrations that correspond to the observed populations of HPV
DNA molecules (i.e., the observed intensity proﬁle peaks) of each lane are estimated in this
step. This applies only to the HPV-related lanes of the experiment. For this purpose, each
HPV-related lane is associated with a ladder (possibly the one lying closer to the lane on the
gel matrix), which lends the lane its optimized fragment mobility function (Section 3.3.3).
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Since the peak positions, xi, of a proﬁle have been estimated during the initial intensity proﬁle
ﬁtting, the fragment lengths, li, that are associated with the peaks can be calculated by the
inverse of the calibrated fragment mobility function as follows:
li = d(−1)(xi;πopt) i = 1, 2, . . . ,K , (10)
where the parameter vector πopt optimizes the fragment mobility function of the employed
ladder and we have assumed that the intensity proﬁle includes K peaks.
Equations (5) and (7) are combined to produce the following formula that estimates the
fragment concentrations:
c′i =
2γ1/γii βiΓ(1/γi)
liγi
· Ai i = 1, 2, . . . ,K . (11)
It is worth mentioning that c′i denotes the apparent concentration of the ith fragment population
on the lane, i.e., the concentration that is calculated if we assume that the parameter f in (5) is
equal to 1. This assumption does not harm the employed methodology, since we are only
interested in the relative concentrations of the observed fragment populations – this will
become clear in Section 3.4. For the calculation of the various c′i , the βi and γi values that
have been optimized by (8) and the li values that have been estimated by (10) are employed.
3.4 HPV typing algorithm
In this phase the actual typing decisions are made. The HPV typing algorithm is charged
with the task of deciding which HPV types or combinations of them are able to explain the
observed intensity proﬁle peaks of a lane both qualitatively and quantitatively – by means of
the observation model. First, all the considered genotypes are checked with respect to their
compatibility with the observed peaks (Section 3.4.1) and those that are found incompatible
are rejected. Then, each possible combination of compatible genotypes is treated as a
hypothesis that is tested for its ability to produce the intensity proﬁle (Section 3.4.2). Finally,
the combinations of compatible genotypes are ranked (Section 3.4.3) by a certain score that
combines their results in the previous test with the combination’s prior probability.
3.4.1 Genotype compatibility check
Let us assume that the intensity proﬁle of the investigated lane has K peaks lying at
positions x = [x1, x2, . . . , xK ] and we want to check the compatibility of genotype T with
aforementioned proﬁle. If l = [l1, l2, . . . , lN ] denotes the FLP of T, then we deﬁne the function
a(·) : [1, . . . , N] → [1, . . . ,K] that assigns the FLP components to the proﬁle peaks such that:
a(i) = j denotes that the ith component of l resides at the jth peak.
Among all possible assignments, we select a∗(·) that minimizes:
CT,a(·) =
1
N
N
∑
i=1
(
d(li;πopt)− xa(i)
)2 . (12)
Depending on the gel electrophoresis and imaging parameters, the DNA fragments of lengths
li1 and li2 (li1 = li2 ) that correspond to the FLP components with indices i1 = i2 can be
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perceived as contributing to the same observed peak. However, in the selection of a∗(·)
we permit assignment coincidence for components i1 and i2 (i.e., a(i1) = a(i2)) only if the
expected positions of fragments i1 and i2 are close enough to each other, i.e.,
|d(li1 ;πopt)− d(li2 ;πopt)|  θ5 . (13)
The parameter θ5 is called coincidence threshold and, given a parameter vector πopt, determines
whether two diverse fragment lengths can be assigned to the same peak or not.
The compatibility degree of genotype T is deﬁned as CT = CT,a∗(·) and has to not exceed the
compatibility threshold θ6 should the genotype be considered compatible with the intensity
proﬁle (i.e., CT  θ6).
3.4.2 Genotype combination testing
In the combination testing procedure, the phenomenon of partial digestion is taken into
account. Up to this point, the term FLP has been used to denote the pattern of fragment
lengths that results from the digestion of all the restriction sites in the ampliﬁed DNA molecule
(full digestion). In this sense, if the ampliﬁed molecule of an HPV genotype T contains N − 1
restriction sites, then the genotype’s FLP will be l = [l1, l2, . . . , lN ]. However, sometimes
restriction enzymes fail to digest the ampliﬁed DNA at one or more of the above sites; in
these cases FLPs corresponding to partial digestion coexist with the FLP resulting from full
digestion. For instance, l′ = [l1 + l2, l3 . . . , lN ] is the result of the enzyme’s failure at the ﬁrst
restriction site. To avoid confusion, for the rest of this chapter the terms main FLP (mFLP) and
partial digestion FLP (pdFLP) are employed for full and partial digestion respectively.
For a combination of compatible genotypes t = {T1, . . . , TM}, lk = [lk1, . . . , lkNk ] is employed
to denote the mFLP of Tk, with Nk being the number of fragments in lk. With respect to the
assignment a∗k (·) of Tk we adopt the optimal assignment that was selected for this genotype
during the compatibility check. Then, the operations that are described in the following
paragraphs are performed on combination t.
Qualitative peak justiﬁcation
First, the genotype combination is tested for its ability to qualitatively justify all the observed
peaks of the proﬁle, with or without the help of a number of pdFLPs that result from the
participating HPV genotypes. Only the pdFLPs that result from up to a certain number of
cleavage failures (parameter θ7) are considered. These pdFLPs are combined to form a set
of subhypotheses so that each subhypothesis includes all the mFLPs of t and a speciﬁc subset
of the possible pdFLPs. A subhypothesis is accepted at this step if it satisﬁes the following
qualitative peak justiﬁcation criterion:
∀ j = 1, . . . ,K ∃ k, i such that a∗k (i) = j , (14)
where the assignments of the involved pdFLPs (i.e., a∗k (·) for k > M) are also considered;
these are selected in the same manner as the mFLP assignments (see Section 3.4.1). Among
the subhypotheses that satisfy the above criterion, we select the one that includes the fewest
pdFLPs and this is propagated to the following step. If no subhypothesis satisﬁes the criterion,
combination t is rejected.
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Intensity proﬁle ﬁtting
In this step, the most crucial of the typing algorithm, the investigated genotype combination
hypothesis attempts to explain the intensity proﬁle data as the superposition of contributions
from the involved FLPs. In this task, each genotype combination is “represented” by its
optimally performing subhypothesis from the previous step.
Let us assume that the selected subhypothesis of the investigated combination t consists of Q
FLPs (M mFLPs and Q − M pdFLPs). Based on (5) of the observation model, the individual
contribution of the qth FLP lq = [lq1, . . . , l
q
Nq ] to the observed intensity proﬁle is given by the
equation:
iq(x; c′q,θq, φ) = c′q
Nq
∑
i=1
lqi · r(x
q
i ) · w(x; β
q
i ,γ
q
i , x
q
i ) x = 1, 2, . . . , D , (15)
where φ is the attenuation factor in (3), c′q is the apparent concentration of the FLP and θq =
[β
q
1,γ
q
1, x
q
1, . . . , β
q
Nq ,γ
q
Nq , x
q
Nq ].
The intensity proﬁle model of the investigated genotype combination t results from
aggregating the contributions of the participating FLPs as follows:
pm(x;ρ) =
Q
∑
q=1
iq(x; c′q,θq, φ) x = 1, 2, . . . , D , (16)
where ρ = [c′1,θ1, . . . , c′Q,θQ, φ]. The latter vector plays in the present task the same role with
the parameter vector ρ of the simpliﬁed intensity proﬁle model of (7). The optimal intensity
proﬁle model of t results from the following expression:
ρopt = argmin
ρ
∑
x∈XF
(
p(x)− pm(x;ρ)
)2 . (17)
In the minimization of (17) the following constraint applies: The concentration of a pdFLP
is not allowed to exceed a percentage (parameter θ8 < 1) of the concentration of the
corresponding mFLP. The calculation of ρopt in (17) under the aforementioned constraint is
undertaken by an established optimization algorithm. The initialization of the optimization
procedure is performed with the help of the estimates that have been obtained for the
fragment properties from the initial intensity proﬁle ﬁtting (Section 3.3.2).
3.4.3 Genotype combination ranking
The score that is employed for ranking the tested combinations of compatible genotypes takes
into account both the ﬁtting results of the previous step (Section 3.4.2) and the prior probability
of the combination.
Focusing on genotype combination t, if ρtopt is the optimized parameter vector of the
combination’s proﬁle model and ‖XF‖ is the number of employed ﬁtting points, the mean
squared ﬁtting error of t is deﬁned by the expression
J(t) =
1
‖XF‖ ∑x∈XF
(
p(x)− pm(x;ρtopt)
)2 . (18)
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Moreover, if J0 is the mean squared error obtained from the initial ﬁtting of the investigated
proﬁle (Section 3.3.2), i.e.,
J0 =
1
‖XF‖ ∑x∈XF
(
p(x)− pm(x;ρopt)
)2 , (19)
P0(t) is the joint prior probability of the HPV types from which the genotypes in t stem, and
K is the number of peaks in the proﬁle, then, the score of t is given by the formula
R(t) = −2K J(t)
J0
+ θ9 · ln
(
P0(t)
)
. (20)
The parameter θ9, which is called prior weight, is employed to adjust the signiﬁcance of the
prior probability in the ranking process. Its value is positive and defaults to 1.
As one can anticipate from (20), the score only takes negative values, and a genotype
combination whose score is close to 0 denotes a better solution than an combination with
lower score. The eligibility threshold θ10 is employed to discriminate between the tested
genotype combinations that are considered to be solutions to the problem (i.e., R(t)  θ10)
and those that are not.
4. Description of HPVTyper
HPVTyper is a novel software application for analyzing images that have resulted from the
PCR-RFLP examination with the intention of performing accurate and automatic HPV typing.
This is achieved by employing the typing methodology that has been presented in Section 3.
The application consists of an engine module that undertakes all the computations which are
involved in the typing methodology (e.g., the initial intensity proﬁle ﬁtting of Section 3.3.2)
and a user interface module that allows the user to interact graphically with the application.
The classic client-server architecture has been employed for implementing the communication
between the engine and the user interface.
HPVTyper has been designed upon the following principle: The application automates as
many of the involved operations as possible while, at the same, it allows the user to intervene
essentially at any stage of the typing procedure. This principle is implemented by means of an
abundant set of parameters – the already deﬁned parameters θ1 to θ10 are among them. Each
parameter possesses a predetermined default value which is used in the involved operations,
unless the user wishes to change/adjust it via the graphical user interface.
All the functionalities of the application are made available through four windows, which are
described in detail in the following sections.
4.1 Image Processing Window
The main window of HPVTyper is called Image Processing Window. This window is presented
to the user when HPVTyper initiates and it is mainly concerned with loading the PCR-RFLP
images to be analyzed, performing all the required image preprocessing operations on them
(Section 3.2), and introducing the depicted lanes. The layout of the Image Processing Window
is illustrated in the screenshot of Fig. 4.
As it can be observed in Fig 4, most of the window area is covered by a pane that displays
the currently loaded PCR-RFLP image along with a marker indicating positions on the gel
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Fig. 4. Screenshot of the Image Processing Window.
electrophoresis axis (the vertical axis of the image). This is the image workspace pane and it
can also display certain intermediate image preprocessing results (e.g., the lane boundaries).
Below this pane, there is the message log pane which displays messages from either the engine
module or the user interface module regarding the progress of the HPV typing procedure.
With respect to the engine messages, these are the means of the application for notifying the
user about changes in the status of computationally expensive operations that are queued in
the engine module (e.g., the initiation/termination of the genotype combination testing phase
for a particular lane.).
On the right side of the window there is a column that includes three more panes. The
ﬁrst from the top is the lane status pane, which allows the user to provide a name for each
lane of the active image and to classify it as either HPV-related or ladder. Moreover, it
informs the user about the processing status of each lane (e.g., "Boundaries Detected", "Proﬁle
Extracted"). When the user selects a lane from the current pane, its position on the loaded
image is highlighted as illustrated in Fig. 4. The notes pane is located in the middle of the
column and allows the user to write down their notes on the present HPV typing assignment
in free-text format. The notes are saved and reloaded each time the user opens the same HPV
typing project – the concept of HPV typing project will be deﬁned later in the present section.
Finally, the hint pane contains helpful suggestions of the application to the user regarding the
subsequent steps of the typing procedure.
In addition to the aforementioned panes, the Image Processing Window includes a series of
menus (ordered in a row on the top of the window) that expose most of the HPVTyper’s
functionalities to the user.
The most simple functional usage scenario of the main window of HPVTyper is summarized
in the following paragraphs. All the described operations are triggered by means of the menu
that emerges when right-clicking on the image, unless speciﬁed otherwise. First, a PCR-RFLP
gel electrophoresis image is loaded to the application through the File menu. This action creates
an HPV typing project dedicated to the typing of the lanes that are included in the image. A
number of processing operations can be applied on the image so as to ensure that it passes
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the quality checks of Section 3.2; these operations include cropping the image, rotating it, and
inverting its grayscale levels.
When the image is ready, the user triggers the automatic lane detection operation. Once this
operation is completed, the detected lane boundaries are overlaid on the image. At this point,
the user can revise/adjust the boundaries of some or all the lanes by moving the displayed
boundaries with the help of the mouse. When satisﬁed with the lane boundaries, the user
triggers the background subtraction operation. This is performed automatically and, after
its completion, the background-corrected image replaces the original in the image workspace
pane.
Next, the user visits the lane status pane in order to provide names for the lanes of interest and
classify each of them as HPV-related 3 or ladder. When a lane is selected – by left-clicking on its
cell in the lane status pane – HPVTyper displays its position on the image (image workspace
pane). By right-clicking on the same cell, the user can ask HPVTyper to extract the intensity
proﬁle of the lane. When this happens, HPVTyper creates for this lane either an HPV typing
task, in case of an HPV-related lane, or a mobility calibration task, in case of a ladder. The
created task is tied to the selected lane and is uniquely identiﬁable within the active HPV
typing project.
4.2 Proﬁle Processing Window
All the operations that are necessary for carrying out an HPV typing or mobility calibration
task are performed in the Proﬁle Processing Window. This includes mainly the operations
described in Sections 3.3 and 3.4. Each of the HPV typing or mobility calibration tasks
that have been created in the main window maintains its own Proﬁle Processing Window.
Upon the creation of such a task, a button that activates the corresponding Proﬁle Processing
Window is added in a column on the left end of the Image Processing Window.
The layout of the Proﬁle Processing Window that corresponds to an HPV-related lane is
illustrated in the screenshot of Fig. 5. This includes three panes. Most of the window area is
covered by the proﬁle workspace pane, which is designed to undertake the fragment information
extraction operations described in Section 3.3. On the other hand, the panes in the right
column, namely the compatibility check pane (top) and the combination testing pane (bottom), are
meant to carry out the operations corresponding to the HPV typing algorithm (see Section 3.4).
In the proﬁle workspace pane, the horizontal axis identiﬁes with the electrophoresis axis. The
pane displays four vertically aligned items, which are (starting from the bottom):
1. The image of the ladder that has been associated with the lane under investigation.
2. The virtual marker that has resulted from the calibration of the aforementioned ladder.
This marker speciﬁes the relation between positions and fragment lengths (in bp).
3. The background-corrected image of the investigated lane.
4. The intensity proﬁle that has been extracted from the aforementioned lane.
At the bottom of the proﬁle workspace pane, the user can adjust the values of parameters θ1 to
θ4 (see Section 3.3.1) and also change the ladder that is associated with the investigated lane.
3 In the application the term HPV lane is employed to denote those lanes that need to be typed.
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Fig. 5. Screenshot of the Proﬁle Processing Window.
The compatibility check pane, which deals with the procedure described in Section 3.4.1,
is divided into two parts. The upper part is employed to control the compatibility check
procedure (parameters θ5 and θ6) and determine the maximum number of compatible
genotypes that can be considered by the application (complexity control slider). This way,
the computational complexity involved in the combination testing phase of the HPV typing
algorithm can be controlled by the user. In the lower part, the compatibility check results are
presented in a table which includes (i) the genotypes that are found to be compatible with the
proﬁle, (ii) the HPV types to which they belong, (iii) the scores that they have achieved in the
compatibility check, and (iv) the selected assignment, a∗(·), of each genotype’s FLP.
The combination testing pane, which serves the operations described in Sections 3.4.2
and 3.4.3, resembles in terms of design the previous pane: It is divided into an upper part
that controls the combination testing and ranking procedure and a lower part that displays
the results. In the upper part the values of parameters θ7 to θ10 can be deﬁned. In the lower
part, the solutions of the HPV typing algorithm are displayed – sorted by their scores – in a
table that includes for each solution (i) its score, (ii) the participating genotypes and associated
concentrations that achieve this score, and (iii) the HPV types to which the genotypes belong.
A color-coding scheme is employed for the types based on their oncogenic risk (e.g., green
denotes low-risk types). The maximum number of solutions that can be displayed is speciﬁed
with the help of a slider at the bottom of the pane.
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When it comes to ladders, only a reduced set of operations needs to be supported
(Sections 3.3.1 to 3.3.3). For this reason, the Proﬁle Processing Window that is associated
with a ladder is slightly different from what has been already described. More speciﬁcally,
the compatibility check and combination testing panes are disabled and the lane image item
is missing from the proﬁle workspace pane. The fragment mobility calibration functionality
is provided through the corresponding option in the right-click menu of the aforementioned
pane.
The shortest sequence of actions that completes an HPV typing task is brieﬂy presented
below. First, the user has to calibrate the mobility function from the ladder that is associated
with the HPV-related lane under investigation. This procedure is performed on the ladder’s
Proﬁle Processing Window. At this point, all the operations described in Section 3.3.1 can
be performed automatically by HPVTyper via the right-click menu of the proﬁle workspace
pane and afterwards modiﬁed manually by the user in a context-aware manner. Once the
calibration is achieved, the user switches to the Proﬁle Processing Window of the investigated
HPV-related lane. Operations similar to those performed for the ladder can be attempted on
this proﬁle as well, before requesting HPVTyper to execute the initial intensity proﬁle ﬁtting
process. Following the proﬁle ﬁtting, the application automatically estimates the fragment
properties associated with the proﬁle peaks. Then, the compatibility check is triggered by
the user and the obtained results are displayed in the appropriate table. Finally, the user has
to initiate the combination testing procedure. This is executed by the engine module, and
the computed solutions are displayed along with their characteristics in the respective table
upon completion of the procedure. The optimal intensity proﬁle model corresponding to each
solution can be drawn in the proﬁle workspace pane upon user request, allowing them to
visually supervise the end ﬁtting results.
4.3 Conﬁguration Editors
By the term Conﬁguration Editors we refer to two distinct windows that are employed for
editing the information required for making the HPV typing decisions. These windows,
namely the PCR-RFLP Conﬁguration Editor and the Type Conﬁguration Editor, are meant to
be used rarely, e.g., whenever new scientiﬁc discoveries need to be taken into account in
the typing process. They can both be accessed through the Conﬁgurations menu of the main
window and are described in the following sections.
4.3.1 PCR-RFLP Conﬁguration Editor
Since various combinations of primers and restriction enzymes can be employed for a
PCR-RFLP examination and also various HPV genotypes may be considered in an HPV typing
task, the knowledge of the above parameters – the PCR-RFLP conﬁguration – is necessary when
one attempts to perform HPV typing on an acquired PCR-RFLP image. The present window
allows the user to insert information regarding the above conﬁguration into HPVTyper. The
application can store many different PCR-RFLP conﬁgurations and the user is responsible
for assigning the appropriate one to each HPV typing task through the Tasks menu of the
application’s main window.
The layout of the PCR-RFLP Conﬁguration Editor is illustrated in the screenshot of Fig. 6 and
its usage is straightforward. In the upper part of the window, the user can switch between
the stored conﬁgurations, keep conﬁguration-related notes, and deﬁne the associated PCR
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primers and restriction enzyme(s). In the lower part of the window, the application displays
in a tabular form (i) the HPV genotypes that are considered in the present conﬁguration
(user-deﬁned names are employed), (ii) their GenBank accession ID, (iii) the HPV types to
which they belong, (iv) the length of their amplicon, and (v) their fragment length pattern. On
the right side of this table, there is a form for editing the genotype-speciﬁc information.
Fig. 6. Screenshot of the PCR-RFLP Conﬁguration Editor.
4.3.2 Type Conﬁguration Editor
The HPV types demonstrate signiﬁcant variations in their prevalence in different populations
and tissue types. Since the typing methodology that is employed by HPVTyper explicitly uses
the prior probabilities of the various HPV types to make its typing decisions, it is reasonable
to allow multiple sets of prior probabilities to be included in the application. This way, the
appropriate set of prior probabilities that best suits an examined tissue sample by geographic
and/or anatomic criteria can be employed.
The present window allows the user to edit an existing set of prior probabilities or insert a
new set. In addition, it provides the user with the opportunity to deﬁne the oncogenic risk of
each HPV type; this information is used in the color-coded representation of the types in the
Proﬁle Processing Window.
The design of the present window resembles that of the PCR-RFLP Conﬁguration Editor and
all the provided functionalities are straightforward. The layout of the Type Conﬁguration
Editor is illustrated in the screenshot of Fig. 7.
5. Important features of HPVTyper
As it may have become clear from the presentation of the employed methodology but also
from the description of the application itself, HPVTyper demonstrates several noticeable
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Fig. 7. Screenshot of the Type Conﬁguration Editor.
features. When combined, these features establish HPVTyper as a noteworthy HPV typing
approach that is signiﬁcantly differentiated from its counterparts. The most important of the
application’s features are outlined in this section.
Accurate typing decisions. The typing methodology that has been presented in Section 3
has been adequately evaluated with respect to its accuracy, yielding very satisfactory
results (Maramis et al., 2011). Since HPVTyper employs this methodology, the typing
decisions that are made with the help of the application are very accurate. This is true
for cases of single HPV infection and – more importantly – for complex cases involving
multiple infections. In fact, the aforementioned methodology is the only established way
to resolve the latter cases when attempting HPV typing via PCR-RFLP gel electrophoresis.
Automatic typing procedure. HPV typing with HPVTyper can be performed completely
automatically. This applies to the entire typing procedure (Sections 3.2 to 3.4) but its
importance focuses on the automatic application of the HPV typing algorithm (Section 3.4),
since such a feature has been missing from all the previous typing algorithms. In the
case of HPVTyper, this feature derives from the computerized nature of the employed
methodology along with the use of default values for the set of involved parameters (e.g.,
parameters θ1 to θ10) and signiﬁcantly eases the typing process for the user.
Supervised typing procedure. Although HPVTyper provides the possibility of automatic
typing, at the same time, it allows the user to supervise the entire typing procedure. This
includes presenting intermediate results to the user (the outcome of initial intensity proﬁle
ﬁtting, the outcome of type compatibility check, etc.) and also allowing them to adjust a
wide range of parameters that can inﬂuence the typing result (e.g., parameters θ1 to θ10).
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This way, the user has full control on the typing procedure and is able to verify themselves
step-by-step the correctness of the application’s results.
Free availability. Since HPVTyper can be obtained for free, each molecular biology laboratory
that possesses the required equipment for performing HPV typing via PCR-RFLP gel
electrophoresis can beneﬁt from the presented HPV typing method without any additional
cost. In these laboratories the conventional manual method for HPV typing via PCR-RFLP
could be replaced with minimum effort by HPVTyper in order to update the employed
HPV typing procedure.
Adaptability to emerging discoveries. Scientiﬁc research regarding HPV and its connection
to cervical cancer is very active. For this reason, it is possible to see in the future new
types and genotypes of the virus being discovered, new restriction enzymes and primers
being employed for HPV typing, the infection frequency and risk of some HPV types being
revised, etc. HPVTyper can easily cope with such scientiﬁc discoveries that may emerge
by means of its Conﬁguration Editors. The user simply has to edit the information that has
become obsolete or add new information through the PCR-RFLP or Type Conﬁguration
Editor and the application remains up-to-date. In this sense, HPVTyper is a future-proof
HPV typing method.
Expandability to new domains. Although the application has been originally developed as
a diagnostic method for the domain of cervical cancer, it can easily ﬁnd application to
every cancer domain in which HPV is involved. Similarly to the previous feature, the
information that is related to a new cancer domain can be incorporated in the application
with minimum effort by means of the Conﬁguration Editors.
6. Availability
HPVTyper is made freely available to the public through the webpage http://
hippocrates.ee.auth.gr/HPVTyper/ and is subject to the license described therein.
The powerful engine module that is installed on the aforementioned server is employed for
performing the required computations, while the user interface module is installed to the
user’s computer by means of the Java Web Start Technology. The use of the aforementioned
technology ensures minimum ﬁle downloading, automatic updates, and operating system
independence at the user’s side. A copy of the application’s source code can be obtained for
free from the above webpage under the same license agreement.
7. Conclusion
In this present chapter, we have introduced HPVTyper, a novel software application for
accurate and automatic HPV typing via PCR-RFLP gel electrophoresis. The strength of
HPVTyper derives primarily from the underlying HPV typing methodology. This entirely
computerized methodology has been justiﬁed in parts and as a whole by a series of
scientiﬁc publications (Maramis & Delopoulos, 2010a;b; Maramis et al., 2010; 2011) and its
performance with respect to typing accuracy has been thoroughly evaluated on real HPV
typing data (Maramis et al., 2011). By employing this methodology, HPVTyper is able to make
accurate typing decisions even for multiply-infected cases in an entirely automatic manner.
The second cornerstone of HPVTyper’s strength is its design. The application provides the
user with a friendly and straightforward interfacing mechanism to perform all the operations
that are involved in the typing process, either as suggested by the application (default
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parameter values) or according to the user’s will (user-adjusted parameter values). Any
intermediate results are presented to the user so that they can constantly check the progress
of the typing procedure. Owing to the aforementioned design principles, the user has full
control over the entire typing process and is able to choose their degree of involvement in the
procedure.
The application scope of HPVTyper is impressively wide. By providing tools to easily edit
the information that is required for the typing decision, the application can be expanded to
include new HPV-related discoveries in the domain of cervical cancer as well as to perform
HPV typing in the framework of other cancer domains that are associated with HPV. Finally,
it is worth mentioning that the implemented software application could just as well be
employed for typing other viruses, should this be required.
A foreseeable future addition to HPVTyper concerns the issue of mutation hotspots in the
genome of HPV. When these mutations occur at the restriction sites of the ampliﬁed HPV
DNA sequence, the resulting FLP of an infecting genotype does not match its expected FLP.
Consequently, these mutations constitute a serious threat to the efﬁcacy of the PCR-RFLP
typing method in general, no matter whether this is performed manually or by means of
HPVTyper.
Fortunately, the powerful decision making mechanism of our application along with the
analysis of Section 3.4.2 regarding the phenomenon of partial digestion – already incorporated
in the employed methodology – set the ground for future versions of HPVTyper to tackle
the aforementioned issue. In fact, these altered mutation-related FLPs are essentially partial
digestion FLPs and – just like the latter – they can be foreseen.
With respect to the required modiﬁcations on the employed methodology, the compatibility
check operation must be updated so as to search for a set of reasonably possible
mutation-induced FLPs in addition to the main FLP of an investigated genotype. This ﬂexible
compatibility check will allow us to diagnose – with reduced conﬁdence of course (e.g.,
by adding a penalty to the ﬁnal score) – infections from HPV types with slightly mutated
genomes. However, it should be noted that this approach will induce a signiﬁcant increase on
the computational complexity of the decision making process – an issue that will have to be
tackled – and could potentially disturb the accuracy of the employed methodology.
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